Validation of a Deployable Proteomic Assay for the Serological Screening of Sexual Assault Samples by Brown, Catherine O\u27Sullivan
University of Denver 
Digital Commons @ DU 
Electronic Theses and Dissertations Graduate Studies 
2021 
Validation of a Deployable Proteomic Assay for the Serological 
Screening of Sexual Assault Samples 
Catherine O'Sullivan Brown 
Follow this and additional works at: https://digitalcommons.du.edu/etd 
 Part of the Analytical Chemistry Commons, Biochemistry Commons, and the Other Chemistry 
Commons 







the Faculty of the College of Natural Sciences and Mathematics 





In Partial Fulfillment 
of the Requirements for the Degree 






Catherine O. Brown 
August 2021 
Advisor: Dr. Phillip B. Danielson 
  
©Copyright by Catherine O. Brown 2021 




Author: Catherine O. Brown 
Title: Validation of a Deployable Proteomic Assay for the Serological Screening of Sexual Assault 
Samples 
Advisor: Dr. Phillip B. Danielson 
Degree Date: August 2021 
 
ABSTRACT 
Protein mass spectrometry (MS) has emerged as a technique to supplant traditional 
serological tests for body fluid identification. It was hypothesized that proteomic techniques would 
surpass the sensitivity and specificity of traditional serological techniques. An automated workflow 
coupled with protein MS has been developed for the confirmatory identification of five biological 
fluids. A developmental validation was completed, assessing parameters such as reproducibility, 
sensitivity, ion suppression, and limit of detection. Implementation was determined through tandem 
sample processing by MS, traditional serological tests, and standard DNA profiling methods. The 
MS approach offered superior detection limits while also providing true confirmatory results, 
producing an unambiguous identification of body fluids to the point where the technology can be 
considered comparable to DNA profiling.  
An extensive study was conducted to evaluate the effects of personal lubricants on 
biomarker detection in sexual assault evidence. Lubricants have the potential to inhibit protease 
activity, displace hydrophobic markers during solid phase extraction, and suppress ion detection 
during MS analysis. Three studies were performed: (1) determination of vaginal fluid biomarker 
detection from vaginal swabs fortified with lubricant; (2) the effect of lubricant formula on seminal 
fluid and saliva biomarker detection was established; and (3) the detection of biomarkers condoms. 
Data was interpreted by the overall peak area response (PAR) of the target biomarker, biomarker 
PAR in relation to internal standard, and PAR of digestion control protein. 
Multi-stage workflows associated with proteomic analysis remain a major hurdle towards 
the adoption of the technique in caseworking laboratories. A streamlined sample-to-results 
workflow has been developed using peptidomic analysis, allowing for straightforward preparation 
versus bottom up methodologies. Low molecular weight proteins were extracted and data was 
iii 
 
acquired using an orbitrap-quadrupole HRMS. Numerous protein biomarkers have been 
characterized in human seminal fluid, saliva, and vaginal fluid.  
In conclusion, the implementation of the protein MS approach offers an advantageous 
relationship between a positive identification and downstream DNA testing, including the capacity 
to deliver confirmatory contextual information in a criminal investigation. Furthermore, lubricant type 
does affect the ability to accurate identify protein biomarkers. And lastly, the research presented 
will demonstrate the use of peptidomic analysis for the confirmatory identification of biological fluids 
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CHAPTER 1: INTRODUCTION 
1 Introduction 
Forensic science is the application of scientific testing to criminal and civil law. The 
overarching goal of forensic testing is to establish an association between a piece of physical 
evidence and an individual, whether a victim or suspect of a crime. By exploiting the transfer of 
evidence, as stated by Edmond Locard [1], analysts seek to identify, compare, and associate 
physical evidence in an effort to provide information to a court of law to assist the trier of fact in 
determining the probative value and weight of forensic evidence. The probative value of physical 
evidence stems from the ability to determine an object’s uniqueness. The capabilities of forensic 
testing to narrow down the range of possibilities as to what an item of evidence may be, such as a 
biological stain, or to whom biological evidence may belong, can help to focus an investigation. 
Forensic biology is a subdiscipline within the field of forensic science that seeks to identify 
and individualize the source of biological stains through serological and genetic testing. Forensic 
serology describes the identification of biological fluids, such as blood, semen, and saliva, through 
the use of biochemical techniques to associate an item of evidence with a victim or suspect. 
Common types of crimes that utilize forensic biology testing include homicide, assault, and rape. 
Prior to the advent of DNA analysis, forensic biologists depended heavily on antigen and protein 
polymorphisms as a means of discriminatory identification. For example, the identification system 
of ABO blood type groups was developed during the early 20th century. The frequency and 
inheritance of A and B antigens present on the surface of erythrocytes were mapped and used as 
the first form of human identification apart from fingerprint analysis. While this discovery lead to a 
more advanced classification system, the use of erythrocyte antigen characterization was primarily 




1.1 Modern Genetic Typing for Forensic Identification 
It was not until the late 20th century that DNA polymorphisms, in the form of variable number 
tandem repeats, were applied to forensic evidence successfully. This novel technique 
demonstrated greater individual variability than protein polymorphic markers, with DNA profiling not 
only capable of identifying a true perpetrator but excluding innocent suspects. With the 
simultaneous development of the polymerase chain reaction (PCR), the use of DNA polymorphisms 
quickly surpassed that of more established techniques. Rapid advancements in PCR chemistries, 
polymorphism fragment length, and automation have led to genetic typing being crowned the gold 
standard within the field of forensic biology. For example, the National DNA Index System (NDIS), 
launched in October 1998, contains 1,096,398 forensic profiles and over 14,492,991 offender 
profiles (i.e., convicted offender, detainee, and legal profiles) to date [2]. Forensic uses of DNA 
typing expand beyond the capability of identifying potential suspects and include the identification 
of mass catastrophe victims, missing persons, and endangered or protected species. 
The process of genetic testing follows five central procedural steps: extraction, quantitation, 
amplification, separation, and interpretation. It is estimated that the human genome shares 99.7% 
sequence homology between individuals, limiting forensic researchers to target the remaining 0.3% 
for discriminatory analyses. Short tandem repeat (STR) regions, a type of microsatellite, are 
currently targeted for forensic genetic typing as they are small in size (approximately 2 to 7 base 
pairs in length) and the number of repeats at a given location is highly variable among individuals. 
Simply, they describe a pattern of nucleotides that are repeated directly adjacent to each other, 
with the number of consecutive repeats varying between individuals. STR regions can be further 
classified as simple, non-consensus, compound, or complex repeats based on their incremental 
repeat patterns. Twenty STR locations are accepted into the Combined DNA Index System 
(CODIS), with the number increased from the original thirteen locations in the year 2017. As interest 
in the analysis of highly degraded evidence continued to push the lower sensitivity limits of genetic 
typing, the use of single nucleotide polymorphism (SNP) markers emerged to supplement STR 
typing. SNPs are single base pair sequence variations at a particular point in the genome that arise 
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due to spontaneous mutation. These mutations can be present in coding, regulatory, and intronic 
sequences within genes or in intergenic regions. SNP markers are attractive for forensic 
investigations given their short amplicon size, lack of stutter artifact formation during amplification, 
and their ability to predict ethnicity and phenotypic characterizations.  
Common practice for DNA size fractionation traditionally involves the use of capillary 
electrophoresis. However, crime laboratories have begun implementing next generation 
sequencing (NGS) methodologies for challenging casework. NGS, also referred to as massively 
parallel sequencing (MPS), allows for the simultaneous sequencing of many DNA samples, instead 
of one sample at a time as with capillary electrophoretic separation. The benefits of this type of 
analysis allow for an influx of data that is not normally obtained with traditional sequencing, such 
as the discovery of different types of genomic features in a single sequencing run (e.g., SNPs, copy 
number variants, structural variants). In regard to forensic genetic applications, NGS can be used 
for a variety of analyses such as STR identification for relationship testing, SNP identification for 
phenotypic characterization, and mitochondrial genome sequencing. NGS is currently used for 
investigative lead generation and genetic genealogy practices, seen in cases such as the Golden 
State Killer [3] or the identification and conviction of W.M. Talbot in Washington state for the 1987 
murders of Jay Cook and Tonya Van Cuylenborg [4].  
Modern genetic testing procedures have rapidly exceeded the anticipated sensitivity limits 
to the extent that trace DNA can be identified from an individual that had prior interaction with a 
person but was not involved in criminal activity. The concept of indirect transfer of genetic material 
describes the deposition of one’s DNA onto an object or person and subsequently having their DNA 
relocated to a secondary object or person without physical contact. This phenomenon has been 
rigorously evaluated within the forensic community in an attempt to provide reason in the event of 
explaining alternate transfer propositions [5–8]. This limitation has prompted forensic investigators 
to question not what evidence to collect for DNA analysis, but where to collect on an item of 
evidence to obtain accurate results. For example, given the case scenario of a drug facilitated 
sexual assault, a victim that was unconscious during sexual activity would not have recollection of 
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where the offender may have removed an article of clothing or the extent of sexual acts performed. 
In a recent study, simulated digital sexual assault scenarios were conducted in a controlled 
laboratory setting and revealed that the amount of offender DNA deposited on undergarments is 
highly variable. Furthermore, although not an original aim of the study, the DNA of a colleague or 
cohabitating partner was identified in several instances [9].  
The principles of DNA transfer, persistence, prevalence, and recovery are taken into 
consideration during data interpretation to provide insight into activity level reporting and generating 
descriptive probability estimates [10]. It is important to understand these variables as they relate to 
DNA transfer versus contamination or true instances of multiple contributors. As genetic testing 
methodologies have gotten more sensitive and can generate informative results from poor quality 
and lesser quantities of input DNA, the types of DNA profiles obtained have become exceedingly 
more challenging to interpret, particularly in samples with multiple low level contributors. 
Practitioners within the field have responded by shifting to the use of more advanced probabilistic 
modeling. The need for innovative interpretation strategies for low template DNA was reported two 
decades ago [11], and since, various types of semi-continuous and continuous probabilistic 
genotyping models are accepted in the forensic community [12]. In short, probabilistic genotyping 
has unlocked potential for deciphering challenging DNA profiles that would have otherwise been 
deemed uninterpretable with the use of traditional binary methods, such as combined probability of 
inclusion (CPI) calculations.  
DNA profiling and interpretation methodologies have grown very rapidly over the past 25 
years. The lack of consistency in reporting language of advanced probabilistic genotyping 
calculations remains a topic of debate within the greater forensic biology community. Furthermore, 
the proprietary source code of interpretation software, such as TrueAllele® by Cybergenetics, has 
received criticism within the legal community as defendants are unable to visualize how software 
forms decisions [13,14]. In essence, the scientific methodology behind DNA profiling has been well-
demonstrated and is concrete, with limitations arising from the interpretation of generated profiles. 
5 
 
On the contrary, the scientific methodology for modern serological testing has not received the 
same attention.   
1.2 Test Classifications for Traditional Body Fluid Identification 
In contrast to the evolution and occasional transilience of modern genetic testing, the 
identification of biological stains remains rooted in historical biochemical analyses. Traditional 
serological procedures rely on detecting the presence or activity of macromolecules that display a 
level of specificity within a biological fluid. Historically, proteins are the macromolecule of interest. 
Proteins are composed of amino acid monomers that have been bound together through 
polypeptide covalent bonds. Amino acids are simple monomer subunits that contain an amine and 
a carboxyl functional group, providing the monomer with directionality. Amino acids are categorized 
according to their side chain, which extends as a substituent from the backbone structure. There 
are twenty unique side chains, and therefore twenty unique amino acids. Given the combination of 
amino acids within a protein, a nearly endless array of protein sequences can be achieved. It is the 
amino acid side chains, or combination of side chains, that provide a protein with specific chemical 
properties such as polarity and charge state. The primary structure of a protein is defined as the 
sequence of amino acids or unfolded polypeptide chain. The polypeptide chain begins to adopt a 
three-dimensional structure as amino acid side chains initiate new interactions in the form of 
hydrogen bonds and functional group interactions. The orientation and unique combination of 
amino acids at the primary level dictate the interactions formed at the secondary level. Interactions 
become stronger and the protein obtains its true three-dimensional shape at the tertiary level, 
where characteristic folds initiate a protein’s function. When two or more polypeptide subunits are 
joined, a quaternary structure is achieved.  
Protein form and function have remained a primary target for serological assays. A majority 
of historical serological techniques rely on detecting the presence or activity of proteins consistent 
with a target body fluid. Body fluids are rich in protein material, however, the challenge for forensic 
testing is to identify specific targets and not necessarily the most abundant targets. Achieving a 
desirable balance between sensitivity and specificity has proven difficult, with cross-reactivity and 
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false positive identifications fairly common. In general, evidence that is received in the laboratory 
for forensic biology testing will first be screened for the presence of biological stains. This is 
conducted through visualizing stains that may not be evident to the naked eye and conducting 
presumptive testing to narrow down the possible stain origin. For sexual assault evidence, 
confirmatory testing can also be performed to further discriminate the presence of biological stains. 
Once the origin of a stain is revealed, small cuttings or scrapings are acquired, and genetic material 
is extracted for analysis. Together, results from serological and genetic testing deliver associative 
support for a connection between an individual and a biological stain on an item of evidence. 
However, modern genetic testing procedures are more sensitive than their serology counterpart, 
and thus DNA results often take precedence in a criminal investigation.  
The identification of biological fluids on forensic evidence provides important contextual 
information to an investigation. While genetic testing provides individualization to a biological stain, 
serological testing can indicate where the biological stain originated. In this section, the traditional 
techniques used for presumptive and confirmatory identification of biological fluids will be 
summarized. Screening procedures are classified according to their mechanism of action or sample 
preparation procedure and are characterized below into one of the following groups: alternative 
light source, colorimetric assays, enzymatic assays, microscopic visualization, and antibody-based 
assays. Although many techniques exist for each, a select grouping of procedures were chosen to 
exemplify each classification, with the discussion herein not designed to present an exhaustive list 
of historical techniques.  
1.2.1 Alternate Light Source for Body Fluid Identification 
A crime scene investigator or forensic analyst will rely heavily on the use of an alternative 
light source (ALS) for the screening of large surface areas, such as a wall or a mattress. This 
screening technique visually enhances biological stains that may not be visible to the naked eye 
and can be employed for assistance with collection, documentation, and processing of biological 
evidence [15]. The theory behind this investigative tool relies on emission and excitation 
wavelengths. Excitation wavelengths, generally in the visible range of the electromagnetic 
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spectrum, are absorbed by fluorophores within a stain or substrate. The fluorophore absorbs the 
excitation wavelength and transitions the energy to a more excited state, emitting excess energy. 
This excess, or emission wavelength, is detected as fluorescence. Barrier filters or colored goggles 
are necessary for visualization of fluorescence, as the excitation wavelength will otherwise 
overpower the emission wavelength. Colored goggles selectively filter light and allow the emission 
wavelength to pass through and be detected by the eye. ALS is utilized for gunshot residue [16], 
fiber [17], and fingerprint evidence [18], and within forensic biology, is a prevalent tool for localizing 
biological stains, such as semen, saliva, and urine.  
For seminal fluid visualization, flavins and choline contribute to the fluorescence of semen 
as well as any bacterial growth. When irradiated, semen stains will appear bluish-white when 
deposited on dark materials or, in contrast, may appear as dark spots when deposited on white 
fabrics due to high background fluorescence. Similarly, saliva detection is indicated by a bluish-
white illumination and is more difficult to visualize in comparison with other fluids given its simple 
composition [19]. Generally, wavelengths between 450 nm and 495 nm (blue light) are used in 
combination with orange filter goggles for fluorescence visualization. Benefits of ALS include the 
ability to scan larger items of evidence, such as a bed sheet, for trace amount of biological material. 
However, background interferences are common, and are attributed to substrate color and 
presence of whiteners or other substances applied during the manufacturing process. It is accepted 
practice to use ALS as a screening tool prior to further examination of forensic evidence.  
1.2.2 Colorimetric Assays for Body Fluid Identification 
Colorimetric assays utilize the conjugation of electrons across an indicator compound to 
cause a shift in the highest occupied molecular orbital-lowest unoccupied molecular orbital (HOMO-
LUMO) gap to produce a wavelength of light within the visible spectrum. Blood is most frequently 
detected using colorimetric tests that exploit the peroxidase-like activity of the protein hemoglobin. 
The non-protein heme group present within hemoglobin catalyzes oxidation-reduction reactions, 
where colorless indicators are oxidized and cause a color change. The oxidation of a molecule 
describes the loss of an electron whereas the reduction of a molecule describes the gain of an 
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electron. Colorimetric tests for blood detection can be further separated into one-phase and two-
phase procedures [19]. For one-phase procedures, a suspected stain is subjected to hydrogen 
peroxide and an indicator compound, such as tetramethylbenzidine (TMB), simultaneously. 
Although rapid to perform and fairly sensitive, one-phase procedures display a wide variety of false 
positives ranging from plant, animal, and bacterial sources that exhibit strong chemical 
oxidant/reductant properties or peroxidase-like activity [20]. In contrast, two-phase procedures 
subject a suspected stain first to an indicator compound followed by a separate addition of 
hydrogen peroxide. Positive reactions that occur prior to the addition of hydrogen peroxide are 
ruled negative. An example of a two-phase procedure is the phenolphthalein test, also referred to 
as Kastle-Meyer test [21].  
Unlike TMB or phenolphthalein, oxidation-reduction reactions can produce 
chemiluminescence or fluorescence instead of a color change. Luminol test (3-
aminophthalhydrazide) is commonly employed during crime scene investigation for the detection 
of minute traces of blood, even traces that have been wiped clean from surfaces. 
Chemiluminescence is visualized as a blue glow. This test has demonstrated unparalleled 
sensitivity, with a reporting limit of 5,000,000-fold blood dilution detected [22]; however, commercial 
bleach is a false positive [23]. Given its use on large items of evidence such as carpets, walls, and 
flooring, it has been demonstrated that luminol will not negatively affect polymerase chain reaction 
for DNA analysis [24].  
1.2.3 Microscopic and Histological Analysis for Body Fluid Identification 
Microscopic crystal tests were historically performed for the identification of blood but have 
been replaced in favor of catalytic tests and antibody-binding assays. An example of a crystal test 
is the Takayama test [25]. The heme group is dissociated from the hemoglobin protein unit and 
pyridine binds to the fifth and sixth orbital positions on the iron atom, resulting in the compound 
hemochromogen. Under alkaline conditions and in the presence of glucose, hemochromogen is 
pushed out of solution and creates rhomboid-shaped crystals (Figure 1.1A). Although once 
considered confirmatory, it was determined that crystal formation was selective for the iron 
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protoporphyrin ring structure within heme and not the protein itself. Furthermore, crystal growth is 
contingent on creating an ideal environment, which is time consuming and difficult to reproduce.  
In comparison with the visualization of crystal formation, the histological staining and 
visualization of cells is used for semen identification and vaginal fluid detection. The detection of 
vaginal fluid is not common practice in operational laboratories, as the histological staining described 
herein is not discriminatory for vaginal epithelia. Three historical staining techniques include Periodic 
Acid-Schiff (PAS) reagent, Lugol’s iodine, and Dane’s stain. PAS is used to visualize 
polysaccharides present in cells, commonly glycogen and glycoproteins. This staining technique is 
commonly used by pathologists during routine renal biopsy evaluation and determination of alveolar 
sarcoma [26]; however, this stain has been retired from forensic testing of vaginal epithelia, having 
exhibited no differentiating power between vaginal and rectal epithelial cell types [27]. Lugol’s iodine 
stain to detect glycogenated epithelial cells was once considered a reliable indicator of vaginal fluid. 
This was based on the belief that vaginal epithelial cells had a significantly higher glycogen content 
than other epithelial cell types [28,29]. Iodine present in the stain reacts with intra-cellular glycogen, 
producing a dark brown color [29] (Figure 1.1B). Further research revealed that (1) glycogen content 
varies widely during the menstrual cycle [30] and (2) epithelial cells from swabs of the glans penis 
and male urethral secretions contain similar glycogen levels [28,29]. As a result, Lugol’s test is no 
longer common practice for forensic analysis as the value of this technique has diminished. Dane’s 
stain (haematoxylin-phloxine-alcian) uses three dyes that preferentially stain mucopolysaccharides 
from prekeratin and keratin [31]. This technique differs from PAS and Lugol’s iodine in that it can 
distinguish skin epithelial cells, appearing bright red upon microscopic visualization, from 
vaginal/buccal cells which stain orange, based on the high presence of keratin found in skin. Using 
a modified Dane’s stain with methanol fixation, vaginal epithelia were able to be differentiated from 
buccal epithelia [32]. Although a promising solution to challenges encountered with PAS and Lugol’s 
iodine, limitations arise with the analysis of mixed sample types commonly encountered in sexual 
assault evidence.   
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The only accepted confirmatory test within forensic biology is the microscopic visualization 
of spermatozoa in semen. Spermatozoa are unique to semen and exhibit a distinct morphology in 
relation to other cell types, especially epithelial cells. Specifically, the head region contains nuclear 
DNA and is protected by the acrosomal cap, the location of digestive enzymes that break down the 
zona pellucida and assist in penetration of the female ovum. The midpiece connects the head region 
to the tail and contains numerous mitochondria. The most defining characteristic of spermatozoa is 
the tail region. The flagellated cell contains a microfilament that runs the length of the tail region, 
creating rhythmic contractions and forward motion. The histological staining of head and tail regions, 
in addition to the overall morphology of the cell, attribute to the confirmatory nature of this technique.  
The most commonly used histological stain is Kernechtrot-Picroindigocarmine (KPIC), also 
referred to as Christmas tree stain. KPIC uses a series of stains to differentially identify sperm cells 
from epithelial cells. Nuclear fast red dye stains the nuclear material of the head region and picric 
acid-indigocarmine stains the membrane and tail regions a blue-green color [33] (Figure 1.1C). 
Limitations to this technique arise due to the lack of standardization among interpretation guidelines 
within agencies. While there is a generally accepted scale for sperm scoring, subjectivity is 
introduced in the manner in which an analyst interprets the ratio of spermatozoa to epithelial cells. 
In addition, the major challenge faced by most examiners is not the judgement of whether a cell is a 
spermatozoon but rather to locate an intact cell. The severing of the head region from the tail region 
of the spermatozoa is not uncommon and is caused by many factors, such as analyst handling, 
spermicidal lubricants, and extreme temperatures. There are varying opinions in the field on whether 
a spermatozoon needs to be intact to prompt a positive identification. Furthermore, absence of 
spermatozoa in the male ejaculate can be due to hereditary, pathologic, or surgical reasons.  
The product Sperm Hy-Liter™ (Independent Forensics) utilizes a fluorescently labeled, 
human specific, monoclonal antibody that binds to sperm head proteins and further assists with the 
visualization of spermatozoa. Specifically, this commercial kit contains two separate fluorescent 
dyes. The first, 4’,6-diamidino-2-phenylindole (DAPI) stain is incorporated into nuclear material and 
is visualized with a DAPI compatible fluorescent filter. The second dye, green fluorescein 
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isothiocyanate (Alexa 488), is bound to a monoclonal antibody that targets protein antigen in the 
sperm nuclear membrane. With selective filters, dye components can be visualized separately 
(Figures 1.1D and 1.1E) or overlayed (Figure 1.1F), allowing for visualization of sperm cells in a 
dense vaginal epithelial sample. Due to the preferential binding of the antibody, this method is more 
sensitive and specific than traditional histological staining techniques [34]; however, a limitation to 
this method is the breakdown of sperm cells over time [35]. The reporting of a positive result is based 
on the occurrence of a binding event between the paratope of the antibody and the epitope of the 
sperm head proteins. Within the Sperm Hy-Liter™ procedure, the reducing agent dithiothreitol (DTT) 
is applied to the sample and functions to make the spermatozoon cell membrane more permeable 
to staining. As spermatozoa degrade, the specific epitope present on the cell surface may undergo 
a conformational change an impede antibody binding. This lack of binding poses as a limitation to 
basing a confirmatory technique off of the detection of cellular components alone. Furthermore, 
depending upon the severity of degradation, the DTT can potentially lyse cell membranes instead 
of increasing permeability. 
In summary, this classification of serological testing contains the only accepted confirmatory 
technique for body fluid identification. Furthermore, in regard to semen identification, histological 
staining of cellular material is not applicable in instances for suspects that have undergone a 
vasectomy surgical procedure or those that suffer from aspermia. Histological staining has historical 
significance within the field of forensic biology but has largely been replaced by enzymatic and 




Figure 1.1. Histological stains and microscopic visualization for body fluid identification. (A) 
Takayama crystal formation of peripheral blood. (B) Lugol’s iodine stain of a vaginal smear. (C) 
Kernechtrot-Picroindigocarmine stain of a vaginal swab containing spermatozoa. Spermatozoa 
visualized using Sperm Hy-Liter™ with fluorescent microscopy and the (D) DAPI filter displaying 
sperm and epithelial cells, (E) FTIC filter displaying spermatozoa, and (F) filter overlay displaying 
sperm and epithelia nuclei. © 2021 by Catherine Brown.  
1.2.4 Enzymatic Assays for Body Fluid Identification 
Enzymatic assays rely on protein form and function to remain intact in order for the test to 
be carried out successfully. In general, protein enzymes within a biological fluid are mixed with a 
cognate substrate. Through the chemical modification of the substrate, an applied dye compound 
will bind to the modified substrate, resulting in a visible color change. Perhaps the most widely 
accepted presumptive test within the enzymatic classification is the acid phosphatase test for the 
detection of seminal fluid, which was proposed in the early 1950s [36]. Prostatic acid phosphatase 
is produced in the prostate and is currently evaluated as a diagnostic marker for prostate cancer. 
Its physiological function is to cleave the protein semenogelin, resulting in the liquefaction of semen 
and creating a more conducive environment for sperm motility within the female reproductive tract. 
Referred to as the AP Spot Test, a seminal fluid stain is subjected to a reagent containing alpha 
naphthyl phosphate. The acid phosphatase protein cleaves the phosphate functional group of alpha 
naphthyl phosphate, resulting in alpha naphthol. A diazonium salt, such as o-dianiside (Fast Blue 
B), is applied and binds to alpha naphthol, producing a purple color change. This mechanism 
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occurs rapidly, with samples presumptively positive for seminal fluid within 60 seconds of reagent 
application. However, isoforms of acid phosphatase are present in vaginal secretions [37] and 
serum [15] (Figure 1.2). Although the number of false positives is relatively high, the use of AP 
Spot Test has historically been presumptive in nature [38] and is often performed as a quick screen 
for sexual assault evidence prior to sperm scoring.  
 
Figure 1.2. Positive experimental results of AP Spot Test on a (A) positive control swab containing 
semen diluted 2-fold measured at 10 seconds, (B) a vaginal swab containing semen diluted 1,000-
fold measured at 45 seconds, and (C) a semen-free vaginal swab measured at 45 seconds. © 2021 
by Catherine Brown. 
Similarly, saliva identification relies heavily on the detection of amylase. Three classes of 
amylase have been characterized, with alpha amylase being of interest to forensic investigations. 
The isoenzyme salivary alpha amylase is produced in the parotid and submandibular glands and 
is responsible for the breakdown of long-chain carbohydrates. Examples of enzymatic assays for 
saliva detection are the starch iodine diffusion gel and commercial assays such as SALIgAE® 
(Abacus Diagnostics) and Phadebas® Amylase Test (Phadebas®). For starch iodine diffusion gels, 
agarose gel is embedded with starch molecules which are subsequently cleaved by amylase 
present in a sample. When stained with iodine, intact starch will turn blue, showing amylase enzyme 
activity by the absence of blue color (Figure 1.3). Similarly, SALIgAE® and Phadebas® use dye-
labeled starch molecules, and when cleaved by amylase, the dye is released, and a color change 
is observed. The specificity of these tests is poor, as they will react with any type amylase, such as 
pancreatic alpha amylase or beta amylase in bacteria, producing a high false positive rate. For 
example, RSID™-Saliva (an antibody-based assay discussed in the next section) and SALIgAE® 
have been shown to cross-react with urine, breast milk, and feces [39]. A comparison of the three 
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enzymatic methods was performed, with a modified starch iodine test that incorporated 
centrifugation in absence of agarose gel. The sensitivity and specificity of the three methods was 
assessed in addition to a series of mixed source samples and casework-type samples. It was 
concluded that Phadebas® Amylase Test performed with the greatest sensitivity, detecting down to 
a 200-fold dilution of human saliva [40].  
Enzymatic assays rely largely on color-based interpretation of results. Although it may be 
fairly obvious with concentrated samples, the ability to visualize a color change with trace samples 
is less than straightforward. Furthermore, with the testing of mixed source samples, the presence 
of a non-target matrix such as blood can impede the visualization of the necessary color to interpret 
a positive result. For example, the SALIgAE® assay is interpreted based on the change of the 
reagent from clear to yellow. Even with dilute blood samples containing saliva, the positive color 
change can appear more orange in nature.   
 
Figure 1.3. Experimental results of a starch diffusion gel depicting (C1) neat saliva, (C2) negative 
control, (B1) saliva diluted 10-fold, (B2) probiotic yogurt, (B3) triple hop India pale ale style beer, 
and (A4) human breast milk. © 2021 by Catherine Brown. 
1.2.5 Antibody Assays for Body Fluid Identification 
The most widely employed type of test system in operational laboratories are the antibody-
based assays. There is a multitude of commercially available assays on the market, many of which 
achieve greater specificity in comparison with the colorimetric and enzymatic assays described 
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above. The theory behind these commercial assays is centered upon the binding events that occur 
between an antibody and its complementary antigen [15].  
The production of antibodies begins with introducing a foreign antigen to a host organism, 
such as a rabbit, to stimulate an adaptive immune response. The foreign antigen serves as the 
target of the immunological response. The host organism begins producing antibody-forming cells, 
which can be isolated and cultured. As cells begin to divide and increase antibody production, the 
antibodies can be subsequently isolated for use in exogenous assays [41]. Antibodies that are 
capable of binding to a multivalent antigen are referred to as polyclonal antibodies. In comparison, 
antibodies that bind to a single epitope are defined as monoclonal antibodies. Polyclonal antibodies 
display stronger activity because several epitopes can be recognized for a single binding event. 
However, monoclonal antibodies are more specific.  
Antibody-based assays, either in the form of an enzyme-linked immunosorbent assay 
(ELISA) or an immunochromatographic assay, employ a series of dye-labeled mono- or polyclonal 
antibodies. For ELISA tests, antigen is introduced to wells coated with antibody. Once bound, dye-
labeled antibody conjugate is added to create a sandwich complex. Reagents are then added to 
cause a color change in wells containing dye-labeled antibody in the sandwich complex, which is 
read by a spectrophotometer. ELISA testing has largely been replaced with the use of 
immunochromatographic assays, also referred to as lateral flow assays. Simply, a liquid sample is 
introduced to the sample well of a cassette, where dye-labeled antibody present will bind target 
antigen in the fluid sample. As the sample migrates down the membrane, immobilized antibody in 
the test region of the cassette will bind, creating the sandwich complex similar to that of an ELISA. 
Sample well antibodies will continue migrating to the control region of the membrane and interact 
with immobilized antiglobulin. The control zone will exhibit a positive line because the antiglobulin 
will bind to the dye-labeled antibody that originated in the sample well whether antigen is present 
or not [15] (Figure 1.4). A positive identification is made by the presence of a colored line in the 
test zone and the control zone of the viewing window. A negative result is recorded when only a 
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colored line is observed at the control zone. An invalid result entails the absence of a colored line 
in the control zone, indicating the test should be repeated.  
Commercial assays from various manufacturers, such as Independent Forensics of Illinois 
[42–44], Abacus Diagnostics [45,46], and Seratec [47–49], are currently on the market for the 
detection of peripheral blood, menstrual blood, saliva, semen, and urine. Regardless of 
manufacturer, a similar construction to the lateral flow assay is employed, but they vary in target 
antigen and antibody. For example, RSID™-Semen (Independent Forensics of Illinois) targets the 
protein semenogelin for seminal fluid identification, whereas ABAcard® p30 (Abacus Diagnostics) 
and PSA Semiquant (Seratec®) both target the protein prostate specific antigen. In general, dye-
labeled monoclonal antibodies will be present in the sample well and unlabeled monoclonal 
antibodies will be immobilized in the test zone. Manufacturers have opted for the use of monoclonal 
antibodies to increase the specificity of the assay.  
Lateral flow assays have proven rapid and simple to perform for screening purposes; 
however, they have a limited sensitivity range. False negative results can occur if too much target 
antigen is introduced into the sample well. This phenomenon, referred to as the high-dose hook 
effect, results when excess target antigen migrates along the membrane, resulting in competitive 
binding with bound antibody-antigen complexes at the test zone. The excess antigen binds to the 
immobilized antibody, preventing the formation of a sandwich complex. To avoid the high-dose 
hook effect, the sample should be diluted to reduce the amount of antigen applied to the membrane. 
Conversely, the lower sensitivity limit of lateral flow assays has been well documented. For 
example, a validation study of RSID™-Semen reports a sensitivity limit of 2.5 nL of semen [50], with 
a similar study reporting 50 nL of saliva as a lower limit of detection for RSID™-Saliva [51]. 
Similar to enzyme-based tests, antibody-based assays are categorized as presumptive 
because the binding specificity and avidity are not absolute, even with monoclonal antibodies. The 
reading and reporting of results create instances of analyst subjectivity when interpreting color 
change, particularly with low-level samples. Although these assays are marketed as confirmatory 
tests, they are prone to high false positive rates. For example, an internal assessment of lateral 
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flow assays for seminal fluid identification was previously performed. Semen-free vaginal swabs 
were tested using RSID™-Semen, ABAcard® p30, and PSA Semiquant. Of the 100 samples tested, 
RSID™-Semen returned a false positive rate for 6% and both ABAcard® p30 and PSA Semiquant 
demonstrated a false positive rate for 17% [52]. False positive reactions have also been reported 
for extracts recovered from condoms when evaluated with PSA Semiquant [53] and extracts 
subjected to topical lubricants with ABAcard® p30 [54]. Furthermore, when evaluated in absence 
of body fluid, immunochromatographic assays have been shown to display false positives in the 
presence of organic acids, lending insight into the mechanism behind which dyes are bound to 
sample well antibodies [55]. Therefore, reliance on antibody-binding as a confirmatory assay is not 
supported by the literature and forensic analysts should use caution in reporting of results.  
In summary, traditional techniques for body fluid identification lend value to forensic 
investigations but suffer from numerous limitations that have suppressed the progression of the 
field as a whole. Regardless of test classification selected for serological screening, perhaps the 
greatest limitation is the lack of multiplex testing. All of the previously described classifications are 
single-plex assays. Furthermore, there is an obvious lack of confirmatory tests available for target 
fluids or lack of tests in general for fluids such as vaginal/menstrual fluid. It is for these reasons that 
operational laboratories have shifted to a “direct to DNA” workflow, where serological screening is 
omitted in favor of more sensitive genetic typing chemistries. For more than two decades, the 
forensic community has focused on improving the sensitivity and robustness of DNA profiling. While 
advances have made it possible to individualize biological traces on challenging types of 
evidentiary material, DNA alone does not readily indicate the body fluid source from which it was 
extracted. Serological testing to identify the body fluid from which a DNA profile has been 
generated, however, can provide vital contextual information to facilitate a successful prosecution. 
While this approach has a number of advantages, serological testing is especially important when 
the item of evidence in question (e.g., a towel or bedding) does not readily lend itself to an 
interpretation of likely contact to the same degree as an intimate swab or underwear where the 




Figure 1.4. Schematic of a lateral flow assay, depicting a (A) positive identification, (B) negative 
identification, and (C) invalid test. Blue diamond represents target antigen. © 2021 by Catherine 
Brown. 
1.3 Next Generation Techniques for Body Fluid Identification 
Serology testing, at one point in time, was heavily regarded as a means of not only 
identifying a sample but individualizing a biological stain. With the advent of PCR amplification and 
DNA profiling, the novelty of serology screening began to fade. Practitioners, researchers, and 
academics have exponentially grown the capabilities of genetic typing since its first use in a criminal 
investigation in the mid-1980s. DNA profiling was propelled into the public eye and swiftly exceeded 
expectations as to the information attainable. However, this rapid change in the field of forensic 
biology left advancements in serology testing as an afterthought. With the ability to deconvolute 
profiles originating from multiple contributors, generate partial profiles from DNA quantities less 
than those present in a single cell nucleus, or elucidate phenotypic characteristics from SNP 
locations, the sensitivity limits of modern genetic typing have remained unchallenged. Given the 
substantial limitations characteristic of traditional serological procedures, several next generation 
approaches have been proposed and evaluated by researchers. DNA methylation, RNA assays, 
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Raman spectroscopy, and proteomic techniques seek to advance serological testing to sensitivity 
and specificity levels currently achievable with modern genetic typing chemistries.  
1.3.1 DNA Methylation Assays for Body Fluid Identification 
Epigenetics is the study of changes in gene expression that result from modifications other 
than those made to the DNA sequence. These changes can be categorized as those made to DNA 
nitrogenous bases or those made to histone proteins after the process of translation [56]. For the 
purposes of this section, DNA base modifications will be discussed, specifically cytosine/5’-CpG-3’ 
methylation or CpG sites. There are approximately 30,000 CpG sites within the human genome 
[57]. At these locations, methyl groups are added to the 5’ carbon position on cytosine rings and 
are adjacently followed by a guanine base pair. In vivo, this process is carried out by the enzyme 
methyltransferase. Modifications occur largely in promotor regions upstream of target gene 
sequences. In the event a promoter region becomes methylated, the region becomes  less 
accessible by transcription factors and gene transcription is reduced or halted. Therefore, the 
mapping of DNA methylation regions can provide useful information, not only for human disease, 
but for forensic purposes. Targeting specific gene regions and mapping the presence or absence 
of DNA methylation has the ability to generate a methylation fingerprint for body fluid identification.  
 The most commonly employed method for determining DNA methylation patterns is with 
the use of bisulfite conversion, a chemical modification made to unmethylated cytosine residues 
[58]. With the addition of bisulfite, all unmethylated cytosine residues are replaced with uracil. When 
amplified using PCR, resulting amplicons will vary depending on the presence or absence of 
methylation. This change in sequence is analyzed and compared among fluids and tissues to 
determine methylation regions suitable for identification. Methylation sequences can be analyzed 
using a variety of techniques such as methylation-sensitive single-base extension assay 
(SNaPshot™), pyrosequencing, methylation specific PCR, and high resolution melt (HRM) 
analysis. Tissue-associated differences in the form of hypo- and hypermethylated regions are 
mapped and compared between target fluids for determination of methylation-specific patterns.  
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The first use of DNA methylation as a strategy for body fluid identification was reported a 
decade ago [59]. Restriction enzyme PCR targeting methylation regions for blood, semen, saliva, 
and skin identification was performed. Original research has focused on evaluating a single fluid or 
amplifying a single target with the use of pyrosequencing. This procedure describes a sequence 
by synthesis technique. Simply, a chemiluminescent signal is produced after the addition of each 
nucleotide during sequencing. Therefore, the signal measured is proportional to the number of 
nucleotide bases added [60]. Using this technique, procedures for the identification of blood, 
semen, saliva, and skin have been developed and validated [58,61]. The robustness of epigenetic 
profiling was illustrated by the analysis of samples with low input DNA, the presence of amplification 
inhibitors, and aged/degraded samples. More recently, with the use of microarray technology, 150 
candidate markers for blood, saliva, semen, vaginal fluid, and menstrual blood identification have 
been described. Through more rigorous experimentation, a total of nine markers were validated for 
use and assay sensitivity rivaled that of contemporary STR genetic analyses [62]. In a similar study 
that utilized restriction enzyme PCR, eight CpG markers were identified and evaluated 
simultaneously with two control regions [63]. To date, a multiplex assay for blood, semen, saliva, 
and vaginal fluid has been developed with a single PCR procedure [64]. Upon comparison with 
previously developed single-plex assays, the multiplex assay produced comparable methylation 
trends.  
Perhaps one of the most promising aspects of epigenetic analysis is the potential 
differentiation between peripheral and menstrual blood sources. The embryonal fyn-associated 
substrate (EFS) gene, which encodes for a scaffolding protein linked to immune function, was 
demonstrated with bisulfite pyrosequencing to have specific methylation patterns for peripheral 
blood when evaluated in a large population [65]. In a similar analysis of 11 CpG sites, the marker 
BLU2 encoded by the gene C16orf54, was identified as a discriminatory marker between peripheral 
and menstrual blood [66]. In regard to assay sensitivity, an original study that employed 
pyrosequencing illustrated promising results for blood, semen, and saliva; however, an input of 10 
ng of DNA was necessary to execute the procedure [67]. The same research group continued 
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refining the procedure, opting for HRM analysis, citing 1 ng of DNA input to be sufficient for 
successful analysis [61].  
Advantages to exploring DNA methylation expression patterns for serological identification 
include its ability to multiplex target fluids, its high sensitivity and specificity, and its compatibility 
with existing DNA-based methods. Nevertheless, DNA methylation patterns exhibit high rates of 
variability between sexes, individuals, and populations. Furthermore, forensic evidence is more 
often than not in some form of degraded state upon the start of analysis, with DNA loss or 
fragmentation being of concern for the optimization and validation of assays for body fluid 
identification. Additional advancements in assay sensitivity and analysis of authentic samples 
would be beneficial for future implementation in operational laboratories.  
1.3.2 RNA Assays for Body Fluid Identification 
In a similar fashion to differentially methylated regions of DNA typed for epigenetic 
identification, gene expression patterns have been targeted for messenger RNA (mRNA) and micro 
RNA (miRNA) assays for body fluid identification. Both forms of RNA assay seek to detect gene 
transcripts that display specificity to a cell or tissue type. RNA serves as the molecular intermediate 
for the translation of DNA into protein and is formed during the process of transcription. This 
process is catalyzed by RNA polymerase, the enzyme responsible for reading the DNA template 
and matching complementary nucleotides to form mRNA and other small RNAs. The transcription 
unit, or the stretch of DNA template that spans from the promoter region to the terminator sequence, 
produces a single RNA molecule. Post-transcription, the process of alternative splicing removes 
interfering introns and pieces together the desired exons for the generation of a unique RNA 
transcript fit for translation.  
1.3.2.1 Messenger RNA Profiling 
mRNA profiling is performed by analyzing terminally differentiated cells, where gene 
expression is developmentally regulated. By observing transcriptionally silent cells versus actively 
transcribed cells, a pattern of gene expression unique to a group of cells is established. With body 
fluids containing a mosaic of cell mixtures and secretions, multiple gene expression patterns and 
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associated mRNA markers can be exploited for the detection and identification of such fluids. The 
use of mRNA profiling for body fluid identification purposes was first reported in 2003, with a proof 
of concept study developed and candidate genes proposed for saliva identification [68]. It was 
demonstrated that sufficient quantities of total RNA could be isolated from cells, especially dried 
stains that had been solubilized, with mRNA measured through the detection of housekeeping 
genes such as GAPDH. This original work was further developed into a multiplex assay for the 
identification of blood, semen, saliva, and vaginal fluid, with each fluid characterized by two genes 
[69]. Gene transcripts for menstrual blood were subsequently added and an interpretation strategy 
was proposed to illustrate the specificity of each mRNA marker [70]].  
With the promising results of this methodology, a series of collaborative studies organized 
by the European DNA Profiling Group (EDNAP) was initiated to further demonstrate the robustness, 
reliability, and sensitivity of the technique. For each study, participating laboratories could perform 
either an RNA extraction or an RNA/DNA co-extraction on neat stains, diluted stains, and mock 
casework samples of human and nonhuman origin. All of the mRNA panels described herein were 
simultaneously evaluated with markers for housekeeping genes. The first study focused on blood 
identification and employed two mRNA multiplexes: a duplex targeting genes for hemoglobin alpha 
and hemoglobin beta, and a pentaplex targeting genes for ALAS2, CD3G, ANK1, SPTB, and PBGD 
[71]. The following study tested the methodology for the identification of saliva and semen [72]. A 
saliva triplex included genes for histatin-3, statherin, and mucin-7. A semen pentaplex included 
genes for protamine 1 and 2, prostate specific antigen, semenogelin 1, and transglutaminase 4. 
Continuous collaborations then focused on vaginal secretions and menstrual blood [73]. Two triplex 
panels were selected for menstrual blood: the first containing genes for matrix metalloproteinase 
7, 10, and 11, and the second triplex targeting Msh homobox 1, LEFTY2, and SFRP4. Vaginal fluid 
identification was based on two triplexes. The first targeting mucin-4, myozenin-1, and CYP2B7P. 
Interestingly, the second triplex targeted genes of Lactobacillus bacteria (Ljen, Lcris, and Lgas), 
the most abundant vaginal bacteria in the female reproductive tract. A similar panel of matrix 
metalloproteinases was evaluated over the course of the female uterine cycle, confirming the lack 
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of specificity needed to discriminate with vaginal fluid and that target abundance changes over a 
typical menstrual cycle [74]. The final collaborative study demonstrated the use of mRNA profiling 
for the detection of skin and contact traces [75]. Of the eight gene markers evaluated, two genes 
were consistently identified. The inconsistency of detection is likely attributed to the low quantities 
of genetic material deposited by shed skin cells.   
Original research utilized reverse transcription-polymerase chain reaction (RT-PCR) 
procedures for method development [68–70]. Alternative methods using Real-Time PCR [76,77] 
and high resolution melt (HRM) analysis [78] were also proposed during early stages of method 
development. More recently, a digital gene expression method utilizing solution hybridization of 
NanoString® probes was explored [79]. Although RT-PCR is capable of producing informative 
quantitative data, assays are limited to the number of targets that can be assessed. Digital gene 
expression methods have the ability to count the number of individual transcripts for each sample 
and mimics the use of next generation sequencing for genetic analysis. This methodology was 
developed to assess the ability of predicting activity level of a perpetrator based on the quantity of 
sample present through the use of likelihood ratio statistical calculations. A custom set of genes 
was created: 23 gene targets for the identification of blood, menstrual blood, saliva, semen, skin, 
and vaginal secretions as well as an additional 10 targets for housekeeping genes. Authors note 
that saliva biomarkers exhibited poor specificity in relation to previously conducted work, but the 
remainder of targets performed as expected and exhibited high specificity and sensitivity. This 
method development preceded the use of massively parallel sequencing [80] and SNP 
characterization [81]. Reported read counts of mRNA markers for target and non-target fluids 
provided additional insight into the specificity of biomarkers selected in previous studies. Additional 
future directions for this methodology comprise the inclusion of other RNA products, such as 
circular RNAs [82], into multiplex panels to further investigate the sensitivity and specificity 
achieved with mRNA typing.  
In summary, the use of mRNA profiling for forensic purposes has been well developed and 
evaluated. Opposition to implementing this technology in operational laboratories remain from the 
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fear of mRNA stability, particularly in challenging sample types. However, the quality and quantity 
of RNA has been demonstrated in both aged samples and samples subjected to environmental 
insult [83,84].    
1.3.2.2 Micro RNA Profiling 
Comparably, miRNA are the small non-coding RNA sequences that attenuate protein 
translation and have been targeted as viable biomarkers for body fluid identification, but to a lesser 
extent than mRNA profiling. Given their inherent size (approximately 20-25 bases in length), 
miRNAs emerged as an attractive marker for the identification of highly degraded body fluids. A 
majority of miRNA transcripts were selected based on their function within a specific tissue. 
However, these markers proved challenging to type using traditional primer binding strategies given 
their shortened length. Overall, three categories of methods are prevalent in the literature: 
microarray hybridization methods, quantitative reverse transcription PCR, and RNA sequencing. 
The combination of these techniques for miRNA profiling has led to a series of inconsistent results 
reported among research groups [85].  
Original research into their use for forensic purposes was reported in 2009, with nine 
candidate miRNAs for blood, semen, saliva, vaginal secretions, and menstrual blood identified from 
a pool of 452 markers through the use of RT-PCR [86]. When evaluated against 21 tissue types, 
the panel exhibited high specificity and potential for future method development. A similar study, 
utilizing quantitative PCR, confirmed miRNA markers for peripheral blood and semen but described 
a lack of support for candidate markers for saliva, vaginal fluid, and menstrual blood [87]. 
Conversely, a separate research group identified and validated a proof of concept triplex of markers 
for both blood and saliva detection [88].  
Research data presented for mRNA followed a natural evolution and build in regard to 
achievements and application. The same cannot be said for miRNA profiling. Original 
methodologies present conflicting data on the ability to characterize forensically relevant body 
fluids, and with large amounts of miRNA markers to evaluate and multiple methodologies 
performed for analysis, this area lacks a clear direction. In order to elucidate a more reliable path 
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forward, researchers turned to statistical modeling of data. A linear regression model for the 
identification of menstrual blood was generated [89]. Although trained and tested with a limited 
sample set, the model produced accurate identifications. But perhaps the most interesting result of 
this study was the reported limit of detection. The total RNA quantity for the proposed methodology 
was measured to be 50 pg for menstrual blood analysis, whereas comparative mRNA research 
performed at this time, reported an input of 5 ng of total RNA [89]. Apart from the first use of miRNA 
profiling [86], a full panel of biomarkers underwent rigorous experimentation prior to presenting 
candidate selections. From a pool of 1,700 miRNAs, a preliminary panel of 203 markers were 
selected for use in a microarray against blood, semen, saliva, and vaginal fluid. Once the 
preliminary panel was paired down, a set of eight miRNA targets were proposed as candidates: 
miR-484 and miR-182 for blood, miR-223 and miR-145 for saliva, miR-2392 and miR-3197 for 
semen, and miR-1260b and miR-654-5p for vaginal secretions [90].  
More recently, statistical decision making has been continuously applied on validated 
panels of miRNA markers and additional interpretation strategies in normalizing data to 
housekeeping genes has been proposed [91–94]. Using these strategies, the greatest amount of 
body fluid matrices (blood, semen, saliva, vaginal fluid, menstrual blood, urine, feces, and sweat) 
have been successfully sequenced at quantities consistent with low-level forensic evidence [92], 
with authors noting interference in sequence annotations due to bacterial presence in certain fluids. 
A notable benefit of miRNA profiling is the ability to identify markers from DNA extracts, an attractive 
quality for caseworking laboratories seeking to streamline sample preparation procedures from 
commercially available DNA extraction kits [95].  
Although research strongly supports the use of miRNA profiling for the identification of 
blood and semen, there is a lack of evidence encouraging its use for vaginal secretions and 
menstrual blood. There is conflicted data presented on the consistency of saliva miRNA marker 
specificity. In regard to data analysis, miRNA profiling does not lend to straightforward interpretation 
[93]. Furthermore, the stability of miRNA markers is affected by a myriad of factors, such as 
temperature, changes in pH, and radiation [85]. Disease state and the function of miRNA in 
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proliferation and inflammation have been well documented [96,97], illustrating that miRNA 
expression is not static within the human body. In conclusion, miRNA profiling requires 
supplementary research to provide a clear and convincing model for use as an alternative means 
for serological screening. 
1.3.3 Raman Spectroscopy for Body Fluid Identification  
Spectroscopy is a technique that measures the interaction between matter and radiation 
to elucidate physical structure at the molecular or atomic level. There are many different types of 
spectroscopy, each with a unique application and can be distinguished based on the interactions 
that take place. This section will focus specifically on Raman spectroscopy. This type of 
spectroscopy stems from inelastic Raman scattering which occurs when the matrix of interest is 
excited with a high-powered laser, causing the vibrational and rotational energies of the molecules 
to shift [98]. A photon beam is used to excite a molecule into a virtual energy state. The photon 
emitted from the excited molecule will be measured at a higher or lower energy state than the 
photon used to initiate excitement. This light scattering event results in different rotational and 
vibrational states of the atoms and molecules present. The emitted photon, therefore, shifts to a 
different frequency. The vibrational signature, or the specific change in energy, of the molecules 
present is recorded and used to identify the material. This technique requires minimal to no sample 
preparation and is nondestructive in nature; however, the target matrix must be concentrated in 
order to produce a strong vibrational spectrum. 
 In the field of forensic science, Raman spectroscopy has longstanding use for applications 
in drug chemistry [99,100], paint and ink analysis [101,102], and the examination of trace evidence 
[103,104]. For serological purposes, this next generation technique demonstrates gains in 
specificity when considered alongside traditional colorimetric, enzymatic, and antibody-based 
assays. The Raman spectra produced for forensically relevant body fluids is determined by the 
entire molecular composition of the specific fluid. Original research initiatives focused on using 
Raman spectroscopy to generate vibrational signatures of single source body fluids. It was 
hypothesized that the spectra produced would reflect the unique composition and complexity of 
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each fluid and serve as a novel tool with greater discriminatory power than historical techniques. 
Promising results were obtained from preliminary studies containing limited sample sizes, with 
experiments performed under highly controlled laboratory conditions. With the successful 
characterization of molecular components consistent with human semen, blood, saliva, vaginal fluid 
and sweat, researchers saw promise in the use of Raman spectroscopy for more challenging 
sample types and envisioned robust reporting with advanced statistical calculations [105,106]. 
When focusing specifically on human blood characterization, early studies reported the ability to 
make a positive identification of human blood that had been diluted 250-fold; however, the Raman 
signatures produced varied among individuals and even within samples supplied by a single 
individual [107].  
 More recent advancements have been illustrated through the analysis of samples that 
more closely resemble those collected from a crime scene. Although capable of detecting 
components of human blood and semen from various substrates, sensitivity was shown to 
decrease in relation to previous studies, with human blood detected at a 100-fold dilution. Raman 
spectroscopic techniques were unable to identify signatures of human blood from laundered 
substrates but were demonstrated to be unaffected by evidence treated with luminol [108]. 
 Raman signatures for human blood have produced consistent spectral components of 
hemoglobin, heme, and tryptophan, with multiple studies demonstrating the ability to discriminate 
human and nonhuman blood sources [109–111]. Components used for semen identification have 
been reported to display vibrational signatures consistent with acid phosphatase, citric and lactic 
acid, urea, and zinc [112,113]. The use of non-specific signatures, such as those of lactic acid, 
decrease the confidence of an identification, based on endogenous levels of non-specific 
signatures in various fluids and tissues. However, a more recent study was successful in detection 
signatures indicative of prostate specific antigen. This protein is found in high concentrations in 
semen, with low concentrations in serum and male urine, both of which have the potential to 
produce a false positive result. It was successfully demonstrated that the detection of prostate 
specific antigen using Raman spectroscopy can eliminate a false positive detection from male urine 
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when simultaneously assessed with dilute semen samples [114]. Characteristic components of 
vaginal fluid, saliva, and sweat have been reported [113], but limited research as to the extent of 
substrate interference and contamination on the ability to form an accurate identification of these 
fluids has been conducted.  
With the development of portable Raman systems, the use of this technology directly at a 
crime scene allows for rapid sample analysis. Traditional screening techniques for suspected blood 
stains, such as the use of leucomalachite green, can damage genetic material [115]. Advantages 
of screening with Raman spectroscopy are the technique is nondestructive and it maintains the 
integrity of the evidence for additional testing. The success of portable Raman spectroscopic 
analysis has been demonstrated for both human and nonhuman blood samples, in addition to 
positively characterizing a 3 month old stain [109].  
 Perhaps the most alluring attribute for the use of Raman spectroscopy for body fluid 
identification is the ability to use advanced data analysis tools to estimate error rates. The field of 
forensic science has been scrutinized on multiple accounts in regard to the accuracy and reliability 
of testing performed. As such, to determine if a methodology is valid in federal court, the procedure 
must not only have been tested, but potential error rates should be stated [116]. Chemometrics 
applies statistical theories to large and complex data sets [117]. For example, it was demonstrated 
that differentiation of five body fluids can be achieved with the use of interval partial least squares 
discriminant analysis (iPLSDA) [113]. An important aspect of this study involved the separation of 
datasets into those used for calibration and those used for validation. Similar practices are utilized 
for determining type I and type II error rates for genetic typing method validation in operational 
laboratories. More recently, a detection algorithm was successfully applied to the characterization 
of semen in the presence of substrate interferences [118]. This study sought to address one of the 
main limitations of Raman spectroscopy for body fluid identification. Substrates can cause 
interference signatures during evaluation, but given trace level sample analysis, signatures can be 
sufficiently more intense and mask those of the fluid components.  
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As such, limitations to Raman spectroscopic analysis of body fluid evidence stem from the 
inability to completely remove background interferences caused by substrates and sensitivity 
constraints caused by low-level samples. Furthermore, given the inherent complexity of biological 
matrices, advanced understanding of statistical theories is needed for deconvoluting components 
in a mixed source sample. Although the current research is supportive of this next generation 
technique, a majority of studies focus on human blood and semen identification, with a limited 
number of studies reporting on vaginal fluid [119], saliva [120], and sweat [121]. Nevertheless, this 
technique has been explored additionally for sex and race determination of forensic samples [122].  
 In summary, research into the use of Raman spectroscopy for body fluid identification has 
demonstrated a refined technique that is nondestructive, rapid, and confirmatory in nature. With 
the advent of portable instrumentation, this technique is an attractive tool for screening of biological 
material at a crime scene.    
1.3.4 Proteomic Assays for Body Fluid Identification 
 The final next generation serological technique is the use of proteomic assays and will be 
the focus of research disseminated in later chapters. Proteomics is the large-scale study of the 
proteome and protein expression. It describes not just a single technique, but a family of scientific 
approaches that exploit protein structure and function for the purpose of further elucidating the 
enigma that is the human proteome. Simply, proteins are an attractive diagnostic marker because 
they represent intermediate phenotypes for disease and illustrate the effect of non-genetic risk 
factors on cellular function [123]. This concept is adopted for use in forensic biology. Forensic 
proteomics uses advanced analytical techniques, such as liquid chromatography and mass 
spectrometry, in combination with bioinformatics to analyze biological evidence. In addition to 
applications for historical and archeological investigations, proteomic techniques have been 
developed for use in the greater forensic biology workflow for the identification of body fluids, such 
as in cases of sexual assault and rape.  
Biological evidence is, more often than not, subjected to unfavorable conditions. These 
conditions can include both environmental in the literal sense, such as extended UV degradation 
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or excessive heat, or environmental in the biological sense. In regard to the latter, natural protein 
function within biological systems can result in endogenous degradation of other protein material. 
For example, the protein prostate specific antigen in seminal fluid functions by cleaving 
semenogelin isoforms, resulting in the seminal fluid matrix to lose its gel-like structure. Both 
prostate specific antigen and semenogelin are attractive protein targets for seminal fluid 
identification. However, certain serological screening assays rely on protein activity, and therefore 
a protein’s confirmational structure, for testing purposes. It would be prudent for serological 
identification to rely on protein presence more heavily, especially for degraded evidence. 
Proteomics is an attractive alternative to chemical and enzymatic assays because it can detect 
protein presence. Furthermore, with the inherent sensitivity of analytical techniques, proteomics 
has the ability to confirm protein presence based on molecular weight.  
As previously discussed, proteins are highly abundant within the human body and exhibit 
an immense variety of functions. Therefore, proteins and their peptide fragments were a natural 
target for advancing serological testing strategies from traditional activity-based and ligand binding 
assays. One of the main challenges of proteomics is correctly determining the amino acid sequence 
of a protein target, as many proteins can be composed of the same amino acids but in a different 
order, ultimately lending to their unique properties. Liquid chromatography-mass spectrometry 
provides the necessary structural and molecular weight information needed for accurate 
identifications.  
1.3.4.1 Theory of Modern Proteomic Techniques 
1.3.4.1.1 Protein Digestion and Sample Preparation 
 Intact protein identification is challenging given the inherent size of protein molecules. For 
example, prostate specific antigen in seminal fluid has a mass of 28,741 Daltons. In comparison to 
small molecule mass spectrometry utilized for alternative forensic applications, proteins can have 
a molecular weight one hundred times greater than that of a single drug molecule. In addition, 
proteins exhibit variable charge states, sequence variants, and post translational modifications that 
complicate mass spectral analysis. By cleaving large protein molecules into peptide fragments, 
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charge state variations can be controlled, and sequence specific information can be obtained 
through the use of bioinformatics. Ideal peptide targets can range between 8 to 25 amino acids in 
length. As opposed to intact protein identification, peptides ionize well, fragment in a predicable 
manner, and produce good chromatography.  
Protein digestion is comprised of 4 simple steps: denaturation, reduction, alkylation, and 
cleavage [124]. Denaturing agents can be used to compromise the quaternary, tertiary, and 
secondary structure of proteins, causing them to lose their native three-dimensional structure and 
expose amino acid side chains by breaking molecular interactions. Commonly utilized detergents, 
such as SDS, are not compatible with mass spectrometers. However, denaturing agents such as 
urea, trifluoroethanol, or guanidine thiocyanate compete for hydrogen bonding within the complex 
protein folds, resulting in exposure of amino acid side chains and subsequent linearization. While 
the protein is being denatured, bonds are simultaneously being reduced. A commonly utilized 
hydrophilic reducing agent is tris(2-carboxyethyl)phosphine (TCEP), selected for its solubility and 
stability in aqueous solutions at both acidic and alkaline pH. An SN2 nucleophilic substitution 
reaction occurs when TCEP is introduced to the sample. Denaturation and reduction of protein 
targets is necessary in order to ensure complete exposure for enzymatic digestion. Alkylation is 
performed in order to cap exposed and reactive cysteine thiol groups, preventing reformation of 
disulfide bonds or other non-specific reactions. Iodoacetamide is an irreversible alkylating agent 
commonly utilized during protein digestion processes. This compound causes rapid 
carboxymethylation of reduced cysteine residues preventing disulfide bond formation. The peptide 
sequence is then ready for cleavage, producing more manageable peptide fragments for analysis. 
Protease enzymes exhibit specificity with regard to amino acid cleavage sites. For example, the 
serine protease trypsin cleaves at the carboxylic junction of arginine and lysine residues, yielding 
predictable and specific peptide sequences. 
Following digestion, denaturation agents, salts, and unwanted matrix components are 
removed prior to analysis via liquid chromatography-mass spectrometry.  During peptide cleanup, 
solid phase extraction (SPE) employs a sorbent material that preferentially separates and removes 
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any unwanted compounds (Figure 1.5). A sorbent material made up of hydrocarbon chains is 
packed into cartridges. Simply, the sorbent is primed with an acidic organic solvent, which activates 
the functional groups present and removes any trapped air. The cartridge is then equilibrated using 
acidified water in order to maximize the sorbent’s interaction with the sample matrix. Next, the 
digested sample material is applied to the cartridge. Slowly, the sample passes over the sorbent 
material which retains target peptides. Then, the cartridge is washed to remove any unbound 
material from the sorbent, including residual reagents from digestion processes. Lastly, peptides 
are eluted from the sorbent bed with acidified organic solvents. The eluant can be directly injected 
into the liquid chromatograph to begin analysis or lyophilized for storage or concentration.   
 
Figure 1.5. Schematic depicting a solid phase extraction procedure for post-digestion cleanup. © 
2021 by Catherine Brown.   
1.3.4.1.2 Chromatographic Separation and Ionization 
Biological samples are subjected to separation through the use of liquid chromatography. 
Simply, liquid chromatography is the use of a liquid mobile phase to carry target species through a 
column containing a stationary phase (Figure 1.6). The target species will interact with the 
stationary phase differently than interferents or other target species. As mobile phase conditions 
change, the target species elute from the column based on preferential interactions. Liquid 
chromatography is the ideal separation method for proteins because it can analyze samples that 
span a wide range of analyte polarity in addition to capabilities of analyzing large molecular weight 
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species. In general, the mobile phase is continuously pumped through the liquid chromatograph. 
Pre-programmed mobile phase conditions, referred to as the mobile phase gradient, change over 
the course of a sample run time. For example, mobile phase starting conditions more closely 
resemble a high aqueous solvent, such as a 2% acetonitrile in water. Separation and elution from 
the analytical column occur as mobile phase conditions change, with a majority of protein material 
eluting at approximately 30% acetonitrile in water. Protein material that is not as strongly retained 
by interactions with the stationary phase of the analytical column will be carried out of the 
chromatograph by the mobile phase. Eluted material can either be directly detected or further 
fragmented in a mass spectrometer. The resulting chromatogram displays the elution sequence 
and amount of material present. Retention time is plotted on the x-axis and represents the time in 
which a specific analyte eluted from the analytical column. Intensity is represented on the y-axis. If 
a reference sample is available, retention time for compounds should occur within a designated 
amount of time.  
 
Figure 1.6. Schematic of a liquid chromatograph containing (A) mobile phase components, (B) 
mobile phase pumps and mixing chamber, (C) autosampler, (D) analytical column containing 
stationary phase, (E) detector, and (F) resulting chromatogram. © 2021 by Catherine Brown. 
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Multiple variables can be modified to optimize chromatographic separation. For example, 
mobile phase flow rate, solvent composition and pH modifiers, stationary phase composition, and 
column temperature are just a few factors that influence peak resolution, retention time and 
selectivity. Reverse phase liquid chromatography is well suited for protein separation. This mode 
of chromatography employs a water-based mobile phase and hydrocarbon stationary phase, such 
as octadecylsilyl (C18) or octylsilyl (C8) moieties. These moieties are bound to a silica support and 
intrude into the negative space of the analytical column to interact with analytes carried by the 
mobile phase. The column chemistry that ensues is fitting for the separation of compounds that are 
neutral, weakly acidic, and weakly basic. The retention of analytes to the stationary phase is 
dependent on the analyte’s hydrophobicity, and by extension, an analyte’s ionization state. Mobile 
phase is commonly supplemented with an ion pairing agent to control the retention of ionic analytes, 
as retention time is affected by the ionization state of an analyte.  
With continuing structural elucidation using mass spectrometry, eluted analytes must first 
be desolvated and ionized prior to entering the mass analyzer. The process of electrospray 
ionization (ESI) is commonly used to transfer eluate from the chromatograph into gas phase ions 
suitable for mass spectrometric analysis [125] (Figure 1.7). A transfer line carries chromatograph 
eluate into the ESI source, where the eluate is sprayed from a charged capillary as a fine aerosol 
mist into a heated chamber. Nebulization occurs as solvent is readily evaporated and droplets are 
formed. The potential difference applied to the capillary allows the droplets to reduce in size. As 
the radius of the drop decreases, the droplet charge remains constant and repulsion forces within 
the droplet increase. Eventually, the repulsion stress must be released, and droplets undergo 
droplet jet fission to produce small, charged particles. ESI is commonly employed in proteomics 
research because of its ability to produce multiply-charge ions. This inherent characteristic allows 
additional mass-to-charge ratio measurements to be made even with a mass analyzer that have a 
limited mass range [126]. Instrumental parameters that can be modified to reach optimal ionization 




Figure 1.7. Schematic depicting electrospray ionization and the interface between the liquid 
chromatograph and the mass spectrometer. Green arrows represent the drying gas. Blue circles 
represent the charged droplets as they reduce in size due to drying and jet fission forces. © 2021 
by Catherine Brown. 
1.3.4.1.3 Mass Spectrometry Instrumentation and Interpretation 
Within the last two decades, significant advances in mass spectrometry-based 
methodologies have expanded the capabilities and possibilities of scientific achievements. 
Parameters such as increased dynamic range and quantitative accuracy presented attractive 
qualities to disciplines such as clinical diagnostics and forensic science. Mass spectrometry as it 
applies to proteomics has assumed many forms based on the type of analyses conducted.  
In a broad sense, mass analysis is the separation and filtration of ions, from which the 
chemical form of a species, such as its structure and ionization potential, can be elucidated. This 
chemical form is represented by a mass spectrum or a plot that graphs signal abundance against 
mass-to-charge ratio (m/z). Three qualities are evaluated when selecting a specific mass analyzer: 
mass resolution, mass accuracy, and mass range. Mass resolution describes the ability of a mass 
analyzer to separate two adjacent masses and becomes an important property when coelution of 
target ions may exist. Mass accuracy illustrates the mass measurement recorded to that of the true 
mass of the target. And lastly, mass range defines the difference between the highest and lowest 
measurable m/z. There are several types of mass analyzers that exhibit fundamental differences, 
each with a desirable application in regard to proteomics.  
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Quadrupole mass analyzers, which are commonly selected for targeted proteomic 
analysis, function by filtering ions using electrostatic potentials and selecting ions based on m/z. 
The quadrupole is constructed out of four poles that are oriented to create a central channel down 
which charged ions can travel, where they are separated and filtered by electrostatic potentials 
applied to the four poles. An ion will carry a stable trajectory down the central channel if it oscillates 
within a narrow radius. On the contrary, a collisional trajectory occurs when an ion oscillates outside 
of the narrow radius, resulting in collision with the poles and ejection from the central channel. 
Quadrupole mass analyzers are popular given their low cost and uniform performance across a 
wide mass range; however, quadrupole mass analyzers have relatively poor mass resolution and, 
in relation to other mass analyzers, demonstrate a slower speed for scanning travelling ions.  
Time of flight mass analyzers exploit differences in kinetic energy to map flight paths and 
predict ion separation. This type of mass analyzer is attractive for discovery proteomics. Ion clusters 
are subjected to an accelerating voltage, where they are propelled into the flight tube. The time of 
flight for each ion cluster is measured from the onset of the accelerating voltage until clusters reach 
the detector at the end of the flight tube. The speed at which ions clusters travel through the flight 
tube is dependent on the m/z of the ion [127]. Although instrument calibration is more complex than 
a quadrupole mass analyzer, time of flight analyzers have the greatest mass range and fast ion 
scanning speeds.  
And lastly, ion trap mass analyzers rely on applied voltages to further group ions with a 
specific m/z. Ions that do not favor the applied voltage do not cluster and are propelled from the ion 
trap. In addition, because the ion trap is filled with an inert gas, additional fragmentation of selected 
ions can occur [128]. Because of this property, the use of ion trap mass analyzers is popular for 
top down proteomics. These types of mass analyzers display excellent mass resolution and 
sensitivity; however, they are easily saturated and produce unusual spectra if parameters are not 
properly configured.  
Mass analyzers can be combined in unique ways to increase ion filtration and improve 
qualities such as mass range and mass resolution. The goal of using multiple mass analyzers in a 
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single instrument is to gain additional structural information, achieve selectivity, and maximize 
sensitivity for quantitative analyses. Typical examples of mass analyzer combinations are triple 
quadrupole (i.e., two quadrupole analyzers separated by a collision cell) (Figure 1.8) and 
quadrupole time of flight. The use of multiple mass analyzers lends to the process of tandem mass 
spectrometry.   
 
Figure 1.8. Schematic of a triple quadrupole mass spectrometer for the detection of semenogelin 
2 peptide DVSQSSISFQIEK precursor and product ions. © 2021 by Catherine Brown. 
1.3.4.1.4 Proteomic Methodologies 
Once protein targets have been separated, it is important to consider the type of 
information desired from mass spectrometric analysis. Two main next generation proteomic 
methodologies include bottom up proteomics and top down proteomics. Bottom up proteomics 
describes the detection and identification of proteins that are first enzymatically digested into 
predictable peptide fragments. Protein material is subjected to a series of chemical modifications 
prior to identification. Denaturation, reduction, and proteolytic cleavage, with an enzyme such as 
trypsin, break complex protein domains into predictable peptide fragments suitable for mapping 
and targeted analysis. The retention of ionic species is achieved through the addition of ion pairing 
reagents, such as formic acid, into the mobile phase. 
Bottom up proteomics can be further divided into discovery or shotgun proteomics and 
targeted analysis [129]. Discovery proteomics is utilized for the unbiased scanning of peptide ions, 
with specific search parameters applied after data acquisition. This proteomic application earned 
its title from its use in discovering protein and peptide signatures and is often performed to generate 
a targeted ion selection list [130]. But in order to create a targeted list, a vast amount of data must 
first be collected and analyzed. The two most commonly used mass analyzer combinations for data 
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collection are quadrupole time of flight and ion trap mass analyzers. Quadrupole time of flight 
(QTOF) mass spectrometry is a popular analytical platform for discovery proteomics, given its mass 
accuracy and wide dynamic range (Figure 1.9). However, in comparison with other analytical 
platforms, the QTOF system lacks desirable resolution. To address the limitations of QTOF mass 
spectrometry, the Orbitrap analyzer was introduced. Similar to QTOF, the Orbitrap has a wide mass 
range, but also provides high mass resolution. A benefit of bottom up discovery proteomics is the 
limited amount of prior knowledge necessary for data interpretation. By scanning for and measuring 
the masses of precursor and subsequent product ions, a roadmap of related transitions can be 
generated.  
 
Figure 1.9. Schematic of a proteomic workflow with identification via QTOF. © 2021 by Catherine 
Brown. 
Targeted proteomics seeks to identify an analyte or multiple analytes through the use of a 
selective ion list [131,132]. Although sample preparation procedures are shared between shotgun 
and targeted proteomics, the analytical instrumentation differs. A triple quadrupole mass analyzer 
is commonly selected for targeted analysis. The first quadrupole is set up to selectively scan for a 
given precursor mass. In the second quadrupole, or collision cell, the precursor mass is subjected 
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to a charged gas, resulting in further fragmentation. The third quadrupole selectively scans for a 
specific product ion. Single reaction monitoring (SRM) or multiple reaction monitoring (MRM) are 
common targeted proteomic methods for determining the absolute and relative quantification of 
target analytes in a given sample. Isotopically-labeled peptide standards can be simultaneously 
assessed [133,134]. By comparing peak area responses of endogenous peptide fragments with 
those of peptide standards, a relative quantitation can be calculated [135].  
In comparison with bottom up proteomics, which identifies proteins that have been 
subjected to enzymatic cleavage, top down proteomics forgoes enzymatic cleavage [136,137]. This 
category of proteomics can be further classified by conducting intact protein analysis or peptidomic 
analysis, which describes the identification of low molecular weight proteins, naturally derived 
peptides, and truncated amino acid sequences of larger proteins [138]. With this type of proteomic 
analysis, full characterization of proteins can be achieved with increased sequence coverage 
because analysis is not limited to cleavage products. The eliminated laborious digestion procedures 
during sample preparation makes for streamlined and expedited sample analysis. Furthermore, 
post-translational modifications (PTMs) can remain intact and enrich data analysis.  
Similar to shotgun proteomics, Orbitrap analytical platforms are a popular selection for top 
down proteomic analyses. The fundamental construction of the ion trap mass analyzer provides 
the means for intrinsic fragmentation to occur. Although tryptic peptide analysis provides immense 
amounts of information from complex samples, the information remains limited to cleavage sites 
and the length of peptide fragments produced, resulting in some information to be ignored due to 
lack of unambiguous identification. This becomes mitigated with top down procedures and the 
migration from peptide-centered to a protein-centered interpretation.  
Regardless of methodology selected, peptides will fragment in a consistent manner once 
in a mass analyzer due to their repetitive monomer assembly. Peptides become protonated as they 
enter the ESI interface and are selected as precursor ions. Precursor ions are then fragmented into 
a variety of product ions as polypeptide backbone bonds are cleaved. Peptides are sequenced 
according to the bond cleavages that occur as they provide important structural information [139]. 
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The cleavage of peptide bonds between the carboxylic acid and amine functional groups of two 
adjacent amino acids generates product ions that are the sum of their amino acid composition 
residue masses. With this type of breakage, product ions will contain at least one proton that will 
mobilize on either terminus group or any of the amide nitrogens within the fragment. To form 
multiply-charged ions, the analyte must have more than one location that can undergo ionization. 
Typically for peptide sequencing, basic amino acid side chains, such as those of lysine, arginine, 
and histidine, serve as excellent proton acceptors. By determining the number of protons present 
in a mass spectrum, the molecular mass, and ultimately the peptide sequence, can be determined.   
1.3.4.2 Proteomics in Forensic Biology 
Forensic proteomics has been well-defined for the characterization of microbial traces 
[140,141], species identification [142], and protein toxin detection [143,144]. However, only within 
the last two decades has proteomics been proposed as an alternative strategy for forensic serology 
applications. Research initiatives sought to address the sensitivity, specificity, and reliability of 
existing traditional screening techniques in addition to providing a means of identification for fluids 
which lack an existing technique (i.e., vaginal/menstrual fluid).   
Original research conducted employed discovery proteomics for the characterization of 
presumptive and confirmatory peptide signatures for proteins consistent with blood, semen, saliva, 
vaginal fluid, and menstrual blood. Protein material was cleaved into known peptide fragments, and 
because each protein contains a unique amino acid sequence, the mass measurements of each 
fragment can be read and converted into an amino acid alphabet. Perhaps the greatest attribute of 
proteomic analysis is the ability to selectively target characteristic biomarkers, a quality shared with 
RNA and methylation assay but lacking in Raman spectroscopy techniques. Body fluids are rich in 
protein material, a majority of which is shared among cell and tissue types. For example, 
immunoglobulins are expressed in blood, saliva, and vaginal fluid, given their immune function to 
neutralize pathogens. Although shared protein material is important, targeting fluid-specific proteins 
was of interest to forensic researchers. Original candidate biomarkers were selected based on their 
uniqueness or level of enrichment within a target fluid. Studies described candidate markers 
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consistent with blood identification as hemoglobin beta and alpha-spectrin; with semen 
identification as semenogelin-1 and semenogelin-2, prostate specific antigen, and progestogen-
associated endometrial protein; and saliva identification as alpha-amylase 1, cystatin SA, and 
histatin-1 [145,146]. Comparable and additional biomarkers, such as submaxillary gland androgen-
regulated protein 3B for saliva and hemopexin for blood, were characterized in a similar study [130]. 
Tissue specificity of characterized proteins were cross-referenced with existing protein databases 
to demonstrate the specificity of the developed methodology. In addition, the latter study evaluated 
reproducibility by fractionation, an important technique to ensure maximum coverage of the human 
proteome during discovery [130].  
In order to further understand the expression patterns among individuals, candidate 
biomarkers were verified through population studies. With limited sample sizes utilized for 
biomarker characterization, it was critical to evaluate protein levels in a more diverse sample 
population. A population of 50 human body fluids were correctly identified by the presence of one 
or more candidate markers [147]. Authors make a compelling argument that, in comparison with 
STR markers currently targeted for genetic typing, proteins exhibit greater interindividual 
expression variability. Although highly specific targets may be characterized in limited samples, 
they may not be consistently detected or serve as the most robust biomarkers for future method 
development.  
A majority of research aims have included the analysis of forensic-type samples, such as 
complex mixtures, aged stains, and stains on various substrates [145]. In regard to sexual assault 
and rape, evidence commonly contains fluids of mixed source. For example, a vaginal swab taken 
from a rape victim will inherently contain vaginal fluid, but semen and saliva may also be present. 
It is important to have assays sensitive and specific enough to discriminate a mixed-source sample 
in order to provide essential information for investigative purposes. When evaluating 2-component 
mixtures, proteomic techniques were successful in identifying both components, with matrix 
interferences observed for saliva in peripheral blood [147]. Protein material is innately separated 
from genetic material during solubilization of forensic evidence, with the cell pellets reserved for 
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genetic typing and the supernatant used for serological screening. The compatibility of proteomic 
techniques within a DNA-focused forensic biology workflow have been demonstrated by 
researchers [52,146]. One study reports the analysis of authentic crime scene samples, illustrating 
the successful characterization of blood in addition to producing a genetic profile with one seamless 
sample preparation protocol [148]. The sensitivity limits achieved with this analytical 
instrumentation are continuously challenged. It has been shown that laboratory-prepared 
laundered fabrics containing whole blood can be characterized with proteomic techniques [149]. 
Challenging sample type analysis will only continue to illustrate the effectiveness of proteomic 
analyses for body fluid identification, especially as analytical methods become more refined.  
More recent studies have employed quantitative proteomic techniques to detect peptide 
signatures. It was originally hypothesized that semi-quantitation of biomarkers could be used to 
determine the amount of body fluid present in the original stain. Although biomarker concentrations 
were calculated, it was concluded stain amounts could not be inferred due to sufficient expression 
variability among individuals [150]. Similarly, external standards have been employed to monitor 
trypsin processivity, ionization efficiency, and matrix interferences [147]. Currently, protein mass 
spectrometry technology has not been implemented into operational crime laboratories for body 
fluid source determination application.  
A main challenge of proteomic characterization is achieving a sample preparation protocol 
that is successful in extracting and purifying biomarker targets. Given the inherent complexity of 
protein material, differences in polarity and size can hinder the use of a common protocol. The 
conventional procedure for bottom-up targeted proteomics is time intensive to ensure adequate 
cleavage and recovery of protein material prior to analysis. A majority of protocols describe an 
overnight incubation as well as lyophilization steps; however, more recent studies explored 
expedited sample preparation [150,151]. In addition, as seen with other next generation techniques, 
the differentiation of vaginal fluid and menstrual blood remains a challenge. One area of 
improvement necessary for advancement of proteomic techniques is the dissemination of extensive 
interpretation guidelines and reporting language. Because vaginal fluid and menstrual blood 
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originate from the same cavity, guidelines in reporting protein biomarkers is essential to forming 
accurate result statements.    
Benefits of proteomic techniques for body fluid identification include its ability to conduct 
multiplex analyses, its sensitivity range, and potential use for correlation to genetic typing success 
[52]. In comparison with traditional screening techniques, proteomic research has demonstrated 
the ability to consistently characterize five body fluids within a single assay, unlike chemical, 
enzymatic, and antibody-based assays which each target a single fluid. Furthermore, antibody-
based assays have a limited working range, with concentrated samples producing a false negative 
result. Although emphasis is placed on trace level sample analysis within forensic biology, the 
ability to accurately characterize concentrated samples remains valuable for investigation. The 
inherent relationship between protein and DNA expression, characterized by the Central Dogma, 
illustrates the ability to utilize quantitative proteomic results as a means of predicting the quality of 
a genetic profile from a single stain. This relationship has been illustrated outside the realm of body 
fluid identification through the characterization of genetically variant peptides (GVP) and single 
nucleotide polymorphisms (SNP) in bone [152] and hair [153]. The strength of proteomic techniques 
in forensic biology are centered in its selectivity and ability to provide complimentary data to genetic 
testing.  
1.4 Research Objectives 
 This dissertation research was designed to develop and rigorously validate a high-
specificity forensic serology assay. The assay was designed for the simultaneous identification of 
five forensically-relevant body fluids: peripheral blood, seminal fluid, saliva, vaginal fluid, and 
menstrual blood. To achieve this, two well-established technologies, ultra-performance liquid 
chromatography and triple quadrupole mass spectrometry (UPLC-QQQ), were selected in 
combination with automated sample preparation to produce an integrated system well-suited with 
forensic casework needs. A previously developed prototype assay served as the model for further 
method development and validation. Validation procedures were conducted in accordance with the 
Federal Bureau of Investigation’s Quality Assurance Standard for Forensic DNA Testing 
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Laboratories as well as guidelines published by the Scientific Working Group on DNA Analysis 
Methods (SWGDAM). In addition, given the analytical instrumentation employed, appropriate 
guidelines from the Organization of Scientific Area Committees for Forensic Science (OSAC) 
Chemistry: Seized Drug and Toxicology Scientific Area Committee were also considered. The final 
deliverable presents a fully validated analytical assay that demonstrates sensitivity and specificity 
gains over traditional serological screening techniques and is compatible with downstream genetic 
testing.  
 Additional assessments were formulated to better understand and mitigate the deleterious 
effects of personal lubricants and spermicidal products on the ability to accurately identify seminal 
fluid and saliva in cases of sexual assault. Supplementary measures were incorporated into the 
sample processing procedure to diminish competitive binding during sample purification and 
remove the interferents prior to proceeding with protein digestion. The multiplex assay was then 
used as a foundation for the development of a top down peptidomic methodology for the 
assessment of sexual assault evidence. With the prevalence of sexual assault evidence, an 
expedited sample processing workflow that is capable of generating comparable results was 
identified as an area that needed further attention. It was demonstrated that same-day sample 
preparation could be used for the identification of seminal fluid, saliva, and vaginal fluid.  
The successful completion of these objectives has important implications for advancing the 
field of forensic serology by providing alternative means to confirming the presence of body fluids, 
especially in the event of sexual assault or rape.  
1.5 Hypotheses 
 The overarching hypothesis that was tested in the course of this dissertation research is 
that proteomic techniques in the form of bottom up and top down methodologies will surpass the 
sensitivity and specificity capable of traditional serological screening techniques. The specific 
hypotheses that were at the core of this research therefore are: 
1. The transferring of a multiplex mass spectrometry-based assay from a nanoflow to high 
performance chromatographic system will sufficiently increase sample throughput. 
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2. An automated sample processing procedure will mitigate sources of human error and 
contribute to increased sample throughput without a loss in peptide intensity. 
3. A multiplex mass spectrometry-based assay can undergo rigorous validation and 
comparison to illustrate its performance and compatibility with existing forensic biology 
workflows. 
4. Body fluid identification of samples subjected to personal lubricants can be achieved 
through specific sample preparation procedures and detection of protein signatures using 
the validated mass spectrometry-based assay. 
5. An expedited proteomic analysis of body fluids consistent with sexual assault evidence can 
be developed using peptidomic techniques.  
1.6 Dissertation Structure 
 Each chapter within this dissertation will contain an introduction to provide the essential 
background content of the research conducted and present scientific reasoning behind the 
experimental design. Experimental methods and a comprehensive presentation of results will be 
detailed. The significance of research findings will be discussed, including any caveats to the 
developed methodology.  
 Chapter 2 details the transfer of a previously developed prototype LC-MS/MS technique to 
a more sensitive analytical platform. In addition, the optimization and automation of the sample 
processing method will be discussed. Chapter 3 focuses on the full developmental validation of the 
LC-MS/MS technique for the identification of five forensically relevant body fluids. Chapter 4 
evaluates the validated LC-MS/MS method in relation to currently utilized serological screening 
techniques. In addition, the compatibility of the developed LC-MS/MS methodology with 
downstream genetic testing protocols was assessed. Chapter 5 presents the effects of personal 
lubricants on the ability to accurate identify body fluids consistent with sexual assault analysis. And 
lastly, Chapter 6 focuses on a streamlined proteomic approach to biomarker screening for sexual 
assault evidence analysis. 
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CHAPTER 2: METHOD TRANSFER AND DEVELOPMENT OF AN AUTOMATED SAMPLE 
PROCESSING WORKFLOW 
2 Introduction 
 Through previous research initiatives in the Danielson laboratory ([130,147] and 
unpublished research), it has been demonstrated that a targeted mass spectrometry-based 
multiplex assay allows for the unambiguous identification of body fluids in a forensic context. 
Furthermore, the sensitivity and specificity gains achieved with the developed research grade 
assay illustrated the significant advantages of proteomic techniques when compared with reporting 
limits of existing serological screening tests. However, additional areas of interest required further 
development to reach the readiness level expected for implementation into an operational 
laboratory. Areas of interest included decreasing analytical run time without sacrificing sensitivity 
gains, automation of preparation procedures, a direct comparison with existing serological tests, 
and extending the boundaries for high throughput analyses. 
 The research grade assay was developed on an Agilent 6430 mass spectrometer coupled 
to a liquid chromatograph fitted with a 1100 series nanoflow pump. Although this system was a 
triple quadrupole mass spectrometer capable of advanced sensitivity and specificity in comparison 
with other high resolution mass spectrometers, the limitation of the initial assay was the nanoflow 
liquid chromatograph system. While originally chosen for increased sensitivity, to ensure complete 
peptide biomarker separation, and reduce the likelihood of coelution, nanoflow chromatography 
requires inherently small flow rates to achieve greater ionization. A 30-minute analytical run time at 
a 400 nL/min flow rate was necessary to achieve adequate separation of biomarkers on the 
nanoflow system. Furthermore, a manual tryptic digestion and sample cleanup was employed, 
limiting the number of samples processed in a given batch. These processes incorporated multiple 
sample handling steps and incubation times in addition to centrifugation and lyophilization steps. 
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In summary, the research grade assay was limited to 12 samples per batch, which required a full 
day of preparation and an additional full day to acquire data.  
Under this portion of the project, the previously developed research grade assay was 
transferred from the nanoflow chromatography system to an ultra-performance liquid 
chromatography tandem mass spectrometry (LC-MS/MS) platform. Specifically, an Agilent 6495 
mass spectrometer coupled to a 1290 series liquid chromatograph was utilized. With the transfer 
of the analytical method, instrument and chromatography parameters required optimization prior to 
validation. During this portion of the study, synthetic peptide standards were synthesized, an 
internal positive control was selected and tested, and analytical operating parameters were 
determined.  
 This chapter seeks to report and establish a refined protein biomarker panel for the 
identification of peripheral blood, seminal fluid, saliva, and vaginal/menstrual fluid in addition to 
developing an automated sample processing protocol for increased sample throughput. This 
research was completed under three main scientific aims. The first research aim addressed the 
need to transfer the research grade assay to a high resolution analytical platform. The second 
research aim established an automated sample processing procedure and evaluated techniques 
for accurate protein quantification. The final research aim compared the automated processing 
procedure with the existing manual processing procedure for accuracy in the identification of 
selected biomarkers. The results outlined herein provide an optimized sample processing 
procedure and analytical method equipped for a full developmental validation.  
2.1 Methods and Materials 
2.1.1 Body Fluid Collection 
 All research conducted under this phase of the project was reviewed and approved by the 
University of Denver Institutional Review Board (IRB) for research involving human subjects. 
Sample collection and research was conducted in full accordance with the U.S. federal policy for 
the protection of human subjects. In total, 60 subjects were recruited from the graduate population 
at Arcadia University (Glenside, PA) and staff members employed at The Center for Forensic 
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Science Research & Education (Willow Grove, PA). All volunteers agreed and signed a letter of 
consent acknowledging that they had received, read, and understood all protocols involved in 
sample collection. Furthermore, all collected samples were assigned a random unique identifier to 
protect confidentiality.  
 Peripheral blood samples were collected through venipuncture under previous IRB 
approval. Additional blood specimens were purchased from Innovative Research, Inc. (Novi, MI).  
Semen was self-collected from consenting donors. The donor deposited the semen sample 
into a sterile collection cup and was asked to refrigerate the sample until transport to the lab. Upon 
receipt, semen samples were allowed to liquify at room temperature for 30 minutes. Collection cups 
were vortexed and 200 µL single use aliquots were prepared and stored at -80 °C until use.  
 Saliva was collected from consenting volunteers who refrained from eating or drinking for 
1 hour prior to collection. Salivette® collection tubes (Sarstedt, Nümbrecht, Germany) were utilized. 
Donors were instructed to remove the absorbent pad from the Salivette® tube and place the pad in 
their mouth. To stimulate saliva production, donors were instructed to gently chew on the absorbent 
pad. After 45 seconds, the donor placed the absorbent pad back into the Salivette® tube. The 
Salivette® tube was centrifuged for 10 minutes at 1,000 x g and saliva flowthrough was collected. 
200 µL single use aliquots were prepared and stored at -80 °C until use. 
 Vaginal secretions were self-collected by consenting donors. Female participants were 
asked to refrain from unprotected sexual intercourse for 12 days prior to the collection of vaginal 
fluid. The hypoallergenic, over the counter Softdisc™ collection cup (The Flex Company, Venice, 
CA) was utilized. Donors inserted the collection cup into the vagina following manufacturer’s 
instructions. It was requested the cup remain in the vagina for a minimum of 1 hour but could be 
left in for a period up to 12 hours. The entire Softdisc™ was placed into a sterile collection cup and 
transported to the laboratory. The liquid contents were placed into the collection cup and the 
Softdisc™ was repeatedly washed with 1 mL of ultra-pure water to remove mucous-like secretions. 
The liquid contents and mucous secretions were pooled and thoroughly vortexed to create a 
homogenous sample. 200 µL single use aliquots were prepared and stored at -80 °C until use. In 
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addition to vaginal secretions collected with the Softdisc™, female participants were asked to 
provide self-collected vaginal swabs. Consenting volunteers were provided with sterile cotton-
tipped swabs. A single swab was inserted into the vaginal cavity, similar to inserting a tampon. The 
swab was rotated in a circular manner for 15 seconds and gently removed. Swabs were placed into 
sterile manila collection envelopes for transport to the laboratory. Upon receipt, swabs were dried 
at room temperature where the cotton tip was removed from the wooden handle and placed in a 
clean microcentrifuge tube. Swabs were stored at -80 °C until use.  
 Menstrual blood samples were self-collected by consenting donors. Female participants 
were asked to refrain from unprotected sexual intercourse for 12 days prior to the collection of 
menstrual blood. The hypoallergenic, over the counter DivaCup™ (Diva International, Inc., Ontario, 
Canada) was utilized. Donors inserted the DivaCup™ in accordance with manufacturer’s guidelines 
during menses. It was requested the cup remain in the vagina for a minimum of 1 hour but could 
be left in for a period up to 12 hours. The entire DivaCup™ was placed into a sterile collection cup 
for transport to the laboratory. Upon receipt, the liquid contents were poured into the collection cup 
and thoroughly vortexed. 200 µL single use aliquots were prepared and stored at -80 °C until use. 
2.1.2 Method Transfer and Biomarker Selection 
2.1.2.1 Confirmation of Body Fluid-Specific Targets 
 Previously acquired data on candidate target protein and peptide sequences was reviewed 
in tandem with analysis of peptide standards in fluid matrix to reevaluate optimal transitions. In 
total, 26 peptide signatures from previously acquired data were carried over for additional analysis 
[130,147]. Under these previous research efforts, crude (70% purity) peptide standards were 
purchased, and product ions were selected via fragmentation analysis using Quadrupole Time-of-
Flight (QTOF) mass spectrometry. Authentic body fluids were quantitated (Section 2.1.3.1), 
manually digested and purified (Section 2.1.3.3) for analysis with the target inclusion list.   
2.1.2.2 Mass Spectrometer Instrument Parameters 
 Synthetic peptide standards prepared in Section 2.1.2.1 were combined to create a protein 
master mix containing peptide standards at equal concentration. Each protein master mix was 
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directly infused into the Agilent Jet Stream source of the 6495 mass spectrometer. Using the Agilent 
Source and iFunnel Optimizer software (v. B.08.00), starting values of source parameters were 
evaluated in a step-wise fashion. Parameters assessed included sheath gas temperature and flow 
rate, nozzle voltage, nebulizer pressure, drying gas temperature and flow rate, and capillary 
voltage. Resulting data was analyzed in MassHunter Qualitative software (v.B.04.01) for greatest 
peak intensities and peak shape.  
 Collision energy for individual peptides was determined using crude (70% purity) peptide 
standards prepared in Section 2.1.2.1. Skyline Proteomics Environmental software v. 20.1.0.155 
(MacCoss Labs, University of Washington) was used to establish predictive in silico collision energy 
values for each peptide of interest. Values were incrementally increased and decreased around 
the predicted value to determine the maximum signal of each ion transition. Resulting data was 
analyzed using MassHunter Qualitative software.  
2.1.2.3 Chromatographic Optimization 
2.1.2.3.1 Preliminary Assessment 
 Synthetic peptide standards prepared in Section 2.1.2.1 were utilized to assess the effect 
of mobile phase gradient, analytical column internal diameter, and flow rate on chromatographic 
peak separation and signal intensity. Two analytical columns were evaluated: an Agilent Poroshell 
120 EC-C18 3 mm x 100 mm column and an Agilent Poroshell 120 EC-C18 2.1 mm x 100 mm 
column. Flow rates assessed include 0.4 mL/min, 0.5 mL/min, and 1.0 mL/min. Due to the 
construction of the 2.1 mm x 100 mm column, the 1.0 mL/min flow rate could not be assessed on 
this column due to pressure limitations. Run times evaluated include 10, 13, and 15 minutes, each 
with a 3-minute post run to allow for equilibration. Two final analytical methods were selected for 
further analysis: a 10-minute (3.1 mm x 100 mm) method using a 1.0 mL/min flow rate and a 13-
minute (2.1 mm x 100 mm) method using a 0.5 mL/min flow rate. Body fluid samples from five 
donors were pooled, enzymatically digested, and extracted using the AssayMAP Bravo liquid 
handling platform protocol (discussed in Section 2.1.3.2) and analyzed, in addition to prepared 
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peptide standards, on both analytical methods to ensure peak-to-peak resolution remained 
desirable.  
2.1.2.3.2 Sensitivity Assessment 
 Human serum albumin (HSA) peptide (Agilent Technologies, Santa Clara, CA) was diluted 
using 30% ACN with 0.1% FA to the following concentrations: 100 fmol/µL, 10 fmol/µL, 1 fmol/µL, 
0.5 fmol/µL, and 0.1 fmol/µL. A series of seminal fluid and vaginal fluid mixtures were created from 
pooled fluid from five donors. Vaginal fluid was held at a constant 100 µL while 10 µL, 1 µL, 0.1 µL, 
and 0.01 µL of semen were added into the vaginal fluid sample (i.e., a vaginal fluid to semen ratio 
of 1:10 to 1:10,000). Each concentration was prepared and analyzed in triplicate between the 13-
minute (2.1 mm x 100 mm) method and the 10-minute (3 mm x 100 mm) method. Samples were 
digested and extracted using the AssayMAP Bravo liquid handling platform (discussed in Section 
2.1.3.2) and 1 µL of sample was analyzed via LC-MS/MS.  
2.1.2.4 Internal Positive Control 
 Intact Bos taurus myelin basic protein was purchased at a concentration of 1 mg/mL 
(Millipore Sigma, Darmstadt, Germany). Upon receipt, intact myelin was diluted with 50 mM 
ammonium bicarbonate (ABC) to a final concentration of 10 ng/µL. Isotopically-labeled Bos taurus 
myelin basic protein peptide DTGILDSLGR was purchased (New England Peptide) at a 
concentration of 1 mg/mL and diluted in 30% ACN 0.1% FA for a final concentration of 0.5 mg/mL. 
Single use aliquots of both the intact and labeled internal positive control (IPC) were stored at -80 
°C. Upon use, aliquots were thawed at room temperature for 30 minutes, vortexed, and pulse spun. 
Isotopically-labeled IPC stock solution was further diluted with 30% ACN and 0.1% FA in deionized 
water to a concentration of 1 pmol/µL. 
 Seminal fluid and peripheral blood were used for IPC concentration analysis as they are 
the most protein rich fluids analyzed within this assay. A series of four 2-fold dilutions were prepared 
by mixing 100 µg of body fluid matrix pooled from 5 donors with either 200 ng, 100 ng, 50 ng, or 25 
ng of a 1:1 molar ratio of intact myelin basic protein and isotopically-labeled peptide standard. 
Samples were digested and extracted using the AssayMAP Bravo liquid handling platform 
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(discussed in Section 2.1.3.2) and 1 µL of sample was analyzed via LC-MS/MS. Intact IPC was 
added to samples prior to tryptic digestion and isotopically-labeled myelin IPC was added prior to 
solid phase extraction cleanup.  
2.1.3 Sample Preparation Optimization 
2.1.3.1 Protein Quantitation 
 A comparison of two protein quantitation techniques was conducted. A previously 
optimized protocol for the bicinchoninic acid (BCA) assay was selected (Thermo Fisher Scientific, 
Waltham, MA). Assay standards were prepared by diluting concentrated bovine serum albumin 
(BSA) in 100 mM tris-hydrochloride (tris-HCl) to the following concentrations: 1,500 µg/mL; 1,000 
µg/mL; 750 µg/mL; 500 µg/mL; 250 µg/mL; 125 µg/mL; and 25 µg/mL. To a 96-well flat bottom 
plate, 25 µL of standard or sample was added in duplicate. Samples and standards were treated 
with 200 µL of working reagent containing 200 µL of Reagent A and 50 µL of Reagent B per sample. 
The plate was incubated at 37 °C for 30 minutes followed by 10 minutes at room temperature. 
Samples were read using a spectrophotometer at 652 nm wavelength. The second quantitation 
technique utilized a Nanodrop™ One Microvolume UV-Vis spectrophotometer (Thermo Fisher 
Scientific). To operate, 1 µL of sample or standard was applied to the stage. Two quantitation 
functions on the Nandrop™ were selected for evaluation: the 280 nm absorbance assay and the 
built-in BCA application.  
 For comparison, single use body fluid aliquots were thawed at room temperature for 30 
minutes then centrifuged for 10 minutes at 10,000 x g. Supernatant was transferred to a clean 
microcentrifuge tube and cell pellets were discarded. Single-fluid and mixture samples were 
prepared. Single-fluid samples were analyzed neat and diluted 10-fold, 100-fold, and 1,000-fold in 
50 mM ammonium bicarbonate. Two-fluid mixture samples were prepared by combining 50 µL of 
each fluid for 1:1 volume mixtures. Mixture samples were thoroughly vortexed and pulse spun prior 
to analysis. All samples were evaluated in triplicate. Descriptive statistics were calculated and 




2.1.3.2 Automation Procedure Development 
 A previously developed manual tryptic digestion was modified and transferred to the 
AssayMAP Bravo liquid handling platform (Agilent Technologies). A denaturant solution of 8 M urea 
and 5 mM tris(2-carboxyethyl)phosphine (TCEP) was prepared in 100 mM tris-HCl. Upon 
procedure development, varying volumes of 40 µL, 55 µL, and 90 µL denaturant solution were 
added to samples for evaluation. Alkylation solution was prepared as 100 mM iodoacetamide in 
deionized water. 100 mM tris-HCl was utilized as diluent prior to the addition of 0.25 µg/µL 
sequencing grade modified trypsin (Promega Corporation, Madison, WI). With the exception of the 
sample load volume, the default peptide cleanup parameters on the AssayMAP Bravo software 
were utilized for removal of residual digestion solutions.  
2.1.3.3 Workflow Testing and Optimization 
A comparative assessment between the manual and automated processing procedures 
was conducted. For the manual tryptic digestion, lyophilized sample was reconstituted in 15 µL of 
50 mM ABC, vortexed for 10 seconds, and pulse spun. Protein was denatured with 15 µL of 
trifluoroethanol (TFE) and reduced with 1 µL of 200 mM TCEP for 30 minutes at 55 °C. After 
incubation, 2 µL of 200 mM iodoacetamide (IAA) was added and samples were vortexed and pulse 
spun. Samples were incubated for 30 minutes in the dark at room temperature. Samples were 
diluted with 250 µL 50 mM ABC for a final concentration of 5mM TCEP and 10 mM IAA. Samples 
were treated with 10 µL of 0.25 µg/µL sequencing grade modified trypsin and incubated at 37 °C 
for 15 hours. Digestion was stopped with the addition of 10 µL of 10% trifluoroacetic acid (TFA). 
Pierce® C18 Spin Columns (Thermo Fisher Scientific) were primed with 300 µL of 50% ACN in 
deionized water and centrifuged at 1.4 x g for 1 minute. Cartridges were equilibrated with 300 µL 
of 0.1% formic acid (FA) in deionized water and centrifuged at 1.4 x g for 1 minute. Total sample 
volume (266 µL) was loaded into the spin column and centrifuged for 1 minute at 1.4 x g. Columns 
were washed with 300 µL of 0.1% FA in deionized water and centrifuged at 1.4 x g for 1 minute, 
for a total of 3 wash steps. Samples were eluted with 2 passes of 20 µL of 70% ACN with 0.1% FA 
in deionized water by centrifuging for 1 minute at 1.4 x g, for a total of 40 µL of eluate. Eluate was 
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lyophilized to dryness. The automated procedures were conducted as described below (Section 
2.4.1). Samples were fortified with 100 ng intact IPC prior to digestion and a final concentration of 
50 fmol/µL isotopically-labelled IPC prior to solid phase extraction (SPE) cleanup. Descriptive 
statistics were calculated and comparisons were performed through observation of peak area 
response and standard error.  
Various consumables were evaluated to provide optimum biomarker recovery. Three 
sample plates were compared: a Non Binding Surface treated 96-well U-bottom plate (Corning®, 
Corning, NY), Lo-Bind treated plate (Eppendorf, Hamburg, Germany), and a non-treated U-bottom 
96-well plate (Greiner, Monroe, NC).  
2.1.4 Final Protocol for Sample Preparation 
 Samples were quantitated using the BCA assay. Standards and working reagent were 
prepared as described above (Section 2.1.3.1). If necessary, samples were diluted with 100 mM 
tris-HCL. Samples were fortified with 20 µL of 0.5 mg/mL intact myelin protein and lyophilized to 
dryness.  
Lyophilized sample was reconstituted and digested using the AssayMAP Bravo liquid 
handling platform. Samples were denatured in 55 µL of denaturant solution (8 M urea, 5 mM TCEP 
in 100 mM tris-HCl) for 45 minutes at 25 °C. 6 µL of 100 mM IAA was added and samples were 
incubated for 30 minutes at 25 °C with a lid on the plate. After 30 minutes, 170 µL of 100 mM tris-
HCl was added. Samples were treated with 10 µL of 0.25 µg/µL trypsin. The sample plate was 
sealed and shaken for 5 minutes prior to incubating at 37 °C for 15 hours.  
 The tryptic reaction was stopped with the addition of 10 µL of 25% TFA. Digested samples 
were manually fortified with 10 µL of 1 µg/mL isotopically-labeled IPC stock solution. The sample 
plate was placed back on the AssayMAP Bravo deck for SPE cleanup. C18 microextraction 
cartridges (Agilent Technologies) were primed with 100 µL 50% ACN 0.5% TFA at a flow rate of 
300 µL/min. Cartridges were equilibrated with 50 µL of 0.5% TFA in deionized water at 10 µL/min. 
200 µL of digested sample was passed over the cartridge at a flow rate of 15 µL/min. Cartridges 
were washed with 50 µL of 0.5% TFA in deionized water at a rate of 10 µL/min. Sample material 
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was eluted from the sorbent in 25 µL of 70% ACN 0.1% FA at 5 µL/min. Eluate was lyophilized to 
dryness and prepared for LC-MS/MS analysis. 
 Lyophilized samples were reconstituted in 100 µL of 2% ACN with 0.1% FA in deionized 
water. Acquisition was performed using 10 µL of sample per injection on an Agilent 6495 mass 
spectrometer coupled to a 1290 series liquid chromatograph. An Agilent Poroshell 120 EC-C18 3 
mm x 100 mm analytical column was used for separation. Mobile phase A consisted of water with 
0.1% FA and mobile phase B consisted of ACN with 0.1% FA. Separation initiated at 5% B followed 
by a linear 8-32% B gradient over 8.5 minutes, a 1-minute hold at 80% B, followed by a 3-minute 
re-equilibration at a 1.0 mL/min flow rate and column temperature of 50 °C. Data was analyzed 
using Skyline Proteomics Environmental software v. 20.1.0.155.  
2.2 Results and Discussion 
 The objective of this phase of the research was the design and optimization of the LC-
MS/MS method utilized for the remainder of the project. Specifically, human body fluid-specific 
biomarkers were selected; peptide standards were synthesized; an internal positive control was 
designated; and the Agilent 6495 LC-MS/MS operating parameters were determined. Furthermore, 
experimentation was conducted to determine if sample processing procedures were amenable to 
automation. It should be noted that all preliminary target selection included the analysis of 
biomarkers consistent with the identification of urine (in addition to peripheral blood, seminal fluid, 
saliva, and vaginal/menstrual fluids). Upon development of the sample preparation procedures 
outlined in Section 2.1 and in consultation with senior practitioners, the identification of urine was 
dropped from the analytical method to allow for consistency in sample processing and preparation. 
However, preliminary results for urine identification are included within portions of this chapter to 
demonstrate the inconsistencies of preparation chemistries at accurately identifying peptide 






2.2.1 Method Transfer and Biomarker Selection 
2.2.1.1 Confirmation of Body Fluid-Specific Targets 
 To maximize the sensitivity and specificity of the assay, an extensive evaluation of protein, 
peptide, and peptide fragment ions were identified during method development. Preliminary peptide 
fragments were selected from the most abundant proteins present in the target body fluids (i.e., 
peripheral blood, seminal fluid, saliva, vaginal/menstrual fluids) through review of previously 
acquired data from prior research initiatives [130,147]. Proteins were reassessed using proteomic 
databases (i.e., UniProt, NCBI gene) for species- and fluid-specificity. Selected targets were 
evaluated experimentally to ensure the targets were abundant and not effected by endogenous 
matrix interferences, and top fragmentation products were selected for inclusion in the remainder 
of the study. Whole proteins, peptide sequences, or ion transitions were eliminated based on signal 
intensity, retention time, and fragmentation observed via LC-MS/MS. High purity isotopically-
labeled peptide standards were custom synthesized for the final biomarker target list and used in 
the remainder of the study.  
 Product ion transition selection was carried out using QTOF analysis of synthetic peptide 
standards. Figure 2.1 provides an illustrative example of peripheral blood protein alpha 1 
antitrypsin peptide LSITGTYDLK peak area response, fragmentation spectra, and product ion 
detection and selection. The peptide precursor m/z ratio of 555.80 was fragmented and the four 
most abundant product ions (i.e., m/z 997.5201, 910.4880, 797.4040, 696.3563) were selected for 
inclusion. This process was repeated for all protein/peptide pairings prior to being transferred to 
the Agilent 6495 LC-MS/MS platform. The preliminary inclusion list contained 30 protein targets 
characterized by 136 peptides (including markers for urine identification).   
 The inclusion list was drastically paired down during the remainder of this portion of the 
study. This was performed to increase the sensitivity and specificity of the analytical method by 
limiting the likelihood of coelution of peptide signatures. Such a large transition list results in 
decreased dwell times, which in turn limits the amount of time the mass spectrometer scans for the 
target compound, therefore preventing informative data points from being obtained. Furthermore, 
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as instances of fluid cross-reactivity or interference were observed, candidate protein and peptide 
markers were subsequently eliminated in favor of more specific protein targets. In summary, a total 
of 21 proteins were selected for the final inclusion list, characterized by 45 amino acid sequences 
and 132 unique ion transitions. Figures 2.2-2.6 illustrate the chromatographic separation of the 
final peptide inclusion list for each body fluid.  A complete list of protein, peptide, and transition 
targets is detailed in Appendix A. Although representative of fluid-specific and abundant targets, 
the diversity in protein composition of the inclusion list presented further analytical challenges for 
method optimization. Peptide targets exhibited a wide range of physical properties including 




Figure 2.1. Analysis of alpha 1 antitrypsin peptide LSITGTYDLK by QTOF and LC-MS/MS. Top 
image represents the precursor ion response. Middle figure represents the fragmentation spectra 
of the precursor ion. Bottom figure represents the product ion distribution. The product ions 




Figure 2.2. Assay results for the detection of human peripheral blood. Peaks represent selected 
peptides consistent with proteins (A) hemopexin, alpha 1 antitrypsin, apolipoprotein, 





Figure 2.3. Assay results for the detection of human menstrual blood. Peaks represent selected 
peptides consistent with proteins (A) hemopexin, alpha 1 antitrypsin, apolipoprotein, 
serotransferrin, cornulin, neutrophil gelatinase, Ly6/PLAUR, suprabasin, periplakin, involucrin, 
small proline rich protein 3, and (B) hemoglobin. 
 
Figure 2.4. Assay results for the detection of human seminal fluid. Peaks represent selected 
peptides consistent with proteins semenogelin 1, semenogelin 2, prostate specific antigen, 




Figure 2.5. Assay results for the detection of human saliva. Peaks represent selected peptides 
consistent with proteins (A) submaxillary gland androgen-regulated protein 3B, cystatin SA, 
statherin, and (B) alpha amylase. (C) Alpha amylase peptides on a smaller retention time scale to 




Figure 2.6. Assay results for the detection of human vaginal fluid. Peaks represent selected 
peptides consistent with proteins (A) neutrophil gelatinase, Ly6/PLAUR, suprabasin, periplakin, 
involucrin, (B) cornulin, and small proline rich protein 3. 
2.2.1.2 Mass Spectrometer Instrument Parameters 
 Given the formation of a targeted list of target protein and peptide biomarkers, additional 
instrument parameters were optimized for each target to ensure optimal detection and 
identification. In order to optimize ionization efficiency, Agilent mass spectrometer Jet Stream 
source conditions were adjusted (Figure 2.7). The source conditions modified for maximum peak 
area response included nebulizing gas flow rate and temperature, sheath gas flow rate and 
temperature, capillary voltage, nebulizer pressure, and nozzle voltage. Conditions were optimized 
by injecting peptide standards and manually modifying the aforementioned parameters until a 
maximum peptide response signal was observed. Finalized source condition parameters are 
detailed in Table 2.1.  
While source parameters were established based on response signal of the biomarker 
panel as a whole, the optimal collision energy was determined for each individual peptide transition. 
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Collision energy optimization is necessary to achieve maximum ion transmission and fragmentation 
within the mass spectrometer. Similar to source parameter conditions, collision energy was 
incrementally modified until a maximum peptide response signal was observed. Using Skyline 
Proteomics Environment Software, in silico predictions of optimal collision energy for each target 
peptide sequence were generated. Using synthetic peptide standards, the collision energy was 
modified in a stepwise manner both above and below the predicted value. A complete list of final 
collision energy values for target peptide sequences is detailed in Appendix A. For example, 
semenogelin 2 peptide DVSQSSISFQIEK had a predicted collision energy value of 23.8 V. The 
positive addition collision energies are shown in Figure 2.8, with 25.8 V producing the greatest 
peak intensity of those tested. 
 
Figure 2.7. Agilent Jet Stream source schematic. Reprinted from Agilent Jet Stream Thermal 
Gradient Focusing Technology (p. 1) by A. Mordehai and J. Fjeldsted. Publication number 5990 













Figure 2.8. Collision energy optimization of semenogelin 2 peptide DVSQSSISFQIEK. Retention 
time is depicted on the x-axis and peak intensity on the y-axis. Colored peaks represent peak area 
intensity of the peptide at a given collision energy. The collision energy that produced the greatest 
peak intensity (i.e., 25.8 V in tan) was selected.  
2.2.1.3 Chromatographic Optimization 
 An area of interest that was identified for assay development in relation to the previous 
research grade assay was decreasing analytical run time in order to increase sample throughput. 
In addition to automated sample preparation (discussed in section 2.2.2.2), increasing sample 
throughput is an attractive quality for consideration in operational laboratories. One of the main 
challenges associated with a decrease in analytical run time is the loss of resolution between target 
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compounds due to coelution and potential ion suppression. Run time optimization and 
chromatographic separation were evaluated during this portion of the project using synthetic 
peptide standards and challenging sample types. During analysis, the LC-MS/MS mobile phase 
gradient, specifically for the acetonitrile organic solvent, was monitored and adjusted to prevent co-
elution of peptide targets. 
2.2.1.3.1 Preliminary Assessment 
 The starting analytical gradient was set for a 15-minute run time with a 3-minute post time 
at a 0.4 mL/min flow rate, for a total run time of 18 minutes. With the implementation of robotic 
sample preparation, the analysis of a 96-well sample plate would take approximately 30 hours. This 
was determined to be unsuitable for an operational environment faced with quick turn-around times, 
given that a single 96-well plate could not be analyzed within a single day. Therefore, two additional 
chromatographic run times were evaluated: a 13-minute run time and a 10-minute run time, both 
with a 3-minute post time (Table 2.2). To account for the analysis of such a large number of target 
compounds and the speed of analysis, two analytical columns were also assessed. The 13-minute 
gradient was developed using a 2.1 mm x 100 mm AdvanceBio Peptide Map column with a flow 
rate of 0.5 mL/min. The 10-minute gradient was developed using a 3 mm x 100 mm AdvanceBio 
Peptide Map column and a flow rate of 1.0 mL/min, with both columns containing a 2.7-micron pore 
size (Table 2.2). The increase in internal diameter of the analytical column, from 2.1 mm to 3 mm, 
allowed for increased flow rate due to the larger bore column. However, as flow rate is increased, 
peak-to-peak resolution will compress, generating potential challenges in maintaining assay 
sensitivity. A preliminary assessment of the analytical methods included the analysis of digested 
protein material from the target body fluids. While some compression was expected, no loss in 
resolution was observed with the 10-minute method for any of the body fluids. For example, Figure 
2.9 depicts chromatographic separation and resolution of a seminal fluid peptide targets for both 
the 13-minute (2.1 mm x 100 mm) and 10-minute (3 mm x 100 mm) methods. No consequential 
loss in peak resolution was observed while three minutes of instrument run time was spared per 
sample assayed.  
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Table 2.2. Chromatographic parameters for the three analytical gradients evaluated.  
 
 
Figure 2.9. Normalized chromatographic separation of seminal fluid peptide DVSQSSISFQIEK 
across the three developed gradients (15-minute run time, orange; 13-minute run time, light green; 
10-minute run time, dark green).  
2.2.1.3.2 Sensitivity Assessment 
 A serial dilution of human serum albumin (HSA) was prepared and analyzed on the 13-
minute and 10-minute analytical methods. A slightly greater (i.e., <2%) peak area was observed in 
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favor of the 13-minute analytical method (Figure 2.10). It was determined that the 10-minute 1.0 
mL/min flow rate did not negatively impact the ability of low-level sample detection and 
identification. Following these results, all body fluids were analyzed using the 13- and 10-minute 
methods to observe any consequential loss in peak-to-peak resolution due to compressed 
chromatographic separation. While peak compression was expected, no loss in resolution was 
observed with the 10-minute method for any of the fluids. For example, chromatographic separation 
for saliva is depicted in Figure 2.11. A change in elution order was observed for the two alpha-
amylase peptides IAEYMNHLIDIGVAGFR and LSGLLDLALGK (green and pink peaks). The 
LSGLLDLALGK peptide eluted first on the 13-minute method and second on the 10-minute method. 
Other than compression of peak elution, no other changes in elution order were observed for the 
remaining body fluids.  
To simulate sexual assault type samples, a series of semen dilutions in vaginal fluid were 
prepared. Of the four dilutions prepared, results for two are illustrated, with the 0.01 µL representing 
the lowest dilution point assessed. A marginal loss in peak area was observed for semenogelin 2 
on the 10-minute method; however, greater peak responses for prostate specific antigen were 
observed on the same method (Figure 2.12). Based on the data obtained, the tradeoff between 
peptide response and sample throughput favors the faster 10-minute (3 mm x 100 mm) run time. 





Figure 2.10. Peak area comparison between the 13-minute (purple) and 10-minute (blue) analytical 
methods for human serum albumin peptide (A) YLYEIAR and (B) AAFTECCQAADK. Error bars 
represent standard error. The amount of protein material on column (in femtomoles) is represented 
on the x-axis. Peak area response is represented on the y-axis.  
 
Figure 2.11. Chromatographic resolution comparison between saliva biomarker peptides on the (A) 





Figure 2.12. Peak area response comparison for low-level seminal fluid in a vaginal fluid matrix 
between the 10-minute and 13-minute analytical methods. Semenogelin 2 peptide GSISIQTEEK 
at the 10-minute (orange) and 13-minute (red) retention times. Prostate specific antigen peptide 
FMLCAGR at the 10-minute (green) and 13-minute (grey) retention times. Peak area response is 
represented on the y-axis.  
2.2.1.4 Internal Positive Control 
 In order to monitor inhibition of proteolytic digestion due to the presence of sample-specific 
contaminants or inhibitors, an internal positive control (IPC) was designed. Two versions of the IPC 
were acquired: an intact protein to evaluate digestion efficiency and a heavy isotope-labeled 
peptide from the same protein to monitor purification and chromatographic analysis. Inhibition in 
protein cleavage efficiency was indicated by a reduction in the signal intensity of the control intact 
protein in comparison with the heavy-labeled peptide sequence of the same protein. Bovine myelin 
basic protein, both an intact protein version and an isotopically-labeled peptide sequence, were 
selected for use as the IPC (Figure 2.13). This protein had been used as an IPC in previous 
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research studies and was selected for it’s conserved amino acid sequence. Using seminal fluid and 
peripheral blood sample matrices, a dilution series of a 1:1 molar ratio of intact myelin and labeled 
peptide standard were evaluated. The theory behind selecting only seminal fluid and peripheral 
blood for IPC evaluation rests in the inherent matrix effects and protein concentration of these two 
fluids. 
 As expected, the heavy peptide standard to digested myelin response ratios did not reach 
the theoretical 1:1 ratio maximum for any protein cleavage reaction in tested authentic body fluids. 
The ratio that was obtained, however, was constant for both the seminal fluid and peripheral blood 
matrices over the full range of concentrations tested. Figure 2.14 shows the peak response for the 
digested myelin protein and heavy peptide standard for a 100 ng assessment in seminal fluid and 
peripheral blood. Both fluid matrices have matching peak heights, retention times, and a stable 
ratio of heavy peptide standard to digested myelin. The experiment was repeated across all body 
fluids using the same 1:1 molar ratio of intact myelin to labeled peptide standard, created in 100 µg 
of fluid matrix. Similar to results observed previous, the theoretical ratio of 1:1 was not illustrated. 
However, among the dilutions of each fluid matrix, the response ratios obtained had coefficients of 
variation (CV) values of 2% or less (Table 2.3). Therefore, the 100 ng quantity of intact IPC was 
selected for use in developmental validation studies.  
 The discordance in obtaining the theoretical 1:1 response ratio is best described by the 
relationship between enzymatic digestion of intact protein and monitoring of surrogate peptides that 
is characteristic of bottom up proteomic analyses [154]. The relative quantitation of surrogate 
peptides relies on the catalytic activity of trypsin. A 1:1 response ratio would assume a catalytic 





Figure 2.13. Protein sequences for myelin basic protein in (A) Bos taurus and (B) Homo sapiens. 
The Bos taurus specific peptide (DTGILDSLGR, pink) and Homo sapiens specific peptide 
(DTGILDSIGR, purple) lack 100% sequence identity, making it possible to discriminate between 
bovine-based IPC and endogenous human myelin basic protein.  
 
Figure 2.14. Detection of myelin bovine albumin peptide DTGILDSLGR in peripheral blood (left) 
and seminal fluid (right). Digested internal positive control is depicted in red (m/z 523.7775++). 








Table 2.3. Detection of IPC at 100 ng quantities. Response ratio was calculated by dividing the 
peak area response of the heavy peptide standard by the peak area response of the natural (intact) 
protein.  
 
2.2.2 Sample Preparation Optimization 
 The purpose of this portion of the study was to develop an automated and expedited 
sample preparation protocol aside from initial swabbing or cutting of evidentiary material. This 
protocol was determined through the completion of three objectives. First, through evaluating two 
techniques for total protein quantitation. Second, development of an automated processing 
workflow. And lastly, comparing the automated workflow with a previously developed manual 
procedure.  
2.2.2.1 Protein Quantitation 
 Accurate determination of protein quantitation is vital for biochemical experimentation, 
specifically for enzymatic digestion of protein material. A multitude of quantitation techniques are 
available [155], with two UV absorbance techniques chosen for comparison. The bicinchoninic acid 
assay (BCA) is a standard technique for the reliable and specific quantitation of protein content. 
While analytically reliable and conservative with regard to consumption of evidentiary material, 
newer instrumentation employing micro spectrophotometry have been promoted by some 
practitioners within the field. The NanoDrop™ One Microvolume UV-Vis spectrophotometer (herein 
referred to as NanoDrop™) was acquired and compared to a previously optimized BCA assay. It 
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was hypothesized that the NanoDrop™ would provide a faster alternative to obtaining protein 
concentration data while consuming as little as 1 µL of extract.  
 Three experiments were designed to compare the two quantitation procedures. Single 
source and mixed source body fluids were prepared for the BCA assay and NanoDrop™ method at 
280 nm absorbance. The NanoDrop™ produced greater protein concentrations in comparison to 
the BCA reaction when assessing single source fluids (Figure 2.15). However, any notation of 
improvement between the two assays was highly inconsistent across fluids. For example, the 
NanoDrop™ indicated an average protein concentration for semen that was 50% greater than that 
obtained using the BCA assay. Moreover, this irregularity was observed across 15 samples that 
contained 1:1 mixtures of the target body fluids (Figure 2.16). The greatest discrepancy in 
quantitation results for both single source and mixture samples were produced by samples 
containing urine. Urine is primarily composed of water and non-protein compounds such as uric 
acid and creatinine. Both of these compounds have the ability to absorb 280 nm wavelength UV 
light [156].  
Ultimately, the protein quantitation estimates provided by the NanoDrop™ with the 280 nm 
absorbance mode were determined to be inconsistent and unreliable. This was attributed to the 
presence of non-protein matrix components that absorb light in the 280 nm range. Measuring 
protein absorbance at 280 nm is routinely conducted in biological procedures given that 
measurements can be quickly taken and are highly reproducible when using purified sample 
material. It has been reported that aromatic amino acids, such as tyrosine and tryptophan, strongly 
absorb UV light at the 280 nm wavelength [157]. However, other aromatic ring containing 
structures, such as enzymatic cofactors, can also absorb UV light at the 280 nm wavelength. 
Furthermore, UV absorbance can be affected by protein structure, peptide sequence, and pH 
environment.  
 The NanoDrop™ had a built-in BCA application, which was run in parallel with the manual 
BCA assay to evaluate the inconsistent results observed with single and mixed source samples. 
This was conducted with only peripheral blood, seminal fluid, and saliva matrices. For this 
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experiment, all samples were treated with the Bradford reagent and samples were analyzed in 
parallel with the manual BCA assay and NanoDrop™ system. Protein concentrations were 
consistent between the two analyses; however, the standard spectrophotometer proved to be the 
faster of the two methods (Figure 2.17). 
 Due to the inconsistent results observed with the 280 nm quantitation approach, it was 
determined that all samples would require quantitation with the BCA assay. In addition, pipetting 
individual samples onto the NanoDrop™ system introduced more analyst hands-on time and sample 
handling than with the standard BCA analysis. The discrepancies in urine quantitation values were 
an underlying source of concern and attributed to the removal of urine form the target inclusion list. 
In conclusion, the manual BCA assay using a standard spectrophotometer was selected as the 






Figure 2.15. Single source body fluid comparison using the NanoDrop™ 280 nm (blue) and BCA 
assay (purple). Representative dilution samples are represented on the x-axis. Average protein 




Figure 2.16. Mixture sample comparison using the NanoDrop™ 280 nm (blue) and BCA assay 
(purple). Mixture samples were prepared as a 1:1 ratio and are represented on the x-axis. Samples 
were diluted prior to analysis with quantitation methods. Average concentration is represented on 






Figure 2.17. Comparison of the NanoDrop™ BCA function (blue) and manual BCA assay (purple) 
using peripheral blood, seminal fluid, and saliva. Average concentration is represented on the y-
axis. Error bars represent standard error.  
2.2.2.2 Automation Procedure Development 
 A previously developed tryptic digestion and SPE cleanup were reformatted to be 
conducted on the AssayMAP Bravo liquid handling platform. The reagent volumes and robotic 
processes were developed using an existing protocol [158]. Parameters such as liquid flow rates 
and reagent transfer volumes were evaluated to ensure optimal digestion efficiency and retention 
of target protein material during extraction. Specific handling parameters and deck layouts for 
tryptic digestion and SPE cleanup are depicted in Figures 2.18 and 2.19, respectively.  
 To demonstrate the consistency of results obtained by the automated procedure, six 
seminal fluid samples were prepared in duplicate and digested, desalted, and purified on the 
AssayMAP Bravo liquid handling platform. Representative results for the semenogelin 2 peptide 
GSISIQTEEK are depicted in Figure 2.20 and Table 2.4. Resulting peak area responses for the 
quantifier ion (m/z 834.4203+) were reproducible across all 12 samples using the AssayMAP Bravo 
liquid handling platform, with a calculated coefficient of variation less than 15%. The same 
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preparation was conducted for the remaining body fluid matrices, with similar results observed as 
those described above (Figure 2.21).  
 Digestion variability was observed when large volumes of fluid were processed using the 
AssayMAP Bravo system. For example, when digesting diluted seminal fluid and saliva, lyophilized 
residue deposited on the side of the microplate wells was not consistently solubilized with the 
addition of denaturant reagent. To address this, varying volumes of denaturant (default 40 µL, 55 
µL, and 90 µL) were added to wells containing lyophilized seminal fluid sample. In addition, a gentle 
mixing step was added to the digestion protocol. It was determined that a 15 µL increase over the 
default application volume produced the most consistent results (Table 2.5). Furthermore, the 
larger amount of denaturant volume (90 µL) may have inhibited trypsin activity, resulting in less 
consistent digestion efficiency.  
 In summary, the developed automation procedure for the digestion and purification of 
protein material was successful. Overall, the procedure was designed with respect to simplicity and 
speed of processing. Reagent preparation and procedure parameters were streamlined into a 
seamless protocol that was further evaluated in the next section.  
 
Figure 2.18. Sample process setting and deck layout for automated tryptic digestion in a 96-well 




Figure 2.19. Sample process setting and deck layout for automated solid phase extraction cleanup 




Figure 2.20. Reproducibility results for six seminal fluid samples (prepared in duplicate) processed 
using the automated procedure. Illustrated is protein semenogelin 2 peptide GSISIQTEEK. (A) 
Chromatograph of sample 7-r001, depicting retention time on the x-axis and peak area response 
on the y-axis. (B) Reproducibility of retention time, depicting minor drifts among the 12 replicates. 









Figure 2.21. Chromatography for (A) peripheral blood, (B) menstrual blood, (C) seminal fluid, (D) 




Table 2.5. Calculated CV (as a percent) for representative peptide biomarkers of seminal fluid 
proteins at three denaturant volumes evaluated for digestion on the AssayMAP Bravo liquid 
handling platform.  
 
2.2.2.3 Workflow Testing and Optimization 
 A comparison between the manual and automated preparation protocols was conducted 
to serve as the final assessment of the performance parameters for each approach. This 
experimentation was carried out with three single-source samples of each body fluid that had been 
fortified with internal standard. Digestion efficiency was determined by calculating the ratio of 
digested peptide in relation to the response of the internal standard. For example, two 
chromatograms depicting peak area responses consistent with saliva are depicted in Figure 2.22. 
As expected, the greatest peak intensity is representative of alpha-amylase peptide 
LSGLLDLALGK; however, peak intensity for the manual preparation was almost twice as much as 
that of the automated preparation. Similar results were observed for saliva protein submaxillary 
gland androgen-regulated protein 3B (Figure 2.23). This particular peptide target is more 
hydrophobic than a majority of the peptide sequences within the multiplex assay. Endogenous peak 
areas across three replicates were greater for the manual preparation in comparison with the 
automated platform (red bars). Internal standard (blue bars) showed greater consistency between 
the two preparation methods, with slightly lower peak area response for the manual preparation.  
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 The small loss in response with the liquid handling platform that was depicted for saliva 
was consistent across all fluids tested (Figure 2.24). It was hypothesized that this loss in response 
could be contributed to the quality of plastic labware utilized between the two preparation methods. 
The manual digestion was performed using coated low-retention microcentrifuge tubes; however, 
the same coating was not utilized for preliminary experimentation on the AssayMAP Bravo liquid 
handling platform. To address this, 96-well microplates containing the same or similar low-retention 
coatings were acquired and evaluated. Eppendorf Lo-Bind and Corning® Non Binding Surface 
treated plates were evaluated, with untreated Grenier U-bottom serving as a control. Single source 
fluids were prepared and processed using each plate type, with the optimal plate selected based 
on peak intensity of peptide targets. For example, peak intensities of seminal fluid peptide 
DIFSTQDELLVYNK on each plate are depicted in Figure 2.25. The greatest peak area intensity is 
illustrated by the Corning® Non Binding Surface plate. Similar results were observed across peptide 
markers of the remaining target fluids. 
 Furthermore, with the manual preparation, the entire sample volume is transferred onto 
sorbent material during SPE cleanup and purification. With the automated platform, however, a 
minimum sample volume (20 µL of the 250 µL digestion product) must remain in each well to ensure 
that no air is injected into the micro cartridges during SPE cleanup. In summary, despite the lower 
peak area responses, the automated sample processing procedure was selected for use for the 
remainder of the study. The automated liquid handling platform deposits purified tryptic peptides 




Figure 2.22. Digestion and purification of saliva via the (A) automated procedure and (B) manual 
procedure. Peak area response for alpha-amylase peptide LSGLLDLALGK is illustrated in pink. 
 
Figure 2.23. Digest and purification comparison of saliva protein submaxillary gland androgen-
regulated protein 3B peptide GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR. Endogenous 
peptide peak area response (red) and internal standard peptide peak area response (blue) 
illustrated for three replicates processed on the automated platform and with the manual procedure. 





Figure 2.24. Single source body fluids processed on the AssayMAP Bravo liquid handling platform 
(blue) and manual procedure (purple). Representative proteins for each fluid evaluated are 
depicted on the x-axis (HBB, hemoglobin; SEMG2, semenogelin 2; SMR3B, submaxillary gland 
androgen-regulated protein 3B; CRNN, cornulin; NGAL, neutrophil gelatinase). Average relative 
response ratio is represented on the y-axis. Error bars represent standard error.  
 
Figure 2.25. 96-well microplate comparison for use in automated digestion and purification. Three 
microplates were evaluated for greatest peak area intensity, depicted on the y-axis. Shown is a 
chromatogram for semenogelin 1 peptide DIFSTQDELLVYNK.  
2.3 Concluding Remarks 
 In summary, the results detailed herein demonstrate the ability to automate sample 
processing and expedite analysis of the research grade multiplex assay without loss of sensitivity. 
Previously identified protein and peptide biomarker targets were subjected to further scrutiny for 
inclusion in the high throughput LC-MS/MS assay. With the creation of a targeted analytical 
method, individual parameters were sufficiently established for optimal target detection and 
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identification. The final biomarker target list includes both presumptive and confirmatory proteins 
consistent with peripheral blood, seminal fluid, saliva, and vaginal/menstrual fluid.  
Implementation of an automated sample processing protocol not only sufficiently increased 
the number of samples amenable to preparation in a given batch but mitigated preventable sources 
of human error during digestion and cleanup procedures. Where small batches averaging fifteen 
samples were prepared for analysis using the research grade assay, the optimized protocol was 
constrained only to the capacity of a 96-well plate. Furthermore, by limiting the amount of sample 
handling time by the analyst, the automated protocol promotes efficiency of additional laboratory 
resources in regard to analysts’ time. The benefits of automation and high throughput screening 
are advantageous to generating interest among practitioners for implementation of a novel 
technique into operational laboratories.  
The following two chapters detail a full developmental validation and comparison 
assessment of the optimized LC-MS/MS assay and sample processing protocol described within 
this chapter. With a verified protein biomarker panel and preparation protocol, the analytical 
boundaries and limitations of the LC-MS/MS needed identifying. Therefore, a full developmental 
validation was conducted in accordance with standard guidelines within forensic biology and 
toxicology. Additionally, compatibility of the LC-MS/MS assay within the greater forensic biology 
workflow was demonstrated.  
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CHAPTER 3: DEVELOPMENTAL VALIDATION OF AN AUTOMATED MULTIPLEX 
ASSAY FOR THE IDENTIFICATION OF BIOLOGICAL FLUIDS 
3 Introduction 
 The objective of this phase of the research was to validate the developed and optimized 
multiplex serological assay. Validation is the final phase of the proteomic workflow, allowing for 
efficacy and reliability of the analytical method to be established as acceptable prior to 
implementation into an operational environment. The experimentation performed during this phase 
was designed in accordance with the Quality Assurance Standards set forth by the Federal Bureau 
of Investigation (FBI) and recommended guidelines published by the Scientific Working Group on 
DNA Analysis Methods (SWGDAM) and the Scientific Working Group on Forensic Toxicology 
(SWGTOX). Due to the hybrid nature of experimentation and data analysis described, it was 
determined that both toxicological and serological guidelines were to be consulted and exercised 
for validation purposes. Specifically, with the use of liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), validation guidelines were referenced via SWGTOX publications for 
experimental procedures such as ion suppression and enhancement, repeatability, reproducibility, 
and limit of detection.  
 This chapter reports the validation results of the previously described proteomic assay for 
the identification of peripheral blood, seminal fluid, saliva, and vaginal/menstrual fluid. Body fluid 
specific protein markers were previously selected under prior funding, where they underwent 
rigorous discovery and verification of the candidate markers within a greater population. The 
selected markers were reconfirmed as described in Chapter Two, with each protein marker and 
subsequent peptide targets assessed both in vitro with analytical identification and in silico using 
bioinformatics software. The successful operation of the method at each level described herein 
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identified working conditions and associated limitations that were acknowledged to estimate the 
true performance of the analytical method.
3.1 Methods and Materials 
 All research conducted under this phase of the project was reviewed and approved by the 
University of Denver Institutional Review Board (IRB) for research involving human subjects as 
described under section 2.1.1.   
3.1.1 Repeatability and Reproducibility Sample Preparation 
 The research scientist prepared all body fluid aliquots for sample preparation following 
protocols outlined in section 2.1.1. Aliquots were stored at -80 ˚C until use. For the remainder of 
the study, both the research scientist and laboratory advisor performed sample processing 
procedures on the prepared aliquots simultaneously, including total protein quantitation, reagent 
preparation, plate loading for digestion and cleanup, and sample reconstitution for instrumental 
analysis. Protocols outlined in section 2.1.4 were followed during this portion of the study on all five 
target body fluids. Procedures were performed over the course of three days. 
 Repeatability was recorded as the variation in precision for results obtained by a single 
analyst. Reproducibility was recorded as the variation in accuracy obtained between analysts 
conducting identical protocols. Coefficient of variation (CV) of total protein quantitation in addition 
to the variation in internal standard were calculated for each individual and between individuals.  
3.1.2 Sensitivity Sample Preparation 
 Target body fluid from five individuals was prepared according to parameters outlined in 
section 2.1.1. A serial dilution of pooled fluid was created in deionized water. For seminal fluid, 
saliva, and vaginal fluid, dilutions were started at 2-fold. Knowing a priori peripheral and menstrual 
blood exhibit concentrated protein material, dilutions were started at 100-fold. Dilutions were not 
quantitated for total protein amount. 200 µL of each dilution was lyophilized and digested followed 
by SPE cleanup using protocols detailed in section 2.1.4. Sample dilutions were prepared in 
triplicate, with 20 µL of sample injected on column. A select set of sample dilutions were prepared 
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and analyzed given laboratory resources. Table 3.1 below details dilutions analyzed via LC-MS/MS 
per target body fluid.  
Table 3.1. Dilutions analyzed for the sensitivity study of the multiplex assay validation.  
 
3.1.3 Stability Sample Preparation 
3.1.3.1 Freeze Thaw Stability 
 Target body fluid from five individuals was pooled and prepared in three batches containing 
triplicate samples according to parameters outline in section 2.1.4. The first batch of samples (Day 
1) were processed and analyzed, with 2.5 µg of protein material injected on column. Remaining 
sample batches (Day 2 and Day 3) were stored at -80 ˚C until future use. Day 2 of Freeze Thaw 
Stability started by completely thawing all prepared material to room temperature and continuing 
with the sample processing procedure for batch two (Day 2). Batch three material was again frozen 
at -80 ˚C until future use. Day 3 of Freeze Thaw Stability was conducted in the same manner, 
allowing the final batch to thaw completely prior to sample processing. Vaginal fluid samples were 
analyzed for 2.5 µg and 10 µg on column, to adequately assess any loss of lower abundant target 
peptides.  
3.1.3.2 Autosampler Stability 
 Target body fluid from five individuals was prepared according to parameters outlined in 
section 2.1.4. Samples were analyzed via LC-MS/MS over the course of 3 days, with the microplate 
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containing processed sample remaining in the autosampler kept at 8 ˚C for the duration of the 
study. 2.5 µg of material was analyzed on column. Samples were reinjected 24 hours (Day 2) and 
48 hours (Day 3) after original sample preparation.  
3.1.4 Mixtures Sample Preparation 
 Target body fluid from five individuals was pooled, filtered, and quantitated according to 
parameters outlined in section 2.1.1. Mixtures in a 1:1 ratio of 50 µg total protein per fluid were 
generated, for a total of 100 µg protein material. All possible combinations of two-fluid mixtures 
were created: vaginal fluid (VF) and saliva (SA); VF and seminal fluid (SE); VF and peripheral blood 
(PB); VF and menstrual blood (MB); MB and PB; MB and SE; SA and MB; SA and PB; SA and SE; 
SE and PB. Mixture samples underwent digestion and SPE procedures outlined in section 2.1.4. 
10 µg of material was analyzed on column.  
3.1.5 Specificity Sample Preparation 
 Whole blood samples from 11 different species (Rhesus monkey, horse, pig, chicken, cow, 
beagle, mouse, black bear, coyote, white-tailed deer, river otter) and saliva samples from 2 species 
(cow, Rhesus monkey) were purchased from Innovative Research™ (Novi, MI). Blood samples 
were treated with potassium ethylenediamine tetraacetic acid anticoagulant. In addition, oral swabs 
from 2 species (alpaca, tortoise) were obtained by the research scientist. 
 Oral swabs were resuspended in 500 µL of deionized water and allowed to solubilize for 
30 minutes at room temperature with frequent vortexing. All samples (blood, saliva, oral swabs) 
were microcentrifuged at 12,000 x g for 10 minutes. Supernatant was filtered using Costar® Spin-
X® centrifugal filters (Corning®, Corning, NY) at 10,000 x g for 2 minutes. The remaining sample 
preparation follows procedures outlined in section 2.1.4. 2.5 µg of material was analyzed on 
column.  
3.1.6 Casework Type Sample Preparation 





3.1.6.1 Substrate Samples 
Substrates tested include cotton, denim, leather, carpet, drywall, plastic beverage bottle, 
aluminum beverage can, and feminine hygiene menstrual pad. Substrates were cut into 
approximately 2 cm x 2 cm squares upon which 50 µL of single source body fluid was applied. 
Samples were dried at room temperature overnight. Substrates were solubilized in 1 mL deionized 
water for 30 minutes with frequent vortexing. Substrates were placed in a centrifugal basket and 
centrifuged at 10,000 x g for 10 minutes. Supernatant was transferred for analysis following 
procedures outlined in section 2.1.4 and cell pellets were discarded.  
3.1.6.2 Environmental Contaminant Samples 
 Environmental contaminants tested include dirt slurry, rust slurry, 10% bleach in water 
solution, chewing tobacco, cigarette butt, lubricated condom with spermicide additive, and water-
based personal lubricant. Dirt slurry was prepared by mixing 1 gram weather-conditioned soil with 
1 mL tap water. In a similar manner, the rust slurry was prepared by mixing 500 µg rust with 500 
µL of tap water. Rust was obtained by scarping the external surface of a weather-conditioned chain 
link fence. Neat bleach was diluted 10-fold with deionized water for a final concentration of 10% 
bleach. Chewing tobacco expellant was obtained from a volunteer that actively engages in using 
smokeless tobacco products. Water-based personal lubricant containing glycerin was purchased 
(CVS Pharmacy™, Woonsocket, RI).  
 Liquid matrix contaminants (i.e., dirt slurry, rust slurry, 10% bleach solution, chewing 
tobacco, and water-based lubricant) were thoroughly mixed in a 1:1 v/v ratio with corresponding 
target body fluid. A 100 µL volume of the resulting mixture was applied to a full cotton swab and 
allowed to dry at room temperature overnight. Solid matrix contaminants (i.e., cigarette butt, 
spermicide lubricated condom, menstrual pad) were cut into a 2 cm x 2 cm square prior to applying 
50 µL target body fluid. Prepared samples were dried at room temperature overnight. Full swabs 
and 2 cm x 2 cm contaminant samples were extracted in 1 mL deionized water for 30 minutes with 
frequent vortexing. Substrates were placed in a centrifugal basket centrifuged at 10,000 x g for 10 
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minutes. Supernatant was transferred for analysis following procedures outlined in section 2.1.4 
and cell pellets were discarded.  
3.1.6.3 Mixtures Samples 
 Mixture samples were prepared using single source body fluid from consenting donors. A 
50-fold two-component mixture solution was created by thoroughly vortexing 10 µL of neat body 
fluid serving as a minor contributor with 500 µL neat body fluid serving as the major contributor. 
100 µL of mixture solution was applied to a cotton-tipped swab and allowed to dry at room 
temperature overnight. Full swabs were extracted in 1 mL deionized water for 30 minutes with 
frequent vortexing. Substrates were placed in a centrifugal basket and centrifuged at 10,000 x g for 
10 minutes. Supernatant was transferred for analysis following procedures outlined in section 2.1.4 
and cell pellets were reserved for genetic testing, described in Chapter 4.  
 Five two-component mixture samples were prepared for this portion of the project: (1) 
vaginal fluid in urine, (2) saliva in vaginal fluid, (3) seminal fluid in vaginal fluid, (4) saliva in 
menstrual blood, (5) seminal fluid in menstrual blood.  
3.1.6.4 Sexual Assault Samples 
3.1.6.4.1 Simulated Sexual Assault Samples 
 Simulated sexual assault samples were prepared by thoroughly mixing 10 µL neat semen 
with 1 mL neat vaginal fluid, both fluids being from a single donor. This was repeated for a total of 
seven samples. The semen and vaginal fluid utilized for all seven samples were donated by the 
same individuals to prevent inconsistency in protein expression. Samples were incubated at 37 ˚C 
for one day, three days, five days, seven days, nine days, and eleven days, with time zero samples 
immediately stored for future processing. When the designated time point was reach, samples were 
removed from the incubator and frozen at -80 ˚C until analysis. Samples were prepared and 
analyzed following procedures outlined in section 2.1.4. 
3.1.6.4.2 Mock Sexual Assault Kit Samples 
 Vaginal, oral, and rectal swabs were obtained from a single, consenting female individual. 
Immediately after sampling, neat semen from a single donor was applied in order to most accurately 
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simulate an authentic sample collection. Semen was diluted 100-fold with deionized water prior to 
application. 10 µL of diluted semen was applied, for a volume equivalent of 0.1 µL semen applied 
to each swab. Samples were prepared in duplicate and allowed to dry at room temperature 
overnight. Full swabs were extracted in 1 mL deionized water for 30 minutes with frequent 
vortexing. Substrates were placed in a centrifugal basket and centrifuged at 10,000 x g for 10 
minutes. Supernatant was transferred for analysis following procedures outlined in section 2.1.4 
and cell pellets were reserved for genetic testing, described in Chapter 4. This preparation protocol 
was duplicated using semen provided by a vasectomized male individual, for a total of 12 mock 
sexual assault kit samples (6 non-vasectomized and 6 vasectomized male donors).  
3.1.6.4.3 Digital Swab Samples 
 Three types of digital swab samples were prepared for this portion of the study: vaginal 
swabs, menstrual blood swabs, and saliva swabs. One consenting female donor was utilized. The 
volunteer thoroughly washed their hands prior to self-penetration. In the comfort of the individual’s 
home, the volunteer was instructed to digitally penetrate the vagina both during menses and in the 
absence of menses using the index finger for 20 seconds. The volunteer removed their finger and 
allowed the deposited material to dry for approximately 5 minutes. Self-collection using a dry cotton-
tipped swab was performed, with the entire area of the finger swabbed for collection. Collection 
was repeated in duplicate for each form of penetration, with each sample taken on a separate day. 
Upon receipt at the laboratory, swabs were dried at room temperature overnight to ensure 
consistency. Full swabs were extracted in 1 mL deionized water for 30 minutes with frequent 
vortexing. Substrates were placed in a centrifugal basket and centrifuged at 10,000 x g for 10 
minutes. Supernatant was transferred for analysis following procedures outlined in section 2.1.4 
and cell pellets were reserved for genetic testing, described in Chapter 4. 
3.1.6.5 Degradation Samples 
 Degradation samples simulating laundered items of evidence were generated for this 
portion of the study. Peripheral blood and semen were the selected target body fluids. To a cotton 
bath towel and to denim jeans, 1 mL of single-source peripheral blood was applied to the substrate, 
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outlined with permanent marker, and allowed to dry at room temperature overnight. In addition, a 
control region to which no body fluid was applied approximately 20 cm from the stain region was 
marked for analysis. To a cotton-blend bed sheet and a cotton pair of women’s underwear, 1 mL 
of single-source semen was applied to the substrate, outlined with permanent marker, and allowed 
to dry at room temperature overnight. In addition, a control region to which no body fluid was applied 
approximately 20 cm from the stain region (bed sheet) or 8 cm from the stain region (underwear) 
was marked for analysis. Target body fluid was applied to simulate stained items of evidence that 
are commonly received in caseworking laboratories. 
 Substrates were washed individually with 1.5 fl. oz. commercially available laundry 
detergent (Seventh Generation™ Free and Clear, Burlington, VT) in cold water for a 15-minute wash 
cycle using a household grade washing machine. Substrates were individually dried in a heated 
commercial dryer for approximately 40 minutes. 2 cm x 2 cm cuttings of the stain and control region 
were excised from the substrate. Cuttings were solubilized in 1 mL deionized water for 30 minutes 
with frequent vortexing. Substrates were placed in a centrifugal basket centrifuged at 10,000 x g 
for 10 minutes. Supernatant was transferred for analysis following procedures outlined in section 
2.1.4 and cell pellets were reserved for genetic testing, described in Chapter 4. 
3.1.6.6 Aged Samples 
 Aged swabs were prepared by spotting 50 µL of neat, single-source peripheral blood, 
menstrual blood, saliva, semen, or vaginal fluid on a full cotton swab. An additional set of samples 
were prepared using 150 µL of neat, single-source vaginal fluid. Swabs were allowed to incubate 
at room temperature for 35 days, with collections at time zero, Day 1, Day 3, Day 7, and Day 35. 
Upon collection, full swabs were frozen at -80 °C until analysis. All time points were prepared in 
duplicate. Samples were prepared according to procedures outlined in section 2.1.4. 
3.1.6.7 Sensitivity Samples 
 Sensitivity samples were prepared by diluting single-source, neat body fluid in deionized 
water in a serial manner to cover a range of final concentrations. Dilutions prepared are detailed in 
Table 3.2. 150 µL of each dilution was spotted on a full cotton swab and allowed to dry at room 
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temperature. Full swabs were solubilized in 1 mL deionized water for 30 minutes with frequent 
vortexing. Substrates were placed in a centrifugal basket and centrifuged at 10,000 x g for 10 
minutes. Supernatant was transferred for analysis following procedures outlined in section 2.1.4 
and cell pellets were reserved for genetic testing, described in Chapter 4.  
Table 3.2. Dilutions analyzed for the sensitivity study within casework sample analysis.   
 
3.1.7 Limit of Detection Sample Preparation 
 Isotopically-labeled peptide internal standards (AQUA) were purchased (New England 
Peptide, Inc., Gardner, MA) for each selected peptide marker, with the exception of proteins 
statherin and submaxillary gland androgen-regulated protein 3B. AQUA were received as 1 nmol 
of material, lyophilized to dryness. Material was reconstituted in 200 µL of 30% ACN with 0.1% FA 
in LC-MS grade water. Standards were pooled and brought up to volume in 30% ACN with 0.1% 
FA for a final concentration of 100 pmol/mL. 20 pmol aliquots (200 µL) were prepared, lyophilized, 
and stored at -80 ⁰C. Upon use, 20 pmol aliquots were resuspended in 40 µL of 30% ACN with 
0.1% FA for a 0.5 pmol/µL stock solution.  
 Blank matrix was prepared by pooling target body fluid from five individuals. 100 µg total 
protein underwent tryptic digestion and SPE cleanup prior to AQUA fortification. The 0.5 pmol/µL 
stock solution was further diluted with 30% ACN with 0.1% FA to 50 fmol/µL and 5 fmol/µL 
substocks, used for creation of the serial dilution. Matrix was fortified with AQUA material following 
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volumes and target concentrations listed in Table 3.3. Samples were analyzed following 
parameters outlined in section 2.1.4.  
Table 3.3. Volumes and concentrations of internal standard used during the limit of detection 
experimentation.   
 
3.1.8 Ion Suppression Sample Preparation 
 Target body fluid from five individuals was prepared and pooled for ion suppression and 
enhancement analysis. 100 µg of total protein was targeted for digestion. AQUA stock solution was 
prepared in the same manner as detail in section 3.1.7. Two sample sets were prepared for this 
portion of the study. First, 20 µL of 0.5 pmol/µL AQUA stock solution was analyzed independently 
(i.e., in the absence of blank matrix). Second, pooled body fluid was fortified with 20 µL of 0.5 
pmol/µL AQUA stock for a target amount of 10 pmol, with all samples prepared in triplicate. 
Samples were prepared according to procedures outlined in section 2.1.4. 2.5 µg of sample was 
analyzed per injection.  
3.1.9 Carryover Sample Preparation 
  Samples were prepared in triplicate for a preliminary carryover study by pooling fluid from 
five different individuals and digesting 100 µg of total protein. Following tryptic digestion and SPE 
cleanup parameters outlined in section 2.1.4, samples were reconstituted in 100 µL of 2% ACN 
with 0.1% FA. 10 µg, 20 µg, and 30 µg of processed sample were injected on column, with each 
injection followed by a blank mobile phase injection (0.1% FA in water) of the same volume. 
Carryover was assessed by the presence of compounds within the subsequent blank injection.  
 A second set of samples targeting smaller quantities of total protein were prepared in 
triplicate and analyzed. Following the same procedure as described above, 0.5 µg, 1 µg, 2.5 µg, 
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and 5 µg quantities of digested protein were evaluated per body fluid. A blank mobile phase sample 
(0.1% FA in water) of the same volume was injected directly after each sample.  
3.1.10 Blind Sample Analysis 
 A series of 50 blind samples were received from the grant agency for analysis. No 
information was supplied with the samples received. Samples consisted of pre-halved fiber-tipped 
swabs, swatches of cloth, and condoms. Exhibits were taken according to a pre-defined laboratory 
sampling protocol. Swab samples received were cut in half (i.e., approximately ¼ of a full swab), 
reserving the remain section for additional testing, if necessary. Cuttings measuring 2 cm x 2 cm 
were taken from cloth swatch samples received, reserving the remaining cloth for additional testing, 
if necessary. The inside and outside of condom samples were double swabbed using a sterile 
cotton swab wetted with 2% sodium dodecyl sulfate (SDS) followed by a dry cotton swab. Condom 
swabs were dried at room temperature for at least 2 hours. Wet and dry swabs were combined and 
processed as a single sub-exhibit. Sub-exhibits were solubilized in 500 µL of deionized water for 
30 minutes with frequent vortexing. Substrates were placed in a centrifugal basket and centrifuged 
at 10,000 x g for 10 minutes. Supernatant was transferred for analysis following procedures outlined 
in section 2.1.4 and cell pellets were discarded. 
3.2 Results and Discussion 
3.2.1 Repeatability and Reproducibility 
 Reproducibility was assessed to ensure robust results could be obtained over a period of 
multiple analysis batches prepared by a single individual. Repeatability was evaluated to ensure 
reliable results could be obtained between individual analysts across a period of multiple analysis 
batches. For this portion of the validation, reproducibility and repeatability were assessed in tandem 
through the preparation, analysis, and data acquisition of samples by two analysts over the course 
of a three-day period. This entailed BCA quantitation, robotic digestion, SPE cleanup, and analysis 
via LC-MS/MS.  
 Body fluid samples were received and prepared for testing by a single individual within the 
laboratory. Pooled fluid was aliquoted into single use tubes to ensure consistency of the samples 
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being processed for this portion of the validation. On each day of preparation, analysts performed 
a BCA quantitation on a single use aliquot for each target body fluid to determine the total protein 
concentration prior to tryptic digestion. The necessary reagents for robotic digestion and SPE 
cleanup were prepared individually by the analysts. Data presented in this section is representative 
of the variation observed for the BCA total protein quantitation in addition to the mass spectrometry 
results obtained including signal response, retention time, and qualitative response ratios. 
Furthermore, the performance of the internal positive control between analysts and across the 
three-day period was evaluated for reliability and robustness. 
3.2.1.1 BCA Quantitation 
 BCA quantitation is required prior to tryptic digestion in order to normalize the amount of 
total protein input into the robotic preparation process. This is to ensure that the proper ratio of 
digestion enzyme to protein substrate is met, in addition to monitoring the amount loaded onto the 
SPE cleanup cartridges and LC-MS/MS system. The average protein concentration, as well as the 
measured combined and individual variability of the BCA quantitation assay for each body fluid, is 
detailed in Table 3.4. Coefficient of variation (CV) values both within and between analysts was 
less than 10% across this portion of the validation.  
Table 3.4. Calculated CV (as a percent) of average protein concentration between analysts and 
combined for each fluid assayed. 
 
3.2.1.2 Signal Response 
 The peak area of each peptide in the assay was assessed for all replicates as well as 
across the replicates for the two analysts individually. Of the 46 peptides included in the assay, 41 
showed CV values less than 25%, with the majority of these targets showing less than 10% 
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variation. Data for this portion of the study can be found in Appendix D, with results for seminal 
fluid depicted in Table 3.5.  
 As previously stated, a small fraction of peptides did display higher degrees of peak area 
variability. High CV values were associated with either small hydrophilic (i.e., eluting early during 
chromatographic separation) or large hydrophobic (i.e., eluting late during chromatographic 
separation) peptides. For example, semenogelin 2 peptide GSISIQTEEK is one of the first eluting 
peptides in the assay, with a retention time of 1.9 minutes, and had a combined peak area CV of 
51.764%. It is hypothesized that this specific peptide target is not captured efficiently during the 
SPE cleanup, resulting in more variable recovery across replicates. Likewise, it is hypothesized 
that more hydrophobic peptide markers will be bound, essentially irreversibly, to plastics during 
tryptic digestion and to the sorbent material of SPE cartridges. In addition, there may be reduced 
resolubilization issues after any lyophilization step. At the onset of peptide target selection, it was 
expected that some peptides would display more variability in recovery, solubility, and nonspecific 
absorption than others, simply due to the specific chemistries associated with each amino acid 
sequence. As a counter to this potential challenge, the ability to target multiple proteins per fluid 
and multiple peptides for each protein (i.e., a fundamental concept underlying the design of the 
assay), helped to ensure that there are reliable peptide biomarkers which can be consistently 
detected for identification of each fluid. For example, other semenogelin 2 peptides (e.g., 










Table 3.5. Calculated CV (as a percent) for peak area response of seminal fluid peptide markers 
between analysts and combined. 
 
3.2.1.3 Retention Time 
 The retention time of each peptide biomarker in the assay was assessed for all replicates 
as well as across the three replicates for the two analysts. Retention time averages for each analyst 
were used to calculate the variability. Percent CV values for this dataset were all below 0.5%. An 
illustrative example of results for seminal fluid is shown in Table 3.6. The remainder of the data are 
presented in Appendix E.  
Table 3.6. Calculated CV (as a percent) for retention time of seminal fluid peptide markers between 
analysts and combined. 
 
3.2.1.4 Qualitative Response Ratios 
 The ion ratio for each peptide biomarker was assessed by dividing the peak area response 
of the quantifier ion (i.e., more abundant transitions observed during target selection) by the peak 
area response of the qualifier ion(s) (i.e., lower abundant transitions observed during peptide 
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selection). Ion ratios were assessed for all replicates as well as across the two analysts. The ion 
ratios for all peptides were found to be highly consistent, with a majority of calculations showing 
CV values less than 5%. An illustrative example of results for seminal fluid is shown in Table 3.7. 
Epididymal secretory protein peptide DCGSVDGVIK exhibited a higher CV value but was 
consistent between the two analysts, demonstrating a high rate of precision both within-run and 
between-run. The remainder of the data are presented in detail in Appendix F. Only neutrophil 
gelatinase protein in menstrual blood exhibited higher variability in the qualitative response ratio. 
In this case, the proteins were of very low abundance in the pooled sample being assessed.  
Table 3.7. Calculated CV (as a percent) for ion ratios of seminal fluid peptide markers between 
analysts and combined.  
 
3.2.1.5 Internal Positive Control 
 The performance of the internal positive control (IPC) was assessed by comparing the 
response ratio of the digested myelin basic protein to that of an isotopically-labeled internal 
standard added to the sample being analyzed. The response ratio was found to be highly consistent 
across all body fluids. The variability observed both among different samples of individual body 
fluid and between different body fluids consistently displayed CV values less than 8% (Table 3.8 
and Figure 3.1). Samples evaluated for this portion of the validation displayed and average peak 





Table 3.8. Combined calculated CV (as a percent) for the internal positive control peak area 
response ratio for the duration of repeatability and reproducibility experimentation. 
 
 
Figure 3.1. Internal positive control response ratio for the duration of repeatability and 
reproducibility experimentation.   
3.2.2 Sensitivity 
 A series of dilutions were prepared for each body fluid using pooled material from multiple 
individuals. These samples were assayed in order to establish the minimal protein quantity in which 
reliable results can be obtained. Based on data acquired under previous phases of this research 
and the sensitivity limits observed under previously completed research (NIJ awards 2009-DN-BX-
K165; 2012-DN-BX-K035) the lower end of the dilution series was considerably extended from prior 
studies in order to evaluate lower limits of the assay. For peripheral blood and menstrual blood, a 
2-fold dilution series was made, from a 1:100 dilution to a 1:6,533,600 dilution. For seminal fluid, a 
2-fold dilution series from 1:2 through 1:524,288 was made. And lastly, for saliva and vaginal fluid, 
a 2-fold dilution series from 1:2 to 1:65,536 was generated. Not all created dilutions were analyzed 
via LC-MS/MS.  
 Data for each body fluid is summarized in Tables 3.9-3.13. Results were evaluated for 
retention time consistency, chromatographic peak shape, peak area response, as well as 
calculated ion ratios. Overall, peripheral blood was confidently identified at a 1:6,533,600 dilution 
(Table 3.9) and menstrual blood at 1:6,400 dilution (Table 3.10). Although both peptide targets for 
hemoglobin were accurately detected at the lowest dilution in the peripheral blood matrix, a majority 
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of the remaining protein markers exhibited dropout at the 1:204,800 dilution. Similar results were 
observed for peripheral blood protein markers in menstrual blood; however, vaginal fluid markers 
in menstrual blood were shown to exhibit less sensitivity. Four protein targets failed to be detected 
within the menstrual blood matrix (Ly6 PLAUR, suprabasin, periplakin, and involucrin), with 
remaining biomarkers exhibiting dropout at the protein level after the 6,400-fold dilution. Small 
proline rich protein 3 was detected in each dilution assessed, however, peptide peak areas did not 
display negative linearity as the dilution series decreased. Peak area intensities for peptide 
VPEPGCTK remained consistent between the 25,600-fold dilution and the 6,533,600-fold dilution 
(Figure 3.2). Therefore, this marker was not considered when characterizing menstrual blood for 
biomarker sensitivity. Strong instances of peptide and protein dropout, particularly for the vaginal 
fluid biomarkers in this matrix, may be attributed to expression variability during the menstruation 
cycle.  
 Seminal fluid was accurately detected at the lowest dilution assessed, with three peptides 
identified at the 524,288-fold dilution (Table 3.11). All peptide targets were correctly detected at 
the 16,389-fold dilution, with linear peptide and protein dropout displayed as the dilution series 
decreased. Semenogelin 1, semenogelin 2, and acid phosphatase peptide targets met all 
acceptance criteria at the lowest dilution sample.  
 Saliva was characterized at the lowest dilution tested, with a single alpha amylase peptide 
detected at the 65,536-fold dilution (Table 3.12). All peptide markers were detected through the 
256-fold dilution, and similar to seminal fluid, exhibited linear protein and peptide dropout as the 
dilution series decreased. With the exception of alpha amylase, remaining protein markers 
displayed complete dropout at the 8,192-fold dilution tested.  
 Vaginal fluid was identified in a two-tiered manner. Because the target biomarkers exhibit 
a wide range of specificity for vaginal fluid, the confidence level of accurately detecting and 
identifying vaginal fluid fluctuates. For this data set, vaginal fluid was confidently identified down to 
the 2,048-fold dilution by the presence of cornulin and neutrophil gelatinase, both of which exhibit 
strong specificity for vaginal fluid (Table 3.13). However, small proline rich protein 3 was detected 
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at the 32,768-fold dilution. Given the known cross-reactivity this protein exhibits, vaginal fluid 
detection was made with less confidence at this lower range. The use of this protein as a 
presumptive biomarker has been thoroughly detailed in interpretation guidelines.  
Table 3.9. Observed sensitivity limit of peripheral blood. Proteins that were positively identified by 
all of their respective peptide markers are shown in dark green. Light green indicates where at least 
one peptide marker for the respective protein dropped out. White indicates complete protein 
dropout.  
 
Table 3.10. Observed sensitivity limit of menstrual blood. Proteins that were positively identified 
by all of their respective peptide markers are shown in dark green. Light green indicates where at 
least one peptide marker for the respective protein dropped out. White indicates complete protein 
dropout. 
 
Table 3.11. Observed sensitivity limit of seminal fluid. Proteins that were positively identified by all 
of their respective peptide markers are shown in dark green. Light green indicates where at least 
one peptide marker for the respective protein dropped out. White indicates complete protein 
dropout. 
 
Table 3.12. Observed sensitivity limit of saliva. Proteins that were positively identified by all of their 
respective peptide markers are shown in dark green. Light green indicates where at least one 




Table 3.13. Observed sensitivity limit of vaginal fluid. Proteins that were positively identified by all 
of their respective peptide markers are shown in dark green. Light green indicates where at least 




Figure 3.2. Small proline rich protein 3 peptide VPEPGCTK peak area response. (A) Peak area 
intensity at a 25,600-fold dilution. (B) Peak area intensity at a 6,553,600-fold dilution. (C) Peak area 
response across all replicates evaluated, progressing from 1,600-fold to 6,553,600-fold dilution.  
3.2.3 Stability 
 Stability was evaluated to ensure that samples remain viable if an instrumentation error or 
power outage were to occur that causes samples either: (1) to remain in the autosampler overnight 
without being processed or (2) to be subjected to additional freeze-thaw cycles. This portion of the 
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validation assessed two aspects of a sample’s stability. First, freeze thaw stability was evaluated 
using aliquots of pooled samples. Three samples were assayed immediately and served as 
baseline peak area response. The remaining six samples were stored at -80 ˚C. All six remaining 
aliquots were thawed the following day. Three of the thawed samples were analyzed on the second 
day and the remaining three were refrozen for subsequent thawing and analysis on day three. The 
second form of stability assessed, autosampler stability, was evaluated by storing processed 
samples in the chilled autosampler and analyzing them over a period of 3 days.  
3.2.3.1 Freeze Thaw Stability 
 Single use aliquots of pooled body fluid were evaluated over two freeze thaw cycles to 
evaluate if storage would have a negative effect on the detection of a particular fluid (Tables 3.14 
and 3.15). A significant reduction in signal intensity would indicate that samples are degrading 
during the freeze-thaw process and would require re-extraction, digestion, and cleanup prior to 
reliable analysis. Overall, only one vaginal fluid peptide was affected by repeated freeze thaw 
cycles (Table 3.15). Suprabasin peptide FGQGVHHGLSEGWK was detected in Day 1 samples 
but was absent after the first freeze thaw cycle (Figure 3.3). Because FGQGVHHGLSEGWK is a 
low abundant target, even minor degradation of the sample appears to have deleterious effects. In 
addition to the one suprabasin peptide in vaginal fluid, several markers (e.g., suprabasin, periplakin, 
etc.) in menstrual blood were not detected during this portion of the study. These results may be 
attributed to the low abundance of these markers in the menstrual blood matrix, which is consistent 
with results observed under subsequent aims. Furthermore, given that protein dropout was 
observed on Day 1 of the study, it is more likely due to low abundance in comparison with protein 
biomarker degradation due to instability. Finally, performance of the IPC was assessed to ensure 
complete sample preparation over the course of this study (Figure 3.4). Although a negative trend 
pattern is visible when plotting the IPC response ratio over time, all calculated ratios fell within 




Table 3.14. Freeze thaw stability results for peripheral blood, saliva, and seminal fluid. Peptide 






Table 3.15. Freeze thaw stability for vaginal fluid and menstrual blood. Peptide markers that were 





Figure 3.3. Suprabasin peptide FGQGVHHGLSEGWK peak area response in vaginal fluid. (A) 
Peak area intensity on Day 1. (B) Peak area intensity on Day 2. (C) Peak area response on Day 3. 
(D) Peak area response across all triplicates evaluated, progressing from Day 1 to Day 3.  
 
Figure 3.4. Internal positive control response ratio for the duration of freeze thaw stability 
experimentation.   
3.2.3.2 Autosampler Stability 
 Three replicates of the five target body fluids were processed and evaluated over a period 
of 3 days. Samples were analyzed on Day 1 (i.e., 0 hours) and stored on the liquid chromatograph’s 
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chilled autosampler set at 8 ˚C. The same samples were then reinjected 24 hours (Day 2) and 
again at 48 hours (Day 3) after original processing to assess fluctuations in detection signal. A 
significant drop in signal strength or quality would indicate that any samples stored in excess of 24 
hours on the autosampler would need to be re-extracted, digested, and cleaned up. Fortunately, 
the resulting data confirms that no such problems occurred. There was no sufficient drop in peak 
area response for any target peptide in the assay. On the contrary, a slight increase in peak area 
response was often observed. This was evident across all fluids; however, this increase is not 
sufficient. This was attributed to sample evaporation and concentration of target peptides that 
occurred after the 96-well sample plate cover was punctured for initial injection, resulting in 
evaporation of reconstitution solvent. Detailed results for this portion of the study are outlined in 
Appendix G. In addition, IPC ion ratios across the three days were calculated, with no significant 
difference between ion ratios for 0 and 24 hours (ts=0.404, df=58, P>0.05) or for 0 and 48 hours 
(ts=1.084, df=58, P>0.05). Percent CV value for the IPC are listed in Table 3.16. Overall, these 
results indicate that samples plated on the autosampler can be analyzed within two days of being 
processed without significant change in signal strength.  
Table 3.16. Calculated CV (as a percent) for the internal positive control for the duration of the 
autosampler stability study.  
 
3.2.4 Mixtures Study 
 Pooled samples from five individuals were prepared in triplicate as 1:1 v/v mixtures among 
each of the five target fluids. The primary purpose of this mixture study was to identify potential 
cross-fluid interference and ion suppression that could produce a false negative or false positive 
result. The pairwise matrix of five body fluids includes all possible combinations of fluid interactions. 
Typical of toxicological assays, this study was designed to mimic interference studies performed 
as part of LC-MS/MS validations in operational toxicology laboratories. It is important to emphasize 
that the objective of this study is fundamentally different from mixture studies performed in forensic 
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DNA testing. In the context of DNA assay validation, the goal of a mixture study is typically to detect 
and resolve major and minor contributors.  
 In several cases, cross-fluid interferences were detected, potentially leading to difficulties 
in the interpretation of results. These have been identified, and using an abundance of caution, the 
interfering transition was either removed or replaced. For example, a major interference peak was 
detected with prostatic acid phosphatase peptide FVTLFR when seminal fluid was mixed with 
peripheral blood (Figure 3.5). In this case, the transition m/z 534.3398+ (purple peak) generates 
the interference peak. By replacing transition m/z 534.3398+ with transition m/z 247.1441+, the 
problem was readily eliminated in all subsequent analyses.  
 
Figure 3.5. Prostatic acid phosphatase peptide FVTLFR peak area response in (A) neat seminal 
fluid and (B) seminal fluid and peripheral blood mixture. The m/z 534.3398+ transition (purple peak 
denoted with arrow) was removed and replaced.  
3.2.5 Specificity Samples 
 The amino acid sequences of each biomarker were previously screened against protein 
databases to assess the possibility of obtaining positive results from non-human proteins. To 
remain in concordance with governing validation guidelines, additional in vitro experimentations 
was conducted to demonstrate species specificity. The data presented in this section demonstrates 
this empirically, through the analysis of domestic pet and livestock body fluid samples. Seven 
peripheral blood samples (Rhesus monkey, pig, horse, chicken, cow, mouse, and dog) were 
purchased and four peripheral blood samples (coyote, white-tailed deer, black bear, and river otter) 
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were acquired from previous projects. In addition, four saliva samples (cow, Rhesus monkey, 
tortoise, and alpaca) were procured.  
 The results of this study are outlined in Table 3.17. It was previously determined through 
investigation of database entries that the selected hemoglobin peptide sequences were not human 
specific. It is well known that the hemoglobin amino acid sequence is highly conserved across 
mammals, particularly in higher order primates (Figure 3.6). As hypothesized, hemoglobin was 
identified across most of the species assayed. In addition, there were two instances of trace vaginal 
fluid biomarkers, neutrophil gelatinase and Ly6 PLAUR, detected in cow and Rhesus monkey saliva 
(Figure 3.7). Trace levels of acid phosphatase and epididymal secretory protein were detected in 
cow and Rhesus monkey peripheral blood samples as well.  
Table 3.17. Species specificity of protein biomarkers within the multiplex assay. Light green is 
indicative of at least one peptide marker identification for the respective protein. White indicates no 





Figure 3.6. Hemoglobin peptide LLVVYPWTQR peak area response in (A) Rhesus monkey and 
(B) human peripheral blood.  
 
Figure 3.7. Peak area response of vaginal fluid markers in saliva samples. Ly6/PLAUR peptide 
GCVQDEFCTR peak area intensity in (A) bovine saliva, (B) Rhesus saliva, and (C) human vaginal 
fluid control samples. Neutrophil gelatinase peptide MYATIYELK peak area intensity in (D) Rhesus 
saliva and (E) human vaginal fluid control samples. 
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 There were no instances of cross reactivity with the established assay for peripheral blood 
from chicken, coyote, or dog in addition to alpaca saliva (Figure 3.8). A more comprehensive 
assessment with the inclusion of additional target fluids from various species could present further 
chromatographic interferences. Overall, the results of this experimentation stress the importance 
of clear interpretation guidelines, particularly when examining potential trace amounts of body fluid 
when only one biomarker is present.  
 
Figure 3.8. Peak area response of species specificity samples evaluated. (A) alpaca saliva sample 
protein cystatin peptide ALHFVISEYNK, (B) alpaca saliva sample protein amylase peptide 
LSGLLDLALGK, (C) hemoglobin peptide LLVVYPWTQR across all blood sample obtained.  
3.2.6 Casework Type Samples 
 Laboratory simulated forensic casework type samples were evaluated to identify additional 
performance limitations, particularly with the analysis of trace level samples, and to aid in the 




3.2.6.1 Substrate Samples 
 Various substrate compositions were analyzed to ensure chemical products (i.e., indigo 
dye) or extraction efficiency off different materials (i.e., cotton versus leather) would not interfere 
with the detection of protein biomarkers. Single source body fluids were evaluated on the following 
substrates: cotton, leather, denim, carpet, drywall, plastic bottle, aluminum bottle, and feminine 
hygiene menstrual pad. Results from this study are detailed in Table 3.18.  
 Peripheral blood was applied to cotton, denim, carpet, leather, and drywall. Upon 
processing, all peripheral blood peptide markers were detected and identified for each substrate 
type. No indication of suppression due to substrate composition was observed during analysis. 
Saliva was applied to plastic bottle and aluminum bottle cuttings. Analysis of the substrates showed 
that all saliva peptide markers were accurately identified. Similar to peripheral blood results, 
biomarkers were not suppressed due to substrate composition. Seminal fluid was applied to cotton 
and leather. All seminal fluid peptide markers were detected during analysis, indicating substrate 
composition did not affect the ability to accurately identify seminal fluid.  
 Vaginal fluid was applied to cotton, denim, and leather. Instances of vaginal fluid peptide 
dropout were observed during evaluation. For the cotton sample analyzed, all peptide markers with 
the exception of suprabasin peptide FGQGVHHGLSEGWK were detected. Similarly, peptide 
dropout for suprabasin peptide FGQGVHHGLSEGWK and involucrin peptide 
HLVQQEGQLEQQER were observed during analysis of vaginal fluid recovered from leather. The 
greatest instance of peptide dropout was observed with the analysis of vaginal fluid when applied 
to denim. Five vaginal fluid proteins, neutrophil gelatinase, Ly6/PLAUR, suprabasin, periplakin, and 
involucrin were incompletely detected, with dropout of at least one peptide per protein.  
 Similar vaginal fluid biomarker dropout was evident during menstrual blood analysis. 
Menstrual blood was applied to cotton, denim, and a feminine hygiene menstrual pad. Although all 
peripheral blood markers were positively detected, instances of vaginal fluid peptide dropout and 
complete protein dropout were observed. Across all substrates tested, three proteins exhibited 
complete dropout: suprabasin, involucrin, and Ly6/PLAUR. Furthermore, peptide dropout for 
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proteins cornulin and periplakin was also observed, leaving proteins neutrophil gelatinase and small 
proline-rich protein 3 as the only vaginal fluid markers completely identified. 
Although suppression from substrate composition is a possible explanation as to the 
dropout of vaginal fluid peptide markers for both the analysis of vaginal fluid and menstrual blood 
matrices, the endogenous low-level abundance of these proteins must be taken into consideration. 
The dilution of protein material during extraction is a more probable explanation, causing the protein 
markers to be below the limit of detection. Furthermore, because the protein biomarker dropout 
during menstrual blood analysis was not dictated by the substrate on which the fluid was applied, 
the consistency across substrate type further substantiates the lower abundance of vaginal markers 
to protein absence during analysis. In conclusion, the composition of common substrates 
encountered during forensic analysis do not affect the ability for protein biomarkers to be identified 
using the developed workflow.  
Table 3.18. Detection of body fluid markers in substrate samples. Proteins that were positively 
identified by all of their respective peptide markers are shown in dark green. Light green indicates 
where at least one peptide marker for the respective protein dropped out. Red indicates complete 
protein dropout. White indicates not tested.  
 
3.2.6.2 Environmental Contaminant Samples 
 A variety of environmental contaminants were selected and tested to evaluate potential 
concerns with enzymatic digestion, peptide cleanup, or to detect any instances of unanticipated 
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interferences during instrumental analysis. Single source body fluids were tested with the following 
environmental contaminants: dirt, rust, 10% bleach solution, chewing tobacco, cigarette butt, 
spermicide lubricated condom, and water-based personal lubricant. Results from this study are 
detailed in Table 3.19.  
 Peripheral blood was applied and mixed with dirt, rust, and a 10% bleach solution. All 
peripheral blood peptide markers met acceptance criteria and were positively identified during 
analysis. Similarly, saliva was applied and mixed with chewing tobacco and a cigarette butt. All 
saliva peptide biomarkers met acceptance criteria and were positively identified. Seminal fluid was 
applied and mixed with water-based personal lubricant, spermicide lubricated condom, and 10% 
bleach solution. With the exception of the 10% bleach solution, all seminal fluid peptide markers 
were positively identified. Epididymal secretory protein E1 peptide SGINCPIQK was not detected 
in 10% bleach solution.  
 Vaginal fluid was applied or mixed with water-based personal lubricant and a spermicide 
lubricated condom. This study was repeated with menstrual blood following equivalent sample 
preparation parameters. Detection of vaginal fluid peptide markers within these two matrices was 
determined to be specific for the environmental contaminant being assessed. Beginning with the 
vaginal fluid matrix, no instances of protein dropout were observed when analyzed from a 
spermicide lubricated condom. However, peptide and protein dropout were exhibited with the 
introduction of water-based personal lubricant. Complete protein dropout of suprabasin, 
Ly6/PLAUR, periplakin, small proline rich protein 3, and involucrin in addition to peptide dropout of 
protein cornulin were observed. The lack of detection when subjected to lubricant is likely due to 
two separate chemical interactions. First, lubricant is composed of long, lipophilic hydrocarbons 
that act as a competitive species during SPE cleanup. Lubricant hydrocarbons are preferentially 
bound to sorbent material during SPE as a result of their chemical structure. Although a simple 
addition of sodium dodecyl sulfate (SDS) would eliminate this interference, SDS is not compatible 
with mass spectrometry analysis.  
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Second, the specific type of personal lubricant utilized during this study contained glycerol 
(propane-1,2,3-triol), a compound produced from the hydrolysis of triglycerides that increases the 
solubility of proteins when in matrix. At concentrations greater than 10%, glycerol causes inaccurate 
protein quantitation [159]. Diluting the sample to decrease the interference caused by this 
ingredient is not suitable for analysis as the vaginal fluid peptide markers exist endogenously in low 
abundance, resulting in a misleading quantitation value.  
 Similar with menstrual blood containing samples, protein and peptide dropout was 
exhibited. Vaginal fluid protein biomarkers Ly6/PLAUR, suprabasin, and involucrin were not 
detected and peptide marker dropout was exhibited for proteins cornulin and periplakin. However, 
there was consistency in protein dropout observed between contaminant sample types, indicating 
that the natural low-level abundance of vaginal fluid markers attributes to the lack of detection. 
Furthermore, the protein detection for these sample types is equivalent to that reported during the 




Table 3.19. Detection of body fluid markers in samples subjected to environmental contaminants. 
Proteins that were positively identified by all of their respective peptide markers are shown in dark 
green. Light green indicates where at least one peptide marker for the respective protein dropped 
out. Red indicates complete protein dropout. White indicates not tested. 
 
3.2.6.3 Mixtures 
 The purpose of this study was to evaluate the performance of the optimized assay when 
analyzing mixed samples with a major and minor component. Five two-fluid mixtures were 
prepared, with pairings selected based on sample types routinely tested for in operational forensic 
laboratories. For example, a seminal fluid minor contributor in a vaginal fluid major contributor was 
prepared to simulate a sexual assault type sample. Results from this study are summarized in 
Table 3.20.  
 With the exception of urine, for which protein biomarkers are not included within the 
developed assay, all major and minor body fluid contributors were correctly identified. Beginning 
with the vaginal fluid minor contributor in a urine major contributor, high rates of vaginal fluid protein 
marker dropout were observed. Fluid identification was made from the presence of small proline 
rich protein 3 and cornulin. The urine matrix predictably diluted the vaginal fluid markers past the 
limit of detection of the assay. In addition, although the average urea composition (9.5 g/L) in urine 
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is below the concentration incompatible with the BCA protein quantitation assay [159], the presence 
of urea and additional salts endogenous to urine may have negatively affected the ability to produce 
a reliable protein quantitation value. Therefore, if the total protein quantitation was underestimated, 
less then optimal protein amounts would have been utilized for testing.  
 The saliva minor contributor was confirmed present in a vaginal fluid major contributor 
based on the presence of alpha amylase and submaxillary gland androgen-regulated protein 3B. 
Furthermore, all vaginal fluid protein markers were accurately identified. 
 The third two-component mixture tested was a seminal fluid minor contributor in a vaginal 
fluid major contributor. Only one instance of peptide dropout was observed, with seminal fluid 
protein prostate specific antigen peptide FLRPGDDSSHDLMLLR being undetected. The remaining 
protein markers were positively identified, particularly confirmatory markers semenogelin 1 and 
semenogelin 2. As expected, the vaginal fluid major contributor was also positively identified by all 
protein biomarkers consistent with vaginal fluid. 
 The seminal fluid minor contributor was positively confirmed in a menstrual blood major 
contributor, with all protein biomarkers accurately detected and identified. However, as seen with 
other casework type samples, instances of peptide and protein dropout were observed for 
menstrual blood characterization. Although vaginal fluid proteins cornulin, neutrophil gelatinase, 
and small proline rich protein 3 were present, in addition to peptides consistent with periplakin and 
involucrin, protein dropout of Ly6/PLAUR and suprabasin was exhibited. This dropout is consistent 
with results obtained during Substrate and Environment Contaminant studies (sections 3.2.6.1 and 
3.2.6.2, respectively), with endogenous low-level abundance negatively affecting the ability to 
detect these proteins in a complex matrix such as menstrual blood.  
 The last two-component mixture analyzed was a saliva minor contributor in a menstrual 
blood major contributor. The saliva contributor was identified based on the sole presence of protein 
alpha amylase. Because this protein has demonstrated cross-expression in other body fluids and 
tissues, the presence of saliva in this particular sample cannot be reported as confirmatory. 
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Furthermore, as observed with the seminal fluid in menstrual blood mixture previously described, 
there was consistent vaginal fluid protein biomarker dropout exhibited in this sample.  
Table 3.20. Detection of body fluid markers in mixture samples. Proteins that were positively 
identified by all of their respective peptide markers are shown in dark green. Light green indicates 
where at least one peptide marker for the respective protein dropped out. Red indicates complete 
protein dropout. White indicates not tested. 
 
3.2.6.4 Sexual Assault Samples 
3.2.6.4.1 Simulated Sexual Assault Samples 
 Prepared samples were allowed to incubate at 37 ˚C for up to and including eleven days 
after preparation. At time zero, proteins semenogelin 1, semenogelin 2, and epididymal secretory 
protein were positively identified (Table 3.21). The complete panel of seminal fluid peptide markers 
was not detected in full during any timepoints evaluated during this study. Only epididymal 
secretory protein was consistently detected over the course of the eleven-day incubation study. 
Furthermore, a single peptide for both semenogelin 1 and 2 were consistently identified over the 
course of the study (Figure 3.9). Peptide dropout for proteins prostatic acid phosphatase and 
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prostate specific antigen was observed at time zero, with complete protein dropout of prostate 
specific antigen observed for the remainder of the study. Prostatic acid phosphatase exhibited 
protein dropout after day seven.  
 This study demonstrates the robustness of the seminal fluid peptide markers selected for 
inclusion within the larger multiplex panel. For example, prostate specific antigen’s inherent function 
is to cleave semenogelin proteins in order to liquify ejaculated semen. With the ability to detect 
semenogelin proteins after incubation for eleven days further exemplifies that the selected peptide 
markers do not fall within amino acid cleavage sites. Furthermore, the inherent hostile environment 
of vaginal fluid in terms of acidic pH and endogenous proteases, did not negatively affect the ability 
to positively characterize “invasive” seminal fluid proteins to an extent as great as originally 
hypothesized.    
Table 3.21. Detection of body fluid markers in simulated sexual assault samples. Proteins that were 
positively identified by all of their respective peptide markers are shown in dark green. Light green 
indicates where at least one peptide marker for the respective protein dropped out. White indicates 





Figure 3.9. Peak area response of seminal fluid biomarkers in simulated sexual assault samples. 
Semenogelin 1 peptide QITIPSQEQEHSQK peak area intensity (A) at Day Eleven and (B) over the 
entirety of the incubation study. Semenogelin 2 peptide GSISIQTEEK peak area intensity (C) at 
Day Eleven and (D) over the entirety of the incubation study.  
3.2.6.4.2 Mock Sexual Assault Kit Samples 
 Mock sexual assault kit samples were prepared in duplicate using semen provided by a 
vasectomized and a non-vasectomized male individual (Table 3.22). For sexual assault swabs 
prepared with semen from a non-vasectomized donor, seminal fluid was positively identified 
through the detection of the following protein fingerprints. Beginning with vaginal swab samples, 
two occurrences of seminal fluid protein dropout were recorded for a single sample (SA01_01.2). 
Prostate specific antigen and epididymal secretory protein were not positively identified; however, 
prostatic acid phosphatase, semenogelin 1, and semenogelin 2 were completely characterized. In 
addition, given the sample type, vaginal fluid protein markers were successfully detected and 
identified for both samples being assessed. Similar results were recorded for the oral swab sample 
types. All seminal fluid biomarkers were detected, with the exception of epididymal secretory 
protein, which exhibited complete dropout. Furthermore, given the sample type, all saliva 
biomarkers were accurately detected with no protein dropout exhibited. Rectal swab samples were 
shown to exhibit protein inhibition, with occurrences of seminal fluid protein dropout for both sample 
collections. Prostate specific antigen and epididymal secretory protein were not detected, in 
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addition to peptide dropout observed for prostatic acid phosphatase and semenogelin 2 (Figure 
3.10).  
 Similar results were observed for samples prepared with semen from a vasectomized 
donor. Vaginal swab samples produced positive detection of prostatic acid phosphatase and 
semenogelin 1 seminal fluid proteins, in addition to vaginal fluid biomarkers. However, for both 
samples being analyzed, prostate specific antigen was not detected. Furthermore, semenogelin 2 
exhibited peptide dropout. Second, oral swab samples were confirmed to contain seminal fluid due 
to the identification of semenogelin 1 and 2. The first swab analyzed (SA02_02.1) exhibited protein 
dropout for prostate specific antigen and epididymal secretory protein. The second oral swab 
(SA02_02.2) was only lacking epididymal secretory protein. Lastly, comparable with the non-
vasectomized samples, the rectal swabs containing displayed occurrences of protein inhibition. For 
both sample collections, prostate specific antigen and epididymal secretory protein were not 
detected. Furthermore, peptide dropout of proteins prostatic acid phosphatase and semenogelin 2 
were reported, with instances of semenogelin 1 peptide dropout for sample SA02_03.1 (Figure 
3.11).  
 In summary, the LC-MS/MS assay was able to accurately identify trace amounts of seminal 
fluid from both non-vasectomized and vasectomized male individuals. Moreover, the protein 
inhibition reported from rectal swab sample analysis can be attributed to the increased presence of 
bacteria common for this sample type [160]. Bacteria of the human gut microbiome contain serine 
protease inhibitors, which may negatively affect the function of trypsin during protein digestion 








Table 3.22. Detection of body fluid markers in sexual assault kit samples. Proteins that were 
positively identified by all of their respective peptide markers are shown in dark green. Light green 
indicates where at least one peptide marker for the respective protein dropped out. White indicates 





Figure 3.10. Peak area response of seminal fluid biomarkers in mock sexual assault kit samples 
containing semen from a non-vasectomized donor. Prostate specific antigen peptide 
LSEPAELTDAVK peak area intensity in (A) vaginal swab (B) oral swab (C) rectal swab. 
Semenogelin 2 peptide GSISIQTEEK peak area intensity (D) across vaginal, oral, and rectal swab 
sample replicates. Semenogelin 1 peptide QITIPSQEQEHSQK peak area intensity (E) across 




Figure 3.11. Peak area response of seminal fluid biomarkers in mock sexual assault kit samples 
containing semen from a vasectomized donor. Prostate specific antigen peptide LSEPAELTDAVK 
peak area intensity in (A) vaginal swab (B) oral swab (C) rectal swab. Semenogelin 2 peptide 
GSISIQTEEK peak area intensity (D) across vaginal, oral, and rectal swab sample replicates. 
Semenogelin 1 peptide QITIPSQEQEHSQK peak area intensity (E) across vaginal, oral, and rectal 
swab sample replicates. 
3.2.6.4.3 Digital Swabs  
 Digital swab samples were collected on separate days for a total of two swab types, with 
each sample serving as a distinct sample collection. A summary of results is outlined in Table 3.23. 
Beginning with the oral penetration digital swabs, all saliva protein biomarkers were positively 
identified for both sample collections. The first sample evaluated was positive for alpha amylase 
and submaxillary gland androgen-regulated protein 3B, with peptide dropout observed for proteins 
statherin and cystatin SA. The second sample analyzed was positive for submaxillary gland 
androgen-regulated protein 3B and cystatin SA, with peptide dropout exhibited for alpha amylase 
and statherin. There were no instances of complete protein dropout observed for oral penetration 
digital swabs. Although inconsistencies were observed for alpha amylase detection between the 
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two samples received, the identification of submaxillary gland androgen-regulated protein 3B was 
encouraging, as this protein exhibits saliva specificity.  
 Vaginal penetration digital swabs were accurately identified by the presence of at least one 
peptide marker for all vaginal fluid markers within the assay. For the first sample analyzed, peptide 
dropout was observed for proteins cornulin, Ly6/PLAUR, periplakin, involucrin, and small proline 
rich protein 3; however, identification was made due to the presence of neutrophil gelatinase and 
suprabasin. Similarly, the second sample evaluated exhibited peptide dropout for proteins cornulin, 
periplakin, involucrin, and small proline rich protein 3. It should be noted that epididymal secretory 
protein, a presumptive seminal fluid protein biomarker, was detected for both vaginal penetration 
digital swabs. 
 Vaginal penetration during menses swabs were taken at both the beginning and the end 
of menstruation, creating two unique samples. The first digital swab was taken at the beginning of 
menstruation and was positively identified by both vaginal fluid and peripheral blood protein 
markers. Although protein dropout was observed for protein cornulin, three vaginal fluid markers 
were completely identified (neutrophil gelatinase, suprabasin, and involucrin). Furthermore, all 
peripheral blood proteins were detected, with high abundance of protein hemoglobin and alpha-1 
antitrypsin reported. The second sample analyzed was collected at the end of menstruation, 
causing the sample to more closely resemble a vaginal swab than a menstrual swab. No instances 
of vaginal fluid biomarker dropout were observed. In addition, as expected, signal intensities for 




Table 3.23. Detection of body fluid markers in digital swab samples. Proteins that were positively 
identified by all of their respective peptide markers are shown in dark green. Light green indicates 
where at least one peptide marker for the respective protein dropped out. White indicates complete 
protein dropout. 
 
3.2.6.5 Degraded Samples 
 Substrates were prepared to simulate authentic items of evidence that have been 
laundered. Upon analysis, both the stain region and the control (non-stain region) of the same 
substrate were processed concurrently. A complete summary of results is depicted in Table 3.24. 
Peripheral blood containing samples (cotton bath towel, denim) yielded positive identifications for 
all target peripheral blood biomarkers. For the towel sample, peptide dropout for apolipoprotein and 
serotransferrin was observed. The denim sample containing peripheral blood did not exhibit any 
instances of peptide or protein dropout. Both the towel and denim control regions were negative for 
all peripheral blood protein targets.  
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 Seminal fluid was accurately identified on both substrates evaluated (cotton-blend bed 
sheet, cotton underwear). All protein markers were positively detected for the underwear stain 
region, with one instance of peptide dropout exhibited for prostate specific antigen. The control 
region for this substrate was negative for all biomarkers. The bed sheet sample had a single 
occurrence of protein dropout for epididymal secretory protein, with peptide dropout exhibited by 
prostatic acid phosphatase and prostate specific antigen. The control region for this substrate was 
also negative for all protein markers. 
 It was originally hypothesized that the use of laundry detergent may severely inhibit 
biomarker detection, given that detergent is commonly used to lyse cell membranes and denature 
protein, but have additional deleterious effects on SPE chemistries. Furthermore, detergent is 
generally incompatible with mass spectrometer functionality. However, laundering of the stain 
regions did not inhibit the ability to accurately identify target biomarkers within the validated assay. 
Additional studies into the effect of different detergent formulations would be of interest. A detergent 
marketed as “natural” was selected for this subset of samples, however, it is hypothesized that 




Table 3.24. Detection of body fluid markers in degraded samples. Proteins that were positively 
identified by all of their respective peptide markers are shown in dark green. Light green indicates 
where at least one peptide marker for the respective protein dropped out. White indicates complete 
protein dropout. 
 
3.2.6.6 Aged Samples 
 Aged body fluid swabs were prepared to assess the degradation of target protein markers 
in addition to extraction efficiency when target body fluids were not stored under ideal conditions. 
Protein identification results for all aged samples are outlined in Table 3.25. Peripheral blood 
biomarkers were detected at all time points collected. No instances of protein degradation were 
observed, with all peak intensities remaining consistent over the course of the study. Similar results 
regarding peripheral blood markers in menstrual blood were obtained; however, vaginal fluid 
marker dropout was observed. Proteins Ly6/PLAUR, suprabasin, and involucrin were not detected 
during this study. All other vaginal fluid markers did exhibit stability for the time points collected, 
with no additional protein or peptide dropout exhibited. 
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 Seminal fluid and saliva behaved similar to peripheral blood. All target protein markers 
were correctly identified during each time point collected, with no instances of protein or peptide 
dropout over the course of the study. The amount of material present for vaginal fluid (i.e., 50 µL 
vs. 150 µL) effected the positive identification of specific markers, as originally hypothesized. 
Peptide dropout was observed for protein periplakin during the study, with inconsistent peptide 
dropout exhibited by protein suprabasin. This suggests that the selected peptide marker 
AQSLQSAK for suprabasin does not exhibit the same high degree of robustness when compared 
with remaining vaginal fluid markers.   
Table 3.25. Detection of body fluid markers in aged samples. Proteins that were positively identified 
by all of their respective peptide markers are shown in dark green. Light green indicates where at 






3.2.6.7 Sensitivity Samples 
 Sensitivity samples were prepared by extracting a serial dilution of target body fluid from 
cotton swabs. These samples differ from those prepared under section 3.2.2 by diluting target body 
fluid and recovering from a substrate, in comparison with evaluating diluted target fluid directly in a 
test tube. A summary of results is detailed in Tables 3.26-3.28. Beginning with peripheral blood 
detection, all protein markers were successfully identified for neat, 1:2, 1:10, and 1:100 dilution 
samples (Table 3.26). Hemopexin dropout was observed at the 1:1,000 dilution, with additional 
protein dropout of alpha-1 antitrypsin and serotransferrin peptide dropout at the 1:2,000 dilution. 
From this dilution, the only protein marker consistently detected was hemoglobin, with peptide or 
protein dropout reported for all other markers at the 1:5,000, 1:10,000 and 1:20,000 dilutions 
(Figure 3.12). No peripheral blood biomarkers were detected at the 40,000-fold dilution. 
 Similar results were exhibited by menstrual blood sensitivity analysis (Table 3.26). All 
peripheral blood markers were accurately detected through the 100-fold dilution, with peptide 
dropout for serotransferrin and apolipoprotein at the 1:1,000 dilution. Peripheral blood marker 
dropout of hemopexin and alpha-1 antitrypsin was observed at the 1:2,000 dilution, with all proteins 
except hemoglobin not detected at the 1:5,000 dilution. Hemoglobin was detected in all menstrual 
blood dilution samples analyzed. As hypothesized, vaginal fluid protein markers did not exhibit the 
same level of sensitivity as the peripheral blood markers in menstrual blood. Protein dropout for 
involucrin, Ly6/PLAUR, and suprabasin was observed for all samples evaluated. Furthermore, 
peptide dropout for cornulin and periplakin was exhibited for all samples. These results remained 
consistent up to and including the 100-fold dilution sample. Additional protein dropout of periplakin 
and neutrophil gelatinase was reported at the 1,000-fold dilution sample. Further dilutions exhibited 
inconsistent protein and peptide detection. Small proline rich protein 3 was detected at the 1:10,000 
and 1:20,000 dilutions (Figure 3.12); however, exhibited peptide dropout at the 1:5,000 and 
1:40,000 dilutions. As with other casework type samples analyzed, the endogenous low 




 Robust detection of seminal fluid biomarkers over the course of the dilution study was 
observed (Table 3.26). All protein targets were identified in the neat, 1:2, and 1:10 dilutions, with 
two instances of peptide dropout for proteins prostatic acid phosphatase and prostate specific 
antigen at the 1:100 dilution. Prostate specific antigen and epididymal secretory protein were not 
detected at the 1:1,000 dilution, with additional prostatic acid phosphatase dropout at the 2,000-
fold dilution. Although peptide dropout was exhibited, semenogelin 1 and 2 were positively identified 
at the 1:5,000, 1:10,000, and 1:20,000 dilution samples. Furthermore, semenogelin 1 peptide 
QITIPSQEQEHSQK was accurately detected at 40,000-fold dilution extract (Figure 3.12).  
 Saliva dilution samples, as hypothesized, did not demonstrate the same degree of 
sensitivity as semen and peripheral blood based on the lower endogenous levels of protein quantity 
(Table 3.27). All protein markers were positively identified at the neat, 1:2, and 1:10 dilution 
extracts, with complete dropout of cystatin SA at 1:100. From this point, inconsistencies in 
biomarker detection were observed. Beginning with protein alpha amylase, peptide dropout was 
exhibited at the 500-fold dilution but was completely detected at the 1,000-fold dilution sample 
(Figure 3.12). Similarly, submaxillary gland androgen-regulated protein 3B demonstrated protein 
dropout at 1:500, with a single peptide detected at 1:1,000. The remaining samples analyzed 
(1:2,000; 1:5,000; 1:10,000) were negative for all target protein markers consistent with saliva. 
 Lastly, vaginal fluid sensitivity was evaluated (Table 3.28). Three instances of peptide 
dropout were observed at the initial 10-fold dilution analyzed: periplakin, Ly6/PLAUR, and 
involucrin. After this dilution, almost complete protein dropout was exhibited at 1:100, with only two 
peptides being accurately detected for small proline rich protein 3 and periplakin. From this point, 
only a single small proline rich protein 3 peptide was detected for the remainder of the samples 
analyzed (Figure 3.12). It should be restated that the dilution evaluated was initially applied to a 
cotton swab and subsequently extracted in 1 mL of deionized water, further diluting any protein 
material that was originally present. The large extraction volume was necessary to produce enough 
material for additional studies conducted during subsequent aim of this project, as described in 
Chapter 4. This decrease in recovery contributed to poor sensitivity in comparison with the 
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sensitivity study conducted in section 3.2.2. However, in common forensic biology laboratory 
protocols, swabs are extracted in sufficient liquid to ensure saturation, further concentrating present 
targets prior to analysis.  
Table 3.26. Detection of body fluid markers in casework sensitivity samples for peripheral blood, 
menstrual blood, and seminal fluid. Proteins that were positively identified by all of their respective 
peptide markers are shown in dark green. Light green indicates where at least one peptide marker 
for the respective protein dropped out. White indicates complete protein dropout.  
 
Table 3.27. Detection of body fluid markers in casework sensitivity samples for saliva. Proteins that 
were positively identified by all of their respective peptide markers are shown in dark green. Light 
green indicates where at least one peptide marker for the respective protein dropped out. White 
indicates complete protein dropout. 
 
Table 3.28. Detection of body fluid markers in casework sensitivity samples for vaginal fluid. 
Proteins that were positively identified by all of their respective peptide markers are shown in dark 
green. Light green indicates where at least one peptide marker for the respective protein dropped 






Figure 3.12. Peak area response of peptide biomarker at lowest detected sensitivity sample. (A) 
seminal fluid protein semenogelin 1 peptide QITIPSQEQEHSQK at 40,000-fold dilution, (B) 
peripheral blood protein hemoglobin peptide LLVVYPWTQR at 20,000-fold dilution, (C) saliva 
protein amylase peptide IAEYMNHLIDIGVAGFR at 1,000-fold dilution, (D) menstrual blood protein 
hemoglobin peptide LLVVYPWTQR at 40,000-fold dilution, (E) menstrual blood protein small 
proline rich protein 3 peptide VPEPGCTK at 20,000-fold dilution, and (F) vaginal fluid protein small 
proline rich proline 3 peptide VPEPGCTK at 20,000-fold dilution.   
3.2.7 Limit of Detection 
 This study was performed to determine the detection limit for individual target peptides 
contained within their cognate body fluid. This aim was carried out by generating a dilution series 
of isotopically-labeled peptide standards, ranging from 50 femtomoles (fmol) to 500 attomoles 
(amol) per injection. Samples were prepared in triplicate in digested body fluid matrix. In general, 
the limit of detection (LOD) is described as the lowest concentration an analyte can be differentiated 
from analytical noise. The LOD was determined according to acceptable signal peak area 
response, signal to noise ratio, retention time, and qualitative response ratio between each 
transition.  
 A summary of results obtained are detailed in Tables 3.29 and 3.30. Overall, the LOD 
values for target peptide markers ranged from 1.0 to 25 femtomoles per individual peptide. 
Beginning with peripheral blood, the LOD for target peptide markers ranged from 2.5 fmol to 10 
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fmol per injection analyzed (Table 3.29). Hemoglobin peptides SAVTALWGK and LLVVYPWTQR 
were found to have a higher LOD of 10 fmol due to observed peak area fluctuations of qualifier 
ions. Furthermore, this higher LOD is beneficial for analysis because, as discussed later in section 
3.2.9, both hemoglobin peptides were found to have high instances of carryover between sample 
injections.  
 Seminal fluid peptide marker LOD values ranged from 1.0 fmol to 25 fmol (Table 3.29). 
Similar to hemoglobin, semenogelin 1 peptide DIFSTQDELLVYNK exhibited an LOD of 25 fmol, a 
higher value than those observed for remaining targets, and was found to have greater instances 
of carryover (section 3.2.9). On the contrary, LOD values for proteins prostatic acid phosphatase 
and prostate specific antigen were on the lower end of the range, with peptide FVTLVFR exhibiting 
an LOD of 1.0 fmol.  
 Derived LOD values for vaginal fluid ranged from 1.0 fmol to 25 fmol, with two instances of 
target isotopically-labeled peptide standard dropout (Table 3.30). Cornulin peptide 
AHQTGETVTGSGTQTQAGATQTVEQDSSHQTGR and Ly6/PLAUR peptide 
GLDHGLLAFIQLQQCAQDR did not produce sufficient chromatographic peak shape or acceptable 
ion ratios at the 50 fmol fortification (Figure 3.13). Therefore, these peptides were not assigned a 
LOD and should be interpreted with caution. However, more robust protein biomarkers such as 
neutrophil gelatinase, exhibited acceptable LOD values at 5.0 fmol. Similar results were obtained 
with AQUA analysis in menstrual blood matrix, with LOD values ranging from 2.5 fmol to 25 fmol 
for both vaginal fluid and peripheral blood target markers (Table 3.30). In comparison with vaginal 
fluid matrix analysis, eight vaginal fluid targets produced comparable results in menstrual blood, 
including the dropped peptide biomarkers of cornulin and Ly6/PLAUR. However, five peptide 
targets were found to exhibit a greater LOD in menstrual blood than in vaginal fluid matrix. All 
peripheral blood target LOD values were comparable in menstrual blood, with the exception of 
hemopexin peptide NFPSPVDAAFR, exhibiting a greater LOD in peripheral blood than in menstrual 
blood matrix.  
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 Isotopically-labeled peptide standards were not available for purchase at an acceptable 
purity for saliva proteins statherin and submaxillary gland androgen-regulated protein 3B. Peptide 
synthesis becomes exponentially more difficult as peptide length increases, with the peptide targets 
for these particular proteins outside of accurate synthesis range. Furthermore, peptides with a high 
content of certain amino acid residues (i.e., proline) add additional difficulties to the synthesis 
process. The remaining four peptide targets (from proteins alpha amylase and cystatin SA) 
produced LOD values of 5 fmol or less, with LSGLLDLALGK peptide exhibiting an LOD of 2.5 fmol 
(Table 3.29).  





Table 3.30. Limit of detection quantities for vaginal fluid and menstrual blood peptide biomarkers. 





Figure 3.13. Peak area response of peptide biomarkers at 50 fmol limit of detection. (A) Menstrual 
blood matrix detection of cornulin peptide AHQTGETVTGSGTQTQAGATQTVEQDSSHQTGR, (B) 
vaginal fluid matrix detection of cornulin peptide 
AHQTGETVTGSGTQTQAGATQTVEQDSSHQTGR, (C) menstrual blood matrix detection of 
Ly6/PLAUR peptide GLDLHGLLAFIQLQQCAQDR, and (D) vaginal fluid matrix detection of 
Ly6/PLAUR peptide GLDLHGLLAFIQLQQCAQDR.  
3.2.8 Ion Suppression 
 This portion of the validation was performed to assess whether coeluting compounds have 
a suppressing or enhancing effect on peptide response. This study was performed by preparing 
two samples: the first containing only isotopically-labeled peptide standards and the second 
containing body fluid fortified with isotopically-labeled peptide standards. As previously stated, 
AQUA standards were not available for saliva proteins statherin and submaxillary gland androgen-
regulated protein 3B and were therefore not tested during this portion of the validation.  
 To assess peptide suppression or enhancement, the percent difference of peak area 
average between the neat standards and the AQUA fortified fluid matrix was calculated (Tables 
3.31 and 3.32). Peptides that expressed a negative percent difference were marked as having ion 
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suppression, indicating the observed peak area of the peptide in the digested body fluid sample 
was less than that observed of the neat standard. Peptides that expressed a positive percent 
difference were interpreted as having ion enhancement, evident by a greater peak area response 
in the fortified digested body fluid than the neat standard. Substantial ion suppression was observed 
in 22% of peptide targets, with calculated percent difference greater than 30%. For example, the 
hemoglobin peptides SAVTALWGK and LLVVYPWTQR showed 55% and 94% suppression, 
respectively, when analyzed in neat peripheral blood (Figure 3.14). Similar suppression of 
hemoglobin peptides was also observed in menstrual blood. Substantial suppression of 
hemoglobin was expected, although not anticipated at such extreme rates, for both peripheral blood 
and menstrual blood matrices due to their endogenous complexity.  
 Ion enhancement was not observed as frequently as suppression, with only two instances 
of substantial enhancement. First, ion enhancement was observed at peptide 
FGQGVHHGLSEGWK from vaginal fluid protein marker suprabasin. This occurrence was 
observed in both vaginal fluid and menstrual blood matrix, with calculated percent difference of 




Table 3.31. Calculated percent difference of peripheral blood, seminal fluid, and saliva peptide 





Table 3.32. Calculated percent difference of vaginal fluid and menstrual blood peptide biomarkers 





Figure 3.14. Peak area response of (A) endogenous hemoglobin peptide LLVVYPWTQR and (B) 
AQUA hemoglobin peptide LLVVYPWTQR. 
3.2.9 Carryover 
 Carryover was exhaustively evaluated during validation to ensure accurate and precise 
detection of target biomarkers, particularly for assessment of low-level sample types that are 
preceded by highly concentrated samples. Carryover is defined as the unintended presence of an 
analyte peak in an adjacent sample analyzed after a positive sample [161].  
 Preliminary carryover samples included 10 µg, 20 µg, and 30 µg of prepared material 
analyzed on column followed by a blank injection. Carryover in the subsequent blank was observed 
for two protein biomarkers. First, hemoglobin in peripheral blood and menstrual blood matrices was 
detected in blanks after all three loading amounts evaluated (Figure 3.15). Peptide LLVVPWTQR 
produced linear peak response in blank injections, with linearity of sample injections decreasing as 
the loading amount increased, indicating saturation of the mass spectrometer detector. Peptide 
SAVTALWGK was detected in blank injections after 20 µg and 30 µg sample amounts. Second, 
semenogelin 1 exhibited high levels of carryover in all subsequent blank injections (Figure 3.15). 
Peptide DIFSTQDELLVYNK peak area responses produced linear results in blank injection 
analysis, with peak areas greater than 7,400,000 in sample injections at 10 µg loading amounts. 
Similar to hemoglobin peptide LLVVPQTQR, semenogelin 1 peptide DIFSTQDELLVYNK is 
relatively hydrophobic, eluting toward the end of the analytical run time. With reverse-phase liquid 
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chromatography, hydrophobic moieties are strongly retained within the stationary phase, with 
instances of incomplete release of hydrophobic analytes not uncommon.  
 Because hemoglobin and semenogelin 1 carryover was observed at substantial peak area 
responses, samples were reinjected using the same loading amounts previously described 
followed by two blank injections. This was performed to evaluate the retention of the hydrophobic 
peptides. As expected, both hemoglobin and semenogelin 1 were detected in the second blank 
injection analyzed after a 10 µg injection (Figure 3.16).  
 Preliminary carryover studies showed that 10 µg of material on column produced peak area 
responses that greatly exceeded what is necessary for accurate identification of target fluids. 
Keeping in mind common forensic biology laboratory protocol, lower injection volumes were 
evaluated for use in order to conserve precious sample material. For this purpose, vaginal fluid 
protein biomarkers were assessed as they are inherently detected in lower abundance within 
matrix. 10 µg injection quantities produced adequate peak area responses for all vaginal fluid 
peptide markers, with an average response of all peptide markers recorded as 49,800. From the 
data produced during this study, it was concluded that decreased loading amounts would not only 
limit the possibility of carryover with more abundant targets but would still yield reliable responses 
for target peptide markers by limiting chromatographic effects observed with column overload (i.e., 
peak shouldering, peak tailing, etc.). Final carryover studies were performed using 0.5 µg, 1 µg, 
2.5 µg, and 5 µg loading amounts followed by blank injections.   
 Lower sample injection amounts were found to limit instances of carryover while 
maintaining accurate peak area responses for fluid identification. However, hemoglobin and 
semenogelin 1 carryover persisted, albeit at low-level abundance (Figure 3.17). Although 
semenogelin 1 exhibited carryover at the 2.5 µg injection amount, observed peak areas were 
sufficiently less than those observed from hemoglobin carryover at all loading amounts evaluated. 
Due to these effects, hemoglobin and semenogelin 1 targets must be called at a greater intensity, 
regardless of ion ratio and chromatographic acceptance at lower peak areas. Therefore, a 2.5 µg 
loading amount was selected as the optimal amount of protein on column during analysis. Although 
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2.5 µg of material still produced sufficient response for less abundant targets, specifically target 
vaginal fluid biomarkers, two instances of protein dropout, Ly6/PLAUR and epididymal secretory 
protein E1, were observed at the 2.5 µg injection. A complete overview of observed carryover is 
outlined in Table 3.33. The presence of carryover was addressed in drafted interpretation 
guidelines, with strict detail given on the acceptance of semenogelin 1 and hemoglobin peaks 
above a designated value in order to prevent the false identification of carryover peaks.  
 
Figure 3.15. Peak area response of (A) hemoglobin peptide LLVVYPWTQR in peripheral blood, 
(B) hemoglobin peptide LLVVYPWTQR in menstrual blood, and (C) semenogelin 1 peptide 
DIFSTQDELLVYNK in seminal fluid in blank injections directly following a 10 µg sample injection.  
 
Figure 3.16. Peak area response of semenogelin 1 peptide DIFSTQDELLVYNK in (A) 10 µg sample 




Figure 3.17. Peak area response of (A) hemoglobin peptide LLVVYPWTQR in 0.5 µg peripheral 
blood, (B) hemoglobin peptide LLVVYPWTQR in subsequent blank injection, (C) semenogelin 1 
peptide DIFSTQDELLVYNK in 2.5 µg seminal fluid, and (D) semenogelin 1 peptide 




Table 3.33. Detection of body fluid markers during carryover assessment. Proteins that were 
positively identified by all of their respective peptide markers are shown in green. White indicates 
complete protein dropout. 
 
 
3.2.10 Blind Sample Analysis 
 A series of 50 samples containing fiber-tipped swabs, swatches of cloth, and condoms 
were received from the grant agency for blind analysis. Utilizing the described LC-MS/MS method, 
body fluid identification assignments were made. In total, 41 of 50 blind samples (82%) analyzed 
were correctly identified when compared with true sample contents. The remaining 9 samples 
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(18%) were misidentified, with 3 false positive identifications and 5 false negative (i.e., non-
detections observed) results recorded. A comprehensive summation of experimental 
identifications, true identifications, and sample preparation information is outlined in Appendix H. 
For example, a cotton swab sample (Sample #15) was identified as containing biomarkers 
consistent with seminal fluid and vaginal fluid; however, biomarkers consistent with saliva were not 
detected (Figure 3.18). This sample was characterized as a false negative, having contained a 3-
part mixture (10 µL semen and 1 µL of saliva on a vaginal swab). On the contrary, a cotton swab 
(Sample #22) was misidentified as containing biomarkers consistent with vaginal fluid and 
characterized as a false positive identification (Figure 3.19).  
 Receiving true sample contents ex post facto, the validated LC-MS/MS assay 
demonstrated robustness and reliability when challenged with non-target fluids. For example, when 
subjected to samples containing breast milk (Sample #49), sweat (Sample #50), or urine (Samples 
#23, #24, #39), no misidentifications were made. One interesting sample to note (Sample #30) 
contained nasal secretions. Although not a target fluid of the validated method, a peptide biomarker 
profile was previously acquired and utilized to make a special note regarding the experimental 
identification of this particular sample. Although reported as containing peripheral blood and saliva, 





Figure 3.18. Peptide biomarker profile of Blind Sample #15. (A) Biomarkers consistent with seminal 





Figure 3.19. Peptide biomarker profile of Blind Sample #22. (A) Biomarkers consistent with saliva 
and (B) biomarkers consistent with vaginal fluid, prompting a false positive identification. 
3.3 Concluding Remarks 
 With the completion of this phase of the research, the robustness and reliability of the 
multiplex assay described has been exhaustively demonstrated. In addition, the inherent limitations 
observed through the analysis of both routine and challenging forensic type evidence have 
elucidated a defined understanding of presumptive and confirmatory biomarkers utilized for 
identification. Overall, the culmination of results detailed within this chapter are the final product of 
a fully validated analytical method for the serological analysis of peripheral blood, seminal fluid, 
saliva, and vaginal/menstrual fluids. With achieving sufficient sensitivity coverage over several 
orders of magnitude, in addition to demonstrating the specificity of fluid-specific biomarkers, the 
use of protein mass spectrometry as an advanced serological technique offers significant 
advantages over currently existing catalytic and immunological assays routinely employed in 
operational laboratories.  
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 The deliverable to the forensic community following the developmental validation results 
detailed in this chapter include not only a robust analytical multiplex assay, but comprehensive 
interpretation guidelines (Appendix I). Through meticulous evaluation of detection limits, the 
presence of carryover, and the suppression rates of specific biomarkers, potential avenues for 
misidentification or incorrect interpretation have been minimized. The purpose of the drafted 
interpretation guidelines is to serve as a resource for consistent and reliable identification of the 
body fluids assessed between forensic analysts and laboratories; however, an analyst should 
remain cognizant during interpretation and exercise a conservative approach, as stated within the 
guidelines.   
 The remaining two chapters of this dissertation will establish the use of the described 
serological assay as a vital step to the greater forensic biology workflow and further evaluate 
limitations caused as a result of the complexity of sexual assault evidence. By displaying the ability 
of the multiplex assay to compliment forensic genetic testing methodology, the implementation of 
such an emerging technique can further illustrate the necessity of serological results to a criminal 
investigation. Furthermore, a direct comparison to commercially available immunological and 
catalytic tests will further exemplify the unmatched sensitivity and specificity of the validated assay.  
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CHAPTER 4: A COMPARATIVE STUDY OF A VALIDATED PROTEOMIC ASSAY WITH 
EXISTING FORENSIC BIOLOGY CASEWORK MODELS
4 Introduction 
 The objective of this phase of research was to exemplify the use of the validated proteomic 
assay in an operational environment. With the limitations of the assay established in the previous 
chapter, experimentation conducted during this aim demonstrated the efficacy of the validated 
assay within a forensic biology workflow. This was evaluated in two manners; first, by comparing 
the validated assay to existing casework models (i.e., immunochromatographic/lateral flow assays, 
enzymatic assays) for serological screening, and second, the impact of the validated assay on the 
ability to produce a genetic profile. By assessing the validated assay in tandem with existing 
workflow strategies, any adverse effects warranted from implementation were identified and 
addressed.  
 Current testing strategies for serological screening have historically been rooted in 
enzyme- and antibody-based assays that rely on protein structure confirmation to produce a 
positive result. However, given that forensic evidence is commonly subjected to unfavorable 
environmental conditions, protein structure, and therefore protein function, are likely to be 
compromised. In addition, given that the formation of an enzyme-substrate complex or antibody 
binding event lack absolute specificity, these assays are unable to confirm the presence of a target 
body fluid. Therefore, severely degraded samples and cross-reactivity with non-target compounds 
have left both the sensitivity and specificity of serological screening much to be desired, especially 
in comparison with modern genetic testing capabilities. The first aim of this portion of the study was 
to directly compare the developed proteomic assay with available serological screening tests to 
empirically demonstrate the sufficient gains in sensitivity and specificity.  
155 
 
 With the lack of advancements achieved within serological screening, a shift in existing 
casework models has been observed within the forensic biology community. Traditionally, evidence 
received would undergo serological screening, with results dictating the prioritization of samples 
for subsequent genetic testing. However, with the lack of reliable body fluid tests, serological 
screening as a gatekeeper for DNA analysis has been reconsidered. More recently, laboratories 
have opted for a “direct to DNA” approach, with small portions of evidence quickly extracted and 
quantitated for genetic material. The resulting quantity and quality of DNA determines the type of 
genetic testing performed, with serological screening only conducted if needed. Although a practical 
alternative to the traditional workflow, there has been little research on the efficacy of a direct to 
DNA procedure, particularly with challenging sample types. By evaluating the use of the proteomic 
workflow within existing casework models, the use of serological screening as a gatekeeper for 
genetic testing has the capability of providing copious amounts of information vital to criminal 
investigations that would have otherwise been absent, in addition to reducing costs associated with 
advanced genetic analyses.   
 This chapter seeks to establish the viability of the validated proteomic assay within the 
overall forensic biology workflow. This was achieved through the completion of a side-by-side 
comparison of the assay with select available immunological and enzymatic tests and by 
demonstrating the value of proteomic results in relation to the quality of genetic profiles produced. 
For the purposes of direct comparison, this chapter is organized according to sample type, with 
serological and genetic information presented together.  
4.1 Methods and Materials 
 All research conducted under this phase of the project was reviewed and approved by the 
University of Denver IRB for research involving human subjects. Sample collection and research 
was conducted in full accordance with the U.S. federal policy for the protection of human subjects 





4.1.1 Sample Preparation 
 Samples were prepared as outlined in section 3.1 and carried over to this portion of the 
research for operational testing. Three categories of laboratory prepared casework-type samples 
were reserved for serological comparison only: substrate samples (3.1.6.1), environmental 
contaminant samples (3.1.6.2), and aged samples (3.1.6.6). Six categories of casework-type 
samples were reserved for both serological comparison and genetic analysis: sensitivity samples 
(3.1.6.7), mixtures (3.1.6.3), simulated sexual assault samples (3.1.6.4.1), sexual assault type 
samples (3.1.6.4.2), digital swab samples (3.1.6.4.3), and degraded samples (3.1.6.5). Swabs or 
substrates were solubilized as previously described in section 3.1. Remaining supernatant was 
tested against existing serological models in tandem with proteomic analysis, eliminating an 
additional freeze/thaw cycle to ensure consistency in material evaluated. Cell pellets were 
preserved for genetic analysis at -20 ºC and were thawed at room temperature prior to DNA typing.   
4.1.2 Traditional Serological Testing 
 Casework-type samples were prepared using the previously described protocol (section 
2.1.4) and once solubilized, a matched liquid sample was manually processed with a corresponding 
antibody-based assay or enzymatic test. Specifically, antibody-based and enzyme-based tests 
targeting blood, seminal fluid, and saliva were selected. The immunochromatographic assays 
utilized for this portion of the research were as follows: RSID™ Semen, RSID™ Blood, RSID™ Saliva 
(Independent Forensics, Hillside, IL), ABAcard® p30 and ABAcard® HemaTrace (Abacus 
Diagnostics, West Hills, CA). The enzymatic test used for this portion of the research was 
SALIgAE® (Abacus Diagnostics) and was selected given the manufacturer does not supply an 
antibody-based assay for the identification of saliva. See Table 4.1 for more specific information 
regarding the selected commercially available screening tests.   
 For sensitivity samples, the maximum volume suggested by the manufacturer was used 
for testing (200 µL ABAcard® assays, 100 µL RSID™ assays, 50 µL SALIgAE® assay). This set of 
samples was not originally quantitated for total protein amount during the validation phase of this 
research, as outlined in Chapter 3. For remaining sample types, matched liquid samples were 
157 
 
prepared as an equivalent total protein amount. The quantity observed from BCA quantitation was 
diluted up to maximum volume in Universal Buffer™ (Independent Forensics of Illinois). The 
maximum volume, and therefore an equivalent protein amount, was processed on either a lateral 
flow cartridge or enzyme test.  
Table 4.1. Selected traditional serological screening tests for comparison with the developed 
proteomic assay.  
 
4.1.3 Forensic Genetic Testing 
4.1.3.1 DNA Extraction 
 Given the composition of the samples assessed during this phase of the research, two 
DNA extraction protocols were utilized. Knowing a priori the makeup of each sample, all samples 
containing semen or seminal fluid were subjected to a previously validated manual organic 
differential extraction procedure. All other samples (i.e., those free of semen) were subjected to a 
previously validated manual organic extraction protocol.  
 Pelleted cellular material selected for organic extraction was treated with 350 µL of master 
mix containing extraction buffer and proteinase K solution. Samples were incubated at 56 ºC 
overnight (a maximum of 18 hours) on a shaker at 850 RPM. After incubation, samples were 
purified and concentrated. Each sample received two iterations of purification using 300 µL of 
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phenol:chloroform:isoamyl alcohol reagent. An additional cleanup step was performed with the 
addition of 300 µL of water saturated butanol. Purified sample was passed through a Vivacon® 500 
centrifugal concentrator (Vivaproducts, Inc., Littleton, MA), washed with 200 µL of TE-4 buffer 
(10mM Tris-HCl, 0.1mM EDTA, pH 8.0), and eluted in 100 µL of TE-4 buffer.  
 Pelleted cellular material selected for organic differential extraction was treated with 505 
µL of master mix containing extraction buffer and proteinase K solution. Samples were incubated 
at 56 ºC for 40 minutes on a shaker at 850 RPM. Samples were centrifuged for 10 minutes at 
14,000 x g. The supernatant (epithelial fraction) was transferred to a clean tube. Remaining cellular 
material (sperm fraction) was washed with 500 µL of UltraPure water and centrifuged for 10 minutes 
at 14,000 x g, where the wash buffer was removed. Cellular material was treated with 380 µL of 
master mix containing extraction buffer, 1 M dithiothreitol (DTT), and proteinase K solution. The 
sample was incubated at 89 ºC for 40 minutes on a shaker at 850 RPM. Epithelial and sperm 
fractions were purified and concentrated as described above for the organic extraction. 
Concentrated DNA was recovered in 100 µL of TE-4 buffer. Extractions were batched, with each 
batch being assigned a unique reagent control to monitor for any instances of contamination. 
Extracts were stored at -20 ºC for later use.   
4.1.3.2 DNA Quantitation 
 Once purified, all samples were quantitated using Quantifiler™ Trio DNA Quantification Kit 
(Applied Biosystems™, Foster City, CA). Extracts were thawed and brought to room temperature 
prior to quantitation. A previously validated standard operating procedure was used. A standard 
curve was prepared, in addition to a negative control, for each batch of samples. Standards were 
prepared by diluting the DNA Standard with Quantifiler™ THP DNA Dilution Buffer to the following 
final concentrations: 50 ng/µL, 5.0 ng/µL, 0.5 ng/µL, 0.05 ng/µL, and 0.005 ng/µL. TE-4 buffer was 
used for the negative control. Standards, controls, and samples were treated with a master mix of 
kit specific Primer Mix and PCR Reaction Mix. Quantitation was performed on an Applied 
Biosystems™ 7500 Real-Time PCR System. Thermal cycler parameters were set to heat at 95 ºC 
for 2 minutes followed by 40 cycles of 9 seconds at 95 ºC and 30 seconds at 60 ºC. The 
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quantification batch was considered valid if the standard curve slope measured between -3.0 and 
-3.6 and the R2 value was greater than or equal to 0.98. 
4.1.3.3 DNA Amplification 
 Amplification reactions were prepared in accordance with DNA quantification results. All 
samples that underwent an organic extraction (i.e., those free of semen) were amplified for STR 
analysis using GlobalFiler™ PCR Amplification Kit (Applied Biosystems™). Samples that were 
subjected to an organic differential extraction that produced a male quantification value were also 
prepared for routine STR amplification using GlobalFiler™ PCR Amplification Kit. However, 
remaining organic differential samples that did not produce a male quantification value were 
prepared for Y-STR amplification using Yfiler™ Plus PCR Amplification Kit (Applied Biosystems™).  
 Full scale amplification was performed, with a total of 1.0 ng of DNA targeted. Maximum 
extract volume (15 µL GlobalFiler™, 10 µL Yfiler™ Plus) was used for samples that did not produce 
a sufficient quantitation value. Manufacturer recommended protocols for GlobalFiler™ and Yfiler™ 
Plus were followed, with no changes made to the respective protocols. Amplification was performed 
on an Applied Biosystems™ 9700 Thermal Cycler. 29 amplification cycles were performed for 
GlobalFiler™ and 30 amplification cycles were performed for Yfiler™ Plus. Samples were batched, 
with each batch assigned a positive and negative control to ensure amplification was performed 
properly. Amplicons were stored at 4 °C until separation.  
4.1.3.4 DNA Separation and Analysis 
 Amplicons were separated and detected using a 3500 Genetic Analyzer (Applied 
Biosystems™) fitted with an 8-capillary array. POP-4™polymer (Applied Biosystems™) was utilized 
as the separation matrix. GeneScan™ 600 LIZ™ Dye Size Standard (v2.0) and DNA Control 007 
were used for both GlobalFiler™ and Yfiler™ Plus amplicons. The Yfiler™ Plus Allelic Ladder and 
GlobalFiler™ Allelic Ladder were employed for their respective amplicon samples.  
 GeneMapper® ID-X software (v.1.4) was utilized for profile interpretation. Through internal 
validation that independently evaluated the signal-to-noise characteristics of each dye channel, the 
following analytical thresholds were set for a 10 second injection with GlobalFiler™: 6-FAM™, 60 
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relative fluorescence units (RFUs); VIC™, 75 RFUs; NED™, 50 RFUs; TAZ™, 60 RFUs; and SID™, 
60 RFUs. From a separate internal validation, the following analytical thresholds were set for a 10 
second injection with Yfiler™ Plus: 6-FAM™, 50 RFUs; VIC™, 50 RFUs; NED™, 40 RFUs; TAZ™, 40 
RFUs; and SID™, 40 RFUs. 
4.2 Results and Discussion 
 For the purposes of direct comparison, results for sensitivity in the operational environment 
and compatibility with existing casework models have been merged for each sample type 
evaluated.  
4.2.1 Substrate Samples 
 Substrate samples were designed to ensure chemical products or composition would not 
interfere with protein biomarker detection or recovery. Overall, the proteomic assay was successful 
in identifying the target body fluid of each substrate sample (Table 3.18), with three instances of 
vaginal fluid protein dropout observed for menstrual blood samples. Matched samples were 
compared with serological screening tests (Table 4.2). With the exception of two peripheral blood 
samples, all substrate samples were positive on traditional immunological and enzymatic based 
assays. Peripheral blood applied to carpet (sample ID SUB03) and to leather (sample ID SUB04) 
produced a negative result when evaluated with RSID™ Blood, with carpet exhibited in Figure 4.1A. 
In addition, when compared with a positive control test, a majority of peripheral blood and menstrual 
blood containing samples resulted in weak or very weak positive results. For example, menstrual 
blood on cotton resulted in a weak positive result on RSID™ Blood in comparison with ABAcard® 
HemaTrace (Figure 4.1B). However, the proteomic assay was able to positively identify blood-
containing samples by all targeted peptide biomarkers. Similarly, target proteins for semen and 
saliva samples were positively characterized by the proteomic assay, in addition to positive 
identification using traditional screening tests, with examples highlighted in Figure 4.1C and Figure 
4.1D, respectively. DNA analysis was not performed on this set of casework samples.  
 With the exception of the aforementioned negative peripheral blood samples on the single 
manufacturer test, the traditional assays and proteomic assay were comparable in identification of 
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target body fluid. However, given the inherent nature of the LC-MS/MS technology, the proteomic 
assay fundamentally provided precise protein identification and additional information not capable 
of the lateral flow assays.  
Table 4.2. Summary of comparative results for substrate samples. Positive identifications are 
represented by a green box. Negative identifications are represented by a red box. White boxes 
represent no testing was performed with that specific assay. Vaginal fluid samples were removed 





Figure 4.1. Selected serological screening test results on substrate samples. RSID™ tests are  
pictured on the left. ABAcard® tests and SALIgAE® are pictured on the right. Within the lateral flow 
test membrane window, the test line is positioned on the left and the control line on the right. Results 
for (A) peripheral blood on carpet, (B) menstrual blood on cotton, (C) semen on cotton, and (D) 
saliva on plastic bottle. On lateral flow assays, a positive result is indicated by the presence of a 
red line at both the test and control zones. For SALIgAE®, a positive result is indicated by a yellow 
colored reagent.  
4.2.2 Environmental Contaminant Samples 
 This subset of samples was prepared to assess the effects of environmental contaminants 
on sample preparation chemistries of the developed proteomic workflow. When evaluated with the 
proteomic assay, three samples exhibited protein and peptide dropout (Table 3.19). Menstrual 
blood samples (sample ID CON04 and CON05) illustrated vaginal fluid protein and peptide dropout. 
The third sample, vaginal fluid and wate-based lubricant, exhibited complete protein dropout; 
however, this sample was unable to be directly compared with other serological screening tests as 
there are none commercially available. As observed with substrate samples, the traditional and 
proteomic assays produced comparable results in regard to target fluid identification. A summary 
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of serological screening results is outlined in Table 4.3. Overall, samples subjected to chemical 
insult did not inhibit the ability to produce a positive result with traditional serological assays. A very 
weak positive was observed for peripheral blood and 10% bleach (Figure 4.2A), which contradicts 
the positive protein identifications observed during proteomic analysis. It was originally 
hypothesized that the presence of personal lubricant would decrease advantageous protein binding 
events and result in an increase in negative reporting. However, immunological assays accurately 
characterized semen and menstrual blood samples containing personal lubricant (Figure 4.2B and 
4.2C). There was no inhibition of salivary amylase, with both saliva case samples characterized as 
exhibited by saliva extracted from a cigarette filter (Figure 4.2D). DNA analysis was not performed 
on this set of casework samples. In summary, comparable results between the proteomic method 
and traditional methodologies were observed; however, the proteomic method provides a greater 
depth of coverage in specific biomarker identifications.  
Table 4.3. Summary of comparative results for environmental contaminant samples. Positive 
identifications are represented by a green box. White boxes represent no testing was performed 
with that specific assay. Vaginal fluid samples were removed from the table as no additional testing 





Figure 4.2. Selected serological screening test results for environmental contaminant samples. 
ABAcard® test and SALIgAE® are pictured on the left. RSID™ test is pictured on the right. Within 
the membrane window, the test line is positioned on the left and the control line on the right. Results 
for (A) peripheral blood and 10% bleach, (B) menstrual blood and personal lubricant, (C) semen 
and personal lubricant, and (D) saliva on a cigarette. On lateral flow assays, a positive result is 
indicated by the presence of a red line at both the test and control zones. For SALIgAE®, a positive 
result is indicated by a yellow colored reagent. 
4.2.3 Mixture Samples 
 For this portion of the study, mixture samples evaluated are separate from those used 
during validation to determine transition interference. Casework-type mixture samples were 
designed to assess the capability of each testing strategy to detect a minor contributor when in the 
matrix of a major contributor, simulating commonly received sample types in a forensic biology 
laboratory. Of the five mixture samples assessed, the minor contributor was characterized when 
evaluated with the proteomic assay. When directly comparing a matched sample using traditional 
techniques, two instances of negative detection were observed (Table 4.4). With the detection of 
a minor saliva contributor, the enzymatic test SALIgAE® was unable to characterize the presence 
of the target fluid in either a vaginal fluid or menstrual blood matrix; however, RSID™ Saliva 
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exhibited a positive result for both MIX01 and MIX04 samples (Figure 4.3). It should be noted that 
the inherent color of the MIX04 extract caused the SALIgAE® buffer to become discolored, 
potentially masking the visualization of a positive result. There were no reported discrepancies for 
the detection of seminal fluid with either antibody-based assay (Figure 4.4). Due to the lack of 
commercially available serological tests for vaginal fluid, a matched sample for MIX05, vaginal fluid 
in a urine major contributor, was not evaluated using antibody-based or enzymatic tests.  
 Allele calls produced by mixtures samples for short tandem repeat (STR) and Y 
chromosome STR (Y-STR) analyses are outlined in Tables 4.5 and 4.6, respectively, with alleles 
unique to the major contributor removed for ease of comparison. The allele calls presented are 
unique to the minor contributor or shared with the major contributor. For sample MIX01, a minor 
saliva contributor with a major vaginal fluid contributor, 2 out of 4 salivary protein biomarkers were 
detected with the proteomic assay; however, the DNA profile generated was consistent with the 
vaginal fluid major contributor. The DNA profile produced was single source, and even with allele 
sharing between the two contributors, the profile did not indicate instances of peak imbalance or 
YINDEL/DYS391 detection (Table 4.5). For samples MIX02 and MIX03, a minor semen contributor 
in a major vaginal fluid and menstrual blood contributor, respectively, were extracted using an 
organic differential protocol. The sperm fractions were analyzed for Y-STR’s and produced full 
haplotypes (Table 4.6). Furthermore, all 5 target seminal fluid biomarkers were detected with the 
proteomic assay for these samples. For sample MIX04, a minor saliva contributor in a major 
menstrual blood contributor, no unique alleles consistent with the minor contributor were detected. 
And lastly, MIX05, a minor vaginal fluid contributor in a major urine contributor, produced a 







Table 4.4. Summary of comparative results for mixture samples. Positive identifications are 
represented by a green box. Negative results are represented by a red box. White boxes indicate 
no testing with that specific assay.   
 
 
Figure 4.3. Serological screening test results for mixture samples containing saliva as a minor 
contributor. Within the membrane window, the test line is positioned on the left and the control line 
on the right. Results for saliva in a vaginal fluid major contributor using (A) RSID™ Saliva and (B) 
SALIgAE®. Results for saliva in a menstrual blood major contributor using (C) RSID™ Saliva and 
(D) SALIgAE®. On lateral flow assays, a positive result is indicated by the presence of a red line at 





Figure 4.4. Serological screening test results for mixture samples containing semen as a minor 
contributor. RSID™ Semen test is pictured on the left. ABAcard® p30 test is pictured on the right. 
Within the membrane window, the test line is positioned on the left and the control line on the right. 
Results for (A) semen in a vaginal fluid major contributor and (B) semen in a menstrual blood major 
contributor. A positive result is indicated by the presence of a red line at both the test and control 
zones.  
Table 4.5. STR genetic results for mixture samples. Unique allele ratio for the minor contributor 
was calculated using reference profiles. For clarity, unique major contributor alleles have been 






Table 4.6. Y-STR genetic results for mixture samples with semen as a minor contributor. Y-STR 
analysis was performed based on quantification values.  
 
4.2.4 Sexual Assault Samples 
4.2.4.1 Simulated Sexual Assault Samples 
 Simulated sexual assault samples were designed to imitate the environment of the vaginal 
cavity and its effects on the breakdown of semen. The ability to identify constituents of seminal fluid 
post-coitus, particularly after 48 hours, is advantageous to forensic practitioners. The poor 
sensitivity of currently available immunological screening assays has been reported in the literature 
for the detection of seminal fluid in an extended post-coital interval [50,162]. A sufficient difference 
in sensitivity between manufacturers was observed for this subset of samples (Table 4.7). 
Consistent with proteomic identification, RSID™ Semen positively characterized seminal fluid for all 
time points evaluated. However, ABAcard® p30 failed to detect seminal fluid via prostate specific 
antigen after time point zero (Figure 4.5).  
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 In total, samples from all time points assessed produced at least 20 of 24 (83%) unique 
male alleles, with four samples generating 100% unique male alleles (Table 4.8). Time points at 
days three, five, seven, and nine report complete detection of the 24 unique alleles from the male 
contributor, with day zero returning the smallest number of unique alleles, with a minimum of 20 
alleles detected from the male contributor.  
Although simulating the environment of the vaginal cavity, breakdown products are not 
being removed in the process. Loss of sample due to natural removal of target material through 
vaginal drainage as well as breakdown of biomarkers by endogenous protease enzymes within the 
vaginal vault make the detection of seminal fluid and saliva in sexual assault samples more 
challenging. Protein denaturation via naturally occurring protease activity is one limitation affecting 
post-coital detection intervals for immunochromatographic assays. It is important to understand 
whether proteolytic digestion of seminal fluid and saliva targets in the vaginal vault occurs within a 
target peptide sequence. From the results of this study, the endogenous breakdown of semenogelin 
does not affect the positive characterization when using RSID Semen™; however, it can be 
hypothesized that the lack of p30 detection using ABAcard® p30 test can be attributed to 
unfavorable protein degradation that compromises the targeted protein epitope confirmation. In 
comparison with proteomic assay results, it can be concluded that the selected amino acid 
sequences of target seminal fluid biomarkers are not negatively affected by endogenous 
breakdown and cleavage of protein material. Furthermore, a decrease in allele characterization 
would also be expected with vaginal drainage.  
Table 4.7. Summary of comparative results for simulated sexual assault samples. Positive 





Figure 4.5. Immunochromatographic results for simulated sexual assault samples. ABAcard® p30 
test is pictured on the left. RSID™ Semen test is pictured on the right. Within the membrane window, 
the test line is positioned on the left and the control line on the right. Results for (A) timepoint zero, 
(B) day one, (C) day three, (D) day five, (E) day seven, (F) day nine, and (G) day eleven. A positive 




Table 4.8. STR genetic results for simulated sexual assault samples. The male reference sample 
depicts unique male alleles in bold.  
 
4.2.4.2 Mock Sexual Assault Kit Samples 
 Both sets of laboratory-prepared sexual assault samples, one set containing semen from 
a non-vasectomized donor and the second set containing semen from a vasectomized donor, were 
reserved for analysis during this portion of the study (Table 4.9). When screening for seminal fluid 
using the proteomic assay, at least 3 of 5 target seminal fluid protein markers were detected across 
all swabs. Immunological lateral flow assays produced comparable results among the two sample 
sets evaluated. A positive result was observed for all vaginal swabs on RSID™ Semen and 
ABAcard® p30, with oral swabs producing a positive result on ABAcard® p30 only (Figure 4.6). 
However, all rectal swab samples exhibited a negative result when evaluated with a lateral flow 
assay.  
 For genetic analysis, all samples were subjected to an organic differential extraction 
protocol. Samples containing semen from a non-vasectomized individual produced Total Human 
DNA quantitation values and were analyzed for routine STR typing; however, samples containing 
semen from a vasectomized individual were analyzed for Y-STR markers. As expected, no genetic 
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profiles were generated for samples containing semen from a vasectomized individual (Table 4.9, 
Appendix J). Nonetheless, mass spectrometry results show at least 3 seminal fluid biomarkers 
detected in each sample type of this group. Complete and partial DNA profiles were observed for 
samples containing semen from a non-vasectomized individual (Table 4.10). The variation in profile 
generated can be attributed to each sample having been prepared individually (i.e., not prep 
replicates), in order to best simulate sample-to-sample variability. For example, case sample 
SA01_02.1, an oral swab, generated 9 out of 24 unique male alleles; however, the second oral 
swab produced a full STR profile.  
Table 4.9. Summary of comparative results for mock sexual assault samples containing semen 
from a non-vasectomized and a vasectomized donor. Positive identifications are represented by a 





Figure 4.6. Immunochromatographic results for mock sexual assault samples. Within the 
membrane window, the test line is positioned on the left and the control line on the right. Results 
for (A) oral swab replicates using RSID™ Semen, (B) oral swab replicates using ABAcard® p30, (C) 
oral swab replicates containing semen from a vasectomized donor using RSID™ Semen, and (D) 
oral swab replicates containing semen from a vasectomized donor using ABAcard® p30. A positive 
result is indicated by the presence of a red line at both the test and control zones.  
Table 4.10. STR genetic results for simulated sexual assault samples. The male reference sample 





4.2.4.3 Digital Swab Samples 
 Self-collected digital swab samples were obtained to mimic casework type samples as 
closely as possible. However, it should be noted that because the samples were self-collected, the 
likelihood of a mixed genetic profile was reduced as the body fluid and digit were of the same 
individual. Overall, serological tests produced comparable results with the proteomic assay and full 
genetic profiles were obtained from all samples (Table 4.11). Both oral cavity replicates produced 
a positive result from RSID™ Saliva and SALIgAE® tests (Figure 4.7A). When assessed for the 
presence of blood, menstrual blood was positively characterized by RSID™ Blood, with a negative 
result produced using ABAcard® HemaTrace for a single replicate (Figure 4.7B). A complete DNA 
profile consistent with the female contributor was produced by all digital swab samples (Table 
4.12).  
 Although this subset of samples provided insight into the advantages of the proteomic 
assay over traditional techniques, especially for vaginal fluid samples, authentic digital swab 
samples would need to be evaluated for a veritable comparison. Nevertheless, the proteomic assay 
produced consistent identifications between replicates that were complimentary to genetic testing 
results.  
Table 4.11. Summary of comparative results for digital swab samples. Positive identifications are 
represented by a green box. Negative results are represented by a red box. White boxes indicate 





Figure 4.7. Selected serological screening test results for digital swab samples. ABAcard® test and 
SALIgAE® are pictured on the left. RSID™ test is pictured on the right. Within the membrane 
window, the test line is positioned on the left and the control line on the right. Results for (A) digital 
swab saliva and (B) digital swab menstrual blood. On lateral flow assays, a positive result is 
indicated by the presence of a red line at both the test and control zones. For SALIgAE®, a positive 
result is indicated by a yellow colored reagent. 






4.2.5 Degradation Samples 
 Laundered substrates, composed of a set of substrates containing semen and a set of 
clothing containing peripheral blood, were carried over to this section of research. As noted in 
section 3.1.6.5, all samples and control regions were prepared, laundered, dried, and analyzed. 
Overall, the expected results were observed for the proteomic assay and genetic analyses (Table 
4.13). All samples produced a full genetic profile (Table 4.14). For the set of samples containing 
semen, the proteomic assay was capable of detecting protein signatures on both the bed sheet 
and underwear, with only a single protein biomarker (epididymal secretory protein) not detected on 
the bed sheet (Table 4.13). Conversely, immunological lateral flow assays failed to detect trace 
levels of seminal fluid (Figure 4.8A and Figure 4.8B). Both control regions exhibited negative 
results for both the proteomic assay and immunochromatographic assays. The second set of 
degraded samples, a cloth bath towel and a pair of denim jeans, targeted peripheral blood 
identification. Both samples produced comparable results. All protein biomarkers were detected 
with the proteomic assay and weak positive results were observed with lateral flow assays (Table 
4.13, Figure 4.8C, Figure 4.8D). Interestingly, the extracted control samples from both the towel 
and the jeans produced a positive and weak positive result on RSID™ Blood, respectively. Using 
the LC-MS/MS method as a confirmation, these immunological assay results were not able to be 
verified, as this approach produced no identification of peripheral blood biomarkers. Furthermore, 
no genetic profile was produced from these control samples, even with manual analysis of 
electropherograms identifying no true alleles below the established analytical threshold (Appendix 




Table 4.13. Summary of comparative results for degraded samples. Positive identifications are 














Figure 4.8. Immunochromatographic results for degraded samples. ABAcard® tests are pictured on 
the left. RSID™ tests are pictured on the right. Question samples are oriented on the top of each 
frame. Control samples are oriented on the bottom of each frame. Within the membrane window, 
the test line is positioned on the left and the control line on the right. Results for (A) semen extracted 
from a bed sheet, (B) semen extracted from underwear, (C) blood extracted from a towel, and (D) 
blood extracted from denim jeans. A positive result is indicated by the presence of a red line at both 
the test and control zones. 
4.2.6 Aged Samples 
 Swabs fortified with neat body fluid were kept at room temperature for time points zero, 
three, five, seven, and thirty-five days. Comparative results are outlined in Table 4.15 for this 
portion of the study. No instances of negative detection were recorded for evaluation using 
traditional screening techniques or the proteomic assay (Figure 4.9); however, weak and very weak 
positives were observed for ABAcard® HemaTrace® for peripheral and menstrual blood samples. 
No change in detection was observed over the 35-day period. DNA analysis was not performed on 
this set of casework samples. 
 The traditional serological tests and the proteomic assay produced comparable results. 
However, the weak and very weak positive results exhibited for peripheral blood, menstrual blood, 
and saliva detection with traditional assays pose a cause for concern. With complete and almost 
complete identification of protein material for each target fluid, the LC-MS/MS assay produced 





Table 4.15. Summary of comparative results for aged samples. Positive identifications are 






Figure 4.9. Serological screening test results for aged samples at Day 35. ABAcard® test and 
SALIgAE® are pictured on the left. RSID™ test is pictured on the right. Within the membrane 
window, the test line is positioned on the left and the control line on the right. Results for (A) 
peripheral blood, (B) menstrual blood, (C) semen, and (D) saliva. On lateral flow assays, a positive 
result is indicated by the presence of a red line at both the test and control zones. For SALIgAE®, 
a positive result is indicated by a yellow colored reagent. 
4.2.7 Sensitivity Samples 
 This particular cohort of sensitivity samples were designed differently than those used for 
analytical sensitivity determination of the LC-MS/MS assay. Diluted body fluid was spotted on 
cotton swabs prior to analysis, resulting in further dilution of target material during sample 
solubilization, representing an inherent limitation to the preparation workflow. A summary of 
proteomic, serological, and genetic testing results for each target fluid are outlined in Tables 4.16-
4.20. The lowest diluted sample to still produce a positive result when screened with serological 
tests are picture in Figure 4.10. Reviewing proteomic results, peripheral blood was characterized 
at the 20,000-fold dilution with the detection of a single hemoglobin peptide (Table 4.16). With 
processing a matched sample on commercially available lateral flow assays, the RSID™ Blood and 
ABAcard® HemaTrace tests produced a positive result up to and including the 100-fold dilution. 
Conversely, STR analysis results were more consistent with the rate of peptide identification using 
the proteomic assay (Table 4.17). A complete STR profile was recovered through the 100-fold 
dilution, mirroring the complete characterization of peripheral blood peptide markers to the same 
dilution. The capability of STR profiling drastically decreased at a 5,000-fold and 10,000-fold 
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dilutions, with samples producing a 7% and 5% STR profile, respectively. Remaining samples did 
not generate an STR profile; however, as previously stated, hemoglobin was still detected at the 
20,000-fold dilution with the proteomic assay. Overall, the proteomic assay was demonstrated to 
be 200 times more sensitivity than immunological assays for the detection of peripheral blood. In 
addition, the proteomic assay exceeded the sensitivity of routine STR typing chemistries.  
 Menstrual blood was characterized down to the 40,000-fold dilution sample on the 
proteomic method, with the detection of a single hemoglobin peptide, similar to peripheral blood 
described above (Table 4.18). But only 4 of 7 vaginal fluid markers were accurately characterized 
with the proteomic assay. Cornulin, a more specific vaginal fluid marker, was detected at the 100-
fold dilution, with small proline rich protein 3 sporadically identified for the remainder of the dilution 
series (Table 3.27). Interestingly, two instances of high dose hook effect were observed with 
immunochromatographic testing, with the neat and 2-fold dilution samples exhibiting a negative 
result on the antibody-based assays (Table 4.18). In regard to identifying the blood component of 
menstrual blood, the proteomic assay outperformed the antibody-based tests by a factor of 400. 
Furthermore, with the absence of a vaginal fluid screening test, the proteomic assay inherently 
provided additional pertinent information down to the 100-fold dilution. A complete STR profile was 
obtained through the 100-fold dilution, with informative partial profiles produced at the 1,000- and 
2,000-fold dilutions (Table 4.22). Sufficient allele and locus dropout were recorded for the 
remaining samples.  
 Seminal fluid was accurately identified at the lowest dilution on the proteomic assay, with 
detection of semenogelin peptide QITIPSQEQEHSQK (Table 4.20). However, in comparison, the 
lateral flow assays exhibited poor sensitivity. RSID™ Semen failed to produce a positive result after 
the 100-fold dilution (Figure 4.10C). Furthermore, ABAcard® p30 demonstrated decreased 
sensitivity limits, reproducibly exhibiting a positive result only to the 10-fold dilution evaluated. In 
comparison, the proteomic assay demonstrated comparable results with STR and Y-STR genetic 
typing (Tables 4.23 and 4.24). With all protein biomarkers positively identified through the 100-fold 
dilution and a complete STR profile generated, seminal fluid identification using the validated assay 
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strongly mirrors the abilities of routine genetic testing. As the number of peptides detected 
inherently decreases, so did the number of alleles characterized. In regard to genetic testing, 
samples beginning with the 10,000-fold dilution failed to produce a male quantitation value and 
were therefore amplified for Y-STR typing (Table 4.24). Few Y-STR alleles were characterized at 
the lower end of the dilution series, with the 20,000-fold and 40,000-fold samples producing only a 
7% and a 4% Y-STR profile, respectively. Overall, the proteomic assay demonstrated a sensitivity 
level 400 times more sensitivity than immunological tests but exhibited a similar sensitivity range 
of that of STR and Y-STR chemistries.  
 Diluted saliva was characterized reproducibly at the 1,000-fold dilution, with the detection 
of a single amylase peptide (Table 4.19). One antibody-based test and one enzymatic test were 
acquired for traditional serological testing for this portion of the study. Both RSID™ Saliva and 
SALIgAE® tests performed equally, with positive results observed up to and including the 10-fold 
dilution samples (Figure 4.10D). As previously described, the proteomic assay kept pace with the 
ability to generate an STR profile; however, the capabilities of genetic typing and reaching a larger 
sensitivity range outweigh those of the proteomic assay (Table 4.25). Identification of peptide 
markers began to decrease at the 100-fold dilution, where a full STR profile was still generated. 
Furthermore, out to the 2,000-fold dilution, a 70% complete STR profile was reported whereas the 
proteomic assay failed to detect saliva for the remainder of samples evaluated. To conclude, the 
proteomic assay demonstrated a sensitivity range 100 times more robust than that of the traditional 
screening assays. Conversely, routine genetic testing remained more sensitive than the validated 
assay.     
 Vaginal fluid was characterized by all target protein markers at the 10-fold dilution, with 2 
of 7 markers detected at the 100-fold dilution and only a single protein (small proline rich protein 3) 
detected for the remaining samples (Table 4.20). In comparison, a full STR profile was produced 
down to the 500-fold dilution, with partial profiles observed for the remaining samples (Table 4.26). 
For the 100-fold dilution sample, no quantitation value was recorded and no DNA profile was 
produced. This result is inconsistent with the remaining data, and is therefore, being viewed as an 
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outlier. However, no matched comparison could be generated given the lack of a commercially 
available assay for vaginal fluid screening.  
 Overall, the validated proteomic assay greatly outperformed existing serological screening 
tests. It should be noted that samples were not solubilized in kit-specific buffer provided by the 
commercial entities for immunochromatographic testing. Although solubilization in buffer is 
recommended by the manufacturers, concentrated samples did not seem to inhibit the functionality 
of the assays (with the exception of the high dose hook effect for menstrual blood). Research has 
been conducted on the effect of pH and the ability to produce false positive and false negative 
results on the lateral flow assays. It was determined that extreme acidic or alkaline pH is not the 
sole contributor to false positive or false negative results. One study found that it is the presence 
of additional organic acids that causes disruption in the antibody-dye labeling mechanism [55].   
Table 4.16. Summary of comparative results for peripheral blood sensitivity samples. Positive 
identifications are represented by a green box. Negative results are represented by a white box. 
 
Table 4.17. Summary of comparative results for menstrual blood sensitivity samples. Positive 




Table 4.18. Summary of comparative results for seminal fluid sensitivity samples. Positive 
identifications are represented by a green box. Negative results are represented by a white box. 
 
Table 4.19. Summary of comparative results for saliva sensitivity samples. Positive identifications 
are represented by a green box. Negative results are represented by a white box. 
 
Table 4.20. Summary of comparative results for vaginal fluid sensitivity samples. Positive 






Figure 4.10. Serological screening test results for sensitivity samples. ABAcard® test and SALIgAE® 
are pictured on the left. RSID™ test is pictured on the right. Within the membrane window, the test 
line is positioned on the left and the control line on the right. Results for (A) 100-fold dilution of 
peripheral blood, (B) 100-fold dilution of menstrual blood, (C) 100-fold dilution of semen, and (D) 
10-fold dilution of saliva. On lateral flow assays, a positive result is indicated by the presence of a 





Table 4.21. STR genetic results for peripheral blood sensitivity samples. Complete locus 
identification represented by a green box. Partial locus identification represented by a grey box. 





Table 4.22. STR genetic results for menstrual blood sensitivity samples. Complete locus 
identification represented by a green box. Partial locus identification represented by a grey box. 
Locus dropout represented by a white box. Menstrual blood for this subset of samples was provided 





Table 4.23. STR genetic results for seminal fluid sensitivity samples. Complete locus identification 
represented by a green box. Partial locus identification represented by a grey box. Locus dropout 





Table 4.24. Y-STR genetic results for seminal fluid sensitivity samples. Complete locus 
identification represented by a green box. Partial locus identification represented by a grey box. 





Table 4.25. STR genetic results for saliva sensitivity samples. Complete locus identification 
represented by a green box. Partial locus identification represented by a grey box. Locus dropout 





Table 4.26. STR genetic results for vaginal fluid sensitivity samples. Complete locus identification 
represented by a green box. Partial locus identification represented by a grey box. Locus dropout 
represented by a white box. 
 
4.3 Concluding Remarks 
 In conclusion, the data demonstrated that the validated proteomic assay exhibits sufficient 
gains in sensitivity over currently utilized antibody- and enzyme-based screening techniques. 
Although various types of samples were deployed for this portion of the assessment, perhaps the 
greatest discrepancies between the traditional and proteomic analyses were observed with the 
sensitivity samples. The proteomic assay greatly outperformed traditional tests and provided 
detailed information on the proteins/peptides identified. This information can present other avenues 
for interpretation and subsequent testing to a forensic analyst. Still, one particular area of 
advancement worth highlighting is with the analysis of seminal fluid from a vasectomized individual. 
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When considering the scenario of a suspected rape, the ability to accurately characterize 
semenogelin off a vaginal swab that will test negative for sperm cells has the potential to provide 
critical information to an investigation. This data further supports the necessity for confirmatory 
seminal fluid identification, given that not all male perpetrators may contain sperm cells that could 
be visualized using routine microscopic techniques. 
 Furthermore, it was established that the proteomic assay can be seamlessly integrated into 
the larger forensic biology workflow, having no discernible effect on the ability to produce a genetic 
profile. With the idea of reverting back to a traditional workflow in place of direct to DNA, it can be 
argued that protein characterization may correlate to the likelihood of producing an informative 
genetic profile, particularly with sexual assault samples. For more than two decades, the forensic 
community has focused on improving the sensitivity and robustness of DNA profiling. While 
advances have made it possible to individualize biological traces on challenging types of 
evidentiary material, DNA alone does not readily indicate the body fluid source from which it was 
extracted. Serological testing to identify the body fluid from which a DNA profile has been 
generated, however, can provide vital contextual information to facilitate a successful prosecution. 
With sensitivity and specificity gains established by the developed proteomic method, the 
combination of proteomic screening with advanced genetic profiling presents a model workflow for 
adoption in forensic biology laboratories.   
 The remaining two chapters of this dissertation will focus on the proteomic analysis of 
sexual assault samples. As seen previous and revisited within this chapter, the presence of 
personal lubricants can have deleterious effects on the ability to positively identify vaginal fluid. The 
impact of this particular contaminant will be further explored in the next chapter, in addition to a 
greater assessment on its impact for the identification of seminal fluid and saliva biomarkers. In 
addition, renewed insight into intact protein identification for expedited serological analysis will be 
discussed in the final chapter.  
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CHAPTER 5: ASSESSMENT OF THE POTENTIAL INHIBITORY EFFECTS OF PERSONAL 
LUBRICANTS ON BODY FLUID IDENTIFICATION
5 Introduction 
The Federal Bureau of Investigation’s Uniform Crime Reporting Program solicits 
information from law enforcement agencies to provide reliable and uniform crime statistics for the 
United States [163]. Currently, more than 18,000 agencies across the United States voluntarily 
submit data to this program on an annual basis. For the year 2019, the most current report 
available, there were 64,048 reported rapes and a rate of offense estimated at 42 offenses per 
100,000 people. Of the 61,531 offenses where the sex of the offender was reported, 95.6% of 
offenses had a male offender (equivalent to 58,853 reported offenses). Within a single year, a 6.4% 
increase was observed in reported rape offenses, with 59,945 offenses reported in 2018. Over a 
six-year period, an increase of 37.92% of rape offenses is reported. Although the number of 
submitting agencies has increased by 15% since the year 2013, the prevalence of rape and sexual 
assault has continued to grow in the United States. This data was compiled using the 2013 revised 
definition of rape, with a single report referring to an instance of rape, attempted rape, or assault 
with intent to rape [163]. In the United States, approximately 1 in 6 women will be a victim of 
attempted or completed acts of sexual assault, with females under age 24 three times more likely to 
be a victim of sexual violence than the general population [164,165]. 
 For more than two decades, the forensic community has focused on improving the 
sensitivity and robustness of DNA profiling. While advances have made it possible to individualize 
biological traces on challenging types of evidentiary material, DNA alone does not readily indicate 
the body fluid source from which it was extracted. Serological testing to identify the body fluid from 
which a DNA profile has been generated, however, can provide vital contextual information to 
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facilitate a successful prosecution. In the event of a sexual assault or rape, a Suspect Sexual 
Assault Evidence Collection Kit is taken by a trained nurse and submitted for forensic testing. Kits 
generally include vaginal, oral, and rectal swabs, in addition to articles of clothing and supplemental 
swabs submitted on a case-by-case basis (e.g., breast, labia, inner thigh swabs). In addition, 
objects such as condoms or items used for vaginal penetration can be submitted for testing. Given 
the persistent sexual assault kit backlogs and that the sensitivity of post-coital DNA testing now 
exceeds that of contemporary serological tests, many labs have adopted a “direct to DNA” workflow. 
While this approach has a number of advantages, serological testing is especially important when 
the item of evidence in question (e.g., a towel or bedding) does not readily lend itself to an 
interpretation of likely sexual contact to the same degree as an intimate swab or underwear, where 
the mere presence of suspect’s DNA may be sufficient for criminal proceedings. 
 In the previous chapters, it was demonstrated that protein mass spectrometry techniques 
exhibit increased sensitivity and specificity to conduct accurate screening of evidentiary items for 
the presence of biological fluids. This approach has proven the LC-MS/MS analytical method to be 
robust and reliable in the detection of protein signatures, particularly for sexual assault type samples. 
With the developed workflow, it was demonstrated that protein components were able to be identified 
with a level of sensitivity comparable to that of STR/Y-STR profiling. The Uniform Crime Report 
states that in the year 2019, 17% of rape offenses were also linked with instances of sodomy and 
6.5% with instances of sexual assault with a foreign object [163]. In the context of sexual assault 
sample screening, the identification of seminal fluid in addition to saliva and vaginal fluid play a 
significant role in sample processing and generation of critical sample information. Of the laboratory-
generated case samples utilized during validation and implementation assessments, a particular set 
of samples, those treated with personal lubricant as part of the environmental contaminant subset, 
were identified for additional analyses. In particular, peak area responses of vaginal fluid biomarkers 




The objective of this phase of research was to assess the potential inhibitory effects of 
personal lubricants on the sensitivity of mass spectrometry-based body fluid identification. A two-
prong approach was designed to elucidate potential deleterious effects. First, target biological fluids 
were subjected to multiple lubricant types at varying volumes to illustrate the changes in protein 
biomarker detection. Second, body fluids recovered from lubricated condoms were evaluated. In 
combination, the results of this research provide an inclusive assessment of sample contaminants 
and alternate methodologies for processing challenging sample types received as forensic 
evidence. This research was completed under three scientific aims using the validated LC-MS/MS 
assay previously described. The first aim evaluated the effects of personal lubricant on the 
detection of vaginal fluid protein biomarkers. Similarly, the second aim assessed the effects of 
personal lubricant on seminal fluid and saliva identification, both individually and as mixed source 
samples. And lastly, the final aim evaluated condoms containing lubricant and spermicide 
elements.    
5.1 Methods and Materials  
5.1.1 Sample Collection and Materials 
 All research conducted under this phase of the project was reviewed and approved by the 
University of Denver IRB for research involving human subjects. Sample collection and research 
was conducted in full accordance with the U.S. federal policy for the protection of human subjects 
as described in section 2.11. In total, 10 subjects were recruited from the graduate population at 
Arcadia University (Glenside, PA) and staff members employed at The Center for Forensic Science 
Research & Education (Willow Grove, PA). 
Five classes of personal lubricant were selected for this study: water-based lubricant with 
glycerin (Astroglide®), water-based lubricant without glycerin (Sliquid® H2O), hybrid lubricant 
(Sliquid® Silk), silicone lubricant (Swiss Navy®), and natural oil-based lubricant (Coconut Oil). 




Table 5.1. Personal lubricants utilized for this study. Notes on lubricant ingredients, formula, and 
pH compiled from patent material and/or product descriptions.  
 
5.1.2 Lubricants and Vaginal Fluid Biomarker Detection  
5.1.2.1 Experimental Sample Assembly 
 Two experimental design plans were constructed for the processing and preparation of 
vaginal swab samples subjected to personal lubricants. The original experimental design consisted 
of full vaginal swabs that were cut in half, with one half serving as a control and the second half 
fortified with a set volume of personal lubricant (Figure 5.1). Lubricant volumes of 1 µL, 5 µL, or 15 
µL were added to half swabs. Control half swabs were not fortified with lubricant. Swab halves were 
dried at room temperature overnight. Half swabs were solubilized in 500 µL of deionized water for 
30 minutes with frequent agitation. Swabs were placed in a centrifugal basket and centrifuged at 
10,000 x g for 10 minutes. Supernatant was transferred to a clean microcentrifuge tube and cell 
pellets were discarded. Supernatant was reserved for analysis via LC-MS/MS.  
For the second experimental design, vaginal swabs were solubilized and extract was 
fortified with personal lubricant (Figure 5.2). Swab tips were solubilized in 500 µL of deionized 
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water for 30 minutes at room temperature with frequent agitation. Swabs were placed in a 
centrifugal basket and spun for 10 minutes at 10,000 x g to remove excess liquid. Supernatant was 
transferred and pooled for further preparation. Processed swabs and cell pellets were discarded. 
Pooled vaginal extract was fortified with increasing volumes of personal lubricant. For each 
lubricant type evaluated, 700 µL of pooled vaginal extract was fortified with either 7 µL, 35 µL, or 
105 µL of personal lubricant. These volumes simulate targeting 1 µL, 5 µL, and 15 µL of personal 
lubricant per sample replicate. Control samples consisted of pooled vaginal extract and were not 
subject to any personal lubricant manipulation. Mixtures were thoroughly vortexed and 100 µL 
aliquots were transferred to clean microcentrifuge tubes for triplicate analysis.  
 
Figure 5.1. Original sample preparation strategy using vaginal swabs fortified with lubricant types. 






Figure 5.2. Modified sample preparation strategy developed to mitigate expression inconsistencies 
in vaginal fluid proteins. Vaginal swabs were solubilized and pooled prior to mixing with lubricant 
types.  
5.1.2.2 Pre-Digestion Cleanup 
 Prepared sample aliquots were diluted with 400 µL of 0.5% trifluoroacetic acid (TFA) in 
deionized water. A positive pressure manifold (Biotage® PRESSURE+ 48) was fitted with Waters 
HLB 1cc extraction cartridges (Waters Corporation, Milford, MA). Cartridges were primed with 1 
mL of 50% acetonitrile (ACN) 0.5% TFA in deionized water. Cartridges were equilibrated with 1 mL 
of 0.5% TFA in deionized water. The full 500 µL of diluted sample was applied to and passed 
through the extraction cartridge, which was then washed with 1 mL of 0.5% TFA in deionized water. 
Material was eluted from the cartridge in 200 µL of 70% ACN 0.1% formic acid (FA) in deionized 
water.  
5.1.2.3 Sample Processing and Analysis 
Extracted samples were quantitated using the BCA assay (section 2.1.3.1) and 100 µg 
total protein was lyophilized to dryness. Samples were subjected to the previously described 8 M 
urea tryptic digestion and SPE purification on the AssayMAP Bravo liquid handling platform (section 
2.1.4). Eluate was fortified with 20 µL of 0.5 mg/mL intact myelin protein prior to tryptic digestion 
and 2.5 pmol of isotopically-labeled internal standard prior to SPE cleanup. Eluate was lyophilized 
to dryness and reconstituted in 100 µL of 2% ACN 0.1% FA in deionized water for LC-MS/MS 
analysis. Prepared samples were injected onto the 6495 triple quadrupole mass spectrometer 
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coupled to a 1290 series liquid chromatograph (Agilent Technologies). Data was acquired using 
the validated analytical method developed under Chapter 2, with data analysis performed in Skyline 
Software. 
5.1.3. Lubricants and the Detection of Semen and Saliva Biomarkers  
 Vaginal swabs were collected as previously described. Pooled vaginal extract was fortified 
with various amounts of lubricant and either semen, saliva, or a mixture of semen and saliva. 
Personal lubricant volumes of 1 µL, 5 µL, and 15 µL were also utilized for this portion of the 
assessment. In addition, target volumes of 1 µL of semen and 10 µL of saliva were utilized for 
single fluid experimental samples. For example, 400 µL of pooled extract was fortified with either 4 
µL, 20 µL, or 60 µL of personal lubricant in addition to 4 µL of semen or 40 µL of saliva (Figures 
5.3 and 5.4). Mixture samples were prepared in a similar manner. Pooled vaginal extract was 
fortified with personal lubricant as previously described in addition to 4 µL of semen and 40 µL of 
saliva (Figure 5.5). Control samples were fortified with semen and/or saliva but absent of personal 
lubricant. Samples were thoroughly vortexed and 100 µL of sample was aliquoted for further 
processing. Samples underwent pre-digestion cleanup, tryptic digestion, and SPE purification as 
described in section 5.1.2.2.  
 




Figure 5.4. Sample preparation strategy for control and experimental samples containing saliva. 
 
Figure 5.5. Sample preparation strategy for control and experimental samples containing both 
semen and saliva. 
5.1.4 Vaginal Fluid Biomarker Detection from Condoms 
 Four condom types were selected for evaluation: Trojan™ ENZ™ unlubricated condoms, 
SKYN® Original condoms, SKYN® Extra Lube condoms, and Durex® Performax® condoms. These 
condoms were selected because they were marketed to cover a range of lubricant amounts. A 
summary of condom types and product information is outlined in Table 5.2.  
 Condoms were removed from the packaging, unraveled, and placed on a clean piece of 
butcher paper. Simulating authentic casework, only the external surface (i.e., the surface that 
202 
 
contacts the vaginal cavity when inserted) was swabbed for this study. Vaginal swabs were 
obtained from female volunteers and dried at room temperature. A single swab was moistened with 
two drops of deionized water and used to swab the entire external surface of one condom. This 
was repeated in triplicate, with one vaginal swab per condom. Swabs were allowed to dry at room 
temperature for 30 minutes. Swabs were solubilized in 500 µL deionized water for 30 minutes with 
frequent agitation. Swabs were placed in a centrifugal basket and centrifuged for 10 minutes at 
10,000 x g. Supernatant was transferred and pooled in a clean microcentrifuge tube for further 
preparation. Cell pellets and processed swabs were discarded. Supernatant was subjected to pre-
digestion cleanup, tryptic digestion, and SPE purification as previously described. Eluate was 
lyophilized to dryness and reconstituted in 100 µL of 2% ACN 0.1% FA. 10 µL of sample was 
injected on column for LC-MS/MS analysis.  
Table 5.2. Condom brands utilized for this study. Notes on condom lubricant (if present) and 
material compiled from patent information and/or product descriptions. 
 
5.2 Results and Discussion 
5.2.1 Lubricants and Vaginal Fluid Biomarker Detection  
5.2.1.1 Digest Efficiency 
 The total protein concentration of control and experimental samples was determined using 
the BCA assay. Quantitation was used to normalize the amount of total protein input into the 
enzymatic digestion procedure. Should the presence of personal lubricants negatively impact the 
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ability to accurately determine the total protein quantity in a sample, the protein input for tryptic 
digestion would be incorrect. This would result in insufficient digestion or missed cleavages. No 
effect on digest efficiency was observed across and lubricant type or lubricant volume, resulting in 
no sufficient variation in protein concentration (Figure 5.6). A median protein concentration was 
measured at 266.42 µg/mL and 272.18 µg/mL for control and experimental samples, respectively.  
Trypsin performance was monitored by assessing peak area ratios of intact internal 
positive control to digested internal positive control (IPC). Acceptance criteria outlined during 
validation studies (Chapter 3) were employed during this assessment to ascertain IPC 
performance. IPC ratios that fell within ratio bounds of 15.8 (upper bound) and 11.5 (lower bound) 
were considered acceptable and unaffected by experimental procedures. Digest performance was 
impacted by several personal lubricant types prior to implementing a supplemental pre-digestion 
cleanup (Figure 5.7). Greatest protease inhibition prior to supplemental cleanup was observed for 
Sliquid® H2O, Coconut Oil, and Swiss Navy® lubricants. For example, the average IPC ratio for 1 
µL coconut oil samples was 19.15, a ratio that falls outside the acceptable range. With the addition 
of the pre-digestion cleanup, this ratio fell to an acceptable 12.42. Interestingly, Sliquid® Silk 
demonstrated an inverse dose-response relationship, with 1 µL volumes of personal lubricant 
above the established range, 5 µL volumes within the established range, and 15 µL volumes below 
the established range. Protease activity was not negatively affected by Astroglide®. Acceptable IPC 
ratios for all lubricants assessed were restored with the addition of the pre-digestion cleanup to the 




Figure 5.6. Quantitative results comparing total protein concentration of control and lubricated 
vaginal swab samples. Box = 25th and 75th percentiles; bars = Tukey fences. Outliers were 
calculated as any values outside ± 1.5 Inter Quartile Range (IQR).  
 
Figure 5.7. Internal positive control response ratio for control and lubricated samples which have 
or have not undergone an additional SPE purification during sample preparation. Response ratios 
were averaged across three replicates.  
5.2.1.2 Biomarker Detection 
 The effect of personal lubricant on biomarker detection was assessed by calculating the 
percent difference of endogenous and internal standard peak area responses for all samples 
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evaluated. Similar to the results observed for digestion efficiency, biomarker detection was 
negatively affected by the presence of personal lubricant, particularly prior to the addition of the 
pre-digestion cleanup. Overall, impact of personal lubricant was sufficiently reduced at all lubricant 
volumes with pre-digestion cleanup (Figure 5.8). 
 The greatest deleterious effects were observed for Sliquid® H2O, Coconut Oil, and Sliquid® 
Silk lubricants. Sliquid® H2O, the water-based lubricant without glycerin, exhibited a dose-response 
relationship for both endogenous and internal standard biomarkers. When fortified with lubricant, a 
median percent difference for endogenous vaginal fluid biomarkers of 0.31%, −11.28%, and 
−37.54% were observed at the 1 µL, 5 µL, and 15 µL lubricant volumes, respectively. The greater 
percent difference at the 15 µL volume was mitigated with a pre-digestion cleanup, resulting in a 
percent difference of −14.28% (Figure 5.8B). A similar dose-response relationship was exhibited 
by samples treated with Sliquid® Silk (Figure 5.8D). Samples treated with Coconut Oil exhibited 
negative impact on biomarker detection regardless of lubricant volume. A percent difference of 
−25.04%, −22.15%, and −25.03% were observed for 1 µL, 5 µL, and 15 µL volumes, respectively. 
However, a wide range in response ratios was demonstrated. The lower whisker extends to 
−80.94% and the median lies at the top of the inter quartile range (IQR). Internal standard 
responses exhibited a negative percent difference, but not to the same extent as the endogenous 
biomarkers (Figure 5.8C).  
 To further illustrate the negative effects of certain lubricants on specific endogenous 
biomarkers, Figure 5.9 depicts the response of neutrophil gelatinase peptide WYVVGLAGNAILR 
when subjected to each lubricant evaluated. This biomarker was selected given the specificity of 
neutrophil gelatinase in vaginal fluid and the hydrophobic nature of the WYVVGLAGNAILR peptide 
(retention time of 8.7 minutes). The response of this specific peptide was unaffected by Astroglide® 
and Sliquid® Silk; however, sufficient decrease in response was exhibited with Sliquid® H2O, 
Coconut Oil, and Swiss Navy®. With the addition of a pre-digestion cleanup, inconsistencies were 
not entirely eliminated, but minimized in most cases. For example, Figure 5.10 illustrates the 
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increase in peak area response of endogenous neutrophil gelatinase peptide WYVVGLAGNAILR 
with the addition of the pre-digestion cleanup. 
   
 
Figure 5.8. Effect of (A) Astroglide®, (B) Sliquid® H2O, (C) Coconut Oil, (D) Sliquid® Silk, and (E) 
Swiss Navy® lubricants measured as percent difference on peak area response of endogenous 
vaginal fluid proteins and isotopically-labeled internal standards both with and without pre-digestion 
SPE cleanup. Box = 25th and 75th percentiles; bars = Tukey fences. Outliers were calculated as 




Figure 5.9. Chromatographic peak response for endogenous neutrophil gelatinase peptide 
WYVVGLAGNAILR when subjected to 15 µL of (A) Astroglide®, (B) Sliquid® H2O, (C) Coconut Oil, 
(D) Sliquid® Silk, and (E) Swiss Navy®.  
 
Figure 5.10. Chromatographic peak response for endogenous neutrophile gelatinase peptide 
WYVVGLAGNAILR (A) without pre-digestion cleanup and (B) with pre-digestion cleanup, when 
subjected to 15 µL of Swiss Navy®.  
5.2.2 Lubricants and the Detection of Semen and Saliva Biomarkers 
 The overall effect of personal lubricant was further assessed with mock sexual assault 
samples. Generally, when sexual assault evidence is received in a forensic laboratory, it will be 
screened for the presence of seminal fluid and/or saliva. Therefore, in addition to the effect of 
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personal lubricant on the detection of vaginal fluid, it was vital to establish any deleterious effects 
that may inhibit the identification of seminal fluid and/or saliva. To simulate sexual assault samples, 
pooled vaginal extract was fortified with seminal fluid, saliva, and a mixture of both target fluids in 
addition to increasing amounts of personal lubricant. All lubricant classes and selected volumes 
were evaluated in triplicate.  
 In summary, all seminal fluid and saliva protein biomarkers were detected at all lubricant 
volumes and for all lubricant classes evaluated, in both the prepared single source and mixture 
samples. For prepared samples containing saliva, marginal suppression or enhancement effects 
were observed for samples fortified with Astroglide®, Sliquid® H2O, and Coconut Oil. In comparison 
with the detection of vaginal fluid markers, sufficient losses in peptide response were observed for 
samples fortified with Sliquid® Silk, even with the pre-digest cleanup (Figure 5.11A). A median 
saliva biomarker signal decrease of −37.0%, −54.7%, and −93.3% at the 1 µL, 5 µL, and 15 µL 
volumes was observed with the Sliquid® Silk lubricant. Furthermore, at the 15 µL volume, sufficient 
enhancement effects were observed for Swiss Navy®, with a median signal increase of 120.5%. 
These observed effects were consistent with recorded peak area responses of the internal 
standards of single source saliva samples (Figure 5.11B). The greatest suppression effects were 
illustrated by endogenous seminal fluid protein biomarkers, with consistent suppression noted for 
Astroglide®, Sliquid® H2O, Coconut Oil, and Sliquid® Silk. A median signal decrease of −23.3% and 
−85.7% were observed at the 5 µL and 15 µL Sliquid® Silk volumes, respectively. These two 
samples exhibit a large IQR. However, small instances of enhancement were recorded for the 15 
µL Sliquid® Silk and 1 µL Swiss Navy® lubricants, with signal increases of 4.9% and 4.8%, 
respectively (Figure 5.11C). Conversely, minimal suppression and enhancement effects were 
observed for seminal fluid internal standard responses (Figure 5.11D).  
 Interestingly, the severe instances of peak response suppression for Sliquid® Silk were not 
as evident in samples containing a mixture of seminal fluid and saliva (Figure 5.12A and 5.12C) 
Although an average peptide response loss of −49.7% for saliva and −26.4% for seminal fluid were 
observed at the 15 µL volume of Sliquid® Silk, peak response enhancement for Coconut Oil was 
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illustrated (Figure 5.12A and 5.12C). Internal standard response demonstrated limited 
suppression for both target fluids, with enhancement observed for Coconut Oil and Sliquid® Silk 
lubricants (Figure 5.12B and 5.12D). For example, decrease in peak area response for 
semenogelin 2 and alpha amylase is depicted in Figure 5.13. Endogenous peak area response 
(red peaks) demonstrates a linear decrease while the internal standard response (blue peaks) 
remains relatively unchanged across lubricant volumes. 
 
Figure 5.11. Effects of lubricant on (A) endogenous saliva biomarkers, (B) internal standard saliva 
biomarkers, (C) endogenous seminal fluid biomarkers, and (D) internal standard seminal fluid 
biomarkers. Plotted is the percent difference of average signal intensity for control versus 
experimental samples for all target biomarkers. Box = 25th and 75th percentiles; bars = Tukey 




Figure 5.12. Effects of lubricant on (A) endogenous saliva biomarkers, (B) internal standard saliva 
biomarkers, (C) endogenous seminal fluid biomarkers, and (D) internal standard seminal fluid 
biomarkers in mixture samples. Plotted is the percent difference of average signal intensity for 
control versus experimental samples for all target biomarkers. Box = 25th and 75th percentiles; 




Figure 5.13. Semenogelin 2 peptide GSISIQTEEQIHGK peak area response in mixture samples 
containing (A) 1 µL, (B) 5 µL, and (C) 15 µL volumes of Sliquid® Silk lubricant. Alpha amylase 
peptide LSGLLDLALGK peak area response in mixture samples containing (D) 1 µL, (E) 5 µL, and 
(F) 15 µL volumes of Sliquid® Silk lubricant. Red peaks represent endogenous peptide peak area 
response. Blue peaks represent internal standard peak area response.  
5.2.3 Vaginal Fluid Biomarker Detection from Condoms 
 Pre-lubricated condoms typically contain a proprietary lubricant which may include the 
addition of spermicidal additives, such as the non-ionic detergent nonoxol-9. It was hypothesized 
that such detergents and additives may decrease binding capacity of solid phase extraction 
cartridges. The sorbent material of the validated microextraction cartridges were hydrophobic C18 
hydrocarbons bonded to silica beads. The presence of detergents can introduce competitive 
binding, resulting in a decrease in capture and recovery of hydrophobic markers during analysis. 




 To further assess this hypothesis, lubricated condoms both with and without spermicidal 
additives were evaluated. The external surface of each condom was swabbed with a vaginal swab 
to capture the proprietary lubricant and/or spermicide additive at concentrations commonly 
encountered in forensic casework. Unlubricated condoms (Trojan™ ENZ™) served as the condom 
control, in addition to pooled, untreated vaginal extract serving as the negative control. In addition 
to the unlubricated condom type, SKYN® Original, SKYN® Extra Lube, and Durex® Performax® 
condoms were selected for this portion of the study. After initial observations made during sample 
handling, the Durex® Performax® condoms contained the greatest amount of surface lubricant and, 
although marketed as unlubricated, the Trojan™ ENZ™ condoms did contain a minimal amount of 
lubricant on the external surface.  
Overall, target peptide response of vaginal fluid markers was greater across all condom 
types in comparison to negative control samples (Figure 5.14). It should be noted that 
inconsistency in sample data was observed, as depicted by the percent difference range of 
endogenous targets and large IQR of internal standard response. For endogenous biomarkers, the 
calculated percent differences of peak area response were evenly distributed between the first and 
third quartiles. However, outliers greater than 1.5 IQR were observed for Durex® Performax®, 
SKYN® Original, and SKYN® Extra Lube condom samples. A median 50% gain in peptide response 
was exhibited by vaginal fluid markers recovered from swabs subjected to the surfaces of SKYN® 
Extra Lube and Trojan™ ENZ™ condoms (Figure 5.14A). Overall, peak response of isotopically-
labeled internal standard was enhanced in comparison with control samples (Figure 5.14B). The 
internal standard response demonstrated greater agreement among sample replicates than 
endogenous biomarkers responses, evident by the absence of outliers and a more consistent IQR. 
Chromatographic endogenous and internal standard peak area responses across condom replicate 
samples are depicted in Figure 5.15.  
An active ingredient in Durex® Performax® condoms that may attribute to the larger IQR 
and presence of outlier data points is benzocaine. Benzocaine is a common ingredient in over-the-
counter topical pain ointments, such as those used for oral and otic pain. The mechanism of action 
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of benzocaine that results in pain relief has also been leveraged for use in contraceptives. 
Benzocaine acts by inhibiting voltage-dependent sodium channels, preventing an action potential 
from propagating down a neuron membrane. When applied to condoms, benzocaine can prevent 
premature ejaculation by decreasing sensitivity of male sex organs. Given the compound’s 
structure, it is hydrophobic in nature and readily soluble in alcohol-based solvents. Therefore, 
benzocaine has great affinity for the C18 sorbent material of solid phase extraction cartridges and 
for the acetonitrile-based elution solvent. 
 
Figure 5.14. Effects of condom lubricant on (A) endogenous vaginal fluid biomarkers and (B) 
internal standard vaginal fluid biomarkers. Plotted is the percent difference of average signal 
intensity for control versus experimental samples for all target biomarkers. Box = 25th and 75th 




Figure 5.15. Neutrophil gelatinase peptide WYVVGLAGNAILR peak area response for (A) Durex® 
Performax®, (B) SKYN® Original, (C) SKYN® Extra Lube, and (D) Trojan™ ENZ™ condom triplicate 
samples. Red peaks represent endogenous peptide peak area response. Blue peaks represent 
internal standard peak area response. 
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5.3 Concluding Remarks 
 With the completion of this phase of research, it has been demonstrated that the 
deleterious effects of personal lubricants, specifically oil and silicone-based formulas, can be 
mitigated through the addition of a second solid phase extraction cleanup. When implemented prior 
to digestion, this cleanup eliminated interferents that would otherwise negatively affect trypsin 
processivity and mass spectrometry detection.  
Extraction cartridge sorbent material was selected based on chemical interactions between 
the sorbent functional groups with functional groups of target protein biomarkers. These functional 
groups are considerably different from other structural elements and functional groups of 
interference compounds, such as surfactants. The functional group interaction between the target 
analyte and its surrounding environment was crucial in modifying the sample preparation protocol 
for this portion of the study. Given the presence of interfering compounds present in personal 
lubricants, such as surfactants and medium chain fatty acids, additional steps were needed to 
ensure maximum recovery of target biomarkers.  
Reverse phase solid phase extraction was used for additional sample cleanup. Reverse 
phase employs a polar mobile phase and a nonpolar sorbent stationary phase. Given that 
serological samples are generally maintained in water or saline solution, reverse phase extraction 
was a clear solution to mitigating the effects of hydrophobic compounds common in lubricant 
formulas. A C18 sorbent material was selected for solid phase extraction cleanup and optimized 
as part of the developed protocol under the validation of the LC-MS/MS assay. C18 sorbents are 
nonpolar in nature and therefore attract and retain nonpolar analytes in solution, such as nonpolar 
peptide side chains or nonpolar interferent compounds.  
 Astroglide® contains the compound (1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane 
chloride), referred to as polyquaternium-15. Although water soluble, this compound has surfactant 
properties. Surfactants, even at low concentrations, have the ability to severely suppress ionization 
during mass spectrometry analysis. Swiss Navy®, the silicone lubricant selected for this study, 
contains the compound dimethicone that has surfactant properties as well. Dimethicone is a 
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hydrophobic compound, as is Vitamin E acetate (α-tocopheryl acetate) and cyclopentasiloxane. 
These three compounds would be retained during reverse phase solid phase extraction. In order 
to selectively remove retained proteins from interferents, a relatively polar elution solvent was 
necessary. In comparison with other organic solvents such as ethyl acetate or acetone, acetonitrile 
is a polar solvent. Therefore, protein material would have greater affinity for the elution solvent than 
severely hydrophobic interferents, such as dimethicone, which would stay retained to the sorbent 
material. In summary, it was demonstrated that the analysis of sexual assault samples subjected 
to personal lubricants or condom forms of contraception was achievable with modified sample 
preparation protocols.  
 The remaining chapter of this dissertation will further delve into advancing proteomic 
techniques as they apply to the analysis of sexual assault evidence. Thus far, the protein markers 
targeted using the validated LC-MS/MS assay have been manipulated by the protease trypsin, 
producing distinct peptide fragments. This process has the potential to eliminate high quality 
peptide targets that may fall within or outside of a tryptic peptide. Although it has been demonstrated 
that this bottom up proteomic process can be amenable to high throughput analyses, the multi-day 
workflow is a substantial drawback to the adoption of this workflow by forensic practitioners. 
Therefore, an enzyme-free proteomic identification method of seminal fluid, saliva, and vaginal fluid 
has been developed and assessed.  
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CHAPTER 6: DEVELOPMENT OF A PEPTIDOMIC METHOD FOR BODY FLUID 
IDENTIFICATION 
6 Introduction 
It has been well-established that protein mass spectrometry methodologies demonstrate 
the desired sensitivity and specificity for the confirmatory identification of biological fluids, 
particularly in comparison with traditional serological screening techniques. The research 
presented thus far utilized a bottom up proteomic approach, where protein material was subjected 
to a multi-step workflow of denaturation, enzymatic digestion, cleanup, and analysis. Although this 
bottom up workflow reliably identified biological stains and was amenable to automation, the multi-
day workflow presents a substantial impediment to the implementation of this next generation 
technique in operational forensic laboratories. In contrast to traditional bottom up approaches, top 
down techniques measure intact proteins, naturally derived peptides, or breakdown products of 
larger proteins. Driven primarily by the demands of the biopharmaceutical and biomedical 
industries, it is possible to reliably measure small to medium sized peptides in complex biological 
matrices [166]. Procedural methods are straightforward and require minimal sample preparation to 
remove abundant endogenous proteins, such as albumin. Typically, only a one-step solid phase 
extraction is required prior to detection by high resolution mass spectrometry. Data analysis 
employs advanced bioinformatics software capable of deconvoluting and matching fragmentation 
spectra of large peptides. These technical advances allow for a streamlined same day workflow, 
an attractive alternative to the more laborious bottom up procedures currently required for 
proteomic body fluid identification.  
A multiplex assay using high-specificity protein biomarker panels for the identification of 
five forensically-relevant body fluids (i.e., peripheral blood, saliva, seminal fluid, vaginal/menstrual 
fluids) was developed and validated, as described in Chapters 2 and 3. This approach has proven 
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to be broadly robust and reliable, particularly for the processing of sexual assault-type samples. 
With this workflow, the protein components, and by association the body fluid source, of stains can 
be detected with a level of sensitivity comparable to that of DNA profiling. The assay has been 
rigorously validated in accordance with the Scientific Working Group for Forensic Toxicology 
(SWGTOX) Standard Practices for Method Validation in Forensic Toxicology [167] and the FBI’s 
Quality Assurance Standards (QAS) [168] to establish the reliability and limitations of the 
methodology. Studies on assay performance with casework-type samples have shown that the 
method is fully compatible with downstream genetic testing and that assay sensitivity greatly 
exceeds that of traditional lateral flow assays, particularly with trace level samples. Additional 
studies, discussed in Chapter 5, that targeted the potential impact of substances commonly 
encountered in sexual assault-type evidence (e.g., personal lubricants and spermicidal 
compounds) provided additional insight on how best to maximize the successful detection of body 
fluids in casework. 
The objective of this phase of research was to develop a peptidomic assay for the 
expedited identification of vaginal fluid, saliva, and seminal fluid in sexual assault evidence by high 
resolution mass spectrometry. This research was completed under four scientific aims. First, 
various sample processing protocols were evaluated and compared to ensure optimal biomarker 
recovery from solubilized stains. The second aim sought to adapt and transfer an existing prototype 
assay to a high-flow operational platform. The third aim employed a population study for the 
determination of candidate protein and peptide biomarkers. And lastly, a performance assessment 
was conducted using a targeted acquisition method created with the selected biomarkers for each 
biological fluid. The final deliverable would contain an expedited proteomic methodology, with the 
length enzymatic digestion step eliminated, where surrogate peptides could serve as a means of 
body fluid source determination. This peptidomic approach streamlines body fluid identification by 
coupling direct protein analysis of whole-body fluids in lieu of workflows that employ time-
consuming enzymatic digestion prior to sample analysis. Additionally, it enabled the swift but 
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accurate identification and verification of body fluid-specific biomarkers with a same-day sample 
processing workflow for sexual assault analysis. 
6.1 Methods and Materials 
 All research conducted under this phase of the project was reviewed and approved by the 
University of Denver IRB for research involving human subjects. Sample collection and research 
was conducted in full accordance with the U.S. federal policy for the protection of human subjects 
as described in section 2.11. In total, 10 subjects were recruited from the graduate population at 
Arcadia University and staff members employed at The Center for Forensic Science Research & 
Education.  
Semen was self-collected from consenting donors as described in section 2.1.1. Collection 
cups were vortexed and 200 µL single use aliquots were prepared and stored at -80 °C until use. 
Saliva was collected from consenting volunteers who refrained from eating or drinking for 1 hour 
prior to collection. Salivette® collection tubes (Sarstedt, Nümbrecht, Germany) were utilized as 
described in section 2.1.1. 200 µL single use aliquots were prepared and stored at -80 °C until use. 
Single use body fluid aliquots (semen or saliva) were thawed at room temperature for 30 minutes 
then centrifuged for 10 minutes at 10,000 x g. Supernatant was transferred to a clean 
microcentrifuge tube and cell pellets were discarded. For this study, vaginal secretions were 
collected using only the swabbing method as described in section 2.1.1. Upon receipt, swabs were 
dried at room temperature where the cotton tip was removed from the wooden handle and placed 
in a clean microcentrifuge tube. Swabs were stored at -80 °C until use. Full cotton swabs were 
solubilized in 600 µL of deionized water for 30 minutes with frequent agitation. Swabs were placed 
into centrifugal baskets and centrifuged at 10,000 x g for 10 minutes. Supernatant was pooled and 
transferred to a clean microcentrifuge tube.  
Given laboratory and IRB restrictions in place out of caution for the SARS-CoV-2 virus, 
additional biological matrices were purchased from both Lee Biosolutions, Inc. (Maryland Heights, 
MO) and Innovative Research, Inc. (Novi, MI) for the population assessment. Upon ordering, it was 
requested that each sample was obtained from a unique donor, with no repetitive donors. Biological 
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material was shipped on dry ice and immediately stored at -80 °C until use. Saliva and semen 
samples were thawed at room temperature for 30 minutes, vortexed, and pulse spun. 200 µL was 
removed for analysis and treated as described above. Supernatant was transferred to a clean 
microcentrifuge tube and cell pellets were discarded. Full vaginal swabs were cut and treated as 
described above.  
Body fluid material was quantitated using the bicinchoninic acid (BCA) assay as described 
in section 2.1.4. Protein material was extracted using a method described below.  
6.1.1 Sample Processing Development and Comparison 
 For this portion of the research, single source body fluid samples from at least two 
individuals were prepared in triplicate for analysis as described above. Final preparation protocol 
comparison (Agilent Bond Elut Plexa plate versus Agilent RP-S Cartridges) was performed with 
single source body fluid from two individuals prepared in quadruplicate.  
6.1.1.1 Protein Precipitation 
 A total protein amount of 200 µg was diluted with equal volume of cold acetonitrile 
(maximum volume of 100 µL) and agitated. Samples were centrifuged at 10,000 x g for 15 minutes 
at 4 °C. Supernatant was transferred to a clean microcentrifuge tube and lyophilized to dryness. 
Precipitated protein (pelleted material) was discarded. The procedure was repeated with 150 µg, 
50 µg, 10 µg, and 1 µg protein amounts. Protein quantities smaller than 50 µL volume equivalent 
were brought up to a final volume of 50 µL with 100 mM Tris-HCl prior to acetonitrile addition.  
6.1.1.2 Centrifugal Filtration 
 Two centrifugal filters were evaluated: Spin-XR UF 500 (Corning®, Corning, NY) and 
Amicon® Ultracel® (Millipore Sigma, Darmstadt, Germany), both of which had a molecular weight 
cutoff of 10 kDa. A total protein amount of 200 µg was diluted with 30% acetonitrile (ACN) with 
0.1% formic acid (FA) to a final volume of 500 µL. Centrifugal filters were centrifuged at 10,000 x g 





6.1.1.3 Automated Solid Phase Extraction 
Two microextraction cartridges compatible with the AssayMAP Bravo liquid handling 
platform were selected for evaluation: C18 sorbent and RP-S sorbent, both purchased from Agilent 
Technologies (Santa Clara, CA). A total protein amount of 100 µg was diluted with 0.5% 
trifluoroacetic acid (TFA) in deionized water for a final volume of 250 µL. Microextraction cartridges 
were primed with 100 µL 50% ACN 0.5% TFA at a flow rate of 300 µL/min. Cartridges were 
equilibrated with 50 µL of 0.5% TFA in deionized water at 10 µL/min. 220 µL of diluted sample was 
passed over the cartridge at a flow rate of 15 µL/min. Cartridges were washed with 50 µL of 0.5% 
TFA in deionized water at a rate of 10 µL/min. Sample material was eluted from the sorbent in 25 
µL of 30% ACN 0.1% FA at 5 µL/min. Eluate was lyophilized to dryness prior to analysis. 
6.1.1.4 Manifold Solid Phase Extraction 
 A positive pressure manifold was fitted with either a Bond Elut Plexa or a Bond Elut Plexa 
PCX plate (Agilent Technologies). Plates were received in a 96-well cartridge format. Cartridges 
were primed with 500 µL of 50% ACN with 0.5% TFA in deionized water and washed with 500 µL 
of 0.5% TFA in deionized water. A total protein amount of 100 µg was diluted with 0.5% TFA in 
deionized water for a final volume of 500 µL and loaded onto the cartridge. Sorbent material was 
washed with 500 µL of 0.5% TFA in deionized water. Sample material was eluted with 100 µL of 
30% ACN with 0.1% FA in deionized water. This step was repeated for a total of 200 µL of eluate, 
which was lyophilized to dryness prior to analysis.  
6.1.2 Development of Data Acquisition Method and Analytical Parameter Optimization 
 Mixed-source samples containing various protein quantities of semen and saliva were 
prepared. Neat biological fluid was quantitated using the BCA assay previously described. Two 
sets of samples were generated. First, a saliva major contributor with a semen minor contributor, 
with total protein quantities ranging from 80 µg to 99 µg for the major contributor. All mixture 
samples contained a total of 100 µg total protein. Second, a semen major contributor with a saliva 
minor contributor series was created, prepared in an equivalent manner.  
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 An inclusion list containing desirable peptide biomarkers was generated from data acquired 
during the population study, discussed in the section below. The inclusion list was prepared in 
Skyline Proteomics Environmental software v. 20.2.0.343 (MacCoss Labs, University of 
Washington) and imported into Xcaliber™ control software on the Q Exactive™ Quadrupole-
Orbitrap™ mass spectrometer (Thermo Scientific, Waltham, MA). Analytical parameters on the Q 
Exactive™ Quadrupole-Orbitrap™ mass spectrometer were optimized using single source biological 
fluids. Recommended instrument settings outlined by the University of Washington Proteomics 
Resource (UWPR) were used as a starting point for parameter optimization.  
6.1.3 Population Study and Performance Assessment 
 Twenty semen samples were purchased from Innovative Research and thirty semen 
samples were purchased from Lee Biosolutions, for a total of 50 semen donors. An additional 5 
semen samples from vasectomized donors were purchased from Lee Biosolutions. Twenty-five 
saliva samples were purchased from Innovative Research and Lee Biosolutions for a total of 50 
saliva donors. Twenty-five vaginal swabs were purchased from Lee Biosolutions and seven vaginal 
swabs were collected under IRB, for a total of 32 vaginal swab donors. Regardless of donor source, 
received vaginal swabs were stored at -80 ºC upon receipt. Population samples were purchased 
due to SARS-CoV-2 restrictions put in place for collection of biological samples under the approved 
IRB. Performance assessment samples were divided into six categories: sensitivity, aged, 
substrates, contaminants, mixtures, and simulated sexual assault kit. All samples were prepared 
in triplicate as described in Table 6.1. Substrates were washed with Tide Natural detergent in cold 
water and dried prior to use to ensure consistency between samples.  
Population samples were quantitated using the BCA assay and extracted using the Bond 
Elut Plexa plate protocol as described above. Performance assessment samples were extracted 
using Waters Oasis HLB cartridges (Milford, MA), the manufacturer equivalent of the Bond Elut 
Plexa chemistry. This switch was induced by time constraints and backordered consumables due 
to SARS-CoV-2 testing. 100 µg total protein was used for analysis. Extraction procedures between 
the two manifold cartridges were equivalent, with the exception of increasing the organic elution 
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solvent to 35% ACN with 0.1% FA with the Waters Oasis HLB cartridges, per manufacturer 
recommendations. Eluate was lyophilized to dryness for LC-MS/MS analysis.  
Table 6.1. Performance assessment sample preparation parameters. Room temperature (RT). 




6.1.4 Protein Identification by LC-MS/MS 
 Lyophilized samples were reconstituted in 50 µL of 2% ACN with 0.1% FA in deionized 
water. Acquisition was performed using 5 µL of sample per injection on a Q Exactive™ Quadrupole-
Orbitrap™ mass spectrometer (Thermo Scientific, Waltham, MA). A Waters® ACQUITY UPLC BEH 
C18 analytical column (1 x 100 mm, 1.7 µm, 130Å) was used for separation (Waters, Milford, MA). 
Mobile phase A consisted of water with 0.1% FA and mobile phase B consisted of ACN with 0.1% 
FA. Separation initiated at 5% B followed by a linear 5-35% B gradient over 17 minutes, a 3-minute 
hold at 90% B, followed by a 5-minute re-equilibration at a 0.40 mL/min flow rate and column 
temperature of 50 °C.  
 Acquired data was searched using Protein Metrics Byonic™ (v. 3.8) software (Protein 
Metrics Inc., Cupertino, CA). A no enzyme search method was created with the following criteria: 
for sample digestion parameters, the cleavage site was left blank, the cleavage side was set to C-
terminal, the digestion specificity as nonspecific (slowest), and the number of missed cleavages 
was set to 2; for instrument parameters, the precursor mass tolerance was input as 5 ppm, 
fragmentation type was set to QTOF/HCD, fragment mass tolerance input as 10 ppm, and 
recalibration selected as none; for modification parameter, the total common max was input as 2 
and the total rare max was input as 1, with pyro-Glu, oxidation, and deamidation set as fixed 
modifications. No parameters were input for glycans, S-S Xlink bonded pairs, or inclusion. Under 
the advanced option, the maximum precursor mass was set to 4,000, with the maximum number 
of precursors per MS2 input as 1, and smoothing width set to 0.01 m/z. The whole human proteome 
(UniProt ID UP000005640) was utilized for data searches during preliminary assessments. A 
focused database containing the amino acid sequences of selected protein biomarkers was 
generated for performance assessment data acquisition. Data files searched against either the 
whole human proteome or focused database were further analyzed using Protein Metrics Byologic® 
(v. 3.9-32) software (Protein Metrics, Inc.). Searched Byonic™ files were imported into Byologic® for 




6.2 Results and Discussion 
6.2.1 Sample Processing Development and Comparison 
When analyzing complex matrices such as seminal fluid, saliva, and vaginal fluid, 
pretreatment steps are necessary to isolate peptide material from unwanted salts, intact proteins, 
or cellular debris, as well as environmental contaminants. Traditional sample processing 
techniques for cleanup employ reverse phase solid phase extraction. A previously developed 
Waters Oasis® HLB cartridge extraction protocol using a positive pressure manifold [169] was 
replaced with an improved preparation protocol. Several preparation protocols were developed for 
comparison, including two automated reverse phase extraction approaches on the AssayMAP 
Bravo liquid handling platform, two manifold solid phase extraction plate-based approaches, 
centrifugal filtration methods, and a precipitation method. These various approaches were 
evaluated using a set of single source body fluid matrix samples. Data was acquired using the 
Thermo Q Exactive™ Quadrupole-Orbitrap™ mass spectrometer (herein referred to as the Q 
Exactive). In general, high confident identifications were observed for multiple salivary markers 
including statherin (STAT), submaxillary gland androgen-regulated protein 3B (SMR3B), histatin-1 
(HIS1) and -3 (HIS3), cystatin-SN (CST1), and multiple proline-rich protein isoforms (PRP_1, 
PRP_2, PRP_3, PRP_4, and PRPC). Several seminal fluid biomarkers including semenogelin 1 
(SEMG1), semenogelin 2 (SEMG2), prostate specific antigen (KLK3), and prostatic acid 
phosphatase (PPAP) were detected. Multiple vaginal fluid proteins including cornulin (CRNN), 
suprabasin (SBSN), and involucrin (IVL) were identified as well.  
 Developing a single uniform preparation protocol compatible with all matrices of interest 
proved challenging. Of the preparation protocols initially developed, both centrifugal filtration as 
well as the protein precipitation protocols were removed from further consideration. Centrifugal 
filtration methods utilized molecular weight cutoff (MWCO) filters ranging from 10,000 to 50,000 
Daltons (Da). This methodology was consistently unable to identify the majority of seminal fluid 
markers (Figure 6.1), with dropout of proteins KLK3 and PPAP observed. Regarding the protein 
precipitation protocol, when lower quantities (i.e., below 10 µg of total protein) were prepared, no 
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precipitation occurred, leading to large amounts of 10 kDa or greater proteins binding to the 
analytical column. 
Two automated approaches using the AssayMAP Bravo liquid handling platform were 
developed (C18 and RP-S microextraction cartridges) as well as two manifold-based approaches 
(Agilent Bond Elut Plexa and Bond Elut Plexa PCX plate-based cartridges). Here, the C18 
microextraction cartridges consistently clogged when saliva was applied to the sorbent material, to 
the extent that clogged cartridges did not produce eluate for analysis. This occurred regardless of 
protein quantities applied (50 to 150 µg) and is contributed to the viscosity of the biological matrix, 
even once cellular material was removed. In contrast, the RP-S cartridges did not exhibit the same 
issue, regardless of biological fluid evaluated (Figures 6.2-6.4). Regarding the manifold-based 
procedures, the Bond Elut Plexa consistently provided greater coverage of protein biomarkers, 
albeit at lower intensities than the Plexa PCX sorbent, as exhibited in the saliva matrix in Figure 
6.5. Furthermore, the Bond Elut Plexa displayed greater coverage of peptide signatures (Figure 
6.6). Moving forward, the automated RP-S microextraction cartridge and Bond Elut Plexa manifold 
protocols were selected for further assessment using multiple biological replicates.  
Sample processing protocols were compared using consistent protein quantities to assess 
biomarker identification rates. Four replicate samples from two individuals for a total of eight 
samples per preparation protocol (RP-S and Bond Elut Plexa) were prepared and analyzed on the 
Q Exactive. In summary, the Bond Elut Plexa plate was selected as the optimal sample processing 
protocol for the remainder of the study. Biomarker identification in vaginal fluid was generally 
comparable between the two processing protocols (Figure 6.7). Cornulin and suprabasin were 
consistently identified whereas involucrin was absent from two of four replicates from the Donor #1 
Bond Elut Plexa preparation and one of four replicates of Donor #1 RP-S cartridge preparation. All 
seminal fluid biomarkers were identified across all samples and preparation protocols (Figure 6.8). 
Slightly elevated peak intensities were observed for SEMG1 with the Bond Elut Plexa preparation 
whereas SEMG2, KLK3, and PPAP intensities were slightly elevated with the RP-S cartridge 
protocol. Similar to vaginal fluid and seminal fluid, most salivary biomarkers were detected across 
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all individuals and sample preparation protocols but with varying signal intensities (Figure 6.9). 
However, statherin and histatin-1, which are critical for saliva identification, were absent from a 
subset of the replicates prepared from Donor #2 using the RP-S cartridges (Figure 6.10). Since 
the detection of these proteins is critical for a confirmatory serological identification of saliva, the 
Bond Elut Plexa plate was selected for the remainder of research development. 
The unbalanced distribution of detected proteins is attributed to the various sorbent 
material chemistries of the manifold plate protocols. The Bond Elut Plexa PCX plate utilizes strong 
cation ion exchange chemistries and was designed for the concentration and retention of alkaline 
analytes. In contrast, the Bond Elut Plexa employs a standard nonpolar sorbent, allowing the 
analyst to control retention based on the type and pH of mobile phase passed over the sorbent 
column.  
 
Figure 6.1. Area comparison between Millipore centrifugal filters, protein precipitation, and 
Corning® centrifugal filters for the detection of seminal fluid from two donors. Proteins KLK3 and 




Figure 6.2. Area comparison between C18 and RP-S microextraction cartridges using the 
AssayMAP liquid handling platform for the detection of seminal fluid from two donors. 
 
Figure 6.3. Area comparison between C18 and RP-S microextraction cartridges using the 
AssayMAP liquid handling platform for the detection of saliva from three donors. Two samples 
prepared with C18 cartridges did not produce eluate for analysis and is reflected by the single 




Figure 6.4. Area comparison between C18 and RP-S microextraction cartridges using the 
AssayMAP liquid handling platform for the detection of vaginal fluid from three donors. 
 
Figure 6.5. Area comparison between Bond Elut Plexa PCX and Bond Elut Plexa plates on a 




Figure 6.6. Peptide coverage of salivary protein statherin for Bond Elut Plexa PCX (black, blue, and 
red bars) and Bond Elut Plexa (yellow, purple, and green bars) using triplicate samples.  
 
Figure 6.7. Area comparison between Bond Elut Plexa plate and RP-S microextraction cartridge 




Figure 6.8. Area comparison between Bond Elut Plexa plate and RP-S microextraction cartridge 
protocol for the detection of seminal fluid from two donors prepared in quadruplicate. 
 
Figure 6.9. Area comparison between Bond Elut Plexa plate and RP-S microextraction cartridge 




Figure 6.10. Area comparison between Bond Elut Plexa plate and RP-S microextraction cartridge 
protocol for the detection of saliva with focus on highly specific salivary biomarkers. Elevated 
statherin (dark green) and histatin-1 (light green) bars were observed for Bond Elut Plexa plate 
protocol.  
6.2.2 Development of Data Acquisition Method and Analytical Parameter Optimization 
A previously designed high-flow (0.40 mL/minute flow rate) analytical method that 
employed a 2.1 mm internal diameter analytical column [169] was transferred to a 1 mm internal 
diameter microbore analytical column. The original method was developed for a quadrupole time-
of-flight (QTOF) mass spectrometer and was transferred to the Q Exactive. A Waters® BEH C18 
analytical column (300Å, 1.7 µm, 1 mm X 150 mm) was utilized to develop the initial run conditions; 
however, in order to increase throughput, a Waters® BEH C18 1 x 100 mm analytical column was 
employed to create the final 25-minute analytical run (Table 6.2). In total, 35 minutes of run time 
per sample injection was saved through optimization of the analytical method. Representative 
chromatography for each target biological fluid can be seen in Figure 6.11. Analytical columns are 
manufactured in a multitude of diameters, lengths, and stationary phase materials. Column 
selection has the greatest effect on efficiency and speed of analysis, as seen by the shortening of 
run time during optimization. Although the stationary phase material remained the same, by 
decreasing the internal diameter, the flow rate was subsequently lowered. These reductions 








Figure 6.11. Representative chromatography for (A) saliva, (B) seminal fluid, and (C) vaginal fluid 
biological matrices on the Q Exactive analytical platform.  
The Q Exactive was selected for this research given its enhanced sensitivity limits when 
compared with the original QTOF platform available. Given the inherent construction of the orbitrap 
mass analyzer, the selection and transmission of precursor to product ions was of interest. 
Optimizing acquisition parameters for the Q Exactive was conducted to ensure optimal detection 
of fragmentation products was achieved (Table 6.3). Low-abundance targets, such as salivary 
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protein statherin, were found to have increased signal regardless of matrix complexity. In order to 
ensure the highest ionization efficiency, source conditions including sheath gas flow rate, nozzle 
voltage, and gas temperatures were evaluated for optimal performance. The final source and tune 
parameters for the analytical method are outlined in Table 6.4. Overall, a majority of parameters 
were unchanged from those recommended by UWPR, with the exception of the Normalized 
Collision Energy ((N)CE) and Minimum Automatic Gain Control (AGC) Target. 
To preferentially select desired peptide biomarkers further, a targeted acquisition method 
was developed for use during the performance assessment. The peptide match parameter under 
dd settings of the Q Exactive was set as ‘on’ and a peptide inclusion list was generated in Skyline 
software. Skyline is a vendor-neutral software that assisted with organizing selected peptide 
biomarkers, their m/z ratio, and associated retention times into a file type that could be imported 
into the Thermo Xcaliber™ software. The inclusion list was input into the targeted acquisition; 
however, the Q Exactive MS/MS parameters were still able to detect peptides not within the 
inclusion list, but preference was set for the inclusion list peptides. Although the Q Exactive 
prioritized the inclusion list biomarkers, it was of interest to gather additional information outside of 
the inclusion list for future method validation and additional studies regarding biomarker specificity. 
A series of mixed-source samples were prepared to further evaluate the use of a targeted 
acquisition method (Figure 6.12). Although the targeted and data dependent acquisition methods 
behaved similarly, the detected of additional peptide markers from minor contributor biological fluids 
was observed. For example, when 1 µg of saliva was mixed with 99 µg of semen, one additional 
peptide was identified with the targeted acquisition method. The targeted approach routinely 
identified more peptide biomarkers for a saliva minor contributor in comparison with the data 
dependent acquisition method. Therefore, the peptide biomarkers of the inclusion list were verified 
with reference material and the targeted approach was utilized for the performance assessment 
portion of this research. Verification of peptide mass, charge, retention time, and MS2 spectrum 
quality were all taken into consideration prior to generating the final inclusion list.  
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Historically, the relationship between chromatography and depth of coverage achieved via 
mass spectrometry was an inverse relationship, with a trade-off for speed of separation in relation 
to depth of proteome coverage considered. However, with advancements in analytical 
instrumentation, separation science, and software applications, the gap between sacrificing 
proteome coverage for speed of analysis has been minimized. The proteome is complex in nature 
and introduces inherent analytical challenges, particularly with untargeted characterization. 
Enhancing the chromatographic separation of protein constituents therefore increases the 
efficiency of detection using mass spectrometry techniques, allowing for greater depth of proteome 
coverage. 










Table 6.4. Source parameters optimized on the Q Exactive analytical platform.  
 
 
Figure 6.12. Comparison between a targeted acquisition (blue bars) and a data dependent 
acquisition (purple bars) method using a series of mixed-source samples. Samples were prepared 
by total protein amount and are represented on the x-axis. Methods were compared according to 
the number of selected peptides identified.  
6.2.3 Biomarker Selection and Population Study 
In order to accurately assess the developed analytical method and preliminary biomarkers, 
a population assessment was performed. This experiment was designed to conclude if a candidate 
biomarker was routinely identified within a larger sample population, further supporting its use as a 
specific biomarker for body fluid identification. For this portion of the study, an evaluation was 
conducted at the protein level. Parameters taken into consideration for overall assessment were 
percent coverage of total amino acid sequence, number of unique peptides, signal intensity, and 
best score. Percent coverage describes the portion of the protein sequence identified by the 
software. Using the complete amino acid sequence, percent coverage represents the number of 
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amino acids detected in relation to the full sequence. The number of unique peptides represents 
the number of peptide spectrum matches and does not include duplicate identifications made by 
the software. Signal intensity simply describes the total intensity of the MS/MS peaks produced. 
And lastly, best score represents the quality of the peptide spectrum match and serves as an 
indicator of correctness.  
In summary, purchased semen samples from healthy male donors displayed an average 
donor age of 31.6 years, with an age range of 18 to 54 years. A majority (80%) of semen samples 
were collected from Caucasian donors, with 3 donors of African American descent, 3 donors of 
Hispanic descent, 2 donors of Asian descent, and 2 donors from Asian/Caucasian descent. Semen 
purchased from vasectomized male donors displayed an average donor age of 51.6 years, with an 
age range of 39 to 61 years. All vasectomized samples were donated by individuals of Caucasian 
descent. Overall, this approach consistently identified SEMG1, SEMG2, KLK3, and PPAP across 
the population. Summary search results for non-vasectomized and vasectomized sample sets can 
be found in Tables 6.5 and 6.6, respectively, with complete detailed search results outlined in 
Appendix K. Only a single instance of protein dropout was observed within the sample population 
(sample ID 31978-07), with KLK3 not detected in this particular sample. Otherwise, all non-
vasectomized and vasectomized samples were positive for the four target protein biomarkers 
stated previous. There was little difference between the two sample populations. A slightly greater 
average percent coverage was exhibited by the non-vasectomized population for biomarkers KLK3 
and PPAP, displaying a 15.18% and 15.48% increase, respectively. There was no change in 
percent coverage observed for SEMG2 and a minute 2.48% increase in coverage for vasectomized 
samples for SEMG1. A similar trend was illustrated for the average number of unique peptides 
identified by the bioinformatics software. Overall, the developed sample preparation protocol was 
able to characterize semen-specific protein biomarkers in both non-vasectomized and 
vasectomized samples. These results were used to identify surrogate peptides that are consistently 
identified across all individuals, as described in the next section.  
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Purchased saliva samples from healthy donors displayed an average donor age of 40.38 
years, an age range of 19 to 70 years, with 48% female and 52% male donors represented. Racial 
decent was not provided for this sample set. Similar to the semen samples, consistency in protein 
coverage was observed with multiple protein biomarkers being confidently identified in the saliva 
sample population. Summary search results can be found in Table 6.7 with complete detailed 
search results outlined in Appendix L. Several proteins were identified across all samples (e.g., 
STAT, SMR3B, and HIS1). Other targets, such as HIS3 and CST1 were identified in 64% and 68% 
of samples, respectively. While more protein loss was observed with the saliva population in 
comparison with the semen population, it is likely that this is a function of the data dependent 
acquisition approach utilized. A targeted method would likely detect even the proteins which were 
not identified in each sample. This is due to certain salivary biomarkers being of lower abundance 
in relation to the limited number of precursor ions which the instrument can measure in parallel.  
Unexpected results were observed for the protein alpha amylase-1. Although it was 
detected in 90% of the sample population, this protein was characterized with low percent coverage 
and by a single unique peptide. It was anticipated that the source parameters selected were not 
adequate at producing complete fragmentation of this particular protein. However, given the poor 
specificity of this protein for the saliva biological matrix, parameters were not changed in order to 
continuously identify more characteristic salivary biomarkers. In summary, the developed sample 
preparation protocol was able to characterize saliva-specific protein biomarkers. As with the semen 
targets, these results will be used to identify signature peptides that are both sensitive and specific 
for the creation of a targeted analytical method.  
A total of 32 individuals were retained for the vaginal fluid population assessment. In 
summary, purchased vaginal swab samples (25 samples) from healthy donors displayed an 
average donor age of 39.16 years, with an age range of 23 to 61 years. All vaginal swab samples 
were collected from Caucasian donors. No identifying information was recorded for IRB collected 
samples (7 samples). Summary search results can be found in Table 6.8, with complete detailed 
search results outlined in Appendix M. Overall, no candidate protein biomarkers were consistently 
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detected in all samples of this population; however, cornulin displayed the highest occurrence rate 
with accurate detection in 31 of 32 samples evaluated. Furthermore, this protein demonstrated an 
average coverage rate of 52%. Secondary candidate biomarkers identified during sample 
preparation protocol development, suprabasin and involucrin, exhibited favorable population 
occurrence of 78% and 81%, respectively. The protein periplakin, a biomarker included within the 
previously described bottom up proteomic method (Chapters 2 and 3), displayed poor detection 
and protein coverage, prompting reevaluation of biomarker inclusion. With previous 
experimentation conducted on vaginal fluid, the lower sample occurrence, percent coverage, and 
number of unique peptides was anticipated to be less desirable than the results of seminal fluid 
and saliva evaluation. Nevertheless, the proteins detected are consistent with those of previous 
studies, indicating the reproducibility of biomarker recovery and identification. Of the 32 samples 
evaluated within this population assessment, the four candidate biomarkers were not identified 
within one sample (sample ID C1). As with the semen and saliva targets, these results will be used 
to identify surrogate peptides that are both sensitive and specific for the creation of a targeted 
analytical method.  
A piece of data worthy of consideration is the detection of protein biomarker glycodelin in 
a single sample of the vaginal swab population (sample ID 5488). Although detected in only a single 
sample, this identification is promising for future development of top down proteomic 
methodologies. This particular protein is expressed in multiple body fluids, such as vaginal and 
seminal fluid, but displays variation in N-linked glycosylation patterns that can be exploited for fluid 
specificity [170]. With a challenging body fluid such as vaginal fluid, targeting additional biological 
properties, such as glycan chains, may be beneficial to identifying specific protein biomarkers, and 






















Table 6.8. Descriptive statistics of vaginal swab population.  
 
6.2.4 Target Peptide Biomarker Selection 
Biomarkers were selected for inclusion in body fluid-specific panels under this portion of 
the study and are reported on the peptide level. Here, optimal peptide biomarkers are specific to 
the target body fluid and demonstrate consistency of expression across the sample population 
evaluated under the previous section. Additionally, relative abundance of peptide and protein 
biomarkers within the target matrix was used to facilitate inclusion within the target library.  
To recapitulate, SEMG1, SEMG2, KLK3, and PPAP were consistently identified across the 
semen population samples. Salivary proteins SMR3B, STAT, and HIS1 were identified in all 
individuals with basic salivary proline-rich protein isoforms 1, 2, 3, and 4 (PRP_1, PRP_2, PRP_3, 
and PRP_4), salivary acidic proline-rich protein 1/2 (PRPC), and HIS3 being identified in most 
samples. And lastly, vaginal fluid was characterized by cornulin, suprabasin, involucrin, and 
periplakin. With these protein biomarkers selected, specific peptide fragments were identified for 
inclusion and reference material was synthesized for verification purposes. Purified reference 
material was purchased and employed to confirm the target biomarkers to ensure no erroneous 
identifications were made with the bioinformatics software searches. In addition, reference material 
was utilized to confirm the peptide retention times as well as to develop the targeted method, as 
discussed later in this section. 
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The following criteria were set for peptide filtering: peptide fragments must be within 8 to 
25 amino acid residues in length, preference for peptides detected in at least 80% of the sample 
population, high MS1 signal intensity, high quality MS2 spectra, and those that contain minimal 
potential modification sites (i.e., asparagine, methionine, and cysteine amino acid residues). 
However, these criteria were not concrete, as certain markers may exhibit high quality spectra with 
a lower population occurrence. Therefore, peptide length and sample occurrence were taken into 
consideration, but were not the sole criteria for including or eliminating a peptide marker. Signal 
intensity, spectrum quality, and limiting modification sites were given additional weight in decision 
making.  
Using the criteria stated above, a preliminary list of targets included 77 semen peptides, 
92 saliva peptides, and 30 vaginal fluid peptides, for which reference material was purchased and 
evaluated. The salivary protein HIS3 was removed from the peptide list due to low quality spectra 
and sample occurrence. All other listed protein biomarkers were represented in the peptide list. 
Furthermore, prolactin inducible protein (PIP) found in seminal fluid was re-introduced. Although 
not originally described during the population assessment, this protein exhibited higher quality 
spectra with a range of sample occurrence that prompted additional interest in this particular 
biomarker. In total, 38 seminal fluid peptides, 44 saliva peptides, and 12 vaginal fluid peptides were 




Table 6.9. Peptide markers for seminal fluid. Prostate specific antigen (KLK3), prolactin inducible 
protein (PIP), prostatic acid phosphatase (PPAP), semenogelin 1 (SEMG1), and semenogelin 2 





Table 6.10. Peptide markers for saliva. Histatin-1 (HIS1), basic salivary proline-rich protein 1 
(PRP_1), basic salivary proline-rich protein 2 (PRP_2), basic salivary proline-rich protein 4 
(PRP_4), salivary acidic proline-rich protein 1/2 (PRPC), submaxillary androgen-regulated protein 





Table 6.11. Peptide markers for vaginal fluid. Cornulin (CRNN), involucrin (IVL), periplakin (PPL), 
and suprabasin (SBSN). RT = retention time, AA = amino acid.  
 
6.2.5 Performance Assessment 
 Reported below are results at the protein level for each sample evaluated. Peptide level 
results for the performance assessment are detailed in Appendix N.  
6.2.5.1 Sensitivity Samples 
Sensitivity replicates were prepared by diluting target body fluid with deionized water and 
applying the dilution to a cotton swab. Therefore, the dilution factor was inherently diluted a second 
time during the solubilization step of the developed workflow. Data for seminal fluid, saliva, and 
vaginal fluid dilutions are outlined in Tables 6.12-6.14. Proteins were positively identified by the 
presence of at least one peptide target from the inclusion list. Seminal fluid was reproducibly 
identified at the lowest dilution factor (10,000-fold) by both SEMG1 and SEMG2. However, the 
remaining seminal fluid proteins showed poor sensitivity, with little to no identifications at the 100-
fold dilution. Salivary protein biomarkers demonstrated robust sensitivity, with a majority of proteins 
detected at the 100-fold dilution. Basic salivary proline-rich protein 1, salivary acidic proline-rich 
protein 1/2, and submaxillary gland androgen-regulated protein 3B were detected in at least one 
replicate at the lowest dilution factor. Vaginal fluid sensitivity was contingent on cornulin 
identification, which was positive through the 100-fold dilution. The remaining protein biomarkers 




Table 6.12. Sensitivity sample results for seminal fluid. Prostate specific antigen (KLK3), prolactin 
inducible protein (PIP), prostatic acid phosphatase (PPAP), semenogelin 1 (SEMG1), and 
semenogelin 2 (SEMG2). (+) indicates at least one peptide detected for the designated protein. (-) 
indicates a negative result. 
 
Table 6.13. Sensitivity sample results for saliva. (+) indicates at least one peptide detected for the 
designated protein. (-) indicates a negative result. Histatin-1 (HIS1), basic salivary proline-rich 
protein 1 (PRP_1), basic salivary proline-rich protein 2 (PRP_2), basic salivary proline-rich protein 
4 (PRP_4), salivary acidic proline-rich protein 1/2 (PRPC), submaxillary androgen-regulated protein 
3B (SRM3B), and statherin (STAT). 
 
Table 6.14. Sensitivity sample results for vaginal fluid. (+) indicates at least one peptide detected 
for the designated protein. (-) indicates a negative result. Cornulin (CRNN), involucrin (IVL), 
periplakin (PPL), and suprabasin (SBSN). 
 
6.2.5.2 Aged Samples 
 The effect of biomarker recovery and characterization from aged biological material was 
assessed using a two-pronged approach. Each target fluid was evaluated as a single source in 
addition to a vaginal swab matrix fortified with either semen or saliva. Samples were kept at room 
temperature for 2, 3, 7, and 30 days, with detailed results outlined in Table 6.15. Seminal fluid as 
a single source was positively characterized at every timepoint; however, PPAP exhibited complete 
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dropout. Consistency between replicates was observed, with a single replicate exhibiting a positive 
KLK3 result. Similar results were obtained for seminal fluid recovered from a vaginal swab matrix. 
However, complete dropout of PIP was recorded. It is hypothesized that a protease may be present 
in vaginal fluid that may degrade PIP past the point of characterization. A comparable observation 
was made for saliva and saliva recovered from a vaginal swab matrix. Although consistency in 
replicate characterization was recorded for saliva on its own, complete dropout of PRP_2, histatin-
1, and statherin was exhibited when saliva was recovered from a vaginal swab. And lastly, as seen 
with sensitivity samples, vaginal fluid characterization relied on cornulin detection, which exhibited 
consistency with each replicate at all timepoints.  
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Table 6.15. Aged sample results. (+) indicates at least one peptide detected for the designated protein for each replicate. (-) indicates a negative 
result. NT = not tested. Prostate specific antigen (KLK3), prolactin inducible protein (PIP), prostatic acid phosphatase (PPAP), semenogelin 1 
(SEMG1), and semenogelin 2 (SEMG2), histatin-1 (HIS1), basic salivary proline-rich protein 1 (PRP_1), basic salivary proline-rich protein 2 
(PRP_2), basic salivary proline-rich protein 4 (PRP_4), salivary acidic proline-rich protein 1/2 (PRPC), submaxillary androgen-regulated protein 
3B (SRM3B), and statherin (STAT), cornulin (CRNN), involucrin (IVL), periplakin (PPL), and suprabasin (SBSN). 
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6.2.5.3 Sexual Assault Samples 
Laboratory prepared sexual assault kit samples were generated to simulate authentic 
samples, with results outlined in Table 6.16. Of surprise was the ability of the developed method 
to positively characterize both seminal fluid and saliva when recovered from a rectal swab. Given 
the endogenous bacterial presence common with this sample type, the observation of reproducible 
peptide identifications demonstrates the robustness of a peptidomic strategy. Where previous 
studies have indicated the presence of fecal matter to inhibit the processivity of trypsin, the removal 
of proteolytic cleavage sites has eliminated this issue. For example, during validation of the bottom 
up LC-MS/MS method (Chapter 3), KLK3 was not detected on rectal swab samples, whereas this 
protein was consistently detected on replicates with the peptidomic technique. Furthermore, the 
recovery of saliva from rectal swabs was included in this portion of research. The presence of fecal 
matter exhibited no deleterious effects in the ability to identify saliva. For example, salivary protein 
SMR3B demonstrated excellent ion coverage and spectral quality (Figure 6.13).  
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Table 6.16. Sexual assault kit sample results. (+) indicates at least one peptide detected for the 
designated protein for each replicate. (-) indicates a negative result. NT = not tested. Prostate 
specific antigen (KLK3), prolactin inducible protein (PIP), prostatic acid phosphatase (PPAP), 
semenogelin 1 (SEMG1), and semenogelin 2 (SEMG2), histatin-1 (HIS1), basic salivary proline-
rich protein 1 (PRP_1), basic salivary proline-rich protein 2 (PRP_2), basic salivary proline-rich 
protein 4 (PRP_4), salivary acidic proline-rich protein 1/2 (PRPC), submaxillary androgen-regulated 
protein 3B (SRM3B), and statherin (STAT), cornulin (CRNN), involucrin (IVL), periplakin (PPL), and 
suprabasin (SBSN). 
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Figure 6.13. (A) Mass spectrum of saliva recovered from a rectal swab replicate. Depicted is peptide 
GPGIFPPPPPQP of protein submaxillary androgen-regulated protein 3B (SRM3B). (B) y and b 
ions characterized for the peptide sequence are shown in bold type.
6.2.5.4 Mixture Samples 
Volume mixtures of seminal fluid and saliva were applied to vaginal swabs to assess ion 
suppression, particularly for a minor saliva contributor in a major seminal fluid contributor. Vaginal 
swabs were selected as the matrix in order to simulate sexual assault type samples more closely. 
In summary, all target fluids were positively identified (Table 6.17). Seminal fluid is protein rich, and 
despite the greater volumes, did not inhibit the ability to positively characterize saliva or vaginal 
fluid peptide targets. Saliva was consistently identified by the presence of PRPC, even when the 
amount of semen was greater (MIX03) or equivalent to (MIX04) the saliva contribution. As seen 
with previous performance samples, complete dropout of statherin was exhibited when in the 
presence of vaginal fluid.  
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Table 6.17. Mixture sample results. (+) indicates at least one peptide detected for the designated 
protein for each replicate. (-) indicates a negative result. Prostate specific antigen (KLK3), prolactin 
inducible protein (PIP), prostatic acid phosphatase (PPAP), semenogelin 1 (SEMG1), and 
semenogelin 2 (SEMG2), histatin-1 (HIS1), basic salivary proline-rich protein 1 (PRP_1), basic 
salivary proline-rich protein 2 (PRP_2), basic salivary proline-rich protein 4 (PRP_4), salivary acidic 
proline-rich protein 1/2 (PRPC), submaxillary androgen-regulated protein 3B (SRM3B), and 
statherin (STAT), cornulin (CRNN), involucrin (IVL), periplakin (PPL), and suprabasin (SBSN). 
 
6.2.5.5 Contaminant Samples 
 The recovery of target biomarkers when subjected to chemical insult and environmental 
contaminants was of interest to this research in order to more closely simulate authentic forensic 
evidence received in operational laboratories (Table 6.18). Based on data reported in Chapter 5, 
personal lubricants, in addition to bleach and dish soap, were identified as contaminants that have 
the potential to prevent the identification of seminal fluid. SEMG1 and SEMG2 were positively 
identified when in the presence of all contaminants. Uniform protein dropout PIP and PPAP was 
recorded. Overall, the presence of contaminants did not impede the ability to correctly characterize 
seminal fluid, particularly when in the presence of 10% bleach (Figure 6.14). SEMG2 peptide 
NVVDVREE exhibited a clean and clear spectrum, with characteristic b, y, and y++ ions detected.  
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Saliva characterization in the presence of chemical insults was not as robust as observed 
with seminal fluid biomarkers. Negative results for all peptide targets were recorded for saliva 
treated with 10% bleach. For the remaining samples, salivary acidic proline-rich protein 1/2 and 
SMR3B were identified by the presence of at least one target peptide. And lastly, vaginal fluid was 
identified from a menstrual swab based on the positive characterization of cornulin in all three 
replicates. Detergents and formulations containing halogen substances, such as bleach, present 
additional challenges with mass spectrometric analysis. Halogens, such as chlorine, have a 
characteristic isotope distribution on a mass spectra. This distribution is straightforward with small 
molecule analysis; however, with larger peptide masses, the chlorine isotope distribution can 
impact the quality of a mass spectrum.  
Table 6.18. Contaminant samples results. (+) indicates at least one peptide detected for the 
designated protein for each replicate. (-) indicates a negative result. NT = not tested. Prostate 
specific antigen (KLK3), prolactin inducible protein (PIP), prostatic acid phosphatase (PPAP), 
semenogelin 1 (SEMG1), and semenogelin 2 (SEMG2), histatin-1 (HIS1), basic salivary proline-
rich protein 1 (PRP_1), basic salivary proline-rich protein 2 (PRP_2), basic salivary proline-rich 
protein 4 (PRP_4), salivary acidic proline-rich protein 1/2 (PRPC), submaxillary androgen-regulated 
protein 3B (SRM3B), and statherin (STAT), cornulin (CRNN), involucrin (IVL), periplakin (PPL), and 
suprabasin (SBSN). 
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Figure 6.14. (A) Mass spectrum of seminal fluid treated with 10% bleach. Depicted is peptide 
NVVDVREE of protein semenogelin 2 (SEMG2). (B) y and b ions characterized for the peptide 
sequence are shown in bold type. 
6.2.5.6 Substrate Samples 
In conjunction with contaminants, the ability to positively characterize biological fluids 
recovered from various substrates was important to consider. Four fabric types were selected for 
this portion of the study: 100% cotton, 100% polyester, polyester blend (60% polyester, 40% 
cotton), and denim. Each fabric had small quantities of biological fluid applied, with the 100% cotton 
underwear worn by a female subject prior to fluid application. Detailed results are outlined in Table 
6.19. As with previous data sets, SEMG1 and SEMG2 outperformed the remaining seminal fluid 
protein targets. However, all protein targets were characterized when recovered from denim. It is 
hypothesized that, given the texture of denim fabric, the applied semen was retained over a smaller 
surface area and easily released back into solution once solubilized. In addition to these samples, 
semen stains were excised and recovered from bed sheets to assess biomarker loss during 
laundering. Seminal fluid was positively characterized on both bed sheets evaluated by the 
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presence of SEMG1 and SEMG2, in addition to a single KLK3 peptide identification on the polyester 
blend bed sheet (Figure 6.15). Semenogelin 2 peptide NVVDVREE demonstrated great intensity 
from laundered items in comparison with the 10% bleach solution, further highlighting the lower 
sensitivity limits of the developed methodology.  
 Saliva protein characterization was substrate dependent. As with seminal fluid, recovery of 
saliva from denim was nearly complete, with protein dropout of basic salivary proline-rich protein 4 
exhibited. However, both statherin and SMR3B, confirmatory saliva biomarkers, were identified. 
Additional protein dropout and greater inconsistency between replicates were reported for polyester 
blend and 100% polyester (Table 6.19). 
Table 6.19. Contaminant samples results. (+) indicates at least one peptide detected for the 
designated protein for each replicate. (-) indicates a negative result. NT = not tested. Prostate 
specific antigen (KLK3), prolactin inducible protein (PIP), prostatic acid phosphatase (PPAP), 
semenogelin 1 (SEMG1), and semenogelin 2 (SEMG2), histatin-1 (HIS1), basic salivary proline-
rich protein 1 (PRP_1), basic salivary proline-rich protein 2 (PRP_2), basic salivary proline-rich 
protein 4 (PRP_4), salivary acidic proline-rich protein 1/2 (PRPC), submaxillary androgen-regulated 
protein 3B (SRM3B), and statherin (STAT). 
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Figure 6.15. (A) Mass spectrum of seminal fluid recovered from laundered polyester blend bed 
sheet. Depicted is peptide NVVDVREE of protein semenogelin 2 (SEMG2). (B) y and b ions 
characterized for the peptide sequence are shown in bold type. 
6.3 Concluding Remarks 
In summary, the use of a peptidomic approach for seminal fluid, saliva, and vaginal fluid 
identification revealed that multiple non-tryptic peptide fragments are produced through 
endogenous cleavage during analysis with high resolution mass spectrometry. The protein 
biomarkers identified with this technique were comparable to those detected with the validated 
bottom up LC-MS/MS assay. Therefore, the ability to prepare biological stains for proteomic 
analysis with an expedited, simple extraction prior to chromatographic separation eliminated the 
need for lengthy enzymatic digestion incubation periods. The results presented provide support for 
further development of peptidomic applications in the field of forensic serology. From a forensic 
biology standpoint, it is recommended that reporting of results be based on the identification of 
inclusion peptides. Although additional peptide fragments are identified by the proteomic software, 
the peptides included in the library have undergone quality control assessment during verification 
using purified reference material. Significant proteins include semenogelin 1 and 2 for seminal fluid 
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identification in addition to statherin and submaxillary gland androgen-regulated protein 3B for 
saliva identification.  
Supplemental research is required for the identification of a vaginal fluid-specific protein 
biomarker. Although the four protein biomarkers described, particularly cornulin, demonstrated 
adequate sensitivity and robustness, the selected proteins do not exhibit specificity to vaginal fluid. 
Suprabasin, although expressed in vaginal, cervical, and uterine tissue, shares comparable 
expression patterns in esophagus tissue and keratinocytes of skin tissues. Similar protein 
expression patterns are evident for cornulin and involucrin. In addition, involucrin is expressed in 
tissues of the urinary bladder and epididymis [171].  
The Protein Metrics Byonic™ application is a software tool used for identifying peptides and 
proteins, similar to more traditional applications such as Mascot and SEQUEST. However, this 
software provides additional functionalities that can contribute to areas of future work, such as 
advanced glycopeptide and crosslinking search capabilities.  
Various challenges and limitations exist with the implementation of protein mass 
spectrometry techniques into an operational laboratory. First, the creation of training materials will 
be essential for onboarding molecular biologists in advanced proteomic techniques. Second, 
generating interest with stakeholders so that resources and capital investments are made to 
support the implementation of this screening technique, such as the purchase of the LC-MS/MS 
analytical system, will be crucial for a seamless implementation. And lastly, overcoming a Daubert 
admissibility hearing for using proteomic data in a court of law will impose significant challenges 
moving forward. The case findings from Daubert v. Merrell Dow Pharmaceuticals, Inc. is the 
documentation accepted by the federal government and a majority of state government for the 
admissibility of scientific evidence in court. The findings suggest that scientific methodology be 
testable, have a known or potential error rate, have applicable standards and controls, be subjected 
to peer review and publication, and be generally accepted in the scientific community. Sufficient 
gains have been made for use of protein mass spectrometry in forensic laboratories, specifically in 
the field of forensic toxicology, but additional research into drafting of interpretation guidelines, 
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applicable use of controls, and support within the greater community will be critical for admissibility 
of data in court. Furthermore, the addition of confidence level reporting would be beneficial in 
relaying the weight of data to the trier of fact.  
In toto, the specific hypotheses outlined for completion of this research were successfully 
evaluated. Proteomic techniques in the form of bottom up and peptidomic methodologies were 
demonstrated to surpass the sensitivity and specificity capable of traditional serological screening 
techniques. The transferring of a multiplex mass spectrometry-based assay from a nanoflow to 
high performance LC-MS/MS analytical system sufficiently increased sample throughput. In 
addition, an automated sample processing procedure mitigated sources of human error and 
contributed to increased sample throughput without a loss in peptide intensity. The multiplex LC-
MS/MS assay underwent rigorous validation and comparison, illustrating its robust performance 
and compatibilities with existing forensic biology workflows. It has been demonstrated that the 
ability to produce serological information at sensitivity levels consistent with STR/Y-STR typing is 
achievable with protein mass spectrometry technology. Body fluid identification of samples 
subjected to personal lubricants was achieved through specific sample preparation procedures and 
detection of surrogate peptides using the validated LC-MS/MS assay. And lastly, an expedited 
proteomic analysis of body fluids consistent with sexual assault evidence was developed using 
peptidomic techniques. The use of proteomics and advanced analytical instrumentation is a viable 
solution to meeting the sensitivity and specificity demands of the forensic biology community for 
the confirmation of biological origin, therefore contributing to the identification and individualization 
of evidentiary material. 
6.4 Future Direction and Impact on the Criminal Justice System 
 The identification of biological stains has posed significant challenges since the onset and 
acceleration of DNA individualization. Currently, practitioners have no means of reliably confirming 
the presence of biological stains, especially the differentiation of saliva and vaginal fluid. The 
presumptive results obtained through serological screening prevent definitive statements regarding 
the origin of a biological stain by an expert witness during courtroom testimony. While implementing 
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a new technology such as protein mass spectrometry comes with significant onboarding actions, 
such as new analyst training and purchasing of instrumentation, the cost-to-benefit ratio of investing 
in this next generation technique is substantial.  
Extensive research has demonstrated that protein mass spectrometry exhibits unmatched 
detection capabilities, particularly with trace quantities of biological stains in the presence of 
contaminants. The research presented in this dissertation contributes to the sufficient gains of the 
forensic subdiscipline that has fallen behind its counterpart. Detailed standard operating 
procedures for the validated proteomic methodology are written and presented for the effective 
transfer of this technology into an operational laboratory. However, a comparative assessment of 
proteomics with other next generation techniques, such as RNA-based assays and epigenetic 
profiling, would identify gaps in proposed methodologies and provide the forensic biology 
community with valuable information to aid in technology transfer and retirement of traditional 
serological screening protocols. 
Additional research into characteristic protein biomarkers for vaginal fluid detection is 
necessary for the confirmatory identification of this biological matrix. Given its similarities in protein 
makeup to that of saliva, additional distinctive traits should be taken into consideration. The 
availability of a reliable and sensitive method for the confirmatory identification of vaginal fluid would 
have important forensic utility for the analysis of sexual assault evidence. While the presence of a 
victim’s DNA profile on a suspect’s genitals or underwear provides a strong indication of sexual 
contact on its own, a vaginal fluid assay would increase the probative value of a broader range of 
evidentiary items (e.g., swabs of fingers, fingernail scrapings, outer clothing). Furthermore, items of 
evidence submitted in sexual assault cases involving vaginal rape with a foreign object would greatly 
benefit from such an assay.  
This obstacle can be overcome by leveraging unique post translational modifications (PTM) 
that proteins undergo only in vaginal tissues. A common type of PTM includes glycosylation, and 
with the addition of carbohydrate moieties, glycosylation can have a significant effect on protein 
confirmation and antigenic properties. N-linked glycosylation occurs in the endoplasmic reticulum at 
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specific asparagine sequences (i.e., Asn-X-Ser/Thr), where the addition of sugar residues result in 
unique structural modifications [172]. The process of N-linked glycosylation is highly conserved in 
eukaryotes, indicating the importance of carbohydrate labeling as a means of generating diversity 
within the proteome [41]. For instance, the protein glycodelin exhibits multiple isoforms with 
differential glycosylation that dictates body fluid specific functionalities. For example, the glycodelin-
A (GdA) isoform in amniotic and vaginal fluids induces an immunosuppressive response by silencing 
maternal T cells, preventing an immune response toward an implanted embryo. In addition, this 
isoform also acts as a natural contraceptive by impeding spermatozoa binding to the oocyte outside 
the fertile window of ovulation [173]. In contrast, the glycodelin-S (GdS) isoform in seminal fluid 
blocks spermatozoa capacitation (i.e., destabilization of the acrosomal membrane) prior to passing 
through the cervical mucus of the female reproductive tract [173]. 
Additional advancements in proteomic applications to forensic biology include the use of 
genetically variable peptides (GVPs) and the concept of proteomic genotyping. A single amino acid 
polymorphism can be correlated to a single nucleotide polymorphism (SNP), generating the link 
between identification and individualization of biological material. Research in this area has focused 
on fingermarks [174], bone [152], and hair [175], but the possibilities of expanding to other biological 
matrices are evident. For example, the detection of GVPs for the salivary protein statherin and 
subsequent SNP profiling could provide a confirmatory identification of saliva and the inclusion of a 
suspected individual for an evidentiary item associated with a sexual assault or rape.  
263 
BIBLIOGRAPHY 
[1] E. Locard, L’enquête criminelle et les méthodes scientifiques, E. Flammarion, Paris, 1920.
[2] Federal Bureau of Investigation, CODIS-NDIS Statistics, (2021).
https://www.fbi.gov/services/laboratory/biometric-analysis/codis/ndis-statistics (accessed
May 12, 2021).
[3] S. Stanton, D. Smith, D. Kasler, M. Sullivan, ‘Day of reckoning’ — Joseph DeAngelo admits
guilt in Golden State Killer murders, rapes, The Modesto Bee. (2020).
https://www.modbee.com/news/california/article243868517.html.
[4] Man convicted in 1987 killings of Canadian couple gets life, Associated Press. (2019).
https://apnews.com/article/3ac9a37c2203445ea0c5cf44f371bec0.
[5] R.A.H. van Oorschot, D.L. McColl, J.E. Alderton, M.L. Harvey, R.J. Mitchell, B. Szkuta,
Activities between activities of focus-Relevant when assessing DNA transfer probabilities,
Forensic Science International: Genetics Supplement Series. 5 (2015) e75–e77.
https://doi.org/10.1016/j.fsigss.2015.09.031.
[6] B. Martin, R. Blackie, D. Taylor, A. Linacre, DNA profiles generated from a range of touched
sample types, Forensic Science International: Genetics. 36 (2018) 13–19.
https://doi.org/10.1016/j.fsigen.2018.06.002.
[7] G.E. Meakin, E. v. Butcher, R.A.H. van Oorschot, R.M. Morgan, Trace DNA evidence
dynamics: An investigation into the deposition and persistence of directly- and indirectly-
transferred DNA on regularly-used knives, Forensic Science International: Genetics. 29
(2017) 38–47. https://doi.org/10.1016/j.fsigen.2017.03.016.
[8] B. Szkuta, K.N. Ballantyne, B. Kokshoorn, R.A.H. van Oorschot, Transfer and persistence
of non-self DNA on hands over time: Using empirical data to evaluate DNA evidence given
activity level propositions, Forensic Science International: Genetics. 33 (2018) 84–97.
https://doi.org/10.1016/j.fsigen.2017.11.017.
[9] P. Ramos, O. Handt, D. Taylor, Investigating the position and level of DNA transfer to
undergarments during digital sexual assault, Forensic Science International: Genetics. 47
(2020) 102316. https://doi.org/10.1016/j.fsigen.2020.102316.
[10] R.A.H. van Oorschot, B. Szkuta, G.E. Meakin, B. Kokshoorn, M. Goray, DNA transfer in
forensic science: A review, Forensic Science International: Genetics. 38 (2019) 140–166.
https://doi.org/10.1016/j.fsigen.2018.10.014.
[11] P. Gill, J. Whitaker, C. Flaxman, N. Brown, J. Buckleton, An investigation of the rigor of
interpretation rules for STRs derived from less than 100 pg of DNA, Forensic Science
International. 112 (2000) 17–40. https://doi.org/10.1016/S0379-0738(00)00158-4.
[12] M.D. Coble, J.A. Bright, Probabilistic genotyping software: An overview, Forensic Science
International: Genetics. 38 (2019) 219–224. https://doi.org/10.1016/j.fsigen.2018.11.009.
[13] J.G. Cino, Deploying the Secret Police: the Use of Algorithms in the Criminal Justice
System, Georgia State University Law Review. 34 (2018).
[14] P.W. Nutter, Machine Learning Evidence: Admissibility and Weight, University of
Pennsylvania Journal of Constitutional Law. 21 (2019).
https://edition.cnn.com/2018/03/22/us/.
[15] R. Li, Forensic Biology, 2nd ed., Taylor & Francis Group, LLC, Boca Raton, FL, 2015.
[16] V. Barrera, B. Fliss, S. Panzer, S.A. Bolliger, Gunshot residue on dark materials: a
comparison between infrared photography and the use of an alternative light source,
International Journal of Legal Medicine. 133 (2019) 1115–1120.
https://doi.org/10.1007/s00414-018-1965-7.
[17] K.G. Wiggins, Forensic Textile Fiber Examination Across the USA and Europe, Journal of
Forensic Sciences. 46 (2001) 15150J. https://doi.org/10.1520/jfs15150j.
[18] A. Zamir, B. Springer, B. Glattstein, Fingerprints and DNA: STR Typing of DNA Extracted




[19] R.E. Gaennsslen, F.R. Camp, Sourcebook in forensic serology, immunology and 
biochemistry, Forensic Science International. 14 (1979) 147–148. 
https://doi.org/10.1016/0379-0738(79)90239-1. 
[20] M.N. Hochmeister, B. Budowle, R. Sparkes, O. Rudin, C. Gehrig, M. Thali, L. Schmidt, A. 
Cordier, R. Dirnhofer, Validation studies of an immunochromatographic 1-step test for the 
forensic identification of human blood., Journal of Forensic Sciences. 44 (1999) 597–602. 
[21] J. Glaister, The Kastle-Meyer Test for the Detection of Blood: Considered from the Medico-
Legal Aspect, BMJ. 1 (1926) 650–652. https://doi.org/10.1136/bmj.1.3406.650. 
[22] J.L. Webb, J.I. Creamer, T.I. Quickenden, A comparison of the presumptive luminol test for 
blood with four non-chemiluminescent forensic techniques, Luminescence. 21 (2006) 214–
220. https://doi.org/10.1002/bio.908. 
[23] J.I. Creamer, T.I. Quickenden, M. v. Apanah, K.A. Kerr, P. Robertson, A comprehensive 
experimental study of industrial, domestic and environmental interferences with the forensic 
luminol test for blood, Luminescence. 18 (2003) 193–198. https://doi.org/10.1002/bio.723. 
[24] A.M. Gross, K.A. Harris, G.L. Kaldun, The effect of luminol on presumptive tests and DNA 
analysis using the polymerase chain reaction, J Forensic Sci. 44 (1999) 837–840. 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&
list_uids=10432617. 
[25] D.J.A. Kerr, V.H. Mason, The Haemochromogen Crystal Test for Blood, BMJ. 1 (1926) 134–
136. https://doi.org/10.1136/bmj.1.3395.134. 
[26] N. Pernick, PAS (Periodic Acid-Schiff, PathologyOutlines.Com. (2018). 
http://www.pathologyoutlines.com/topic/stainspas.html. 
[27] B. Randall, Glycogenated squamous epithelial cells as a marker of foreign body penetration 
in sexual assault., Journal of Forensic Sciences. 33 (1988) 511–514. 
[28] R. Hausmann, B. Schellmann, Forensic value of the Lugol’s staining method: Further 
studies on glycogenated epithelium in the male urinary tract, International Journal of Legal 
Medicine. 107 (1994) 147–151. https://doi.org/10.1007/BF01225602. 
[29] R. Hausmann, C. Pregler, B. Schellmann, The value of the Lugol’s iodine staining technique 
for the identification of vaginal epithelial cells, International Journal of Legal Medicine. 106 
(1994) 298–301. https://doi.org/10.1007/BF01224775. 
[30] K. Mirakovitz, Forensic Science: The Basics, 2nd ed., CRC Press, 2016. 
[31] E.T. Dane, D.L. Herman, Haematoxylin-phyloxine-alcian blue-orange G differential staining 
of prekeratin, keratin and mucin, Stain Technology. 38 (1963) 97–101. 
[32] C.E. v French, C.G. Jensen, S.K. Vintiner, D.A. Elliot, S.R. McGlashan, A novel histological 
technique for distinguishing between epithelial cells in forensic casework, Forensic Science 
International. 178 (2008) 1–6. https://doi.org/10.1016/j.forsciint.2008.01.010. 
[33] J.-P. Allery, N. Telmon, R. Mieusset, A. Blanc, D. Rouge, Cytological detection of 
spematozoa: comparison of three staining methods, Journal of Forensic Sciences. 46 
(2001) 349–351. https://doi.org/10.1520/JFS14970J. 
[34] C.G. Westring, M. Wiuf, S.J. Nielsen, J.C. Fogleman, J.B. Old, C. Lenz, K.A. Reich, N. 
Morling, SPERM HY-LITER for the identification of spermatozoa from sexual assault 
evidence, Forensic Science International: Genetics. 12 (2014) 161–167. 
https://doi.org/10.1016/j.fsigen.2014.06.003. 
[35] K.W.P. Miller, J. Old, B.R. Fischer, B. Schweers, S. Stipinaite, K. Reich, Developmental 
validation of the SPERM HY-LITER TM Kit for the identification of human spermatozoa in 
forensic samples, Journal of Forensic Sciences. 56 (2011) 853–865. 
https://doi.org/10.1111/j.1556-4029.2011.01796.x. 
[36] P.S. Raju, N.K. Iyengar, Acid Phosphatase Reaction as a Specific Test for the Identification 
of Seminal Stains, The Journal of Criminal Law, Criminology, and Police Science. 55 (1964) 
522. https://doi.org/10.2307/1140908. 
[37] P.J. Ablett, The Identification of the Precise Conditions for Seminal Acid Phosphatase (SAP) 
and Vaginal Acid Phosphatase (VAP) Separation by Isoelectric Focusing Patterns, Journal 
265 
of the Forensic Science Society. 23 (1983) 254–256. https://doi.org/10.1016/S0015-
7368(83)72254-1. 
[38] A.F. Schiff, Reliability of the Acid Phosphatase Test for the Identification of Seminal Fluid,
Journal of Forensic Sciences. 23 (1978) 10745J. https://doi.org/10.1520/JFS10745J.
[39] B.C.M. Pang, B.K.K. Cheung, Applicability of two commercially available kits for forensic
identification of saliva stains, Journal of Forensic Sciences. 53 (2008) 1117–1122.
https://doi.org/10.1111/j.1556-4029.2008.00814.x.
[40] J.R. Myers, W.K. Adkins, Comparison of Modern Techniques for Saliva Screening, n.d.
[41] B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, P. Walter, eds., Molecular Biology of
the Cell, 5th ed., Garland Science, Taylor Francis Group, LLC, New York, New York, 2008.
[42] K. Reich, Forensic test for human semen, US 2007/0196871A1, 2007.
[43] K. Reich, Forensic test for human saliva, US 2007/0092977A1, 2007.
[44] K. Reich, Forensic test for human blood, US 2008/0171399A1, 2008.
[45] P.S. Bagaria, Test device for detecting semen and method of use, 6,686,167B2, 2004.
[46] P.S. Bagaria, Test device for detecting human blood and method of use, 7,067,264B2,
2006.
[47] Seratec®, SERATEC® HemDirect Hemoglobin Assay A visual one-step immunoassay for
the rapid identification of human blood in forensic samples by the determination of
hemoglobin, Göttingen, Germany, 2009.
[48] Seratec®, SERATEC® AmylaseTest: An Overview for Users, Göttingen, Germany, 2017.
https://www.seratec.com/docs/AmylaseTest_05_2017.pdf.
[49] Seratec®, Seratec® PSA Semiquant In-vitro diagnostic test for professional forensic use for
the detection of seminal fluid by the semi-quantitative determination of PSA (Prostate-
specific antigen), Göttingen, Germany, 2011.
[50] J. Old, B. Schweers, P.W. Boonlayangoor, K. Reich, Developmental Validation Studies of
RSIDTM -Semen A Lateral Flow Immunochromatographic Strip test for the Forensic
Detection of Seminal Fluid, 2010.
[51] J. Old, B. Schweers, P.W. Boonlayangoor, K. Reich, Developmental Validation Studies of
RSID-Saliva Lateral Flow Immunochromatographic Strip test for the forensic detection of
Saliva, (2006).
[52] H.E. McKiernan, Targeted-Ion Mass Spectrometry for the Identification of Forensically
Relevant Biological Fluids and Samples from Sexual Assault Evidence, 2019.
[53] S.E. Bitner, False Positives Observed on the Seratec PSA SemiQuant Cassette Test with
Condom Lubricants, Journal of Forensic Sciences. 57 (2012) 1545–1548.
https://doi.org/10.1111/j.1556-4029.2012.02141.x.
[54] M.C. Snead, A.P. Kourtis, C.M. Black, C.K. Mauck, T.M. Brown, A. Penman-Aguilar, J.H.
Melendez, M.F. Gallo, D.J. Jamieson, M. Macaluso, Effect of topical vaginal products on
the detection of prostate-specific antigen, a biomarker of semen exposure, using ABAcards,
Contraception. 88 (2013) 382–386. https://doi.org/10.1016/j.contraception.2012.10.034.
[55] M.M. Foley, C.O. Brown, C.G. Westring, P.B. Danielson, H.E. McKiernan, Effects of organic
acids and common household products on the occurrence of false positive test results using
immunochromatographic assays, Forensic Science International. 308 (2020).
https://doi.org/10.1016/j.forsciint.2020.110165.
[56] A. Vidaki, M. Kayser, Recent progress, methods and perspectives in forensic epigenetics,
Forensic Science International: Genetics. 37 (2018) 180–195.
https://doi.org/10.1016/j.fsigen.2018.08.008.
[57] D.M. Jeziorska, R.J.S. Murray, M. de Gobbi, R. Gaentzsch, D. Garrick, H. Ayyub, T. Chen,
E. Li, J. Telenius, M. Lynch, B. Graham, A.J.H. Smith, J.N. Lund, J.R. Hughes, D.R. Higgs,
C. Tufarelli, DNA methylation of intragenic CpG islands depends on their transcriptional
activity during differentiation and disease, Proceedings of the National Academy of
Sciences of the United States of America. 114 (2017) E7526–E7535.
https://doi.org/10.1073/pnas.1703087114.
266 
[58] T. Madi, K. Balamurugan, R. Bombardi, G. Duncan, B. Mccord, The determination of tissue-
specific DNA methylation patterns in forensic biofluids using bisulfite modification and
pyrosequencing, Electrophoresis. 33 (2012) 1736–1745.
https://doi.org/10.1002/elps.201100711.
[59] D. Frumkin, A. Wasserstrom, B. Budowle, A. Davidson, DNA methylation-based forensic
tissue identification, Forensic Science International: Genetics. 5 (2011) 517–524.
https://doi.org/10.1016/j.fsigen.2010.12.001.
[60] P. Nyrén, B. Pettersson, M. Uhlén, Solid phase DNA minisequencing by an enzymatic
luminometric inorganic pyrophosphate detection assay, Analytical Biochemistry. 208 (1993)
171–175. https://doi.org/10.1006/abio.1993.1024.
[61] J. Antunes, D.S.B.S. Silva, K. Balamurugan, G. Duncan, C.S. Alho, B. Mccord, High-
resolution melt analysis of DNA methylation to discriminate semen in biological stains,
Analytical Biochemistry. 494 (2016) 40–45. https://doi.org/10.1016/j.ab.2015.10.002.
[62] S. Forat, B. Huettel, R. Reinhardt, R. Fimmers, G. Haidl, D. Denschlag, K. Olek, Methylation
markers for the identification of body fluids and tissues from forensic trace evidence, PLoS
ONE. 11 (2016) 1–19. https://doi.org/10.1371/journal.pone.0147973.
[63] Y.C. Lin, L.C. Tsai, J.C.I. Lee, C.W. Su, J.T.C. Tzen, A. Linacre, H.M. Hsieh, Novel
identification of biofluids using a multiplex methylation sensitive restriction enzyme-PCR
system, Forensic Science International: Genetics. 25 (2016) 157–165.
https://doi.org/10.1016/j.fsigen.2016.08.011.
[64] Q.T. Gauthier, S. Cho, J.H. Carmel, B.R. McCord, Development of a body fluid identification
multiplex via DNA methylation analysis, Electrophoresis. 40 (2019) 2565–2574.
https://doi.org/10.1002/elps.201900118.
[65] A. Vidaki, D. Ballard, A. Aliferi, T.H. Miller, L.P. Barron, D. Syndercombe Court, DNA
methylation-based forensic age prediction using artificial neural networks and next
generation sequencing, Forensic Science International: Genetics. 28 (2017) 225–236.
https://doi.org/10.1016/j.fsigen.2017.02.009.
[66] H. Holtkötter, K. Schwender, P. Wiegand, H. Pfeiffer, M. Vennemann, Marker evaluation for
differentiation of blood and menstrual fluid by methylation-sensitive snapshot analysis,
International Journal of Legal Medicine. 132 (2018) 387–395.
https://doi.org/10.1007/s00414-018-1770-3.
[67] S. Silva, J. Antunes, K. Balamurugan, G. Duncan, C.S. Alho, B. Mccord, Evaluation of DNA
methylation markers and their potential to predict human aging, Electrophoresis. 36 (2015)
1775–1780. https://doi.org/10.1002/elps.201500137.
[68] J. Juusola, J. Ballantyne, Messenger RNA profiling: A prototype method to supplant
conventional methods for body fluid identification, Forensic Science International. 135
(2003) 85–96. https://doi.org/10.1016/S0379-0738(03)00197-X.
[69] J. Juusola, J. Ballantyne, Multiplex mRNA profiling for the identification of body fluids,
Forensic Science International. 152 (2005) 1–12.
https://doi.org/10.1016/j.forsciint.2005.02.020.
[70] J. Juusola, J. Ballantyne, mRNA profiling for body fluid identification by multiplex
quantitative RT-PCR, Journal of Forensic Sciences. 52 (2007) 1252–1262.
https://doi.org/10.1111/j.1556-4029.2007.00550.x.
[71] C. Haas, E. Hanson, M.J. Anjos, W. Bar, R. Banemann, A. Berti, E. Borges, C. Bouakaze,
A. Carracedo, M. Carvalho, V. Castella, A. Choma, G. de Cock, M. Dotsch, P. Hoff-Olsen,
P. Johansen, F. Kohlmeier, P.A. Lindenbergh, B. Ludes, O. Maronas, D. Moore, M.L.
Morerod, N. Morling, H. Niederstatter, F. Noel, W. Parson, G. Patel, C. Popielarz, E. Salata,
P.M. Schneider, T. Sijen, B. Sviezena, M. Turanska, L. Zatkalikovi, J. Ballantyne, RNA/DNA
co-analysis from blood stains - Results of a second collaborative EDNAP exercise, Forensic
Science International: Genetics. 6 (2012) 70–80.
https://doi.org/10.1016/j.fsigen.2011.02.004.
[72] C. Haas, E. Hanson, M.J. Anjos, R. Banemann, A. Berti, E. Borges, A. Carracedo, M.
Carvalho, C. Courts, G. de Cock, M. Dötsch, S. Flynn, I. Gomes, C. Hollard, B. Hjort, P.
267 
Hoff-Olsen, K. Hríbiková, A. Lindenbergh, B. Ludes, O. Maroñas, N. McCallum, D. Moore, 
N. Morling, H. Niederstätter, F. Noel, W. Parson, C. Popielarz, C. Rapone, A.D. Roeder, Y.
Ruiz, E. Sauer, P.M. Schneider, T. Sijen, D.S. Court, B. Sviežená, M. Turanská, A. Vidaki,
L. Zatkalíková, J. Ballantyne, RNA/DNA co-analysis from human saliva and semen stains-
Results of a third collaborative EDNAP exercise, Forensic Science International: Genetics.
7 (2013) 230–239. https://doi.org/10.1016/j.fsigen.2012.10.011.
[73] C. Haas, E. Hanson, M.J. Anjos, K.N. Ballantyne, R. Banemann, B. Bhoelai, E. Borges, M.
Carvalho, C. Courts, G. de Cock, K. Drobnic, M. Dötsch, R. Fleming, C. Franchi, I. Gomes,
G. Hadzic, S.A. Harbison, J. Harteveld, B. Hjort, C. Hollard, P. Hoff-Olsen, C. Hüls, C.
Keyser, O. Maroñas, N. McCallum, D. Moore, N. Morling, H. Niederstätter, F. Noël, W.
Parson, C. Phillips, C. Popielarz, A.D. Roeder, L. Salvaderi, E. Sauer, P.M. Schneider, G.
Shanthan, D.S. Court, M. Turanská, R.A.H. van Oorschot, M. Vennemann, A. Vidaki, L.
Zatkalíková, J. Ballantyne, RNA/DNA co-analysis from human menstrual blood and vaginal
secretion stains: Results of a fourth and fifth collaborative EDNAP exercise, Forensic
Science International: Genetics. 8 (2014) 203–212.
https://doi.org/10.1016/j.fsigen.2013.09.009.
[74] P.P. Albani, J. Patel, R.I. Fleming, Detection of five specified menstrual fluid mRNA markers
over the uterine cycle, Forensic Science International: Genetics. 49 (2020) 102359.
https://doi.org/10.1016/j.fsigen.2020.102359.
[75] C. Haas, E. Hanson, R. Banemann, A.M. Bento, A. Berti, Á. Carracedo, C. Courts, G. de
Cock, K. Drobnic, R. Fleming, C. Franchi, I. Gomes, G. Hadzic, S.A. Harbison, B. Hjort, C.
Hollard, P. Hoff-olsen, C. Keyser, A. Kondili, T. Sijen, D.S. Court, M. Turanská, M. van den
Berge, M. Vennemann, A. Vidaki, L. Zatkalíková, J. Ballantyne, RNA/DNA co-analysis from
human skin and contact traces – results of a sixth collaborative EDNAP exercise, Forensic
Science International: Genetics. 16 (2015) 139–147.
https://doi.org/10.1016/j.fsigen.2015.01.002.
[76] C. Nussbaumer, E. Gharehbaghi-Schnell, I. Korschineck, Messenger RNA profiling: A novel
method for body fluid identification by Real-Time PCR, Forensic Science International. 157
(2006) 181–186. https://doi.org/10.1016/j.forsciint.2005.10.009.
[77] C. Haas, B. Klesser, C. Maake, W. Bär, A. Kratzer, mRNA profiling for body fluid
identification by reverse transcription endpoint PCR and realtime PCR, Forensic Science
International: Genetics. 3 (2009) 80–88. https://doi.org/10.1016/j.fsigen.2008.11.003.
[78] E. Hanson, J. Ballantyne, Circulating microRNA for the identification of forensically relevant
body fluids, Methods in Molecular Biology. 1024 (2013) 221–234.
[79] P. Danaher, R.L. White, E.K. Hanson, J. Ballantyne, Facile semi-automated forensic body
fluid identification by multiplex solution hybridization of NanoString barcode probes to
specific mRNA targets, Forensic Science International: Genetics. 14 (2015) 18–30.
https://doi.org/10.1016/j.fsigen.2014.09.005.
[80] S. Ingold, G. Dorum, E. Hanson, A. Berti, W. Branicki, Body fluid identification using a
targeted mRNA massively parallel sequencing approach – results of a
EUROFORGEN/EDNAP collaborative exercise, Forensic Science International: Genetics.
34 (2018) 105–115. https://doi.org/10.1016/j.fsigen.2018.01.002.
[81] S. Ingold, G. Dørum, E. Hanson, J. Ballantyne, C. Haas, Assigning forensic body fluids to
donors in mixed body fluids by targeted RNA/DNA deep sequencing of coding region SNPs,
International Journal of Legal Medicine. (2020) 473–485. https://doi.org/10.1007/s00414-
020-02252-w.
[82] B. Liu, Q. Yang, H. Meng, C. Shao, J. Jiang, H. Xu, K. Sun, Y. Zhou, Y. Yao, Z. Zhou, H. Li,
Y. Shen, Z. Zhao, Q. Tang, J. Xie, Development of a multiplex system for the identification
of forensically relevant body fluids, Forensic Science International: Genetics. 47 (2020).
https://doi.org/10.1016/j.fsigen.2020.102312.
[83] M. Setzer, J. Juusola, J. Ballantyne, Recovery and stability of RNA in vaginal swabs and
blood, semen, and saliva stains, Journal of Forensic Sciences. 53 (2008) 296–305.
https://doi.org/10.1111/j.1556-4029.2007.00652.x.
268 
[84] D. Zubakov, E. Hanekamp, M. Kokshoorn, W. van IJcken, M. Kayser, Stable RNA markers
for identification of blood and saliva stains revealed from whole genome expression analysis
of time-wise degraded samples, International Journal of Legal Medicine. 122 (2008) 135–
142. https://doi.org/10.1007/s00414-007-0182-6.
[85] S.S. Silva, C. Lopes, A.L. Teixeira, M.J.C. de Sousa, R. Medeiros, Forensic miRNA:
Potential biomarker for body fluids?, Forensic Science International: Genetics. 14 (2015) 1–
10. https://doi.org/10.1016/j.fsigen.2014.09.002.
[86] E. Hanson, H. Lubenow, J. Ballantyne, Identification of forensically relevant body fluids
using a panel of differentially expressed microRNAs, Forensic Science International:
Genetics Supplement Series. 2 (2009) 503–504.
https://doi.org/10.1016/j.fsigss.2009.08.184.
[87] D. Zubakov, A.W.M. Boersma, Y. Choi, P.F. van Kuijk, E.A.C. Wiemer, M. Kayser,
MicroRNA markers for forensic body fluid identification obtained from microarray screening
and quantitative RT-PCR confirmation, International Journal of Legal Medicine. 124 (2010)
217–226. https://doi.org/10.1007/s00414-009-0402-3.
[88] C. Courts, B. Madea, Specific micro-RNA signatures for the detection of saliva and blood in
forensic body-fluid identification, Journal of Forensic Sciences. 56 (2011) 1464–1470.
https://doi.org/10.1111/j.1556-4029.2011.01894.x.
[89] E.K. Hanson, M. Mirza, K. Rekab, J. Ballantyne, The identification of menstrual blood in
forensic samples by logistic regression modeling of miRNA expression, Electrophoresis. 35
(2014) 3087–3095. https://doi.org/10.1002/elps.201400171.
[90] J.L. Park, S.M. Park, O.H. Kwon, H. chul Lee, J. young Kim, H.H. Seok, W.S. Lee, S.H. Lee,
Y.S. Kim, K.M. Woo, S.Y. Kim, Microarray screening and qRT-PCR evaluation of microRNA
markers for forensic body fluid identification, Electrophoresis. 35 (2014) 3062–3068.
https://doi.org/10.1002/elps.201400075.
[91] E. Sauer, A.K. Reinke, C. Courts, Differentiation of five body fluids from forensic samples
by expression analysis of four microRNAs using quantitative PCR, Forensic Science
International: Genetics. 22 (2016) 89–99. https://doi.org/10.1016/j.fsigen.2016.01.018.
[92] S. Seashols-Williams, C. Lewis, C. Calloway, N. Peace, A. Harrison, C. Hayes-Nash, S.
Fleming, Q. Wu, Z.E. Zehner, High-throughput miRNA sequencing and identification of
biomarkers for forensically relevant biological fluids, Electrophoresis. 37 (2016) 2780–2788.
https://doi.org/10.1002/elps.201600258.
[93] M. Sirker, R. Fimmers, P.M. Schneider, I. Gomes, Evaluating the forensic application of 19
target microRNAs as biomarkers in body fluid and tissue identification, Forensic Science
International: Genetics. 27 (2017) 41–49. https://doi.org/10.1016/j.fsigen.2016.11.012.
[94] C. Mayes, S. Seashols-Williams, S. Hughes-Stamm, A capillary electrophoresis method for
identifying forensically relevant body fluids using miRNAs, Legal Medicine. 30 (2018) 1–4.
https://doi.org/10.1016/j.legalmed.2017.10.013.
[95] L.J. Saidi, L.H. Müller, B. Madea, M. Grabmüller, Specific miRNA profiling from DNA eluates
for body fluid identification, Forensic Science International: Genetics Supplement Series. 7
(2019) 692–694. https://doi.org/10.1016/j.fsigss.2019.10.141.
[96] S. Cassol, M.J. Gill, R. Pilon, M. Cormier, R.F. Voigt, B. Willoughby, J. Forbes,
Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots
collected on filter paper, Journal of Clinical Microbiology. 35 (1997) 2795–2801.
https://doi.org/10.1128/jcm.35.11.2795-2801.1997.
[97] R.T. Marquez, S. Bandyopadhyay, E.B. Wendlandt, K. Keck, B.A. Hoffer, M.S. Icardi, R.N.
Christensen, W.N. Schmidt, A.P. McCaffrey, Correlation between microRNA expression
levels and clinical parameters associated with chronic hepatitis C viral infection in humans,
Laboratory Investigation. 90 (2010) 1727–1736. https://doi.org/10.1038/labinvest.2010.126.
[98] J.G. Grasselli, M.K. Snavely, B.J. Bulkin, Applications of Raman spectroscopy, Physics
Reports. 65 (1980) 231–344. https://doi.org/10.1016/0370-1573(80)90065-4.
269 
[99] C.M. Hodges, J. Akhavan, The use of Fourier Transform Raman spectroscopy in the
forensic identification of illicit drugs and explosives, Spectrochimica Acta Part A: Molecular
Spectroscopy. 46 (1990) 303–307. https://doi.org/10.1016/0584-8539(90)80098-J.
[100] M.J. West, M.J. Went, Detection of drugs of abuse by Raman spectroscopy, Drug Testing
and Analysis. 3 (2011) 532–538. https://doi.org/10.1002/dta.217.
[101] L. Burgio, R.J.H. Clark, R.R. Hark, Raman microscopy and x-ray fluorescence analysis of
pigments on medieval and Renaissance Italian manuscript cuttings, Proceedings of the
National Academy of Sciences of the United States of America. 107 (2010) 5726–5731.
https://doi.org/10.1073/pnas.0914797107.
[102] E.M. Suzuki, M. Carrabba, In Situ Identification and Analysis of Automotive Paint Pigments
Using Line Segment Excitation Raman Spectroscopy: I. Inorganic Topcoat Pigments,
Journal of Forensic Sciences. 46 (2001) 15099J. https://doi.org/10.1520/jfs15099j.
[103] S. Botti, L. Cantarini, A. Palucci, Surface-enhanced Raman spectroscopy for trace-level
detection of explosives, Journal of Raman Spectroscopy. 41 (2010) 866–869.
https://doi.org/10.1002/jrs.2649.
[104] P. Buzzini, G. Massonnet, The analysis of colored acrylic, cotton, and wool textile fibers
using micro-raman spectroscopy. Part 2: Comparison with the traditional methods of fiber
examination, Journal of Forensic Sciences. 60 (2015) 712–720.
https://doi.org/10.1111/1556-4029.12654.
[105] K. Virkler, I.K. Lednev, Raman spectroscopy offers great potential for the nondestructive
confirmatory identification of body fluids, Forensic Science International. 181 (2008) 1–5.
https://doi.org/10.1016/j.forsciint.2008.08.004.
[106] V. Sikirzhytski, A. Sikirzhytskaya, I.K. Lednev, Multidimensional Raman spectroscopic
signatures as a tool for forensic identification of body fluid traces: A review, Applied
Spectroscopy. 65 (2011) 1223–1232. https://doi.org/10.1366/11-06455.
[107] S. Boyd, M.F. Bertino, S.J. Seashols, Raman spectroscopy of blood samples for forensic
applications, Forensic Science International. 208 (2011) 124–128.
https://doi.org/10.1016/j.forsciint.2010.11.012.
[108] T. Schlagetter, B.W. Kammrath, C.L. Glynn, The Use of Raman Spectroscopy for the
Identification of Forensically Relevant Body Fluid Stains, Spectroscopy. 32 (2017) 19–24.
[109] J. Fujihara, Y. Fujita, T. Yamamoto, N. Nishimoto, K. Kimura-Kataoka, S. Kurata, Y.
Takinami, T. Yasuda, H. Takeshita, Blood identification and discrimination between human
and nonhuman blood using portable Raman spectroscopy, International Journal of Legal
Medicine. 131 (2017) 319–322. https://doi.org/10.1007/s00414-016-1396-2.
[110] G. McLaughlin, K.C. Doty, I.K. Lednev, Raman spectroscopy of blood for species
identification, Analytical Chemistry. 86 (2014) 11628–11633.
https://doi.org/10.1021/ac5026368.
[111] K.C. Doty, I.K. Lednev, Differentiation of human blood from animal blood using Raman
spectroscopy: A survey of forensically relevant species, Forensic Science International. 282
(2018) 204–210. https://doi.org/10.1016/j.forsciint.2017.11.033.
[112] Y. Zou, P. Xia, F. Yang, F. Cao, K. Ma, Z. Mi, X. Huang, N. Cai, B. Jiang, X. Zhao, W. Liu,
X. Chen, Y.J. Kim, S. Hahn, G. Yoon, K.D. Wael, L. Lepot, F. Gason, B. Gilbert, K. Virkler,
I.K. Lednev, D. Rohleder, G. Kocherscheidt, K. Gerber, W. Kiefer, W. Kohler, J. Mocks, W.
Petrich, F. SaverioRomolo, P. Margot, E. Widjaja, E.M. Ali, H.G. Edwards, I.J. Scowen, C.
Hodges, J. Akhavan, J. Thomas, P. Buzzini, G. Massonnet, B. Reedy, C. Roux, D.
Broughton, C. Rodger, T. Coyle, N. Anwar, V. Sikirzhytski, A. Sikirzhytskaya, I.K. Lednev,
V. Sikirzhytski, K. Virkler, I.K. Lednev, K. Virkler, I.K. Lednev, S. Boyda, M.F. Bertino, S.J.
Seashols, H. Sato, H. Chiba, H. Tashiro, Y. Ozaki, T.G. Spiro, T.C. Strekas, A.
Sikirzhytskaya, V. Sikirzhytski, I.K. Lednev, M. Pecul, A. Rizzo, J. Leszczynski, S. Choi,
T.G. Spiro, K.C. Langry, K.M. Smith, D.L. Budd, G.N. la Mar, M. Abe, T. Kitagawa, Y.
Kyogoku, C.R. Johnson, M. Ludwig, S.A. Asher, M.A. Raso, M. v. Garcia, J. Morcillo, A.I.
Ivanov, R.G. Zhbankov, E.A. Korolenko, E. v. Korolik, L.A. Meleshchenko, M. Marchewka,
H. Ratajczak, J. Liang, Y. Cheng, H. Han, K.L. Aubrey, G.J.T. Jr, A. Eapen, I.H. Joe, V.
270 
 
Fawcett, D.A. Long, A. Bertoluzza, C. Fagnano, P. Finelli, M.A. Morelli, R. Simoni, R. Tosi, 
M. Ludwig, S.A. Asher, J. Twardowski, I. Nowak, D.J. Stufkens, T.L. Snoeck, S. Mohan, N. 
Sundaraganesan, A.J.D. Moreno, P.T.C. Freire, I. Guedes, F.E.A. Melo, J.M. Filho, J.A. 
Sanjurjo, Whole blood and semen identification using mid-infrared and Raman spectrum 
analysis for forensic applications, Anal. Methods. 8 (2016) 3763–3767. 
https://doi.org/10.1039/C5AY03337C. 
[113] C.K. Muro, K.C. Doty, L. Fernandes, I.K. Lednev, Forensic body fluid identification and 
differentiation by Raman spectroscopy, Forensic Chemistry. 1 (2016) 31–38. 
https://doi.org/10.1016/j.forc.2016.06.003. 
[114] I. Feine, R. Gafny, I. Pinkas, Combination of prostate-specific antigen detection and micro-
Raman spectroscopy for confirmatory semen detection, Forensic Science International. 270 
(2017) 241–247. https://doi.org/10.1016/j.forsciint.2016.10.012. 
[115] S.S. Tobe, N. Watson, N.N. Daéid, Evaluation of six presumptive tests for blood, their 
specificity, sensitivity, and effect on high molecular-weight DNA, Journal of Forensic 
Sciences. 52 (2007) 102–109. https://doi.org/10.1111/j.1556-4029.2006.00324.x. 
[116] U S Supreme Court, DAUBERT et ux., individually and as guardians ad litem for DAUBERT, 
et al. v. MERRELL DOW PHARMACEUTICALS, INC., (1992) 585–589. 
[117] K. Varmuza, ed., Chemometrics in Practical Applications, InTechOpen, 2012. 
https://doi.org/10.5772/1150. 
[118] G. McLaughlin, M.A. Fikiet, M. Ando, H. o. Hamaguchi, I.K. Lednev, Universal detection of 
body fluid traces in situ with Raman hyperspectroscopy for forensic purposes: Evaluation of 
a new detection algorithm (HAMAND) using semen samples, Journal of Raman 
Spectroscopy. 50 (2019) 1147–1153. https://doi.org/10.1002/jrs.5621. 
[119] A. Sikirzhytskaya, V. Sikirzhytski, I.K. Lednev, Raman spectroscopic signature of vaginal 
fluid and its potential application in forensic body fluid identification, Forensic Science 
International. 216 (2012) 44–48. https://doi.org/10.1016/j.forsciint.2011.08.015. 
[120] K. Virkler, I.K. Lednev, Forensic body fluid identification: The Raman spectroscopic 
signature of saliva, Analyst. 135 (2010) 512–517. https://doi.org/10.1039/b919393f. 
[121] V. Sikirzhytski, A. Sikirzhytskaya, I.K. Lednev, Multidimensional Raman spectroscopic 
signature of sweat and its potential application to forensic body fluid identification, Analytica 
Chimica Acta. 718 (2012) 78–83. https://doi.org/10.1016/j.aca.2011.12.059. 
[122] E. Mistek, L. Halámková, I.K. Lednev, Phenotype profiling for forensic purposes: 
Nondestructive potentially on scene attenuated total reflection Fourier transform-infrared 
(ATR FT-IR) spectroscopy of bloodstains, Forensic Chemistry. 16 (2019) 100176. 
https://doi.org/10.1016/j.forc.2019.100176. 
[123] K. Suhre, M.I. Mccarthy, J.M. Schwenk, Genetics meets proteomics: perspectives for large 
population-based studies, Nature Reviews Genetics. (2020). 
https://doi.org/10.1038/s41576-020-0268-2. 
[124] A. Bodzon-Kulakowska, A. Bierczynska-Krzysik, T. Dylag, A. Drabik, P. Suder, M. Noga, J. 
Jarzebinska, J. Silberring, Methods for samples preparation in proteomic research, Journal 
of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 849 
(2007) 1–31. https://doi.org/10.1016/j.jchromb.2006.10.040. 
[125] A.P. Bruins, Mechanistic aspects of electrospray ionization, Journal of Chromatography A. 
794 (1998) 345–357. https://doi.org/10.1016/S0021-9673(97)01110-2. 
[126] D. Lin, D.L. Tabb, J.R. Yates, Large-scale protein identification using mass spectrometry, 
Biochimica et Biophysica Acta - Proteins and Proteomics. 1646 (2003) 1–10. 
https://doi.org/10.1016/S1570-9639(02)00546-0. 
[127] R.A. Zubarev, A. Makarov, Orbitrap mass spectrometry, Analytical Chemistry. 85 (2013) 
5288–5296. https://doi.org/10.1021/ac4001223. 
[128] K. Scheffler, R. Viner, E. Damoc, High resolution top-down experimental strategies on the 
Orbitrap platform, Journal of Proteomics. 175 (2018) 42–55. 
https://doi.org/10.1016/j.jprot.2017.03.028. 
271 
[129] Y. Zhang, B.R. Fonslow, B. Shan, M.C. Baek, J.R. Yates, Protein analysis by
shotgun/bottom-up proteomics, Chemical Reviews. 113 (2013) 2343–2394.
https://doi.org/10.1021/cr3003533.
[130] K.M. Legg, R. Powell, N. Reisdorph, R. Reisdorph, P.B. Danielson, Discovery of highly
specific protein markers for the identification of biological stains, Electrophoresis. 35 (2014)
3069–3078. https://doi.org/10.1002/elps.201400125.
[131] P. Picotti, R. Aebersold, Selected reaction monitoring-based proteomics: Workflows,
potential, pitfalls and future directions, Nature Methods. 9 (2012) 555–566.
https://doi.org/10.1038/nmeth.2015.
[132] A. Doerr, DIA mass spectrometry, Nature Methods. 12 (2014) 35.
https://doi.org/10.1038/nmeth.3234.
[133] A. Thompson, J. Schäfer, K. Kuhn, S. Kienle, J. Schwarz, G. Schmidt, T. Neumann, C.
Hamon, Tandem mass tags: A novel quantification strategy for comparative analysis of
complex protein mixtures by MS/MS, Analytical Chemistry. 75 (2003) 1895–1904.
https://doi.org/10.1021/ac0262560.
[134] D.M. Desiderio, M. Kai, Preparation of stable isotope‐incorporated peptide internal
standards for field desorption mass spectrometry quantification of peptides in biologic
tissue, Biological Mass Spectrometry. 10 (1983) 471–479.
https://doi.org/10.1002/bms.1200100806.
[135] D.C. Liebler, L.J. Zimmerman, Targeted quantitation of proteins by mass spectrometry,
Biochemistry. 52 (2013) 3797–3806. https://doi.org/10.1021/bi400110b.
[136] A.D. Catherman, O.S. Skinner, N.L. Kelleher, Top Down proteomics: Facts and
perspectives, Biochemical and Biophysical Research Communications. 445 (2014) 683–
693. https://doi.org/10.1016/j.bbrc.2014.02.041.
[137] O.S. Skinner, N.A. Haverland, L. Fornelli, R.D. Melani, L.H.F. do Vale, H.S. Seckler, P.F.
Doubleday, L.F. Schachner, K. Srzentić, N.L. Kelleher, P.D. Compton, Top-down
characterization of endogenous protein complexes with native proteomics, Nature Chemical
Biology. 14 (2018) 36–41. https://doi.org/10.1038/nchembio.2515.
[138] A. Cristobal, F. Marino, H. Post, H.W.P. van den Toorn, S. Mohammed, A.J.R. Heck,
Toward an Optimized Workflow for Middle-Down Proteomics, Analytical Chemistry. 89
(2017) 3318–3325. https://doi.org/10.1021/acs.analchem.6b03756.
[139] V.H. Wysocki, K.A. Resing, Q. Zhang, G. Cheng, Mass spectrometry of peptides and
proteins, Methods. 35 (2005) 211–222. https://doi.org/10.1016/j.ymeth.2004.08.013.
[140] F. Boulund, R. Karlsson, L. Gonzales-Siles, A. Johnning, N. Karami, O. AL-Bayati, C. Ahrén,
E.R.B. Moore, E. Kristiansson, Typing and characterization of bacteria using bottom-up
tandem mass spectrometry proteomics, Molecular and Cellular Proteomics. 16 (2017)
1052–1063. https://doi.org/10.1074/mcp.M116.061721.
[141] R. Karlsson, M. Davidson, L. Svensson-Stadler, A. Karlsson, K. Olesen, E. Carlsohn, E.R.B.
Moore, Strain-level typing and identification of bacteria using mass spectrometry-based
proteomics, Journal of Proteome Research. 11 (2012) 2710–2720.
https://doi.org/10.1021/pr2010633.
[142] G.J. Parker, T. Leppert, D.S. Anex, J.K. Hilmer, N. Matsunami, L. Baird, J. Stevens, K.
Parsawar, B.P. Durbin-Johnson, D.M. Rocke, C. Nelson, D.J. Fairbanks, A.S. Wilson, R.H.
Rice, S.R. Woodward, B. Bothner, B.R. Hart, M. Leppert, Demonstration of protein-based
human identification using the hair shaft proteome, PLoS ONE. 11 (2016) 1–26.
https://doi.org/10.1371/journal.pone.0160653.
[143] D.M. Schieltz, S.C. McGrath, L.G. McWilliams, J. Rees, M.D. Bowen, J.J. Kools, L.A.
Dauphin, E. Gomez-Saladin, B.N. Newton, H.L. Stang, M.J. Vick, J. Thomas, J.L. Pirkle,
J.R. Barr, Analysis of active ricin and castor bean proteins in a ricin preparation, castor bean 
extract, and surface swabs from a public health investigation, Forensic Science
International. 209 (2011) 70–79. https://doi.org/10.1016/j.forsciint.2010.12.013.
[144] M. Dupré, B. Gilquin, F. Fenaille, C. Feraudet-Tarisse, J. Dano, M. Ferro, S. Simon, C.
Junot, V. Brun, F. Becher, Multiplex Quantification of Protein Toxins in Human Biofluids and
272 
Food Matrices Using Immunoextraction and High-Resolution Targeted Mass Spectrometry, 
Analytical Chemistry. 87 (2015) 8473–8480. 
https://doi.org/10.1021/acs.analchem.5b01900. 
[145] H. Yang, B. Zhou, H. Deng, M. Prinz, D. Siegel, Body fluid identification by mass
spectrometry, International Journal of Legal Medicine. 127 (2013) 1065–1077.
https://doi.org/10.1007/s00414-013-0848-1.
[146] K. van Steendam, M. de Ceuleneer, M. Dhaenens, D. van Hoofstat, D. Deforce, Mass
spectrometry-based proteomics as a tool to identify biological matrices in forensic science,
International Journal of Legal Medicine. 127 (2013) 287–298.
https://doi.org/10.1007/s00414-012-0747-x.
[147] K.M. Legg, R. Powell, N. Reisdorph, R. Reisdorph, P.B. Danielson, Verification of protein
biomarker specificity for the identification of biological stains by quadrupole time-of-flight
mass spectrometry, Electrophoresis. 38 (2017) 833–845.
https://doi.org/10.1002/elps.201600352.
[148] A. Illiano, V. Arpino, G. Pinto, A. Berti, V. Verdoliva, G. Peluso, P. Pucci, A. Amoresano,
Multiple Reaction Monitoring Tandem Mass Spectrometry Approach for the Identification of
Biological Fluids at Crime Scene Investigations, Analytical Chemistry. 90 (2018) 5627–
5636. https://doi.org/10.1021/acs.analchem.7b04742.
[149] S. Jackson, B.S. Frey, M.N. Bates, D.J. Swiner, A.K. Badu-Tawiah, Direct differentiation of
whole blood for forensic serology analysis by thread spray mass spectrometry, The Analyst.
145 (2020) 5615–5623. https://doi.org/10.1039/d0an00857e.
[150] T. Browne, M. Concheiro-Guisan, M. Prinz, Semi quantitative detection of signature
peptides in body fluids by liquid chromatography tandem mass spectrometry (LC–MS/MS),
Forensic Science International: Genetics Supplement Series. (2019).
https://doi.org/10.1016/j.fsigss.2019.09.080.
[151] S. Kranes, S.A. Sterling, K. Mason, D. Anex, B. Hart, G. Parker, M. Prinz, Simultaneous
DNA and protein extraction using trypsin, Forensic Science International: Genetics
Supplement Series. 6 (2017) e203–e204. https://doi.org/10.1016/j.fsigss.2017.09.081.
[152] K.E. Mason, D. Anex, T. Grey, B. Hart, G. Parker, Protein-based forensic identification using
genetically variant peptides in human bone, Forensic Science International. 288 (2018) 89–
96. https://doi.org/10.1016/j.forsciint.2018.04.016.
[153] Z.C. Goecker, M.R. Salemi, N. Karim, B.S. Phinney, R.H. Rice, G.J. Parker, Optimal
processing for proteomic genotyping of single human hairs, Forensic Science International:
Genetics. 47 (2020) 102314. https://doi.org/10.1016/j.fsigen.2020.102314.
[154] J.F. Kellie, J.C. Tran, W. Jian, B. Jones, J.T. Mehl, Y. Ge, J. Henion, K.P. Bateman, Intact
Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and
Biotransformation in Preclinical and Clinical Studies: An Industry Perspective, Journal of the 
American Society for Mass Spectrometry. (2020). https://doi.org/10.1021/jasms.0c00270.
[155] C.M. Stoscheck, Quantitation of protein, Methods in Enzymology. 182 (1990) 50–68.
https://doi.org/10.1016/0076-6879(90)82008-P.
[156] I. Fridolin, M. Magnusson, L.G. Lindberg, On-line monitoring of solutes in dialysate using
absorption of ultraviolet radiation: Technique description, International Journal of Artificial
Organs. 25 (2002) 748–761. https://doi.org/10.1177/039139880202500802.
[157] H. Edelhoch, Spectroscopic Determination of Tryptophan and Tyrosine in Proteins,
Biochemistry. 6 (1967) 1948–1954. https://doi.org/10.1021/bi00859a010.
[158] J.D. Russell, Z. Van, D. Heuvel, M. Bovee, S. Murphy, Automation for LC/MS Sample
Preparation: High Throughput In-Solution Digestion and Peptide Cleanup Enabled by the
Agilent AssayMAP Bravo Platform Application Note, 2016.
[159] Thermo Scientific, User Guide: Pierce BCA Protein Assay Kit, 2011.
https://doi.org/10.1016/j.ijproman.2010.02.012.
[160] H. Mkaouar, N. Akermi, V. Mariaule, S. Boudebbouze, N. Gaci, F. Szukala, N. Pons, J.
Marquez, A. Gargouri, E. Maguin, M. Rhimi, Siropins, novel serine protease inhibitors from
273 
gut microbiota acting on human proteases involved in inflammatory bowel diseases, 
Microbial Cell Factories. 15 (2016). https://doi.org/10.1186/s12934-016-0596-2. 
[161] Scientific Working Group for Forensic Toxicology (SWGTOX) Standard Practices for
Method Validation in Forensic Toxicology, Journal of Analytical Toxicology. 37 (2013) 452–
474. https://doi.org/10.1093/jat/bkt054.
[162] E.S. Boward, S.L. Wilson, A comparison of ABAcard p30 and RSID-Semen test kits for
forensic semen identification, Journal of Forensic and Legal Medicine. 20 (2013) 1126–
1130. https://doi.org/10.1016/j.jflm.2013.09.007.
[163] F.B. of Investigation, Crime Data Explorer, (n.d.). https://crime-data-
explorer.fr.cloud.gov/explorer/national/united-states/crime (accessed May 12, 2021).
[164] S. Sinozich, L. Langton, Rape and Sexual Assault Victimization Among College-Age
Females, 1995-2013, 2014.
[165] P. Tjaden, N. Thoennes, K. v Rhodes, D. Houry, C. Cerulli, H. Straus, N.J. Kaslow, L.-A.
McNutt, R.J. Reid, A.E. Bonomi, F.P. Rivara, M.L. Anderson, P. a Fishman, D.S. Carrell,
R.S. Thompson, A.L. Coker, K.E. Davis, I. Arias, S. Desai, M. Sanderson, H.M. Brandt, P.H.
Smith, H. Cho, B. Callie, M. Rennison, D. Ph, S. Welchans, Full Report of the Prevalence,
Incidence, and Consequences of Violence Against Women, American Journal of Preventive
Medicine. 23 (2000) 260–268. https://doi.org/10.1177/0886260512436391.
[166] G. Menschaert, T.T.M. Vandekerckhove, G. Baggerman, L. Schoofs, W. Luyten, W. van
Criekinge, Peptidomics coming of age: A review of contributions from a bioinformatics angle,
Journal of Proteome Research. 9 (2010) 2051–2061. https://doi.org/10.1021/pr900929m.
[167] S. Scientific Working Group for Forensic Toxicology, Standard Practices for Method
Validation in Forensic Toxicology, (2013) 1–52. https://doi.org/10.1093/jat/bkt054.
[168] F.B. of Investigation, Quality Assurance Standards (QAS) for DNA Databasing Laboratories,
(2020). http://www.fbi.gov/about-us/lab/codis/qas_databasalabs.
[169] C.O. Brown, B.L. Robbins, H.E. McKiernan, P.B. Danielson, K.M. Legg, Direct seminal fluid
identification by protease-free high-resolution mass spectrometry, Journal of Forensic
Sciences. 66 (2021) 1017–1023. https://doi.org/10.1111/1556-4029.14646.
[170] H. Koistinen, R. Koistinen, a Dell, H.R. Morris, R.L. Easton, M.S. Patankar, S. Oehninger,
G.F. Clark, M. Seppälä, Glycodelin from seminal plasma is a differentially glycosylated form
of contraceptive glycodelin-A., Molecular Human Reproduction. 2 (1996) 759–65.
http://www.ncbi.nlm.nih.gov/pubmed/9239694.
[171] M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å.
Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I.M. Olsson, K. Edlund, E. Lundberg, S.
Navani, C.A.K. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober, T. Alm, P.H.
Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J.M. Schwenk, M.
Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von
Heijne, J. Nielsen, F. Pontén, Tissue-based map of the human proteome, Science. 347
(2015). https://doi.org/10.1126/science.1260419.
[172] P. Stanley, N. Taniguchi, M. Aebi, Essentials of Glycobiology Chapter 9 N-Glycans, 3rd ed.,
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2017.
[173] K. Lapid, N. Sharon, Meet the multifunctional and sexy glycoforms of glycodelin,
Glycobiology. 16 (2006) 39–45. https://doi.org/10.1093/glycob/cwj059.
[174] T. Borja, N. Karim, Z. Goecker, M. Salemi, B. Phinney, M. Naeem, R. Rice, G. Parker,
Proteomic genotyping of fingermark donors with genetically variant peptides, Forensic
Science International: Genetics. 42 (2019) 21–30.
https://doi.org/10.1016/j.fsigen.2019.05.005.
[175] L.A. Catlin, R.M. Chou, Z.C. Goecker, L.A. Mullins, D. Silva, R.R. Spurbeck, G.J. Parker,
Demonstration of a mitochondrial DNA-compatible work flow for genetically variant peptide
identification from human hair samples, Forensic Science International: Genetics. 43
(2019). https://doi.org/10.1016/j.fsigen.2019.102148.
274 
APPENDIX A: FINAL BIOMARKER LIST AND ASSOCIATED COLLISION ENERGIES 
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MATERIALS AND REAGENTS 
Equipment 
1. Analytical Balance
2. Refrigerated Microcentrifuge: Capable of speeds up to 12,000 RCF
3. Spectrophotometer: Capable of 562 nm reading
4. SpeedVac Concentrator set to 45 °C
5. Incubator set to 37⁰C
6. Agilent AssayMAP Bravo Liquid Handler
7. Agilent 1290 Series Liquid Chromatography System
8. Agilent 6495 Triple Quadrupole LC/MS
9. Agilent AdvancedBio Peptide Map column, 3x100mm, 2.7 µM, #655950-302
General Plastics and Labware 
1. Disposable scalpels
2. Clean Bench Paper
3. Deionized water
4. 10% Bleach
5. Microcentrifuge tubes Protein LoBind (Eppendorf 1.5 and 2.0 mL #022431081,
022431102)
6. Costar SpinX .45 µm spin filter (Corning #8163)
7. Costar SpinX spin baskets nofilter inserts (Corning #9301)
8. Pierce BSA Protein Assay Kit (Thermo #23225)
9. Corning Costar Assay Plate, clear, flat bottom (Corning #9017)
AssayMAP and Automation Labware 
1. AssayMAP C18 5 µL Cartridge Rack (Agilent #5190-6532)
2. 250 µL sterile pipette tips for AssayMAP Bravo (Agilent #19477-012)
3. Eppendorf 96 well LoBind PCR plate (Eppendorf #0030129512)
4. 12 Column Reservoir Plate (SeahorseBio #201280-100)
5. Greiner U-Bottom White 96 well plate (Greiner #650207)
6. Greiner Universal Plate Lids (Grenier #656199)
7. Eppendorf Storage Film (Eppendorf #0030127870)
Chemicals 
1. 100 mM Tris-HCl (Thermo #15568-025)
a. Dilute 1M Tris-HCl 1:10 in LCMS grade water
2. 8 M Urea (Sigma BioUltra #51456)
a. 3.123 grams in 4 mL 100 mM Tris-HCl
3. 1 M Tris(2-carboxyethyl)phosphine hydrochloride, TCEP (Thermo #20490)
a. 0.286 grams in 1 mL LCMS grade water. 35 µL aliquots stored at -80 ⁰C.
4. 100 mM Iodoacetamide, IAA (Sigma BioUltra #I1149)
a. 0.036 grams in 2.0 mL LCMS grade water
General Solvents 
1. Acetonitrile , LCMS grade
2. Water, LCMS grade
3. Methanol, LCMS Grade
4. Isopropanol, LCMS Grade
5. Formic Acid (FA), LCMS Grade
6. Trifluoroacetic Acid (TFA), HPLC Grade
AssayMAP Solvents 
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1. Priming Solvent: 50% Acetonitrile in water with 0.5% TFA
a. 500 mL acetonitrile, 500 mL water, 5 mL TFA
2. Equilibration and Wash Solvent: Water with 0.5% TFA
a. 1,000 mL water, 5 mL TFA
3. Elution Solvent: 70% Acetonitrile in water with 0.1% FA
a. 700 mL acetonitrile, 300 mL water, 1 mL formic acid
4. Cartridge Wash (60% Methanol)
a. 600 mL Methanol, 400 mL water
Mass Spectrometry Solvents 
1. Mobile Phase A: Water with 0.1% formic acid
a. 1,000 mL LCMS grade water, 1 mL LCMS grade formic acid
2. Mobile Phase B: Acetonitrile with 0.1% formic acid
a. 1,000 mL LCMS grade acetonitrile, 1 mL LCMS grade formic acid
3. Syringe Wash Solution: 1:1:1:1 Methanol:Acetonitrile:Isopropanol:Water
a. 250 mL methanol, 250 mL acetonitrile, 250 mL isopropanol, 250 mL water
4. Seal Wash Solution: 10% Methanol in water
a. 900 mL LCMS grade water, 100 mL LCMS grade methanol
Enzymes: 
1. Sequencing Grade Trypsin (Promega #V511B)
a. 100 µg sequencing grade trypsin reconstituted in 400 µL 50 mM acetic acid for a
final concentration of 0.25 µg/µL
b. 50 µL aliquots stored at -80 ⁰C for up to 1 year.
Myelin Internal Control Reagents: 
1. Intact Bovine Myelin Basic Protein Stock Solution (Sigma #13-104)
a. Reconstituted 10 mg in 20 mL 2% acetonitrile 0.1% FA for 0.5 mg/mL stock
b. Aliquoted and freeze (-80°C) at stock concentration for up to 1 year
c. Intact Bovine Myelin Basic Protein Working Solution
i. Thawed and dilute 1:100 with 30% acetonitrile 0.1% FA for a final
concentration of 5 ng/µL
ii. Spike prior to digest (at dry down stage)
iii. With a repeater pipette add 20 µL of 5 ng/µL for a 100 ng spike per sample
2. Myelin Isotopically Labelled Peptide Stock Solution (DTGILDSLGR^, New England
Peptide)
a. 2 nmol material from NEP (Molar equivalent = 2.11 µg)
b. Reconstituted in 2.11 mL 30% acetonitrile 0.1% FA for 1 µg/mL stock
c. Aliquoted and frozen (-80) at stock concentration for up to 1 year
d. Myelin Isotopically Labelled Peptide Working Solution
i. Thaw
ii. Spiked prior to SPE cleanup





1. HSA Peptide Standard Mix (Agilent #G2455-85001) 
a. To each vial of HSA standard (500 pmol) add 500 µL of 15% acetonitrile with 0.1% 
formic acid for a 1 pmol/µL stock. 
b. Vortex and mix vial for 30 seconds. Allow the vial to stand at room temperature for 
5 minutes 
2. Dilute 1 pmol/µL stock 1:10 for a final concentration of 100 fmol/µL.  
a. Aliquot 50 µL to 250 µL polypropylene snap caps vials.  
3. Cap vials, store at -80°C for up to 1 year 
CONTROLS 
Positive Control (PC) – a known control sample (e.g. human semen or blood) is required for each 
analytical batch which undergoes extraction, digestion, and cleanup alongside questioned 
samples.  
Reagent (negative) Control (RC) – a blank samples that undergoes the same extraction process 
as the samples to test the reagents for contaminants. 
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BODY FLUID EXTRACTION AND QUANTITATION 
Initial preparations: 
1. Clear off a workspace and lay a new, clean piece of bench paper. Check and replace any
reagents that have expired.
2. Prepare one set of 2.0 mL microcentrifuge tubes for each sample marked with a unique sample
identifier.
Extraction protocols: 
1. Gather all utensils (e.g., scalpel, scissors, forceps, weigh paper) needed for sample cutting.
2. Sterilize utensils with a 20% bleach solution followed by a water rinse.
3. If samples were not already collected and prepared during the evidence examination process
(i.e. placed in a 2.0 mL microcentrifuge tube), carefully cut the stain (~1 x 1 cm, or as
appropriate, depending on the nature of the stain) and place in the appropriately marked 2.0
mL microcentrifuge tube.  If the sample is on a swab, use ½ of the swab or the stained area if
the staining is uneven.  In the case of loose flakes, use at the discretion of the analyst.   In the
case of cigarette butts, remove the paper around the filter. If the staining is light, a larger area
may be taken.
4. Extract evidentiary material by soaking in 500 - 1,000 µL of deionized water for 30 minutes.
Vortex the sample frequently to facilitate extraction of biological material from substrate.  Pulse
spin for 10 seconds to remove droplets from the lid, and transfer the sample substrate into a
clean spin basket and centrifuge at 12,000 RPM for 10 minutes.
5. Transfer supernatant to a clean Costar 0.45 µM SpinX filter and reserve pelleted material for
genetic testing. Filter the supernatant by centrifuging at 10,000 RPM for 2 minutes, or until all
extract has passed through the filter. Remove the SpinX filter and discard.




1. Prepare bovine serum albumin standards in 100 mM Tris-HCl using the following table: 





A 2 mg/mL stock None 2000 
B 375 A 125 1500 
C 325 A 325 1000 
D 175 B 175 750 
E 325 C 325 500 
F 325 E 325 250 
G 325 F 400 125 
H 100 G 400 25 
BLANK None All N/A 
 
2. For sample preparation, dilute sample supernatant in 100mM Tris-HCl at the discretion of the 
analyst 
a. Blood and Semen Samples 1:100 dilution 
b. Saliva and Vaginal Fluid 1:50 dilution 
c. Dependent on the concentration and physical appearance of the extract 
3. Prepare BCA Protein Assay working reagent according to the number of samples being 
prepared. 
a. Volume of Reagent A = (total # samples and standards + 2) x 200 
b. Volume of Reagent B = (volume of reagent A) / 50 
4. Prepare a 96 well Corning square bottom plate. Aliquot 25 µL of standard or sample to the 
appropriate well. Add 200 µL of prepared working reagent to each well and seal using a 
protective film. Incubate the plat at 37 ⁰ C for 30 minutes. 







 1 2 3 
A BLANK STD E SAMPLE 
B BLANK STD E SAMPLE 
C STD B STD F SAMPLE 
D STD B STD F  
E STD C STD G  
F STD C STD G  
G STD D STD H  
H STD D STD H  
 
6. Remove the protective film and analyze on a spectrophotometer at 562 nm. Ensure the 
spectrophotometer is programmed accordingly, with the standard concentrations in the 
appropriate well number. 
7. Evaluate the results as follows: 
a. Standard Curve R2 value: >0.98 
8. Calculate the total protein for each question sample, targeting 100 µg total protein 
a. (100 µg) / (Reported protein concentration in µg/mL x Dilution Factor) x 1000 
9. Prepare a 96 well Greiner U-bottom White plate, with a repeater pipette add 20 µL of 5 ng/µL 
for a 100 ng spike per sample of intact Bovine Myelin Basic Protein.  
10. Add up to 100 µg total protein for each sample being analyzed. 
11. Lyophilized to dryness in a SpeedVac concentrator at 45 ⁰ C 
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PROTEIN SAMPLE DIGESTION 
1. Run AssayMAP startup procedure found in Appendix I.
2. Open the Pipette Tip Transfer Utility Application in the VWorks Software Utility Library. Arrange
the pipette tip rack according to the deck layout diagram displayed. Input the number of
columns to transfer according to the number of samples being processed. A full row of tips
should be transferred, regardless of whether the sample plate contains a complete row of
samples to be analyzed. Run the Pipette Tip Transfer Application. Remove the pipette tip rack
from the instrument.
3. Open the In-Solution Digest Single Plate application in the VWorks Software App Library.
4. Prepare the denaturant solution. Add 32.5 µL of 1 M TCEP stock solution to 8 M Urea in 100
mM Tris-HCl (for a 5 mM final concentration). Aliquot 100 µL of denaturant solution into each
well of a Greiner U-Bottom White 96 well plate. Move the plate to deck position 5 on the
AssayMAP.
5. Prepare the alkylant solution. Aliquot 50 µL of 100 mM IAA solution into each well of a Greiner
U-Bottom White 96 well plate. Place a universal black lid on the plate. Check the corresponding
box in the VWorks Software indicating the alkylant plate is lidded. Move the plate to deck 
position 6 on the AssayMAP. 
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6. Prepare the diluent solution. Aliquot 250 µL of 100 mM Tris-HCl into each well of a Greiner U-
Bottom White 96 well plate. Move the plate to deck position 8 on the AssayMAP.
7. Prepare the trypsin solution. Aliquot 15 µL of 0.25 µg/µL sequencing grade trypsin into each
well of an Eppendorf 96 well PCR plate. Move the plate to deck position 9 on the AssayMAP.
8. Move the sample plate containing the lyophilized sample to deck position 4 on the AssayMAP.
Place a universal black lid on the sample plate. Check the corresponding box in the VWorks
Software indicating the sample plate is lidded.
9. Input the correct number of columns to be digested according to the number of samples being
processed in the sample plate. Verify the following parameters into the application:
Digest Solution Addition Volume # Mix Cycles Incubation Time and Temperature 
Denaturant 55 µL 15 mix cycles 45-minute incubation at 25 ⁰ C
Alkylant 6 µL 15 mix cycles 30-minute incubation at 25 ⁰ C
Diluent 170 µL 15 mix cycles No incubation 
Trypsin 10 µL 15 mix cycles No incubation 
10. Run the digestion application.
11. With the completion of the digestion application, remove the sample plate and seal with an
Eppendorf storage film. Place the sample plate in an incubator set at 37 ⁰C for 14-16 hours.
12. Run AssayMap shutdown procedure found in Appendix I.
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PEPTIDE SAMPLE CLEANUP 
Sample Acidification: 
1. Run AssayMap startup procedure found in Appendix I. 
2. Allow the sample plate to come to room temperature. Remove Myelin Isotopically Labelled 
Peptide Stock Solution from freezer.  
3. Remove storage film. With a repeater pipette, add 10 µL of Myelin Isotopically Labelled Peptide 
stock solution at1 µg/mL for a 10 ng spike per sample. 
4. Open the Pipette Tip Transfer Utility Application in the VWorks Software Utility Library. Arrange 
the pipette tip rack according to the deck layout diagram displayed. Input the number of 
columns to transfer according to the number of samples being processed. A full row of tips 
should be transferred, regardless of whether the sample plate contains a complete row of 
samples to be analyzed. Run the Pipette Tip Transfer Application. Remove the pipette tip rack 
from the instrument. 
 
5. Open the Reagent Transfer Utility application in the VWorks Software Utility library. 
6. Fill the appropriate number of channels of a 12 Column Reservoir Plate with 25% TFA solution. 
Move the plate to the source location of the deck layout displayed.  
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7. Place the sample plate containing digested material to the destination location of the deck 
layout displayed. 
8. In the Reagent Transfer Utility application, select the number of columns to be transferred, 
check the box indicating the use of pipette tips to transfer, and input 10 µL of 25% TFA to be 
transferred to each well.  
 
9. Run the Reagent Transfer application. 
10. Discard the pipette tips. 
11. Discard the 25% TFA solution into solvent waste. 
Cartridge Transfer: 
1. Open the Cartridge Transfer Utility application in VWorks Software Utility library. 
2. Arrange the cartridge rack according to the deck layout diagram displayed. 
3. Input the number of columns to transfer according to the number of samples being processed. 
Note that full columns should be transferred. 
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4. Run the Cartridge Transfer application.
5. Remove the cartridge rack from the instrument.
Peptide Cleanup Protocol: 
1. Open the Peptide Cleanup application in VWorks Software application library.
2. Prepare the Prime solution. Fill the corresponding number of channels to capacity of a labeled
12 Column Reservoir Plate to the number of columns being processed.  Move the plate position
5 on the AssayMAP deck.
3. Prepare the Equilibration solution. Fill the corresponding number of channels to capacity of a
labeled 12 Column Reservoir Plate to the number of columns being processed. Move the plate
to position 6 on the AssayMAP deck.
4. Prepare the Elution solution. Fill the corresponding number of channels to capacity of a labeled
12 Column Reservoir Plate to the number of columns being processed. Move the plate to
position 8 on the AssayMAP deck.
5. Place the 96 well plate containing digested and acidified sample in the corresponding position
to the displayed deck layout.
6. Place a 12 Column Reservoir plate in the Organic Waste/position 3 on the deck.
7. Place a 96 well PCR plate in the Eluate Collection/position 9 on the deck.
290 
 
8. Input the appropriate number of columns being processed in the software. 
9. Verify the following parameters in the software: 
Cleanup Step Addition Volume Flow Rate # Wash Cycles 
Initial Syringe Wash --- --- 4 wash cycles 
Prime 100 µL 50% ACN 0.5% TFA 300 µL/min 3 wash cycles 
Equilibrate 50 µL of H2O 0.5% TFA 10 µL/min 3 wash cycles 
Sample Load 220 µL 15 µL/min 3 wash cycles 
Cup Wash 25 µL --- 1 wash cycle 
Internal Cartridge Wash 50 µL 10 µL/min 3 wash cycles 
Stringent Syringe Wash 50 µL --- 1 wash cycle 
Elute 20 µL 70% ACN 0.1% FA 5 µL/min 3 wash cycles 
Final Syringe Wash --- --- 3 wash cycles 
 
 
10. Run the Peptide Cleanup application. 
11. Upon completion, remove the eluate collection plate from the instrument. 
12. Dry down in the SpeedVac concentrator at 45 ⁰C until lyophilized to dryness.  
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ANALYSIS BY MASS SPECTROMETRY 
Initial Preparations: 
1. Run AssayMap startup procedure found in Appendix I.
2. Open the Pipette Tip Transfer Utility Application in the VWorks Software Utility Library. Arrange
the pipette tip rack according to the deck layout diagram displayed. Input the number of
columns to transfer according to the number of samples being processed. A full row of tips
should be transferred, regardless of if the sample plate contains a complete row of samples to
be analyzed. Run the Pipette Tip Transfer Application. Remove the pipette tip rack from the
instrument.
3. Open the Reagent Transfer Utility application in the VWorks Software Utility library.
4. Fill the appropriate number of channels of a 12 Column Reservoir Plate with 2% acetonitrile
with 0.1% formic acid in LCMS grade water.
5. Move the plate to the source location of the deck layout displayed. Place the sample plate
containing lyophilized, purified sample to the destination location of the deck layout displayed.
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6. In the Reagent Transfer Utility application, select the number of columns to be transferred,
check the box indicating the use of pipette tips to transfer, and input 100 µL of 2% ACN 0.1%
FA to be transferred to each well.
7. Run the Reagent Transfer application.
8. Discard the pipette tips.
9. Discard the 2% ACN 0.1% FA solution into solvent waste.
Sample Plate Analysis: 
1. Ensure all solvents are not expired.
2. Verify the Agilent Jet Stream source as been cleaned during the week of analysis or as
necessary. For example, deterioration or material on the spray shield.
3. Verify the 6495 MS has been fully tuned within 1 month and a check tune has been performed
during the week of analysis. If necessary, tune the instrument.
4. Open MassHunter Acquisition Software.




6. If fresh solvents were prepared, update the bottle fillings by right clicking the Binary Pump 
Module.  
 
7. Purge the A and B Mobile Phase pump lines by right clicking the Binary Pump Module. Purge 
at 50:50 mobile phase A:B at 4 mL/min for 4 minutes.  
8. Ensure the correct analytical column is connected in the proper position on the heat block. 
Agilent AdvancedBio Peptide Map column, 3x100mm, 2.7 µM, #655950-302. 
9. Turn on the instrument by clicking the green ‘On’ button in the lower right corner of the Module 
bar. Allow the instrument to idly pump for approximately five minutes. Monitor the pressure 
listed on the Binary Pump Module. Pressures > 350 bar may indicate the column requires 
maintenance or replacement.   
10. Create a new run folder on the computer hard drive, labeling appropriately according to 
laboratory protocol. 
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11. In MassHunter Acquisition Software, under the Worklist Tab, modify the Worklist Run
Parameters. Input the new run folder and ensure the proper method and run folder is selected.
12. Click the Worklist tab in the bottom left corner of the screen. Begin a new worklist by right
clicking the space and selecting Add Sample. Alternatively, open a previously made worklist
by clicking the Worklist Tab at the top of the screen and opening the desired worklist. Label the
samples appropriately and insert blanks where necessary. Always run HSA System Suitability
samples in triplicate at the beginning of the worklist, to ensure proper instrument performance.
Always include a shutdown script at the end of the worklist, communicating to the instrument




13. Once the worklist is prepared, place samples into the autosampler according to the plate/vial 
position.  
14. Select all the samples in the worklist by checking the square box at the top left of the worklist. 
Hit the triangle “Play” button to start the worklist.  
15. Review the results for the HSA System Suitability samples in the Qualitative Analysis Software.  
16. Verify that all six peptides are present in the system suitability injections. Verify retention times, 
relative intensities, as well as peak shape for the peptides. If a problem is observed, 
troubleshoot the issue before running the full batch.  
17. Refer to the table and representative chromatogram below: 
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Peptide Sequence Retention Time (min.) 
Intensity 
(cts.) 
AAFTEC[+57.0]C[+57.0]QAADK 1 5.5 x 103 
AVMDDFAAFVEK 1.7 4.0 x 104 
RPC[+57.0]FSALEVDETYVPK 1.4 2.5 x 104 
HPYFYAPELLFFAK 1.8 2.0 x 105 
LVNEVTEFAK 1.3 1.0 x 105 
KVPQVSTPTLVEVSR 1.3 5.5 x 104 























Cpd 7: YLYEIAR.light: +ESI MRM Frag=380.0V CF=0.000 DF=0.000 CID@13.4 (464.2504 -> 651.3461) HSA_100fmol-r002.d 
1.350
1 1
Counts vs. Acquisition Time (min)
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9
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APPENDIX I ASSAYMAP BRAVO STARTUP AND SHUTDOWN 
Startup 
1. Turn on the AssayMAP Bravo automation system. Ensure the wash station carboy contains a 
sufficient amount of water and the waste carboy is empty. Open the Startup Utility Application 
in the VWorks Software. Run the application and follow the prompts on the computer. 
 
Shutdown 
1. Open the Startup & Shutdown Utility Application in the VWorks Software. Run the application 





APPENDIX II HUMAN SERUM ALBUMIN ACQUISITION PARAMETERS 
Instrument Parameters 
• Instrumentation: Agilent 6495 Tandem Mass Spectrometer with an Agilent 1290 LC system.
o Instrument Mode: MRM
• Agilent AdvancedBio Peptide Map column, 3x100mm, 2.7 µM
o Mobile Phases:
 A:  Water with 0.2% Formic Acid
 B:  Acetonitrile with 0.2% Formic Acid
o Needle Wash:  1:1:1:1 Methanol:Acetonitrile:Isopropanol:Water
o Injection Volume: 2.5 -10 µL
• System Suitability: Agilent Human Serum Albumin peptide mix with 100 fmol on column.
• The ions monitored are listed below.
Compound Group Compound Name Precursor Ion Product Ion 
sp|P02768|ALBU_HUMAN AAFTEC[+57.0]C[+57.0]QAADK.light 686.3 981.4 
sp|P02768|ALBU_HUMAN AAFTEC[+57.0]C[+57.0]QAADK.light 686.3 852.3 
sp|P02768|ALBU_HUMAN AVMDDFAAFVEK.light 671.8 1,172.5 
sp|P02768|ALBU_HUMAN AVMDDFAAFVEK.light 671.8 1,041.5 
sp|P02768|ALBU_HUMAN RPC[+57.0]FSALEVDETYVPK.light 637.6 961.5 
sp|P02768|ALBU_HUMAN RPC[+57.0]FSALEVDETYVPK.light 637.6 851.4 
sp|P02768|ALBU_HUMAN HPYFYAPELLFFAK.light 581.6 779.4 
sp|P02768|ALBU_HUMAN HPYFYAPELLFFAK.light 581.6 482.8 
sp|P02768|ALBU_HUMAN LVNEVTEFAK.light 575.3 937.5 
sp|P02768|ALBU_HUMAN LVNEVTEFAK.light 575.3 595.3 
sp|P02768|ALBU_HUMAN KVPQVSTPTLVEVSR.light 547.3 702.4 
sp|P02768|ALBU_HUMAN KVPQVSTPTLVEVSR.light 547.3 589.3 
sp|P02768|ALBU_HUMAN YLYEIAR.light 464.3 651.3 
sp|P02768|ALBU_HUMAN YLYEIAR.light 464.3 488.3 
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APPENDIX III BODY FLUID IDENTIFICATION ACQUISITION PARAMETERS 
Instrument Parameters: 
• Instrumentation: Agilent 6495 Tandem Mass Spectrometer with an Agilent 1290 LC system. 
o Instrument Mode: MRM 
• Agilent AdvancedBio Peptide Map column, 3x100mm, 2.7 µM 
o Mobile Phases:  
 A: Water with 0.2% Formic Acid 
 B: Acetonitrile with 0.2% Formic Acid 
o Needle Wash: 1:1:1:1 Methanol:Acetonitrile:Isopropanol:Water 
o Injection Volume: 2.5 -10 µL 
• System Suitability: Agilent Human Serum Albumin peptide mix with 100 fmol on column.  




Compound Group Compound Name Precursor Ion 
Product 
Ion 
sp|O95274|LYPD3_HUMAN GLDLHGLLAFIQLQQC[+57.0]AQDR.light 766.1 649.3 
sp|O95274|LYPD3_HUMAN GLDLHGLLAFIQLQQC[+57.0]AQDR.light 766.1 905.4 
sp|O95274|LYPD3_HUMAN GLDLHGLLAFIQLQQC[+57.0]AQDR.light 766.1 1037.6 
sp|P02808|STAT_HUMAN FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF.light 1215.2 1074.5 
sp|P02808|STAT_HUMAN FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF.light 1215.2 1229.6 
sp|P02808|STAT_HUMAN FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF.light 1215.2 1687.8 
sp|P02647|APOA1_HUMAN VSFLSALEEYTK.light 693.9 600.8 
sp|P02647|APOA1_HUMAN VSFLSALEEYTK.light 693.9 940.5 
sp|P02647|APOA1_HUMAN VSFLSALEEYTK.light 693.9 1053.5 
sp|P02814|SMR3B_HUMAN GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR.light 1034.5 850.4 
sp|P02814|SMR3B_HUMAN GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR.light 1034.5 1172.6 
sp|P02814|SMR3B_HUMAN GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR.light 1034.5 1228.6 
sp|P80188|NGAL_HUMAN WYVVGLAGNAILR.light 716.4 350.1 
sp|P80188|NGAL_HUMAN WYVVGLAGNAILR.light 716.4 449.2 
sp|P80188|NGAL_HUMAN WYVVGLAGNAILR.light 716.4 884.5 
sp|P15309|PPAP_HUMAN ELSELSLLSLYGIHK.light 568.0 730.4 
sp|P15309|PPAP_HUMAN ELSELSLLSLYGIHK.light 568.0 817.5 
sp|P15309|PPAP_HUMAN ELSELSLLSLYGIHK.light 568.0 930.5 
sp|P04745|AMY1_HUMAN IAEYMNHLIDIGVAGFR.light 640.3 606.3 
sp|P04745|AMY1_HUMAN IAEYMNHLIDIGVAGFR.light 640.3 867.9 
sp|P04745|AMY1_HUMAN IAEYMNHLIDIGVAGFR.light 640.3 903.5 
sp|P04745|AMY1_HUMAN LSGLLDLALGK.light 550.3 729.5 
sp|P04745|AMY1_HUMAN LSGLLDLALGK.light 550.3 899.6 
sp|P04745|AMY1_HUMAN LSGLLDLALGK.light 550.3 986.6 
sp|P02814|SMR3B_HUMAN IPPPPPAPYGPGIFPPPPPQP.light 710.7 535.3 
sp|P02814|SMR3B_HUMAN IPPPPPAPYGPGIFPPPPPQP.light 710.7 729.4 
sp|P02814|SMR3B_HUMAN IPPPPPAPYGPGIFPPPPPQP.light 710.7 1141.6 
sp|P68871|HBB_HUMAN LLVVYPWTQR.light 637.9 687.4 
sp|P68871|HBB_HUMAN LLVVYPWTQR.light 637.9 850.4 
sp|P68871|HBB_HUMAN LLVVYPWTQR.light 637.9 949.5 
sp|P04279|SEMG1_HUMAN DIFSTQDELLVYNK.light 842.9 424.2 
sp|P04279|SEMG1_HUMAN DIFSTQDELLVYNK.light 842.9 523.3 
sp|P04279|SEMG1_HUMAN DIFSTQDELLVYNK.light 842.9 1309.7 
sp|P02647|APOA1_HUMAN LLDNWDSVTSTFSK.light 806.9 569.3 
sp|P02647|APOA1_HUMAN LLDNWDSVTSTFSK.light 806.9 670.3 
sp|P02647|APOA1_HUMAN LLDNWDSVTSTFSK.light 806.9 971.5 
sp|P15309|PPAP_HUMAN FVTLVFR.light 441.3 247.1 
sp|P15309|PPAP_HUMAN FVTLVFR.light 441.3 421.3 
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sp|P15309|PPAP_HUMAN FVTLVFR.light 441.3 635.4 
sp|O60437|PEPL_HUMAN NLLDEIASR.light 515.8 228.1 
sp|O60437|PEPL_HUMAN NLLDEIASR.light 515.8 690.3 
sp|O60437|PEPL_HUMAN NLLDEIASR.light 515.8 803.4 
sp|P02790|HEMO_HUMAN NFPSPVDAAFR.light 610.8 480.3 
sp|P02790|HEMO_HUMAN NFPSPVDAAFR.light 610.8 775.4 
sp|P02790|HEMO_HUMAN NFPSPVDAAFR.light 610.8 959.5 
sp|P07288|KLK3_HUMAN FLRPGDDSSHDLMLLR.light 468.7 536.3 
sp|P07288|KLK3_HUMAN FLRPGDDSSHDLMLLR.light 468.7 575.6 
sp|P07288|KLK3_HUMAN FLRPGDDSSHDLMLLR.light 468.7 760.4 
sp|P01009|A1AT_HUMAN SVLGQLGITK.light 508.3 531.4 
sp|P01009|A1AT_HUMAN SVLGQLGITK.light 508.3 716.4 
sp|P01009|A1AT_HUMAN SVLGQLGITK.light 508.3 829.5 
sp|P02687|MBP_BOVIN DTGILDSLGR.light 523.8 660.4 
sp|P02687|MBP_BOVIN DTGILDSLGR.light 523.8 830.5 
sp|P02687|MBP_BOVIN DTGILDSLGR.heavy 528.8 670.4 
sp|P02687|MBP_BOVIN DTGILDSLGR.heavy 528.8 840.5 
sp|P80188|NGAL_HUMAN MYATIYELK.light 566.3 295.1 
sp|P80188|NGAL_HUMAN MYATIYELK.light 566.3 837.5 
sp|P80188|NGAL_HUMAN MYATIYELK.light 566.3 1000.5 
sp|P68871|HBB_HUMAN SAVTALWGK.light 466.8 574.3 
sp|P68871|HBB_HUMAN SAVTALWGK.light 466.8 675.4 
sp|P68871|HBB_HUMAN SAVTALWGK.light 466.8 774.5 
sp|Q02383|SEMG2_HUMAN DVSQSSISFQIEK.light 734.4 751.4 
sp|Q02383|SEMG2_HUMAN DVSQSSISFQIEK.light 734.4 951.5 
sp|Q02383|SEMG2_HUMAN DVSQSSISFQIEK.light 734.4 1038.5 
sp|P02787|TRFE_HUMAN SASDLTWDNLK.light 625.3 675.3 
sp|P02787|TRFE_HUMAN SASDLTWDNLK.light 625.3 776.4 
sp|P02787|TRFE_HUMAN SASDLTWDNLK.light 625.3 1091.5 
sp|P01009|A1AT_HUMAN LSITGTYDLK.light 555.8 696.4 
sp|P01009|A1AT_HUMAN LSITGTYDLK.light 555.8 797.4 
sp|P01009|A1AT_HUMAN LSITGTYDLK.light 555.8 910.5 
sp|P09228|CYTT_HUMAN ALHFVISEYNK.light 440.9 424.2 
sp|P09228|CYTT_HUMAN ALHFVISEYNK.light 440.9 568.3 
sp|P09228|CYTT_HUMAN ALHFVISEYNK.light 440.9 640.3 
sp|P09228|CYTT_HUMAN IIEGGIYDADLNDER.light 846.9 947.4 
sp|P09228|CYTT_HUMAN IIEGGIYDADLNDER.light 846.9 1110.5 
sp|P09228|CYTT_HUMAN IIEGGIYDADLNDER.light 846.9 1466.6 
sp|P07288|KLK3_HUMAN LSEPAELTDAVK.light 636.8 472.3 
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sp|P07288|KLK3_HUMAN LSEPAELTDAVK.light 636.8 646.4 
sp|P07288|KLK3_HUMAN LSEPAELTDAVK.light 636.8 943.5 
sp|P07476|INVO_HUMAN QEAQLELPEQQVGQPK.light 608.0 505.8 
sp|P07476|INVO_HUMAN QEAQLELPEQQVGQPK.light 608.0 699.3 
sp|P07476|INVO_HUMAN QEAQLELPEQQVGQPK.light 608.0 812.4 
sp|Q9UBG3|CRNN_HUMAN LLDEDHTGTVEFK.light 501.9 294.2 
sp|Q9UBG3|CRNN_HUMAN LLDEDHTGTVEFK.light 501.9 639.3 
sp|Q9UBG3|CRNN_HUMAN LLDEDHTGTVEFK.light 501.9 695.8 
sp|P15309|PPAP_HUMAN FQELESETLK.light 612.3 276.1 
sp|P15309|PPAP_HUMAN FQELESETLK.light 612.3 819.4 
sp|P15309|PPAP_HUMAN FQELESETLK.light 612.3 948.5 
sp|Q9UBG3|CRNN_HUMAN ISPQIQLSGQTEQTQK.light 893.5 793.4 
sp|Q9UBG3|CRNN_HUMAN ISPQIQLSGQTEQTQK.light 893.5 1006.5 
sp|Q9UBG3|CRNN_HUMAN ISPQIQLSGQTEQTQK.light 893.5 1247.6 
sp|P07476|INVO_HUMAN GEVLLPVEHQQQK.light 502.3 553.8 
sp|P07476|INVO_HUMAN GEVLLPVEHQQQK.light 502.3 610.3 
sp|P07476|INVO_HUMAN GEVLLPVEHQQQK.light 502.3 659.9 
sp|P02787|TRFE_HUMAN DGAGDVAFVK.light 489.7 563.4 
sp|P02787|TRFE_HUMAN DGAGDVAFVK.light 489.7 678.4 
sp|P02787|TRFE_HUMAN DGAGDVAFVK.light 489.7 735.4 
sp|Q6UWP8|SBSN_HUMAN ALDGINSGITHAGR.light 461.2 541.8 
sp|Q6UWP8|SBSN_HUMAN ALDGINSGITHAGR.light 461.2 599.3 
sp|Q02383|SEMG2_HUMAN GSISIQTEEQIHGK.light 509.6 461.6 
sp|Q02383|SEMG2_HUMAN GSISIQTEEQIHGK.light 509.6 635.3 
sp|Q02383|SEMG2_HUMAN GSISIQTEEQIHGK.light 509.6 691.9 
sp|P61916|NPC2_HUMAN DC[+57.0]GSVDGVIK.light 525.3 276.1 
sp|P61916|NPC2_HUMAN DC[+57.0]GSVDGVIK.light 525.3 630.4 
sp|P61916|NPC2_HUMAN DC[+57.0]GSVDGVIK.light 525.3 774.4 
sp|Q6UWP8|SBSN_HUMAN FGQGVHHGLSEGWK.light 513.6 603.8 
sp|Q6UWP8|SBSN_HUMAN FGQGVHHGLSEGWK.light 513.6 696.3 
sp|O95274|LYPD3_HUMAN GC[+57.0]VQDEFC[+57.0]TR.light 636.3 827.3 
sp|O95274|LYPD3_HUMAN GC[+57.0]VQDEFC[+57.0]TR.light 636.3 955.4 
sp|O95274|LYPD3_HUMAN GC[+57.0]VQDEFC[+57.0]TR.light 636.3 1054.5 
sp|Q9UBC9|SPRR3_HUMAN VPVPGYTK.light 430.7 381.2 
sp|Q9UBC9|SPRR3_HUMAN VPVPGYTK.light 430.7 565.3 
sp|Q9UBC9|SPRR3_HUMAN VPVPGYTK.light 430.7 664.4 
sp|Q02383|SEMG2_HUMAN GSISIQTEEK.light 546.3 634.3 
sp|Q02383|SEMG2_HUMAN GSISIQTEEK.light 546.3 747.4 
sp|Q02383|SEMG2_HUMAN GSISIQTEEK.light 546.3 834.4 
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sp|P04279|SEMG1_HUMAN QITIPSQEQEHSQK.light 551.6 599.3 
sp|P04279|SEMG1_HUMAN QITIPSQEQEHSQK.light 551.6 706.3 
sp|P61916|NPC2_HUMAN SGINC[+57.0]PIQK.light 508.8 485.3 
sp|P61916|NPC2_HUMAN SGINC[+57.0]PIQK.light 508.8 645.3 
sp|P61916|NPC2_HUMAN SGINC[+57.0]PIQK.light 508.8 759.4 
sp|P07476|INVO_HUMAN HLVQQEGQLEQQER.light 574.6 560.3 
sp|P07476|INVO_HUMAN HLVQQEGQLEQQER.light 574.6 689.3 
sp|P07476|INVO_HUMAN HLVQQEGQLEQQER.light 574.6 920.5 
sp|Q9UBG3|CRNN_HUMAN AHQTGETVTGSGTQTQAGATQTVEQDSSHQTGR.light 839.9 851.4 
sp|Q9UBG3|CRNN_HUMAN AHQTGETVTGSGTQTQAGATQTVEQDSSHQTGR.light 839.9 886.9 
sp|Q9UBG3|CRNN_HUMAN AHQTGETVTGSGTQTQAGATQTVEQDSSHQTGR.light 839.9 1001.5 
sp|O60437|PEPL_HUMAN NQGPQESVVR.light 557.3 243.1 
sp|O60437|PEPL_HUMAN NQGPQESVVR.light 557.3 814.4 
sp|O60437|PEPL_HUMAN NQGPQESVVR.light 557.3 871.5 
sp|Q9UBC9|SPRR3_HUMAN VPEPGC[+57.0]TK.light 444.2 394.7 
sp|Q9UBC9|SPRR3_HUMAN VPEPGC[+57.0]TK.light 444.2 562.3 
sp|Q9UBC9|SPRR3_HUMAN VPEPGC[+57.0]TK.light 444.2 788.4 
sp|O60437|PEPL_HUMAN AQSLQSAK.light 416.7 200.1 
sp|O60437|PEPL_HUMAN AQSLQSAK.light 416.7 546.3 






















K.DGAGDVAFVK.H [215, 224] 
 






Statherin P02808 |STAT 
 




Submaxillary Gland Androgen-Regulated Protein 3B P02814|SMR3B 
 
R.GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR.I [27, 57] 
 
R.IPPPPPAPYGPGIFPPPPPQP - [58, 78] 
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Cystatin SA P09228|CYTT 
 
R.IIEGGIYDADLNDER.V [28, 42] 
 














Neutrophil Gelatinase P80188|NGAL 
 
K.WYVVGLAGNAILR.E [50, 62] 
 






























K.ALDGINSGITHAGR.E [49, 62] 
 
R.FGQGVHHGLSEGWK.E [331, 344] 
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Prostatic Acid Phosphatase P15309|PPAP 
 











Prostate Specific Antigen P07288|KLK3 
 
R.FLRPGDDSSHDLMLLR.L [109, 124] 
 





Semenogelin 2 Q02383|SEMG2 
 
K.GSISIQTEEK.I [311, 320] 
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APPENDIX I: INTERPRETATION GUIDELINES 
INTERPRETATION GUIDELINES 
Introduction: 
The interpretation of data from LC-MS/MS analyses is a matter of professional training and 
expertise. The following objective criteria are to be used by analysts to guide most routine data 
interpretation scenarios. Not every situation, however, may be fully covered by these interpretation 
guidelines. The treatment of samples that appear to fall outside of these guidelines should be 
addressed through discussion with the Technical Reviewer in order to reach agreement on a 
reportable opinion. In the event that agreement on a reportable opinion cannot be reached, the 
laboratory’s Technical Leader should be consulted to issue a final decision on a reportable opinion 
or other course of action. These interpretation guidelines are based upon validation studies, the 
peer-reviewed scientific literature, and professional training and expertise. These interpretation 
guidelines establish a solid framework of quality criteria to ensure that: 
• Conclusions in the casework report are scientifically supported by the analytical data,
including that obtained from appropriate standards and controls;
• Interpretations are made objectively; and
• Interpretations are consistent and accurate from analyst to analyst and case to case.
Evaluation of Controls: 
Internal Positive Control: This control (e.g., bovine myelin basic protein) serves to demonstrate that 
the sample digest (including digestion, denaturation, reduction and alkylation) performed 
successfully for each sample in the batch.  The internal positive control should be evaluated for 
each sample to determine if it meets the laboratory’s established quality criteria. Specifically, both 
the natural targeted peptide peak as well as the heavy labeled peak should be identified based on 
the appearance of two MRM transitions per peptide. Additionally, peaks should fall within two peak 
widths of the acceptable retention times outlined in the table below (± 0.2 min). The area ratio of 
the heavy labeled peptide to the natural peptide should be 15.0 ± 30%.  Area ratios falling outside 
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of this range may indicate the presence of digestion inhibition.  Notes: As the required heavy 
labelled peptide is not currently commercially available, it should be custom synthesized. In 
addition, the purity of commercially available myelin basic protein can vary. As such, the area ratio 
of the heavy labeled peptide to the natural peptide may fluctuate between reagents lots and should 
be monitored by the analyst. However, within a single preparation of these standards, the ratio will 
remain stable. 
1. If there appears to be an injection or other chromatographic problem, the sample should be re-
injected.
2. If the internal positive control fails to generate a peak for the natural/light peptide, or if the ratio
falls to meet the response criteria indicated above, the sample should be considered for re-
extraction.
Protein Peptide Sequence MRM transitions Retention time (min) 
Myelin 
DTGILDSLGR (Light) 523.7 → 660.3, 830.4 5.5 
DTGILDSLGR (Heavy) 528.7 → 670.3, 840.4 5.5 
Reagent (Negative) Control: This control (e.g., a sample processed in parallel with the casework 
samples of a batch but to which no protein source material was added) serves to demonstrate that 
the protein extraction and processing reagents do not contain targeted protein. The negative 
reagent control should be evaluated and meet the laboratory’s quality criteria.  Specifically, the 
negative reagent control should be free of detectible target protein upon analysis. The occurrence 
of more than one targeted peptide peak should be considered an indication of protein 
contamination. Such findings should be considered necessary but not sufficient for failing the 
negative reagent control. The official designation of a failure of the negative reagent control should 
be reviewed and documented by the laboratory’s supervisor or Technical Leader. 
1. If protein contamination is observed in a negative reagent control, acknowledgment of the
contaminant and subsequent actions should be documented in the case file.  In addition, the
analyst should endeavor to determine the point at which the contamination was introduced,
and the scope of the samples affected by the contamination.
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2. If the contaminating source affects all samples in the extraction set, the analysis should be
redone from the point at which the contamination was introduced.
3. If it is unclear at what point the contamination was introduced, the analysis should be repeated
from the protein sample preparation step forward.
4. If additional negative reagent controls were prepared with the batch and these show no sign of
contamination AND the associated samples show no sign of contamination, the incident may
be considered tube-specific. The data already derived from these samples can be used for fluid
identification purposes.
Additional Considerations: 
Carryover – Carryover was observed for Semenogelin-1 and Hemoglobin during the validation 
studies of the analytical method. Accordingly, any elevated signal from these proteins should be 
evaluated in subsequent injections.  A Blank (i.e., neat methanol) can be run after every sample in 
order to wash the column and prevent sample carryover.   
Peak Designation and Peptide Identification 
Proteins are composed of a sequence of amino acids arranged in a linear order.  This allows for 
the prediction, to a given degree of confidence, of the fragmentation pattern and MS/MS spectra 
that will be produced. To enhance the specificity of the method, up to three MRM transitions for 
each peptide are employed.  Detectable peptide peaks are those that meet the following criteria: 
• The peak has a signal to noise ratio greater than 3
• The peak height is greater than 1,000 counts
• The peak for the peptide should fall within two peak widths  (± 0.2 min) from the target
retention time
• The response ratio for the qualifier ions should be within ± 20% of the target. Note: extreme 
low or high signal intensity can result in a deviation from expected ion ratios.
Body Fluid Identification and Reporting Language 
Confirmatory Identification: The presence of at least one confirmatory protein (see Body Fluid 
Specificity Table below) for a body fluid of interest provides a confirmatory indication of the 
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presence of the corresponding targeted biological fluid.  This will be reported as “A confirmatory 
identification of (blood/saliva/semen) was obtained for item…” 
Presumptive Detection: The presence of at least one presumptive protein (see Specificity Table 
below) for a body fluid of interest provides a presumptive indication of the presence of the 
corresponding targeted biological fluid.  This will be reported as “A presumptive indication of 
(vaginal fluid) was obtained for item…” 
Not Detected: In all cases, a failure to detect a minimum of one targeted peptide for any body fluid 
represents a negative result. This will be reported as “No targeted biological fluids were detected”.  
Statements Regarding Human Specificity: Within the context of a confirmatory result, reporting of 
the result as human specific requires the detection of a peptide target unique to humans (see 
Species Specificity Table below).  This will be reported as “the confirmatory identification of human 
(blood/vaginal fluid/saliva/semen) was obtained” 
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Body Fluid Specificity 





Trace levels in some 




Trace levels in some 
saliva/seminal fluid (<2,000 
cts.) 
P02787|TRFE Y Detectable in seminal fluid 
Saliva 
P02808 |STAT Y 
P02814|SMR3B Y 




O95274|LYPD3 Y Consistent trace levels in saliva (<1,000 cts.) 
P80188|NGAL Y Consistent trace levels in saliva (<1,000 cts.) 
O60437|PEPL Y 
P07476|INVO Y Consistent trace levels in saliva (<2,000 cts.) 
Q9UBG3|CRNN Y Consistent trace levels in saliva (<1,000 cts.) 
Q6UWP8|SBSN Y Detectable in saliva 
Q9UBC9|SPRR3 Y Detectable in saliva 
Seminal 
Fluid 
P15309|PPAP Y Detectable in vaginal fluid 
P07288|KLK3 Y Consistent Trace levels in vaginal fluid 
Q02383|SEMG2 Y 
P04279|SEMG1 Y 









P02647|APOA1 LLDNWDSVTSTFSK N Chimpanzee 
P02647|APOA1 VSFLSALEEYTK N Primates 
P68871|HBB LLVVYPWTQR N Primates / mammals 
P68871|HBB SAVTALWGK N Primates / mammals 
P02790|HEMO NFPSPVDAAFR N Orangutan 
P01009|A1AT SVLGQLGITK Y  
P01009|A1AT LSITGTYDLK N Orangutan 
P02787|TRFE SASDLTWDNLK N Chimpanzee 
P02787|TRFE DGAGDVAFVK N Primates 
Saliva 
P02808 |STAT FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF Y  
P02814|SMR3B GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR Y 
 
P02814|SMR3B IPPPPPAPYGPGIFPPPPPQP Y  
P04745|AMY1 IAEYMNHLIDIGVAGFR Y  
P04745|AMY1 LSGLLDLALGK Y  
P09228|CYTT ALHFVISEYNK Y  
P09228|CYTT IIEGGIYDADLNDER Y  
Seminal 
Fluid 
P15309|PPAP ELSELSLLSLYGIHK N Mouse 
P15309|PPAP FVTLVFR N Mouse 
P15309|PPAP FQELESETLK Y  
P07288|KLK3 FLRPGDDSSHDLMLLR Y  
P07288|KLK3 LSEPAELTDAVK Y  
Q02383|SEMG2 GSISIQTEEK N Primates 
Q02383|SEMG2 DVSQSSISFQIEK Y  
Q02383|SEMG2 GSISIQTEEQIHGK N Primates 
P04279|SEMG1 QITIPSQEQEHSQK Y  
P04279|SEMG1 DIFSTQDELLVYNK Y  
P61916|NPC2 DC[+57.0]GSVDGVIK Y  










O95274|LYPD3 GC[+57.0]VQDEFC[+57.0]TR Y  
O95274|LYPD3 GLDLHGLLAFIQLQQC[+57.0]AQDR Y  
P80188|NGAL WYVVGLAGNAILR Y  
P80188|NGAL MYATIYELK Y  
O60437|PEPL NQGPQESVVR Y  
O60437|PEPL NLLDEIASR Y  
O60437|PEPL AQSLQSAK Y  
P07476|INVO GEVLLPVEHQQQK Y  
P07476|INVO QEAQLELPEQQVGQPK N Chimpanzee 
P07476|INVO HLVQQEGQLEQQER Y  
Q9UBG3|CRNN LLDEDHTGTVEFK Y  
Q9UBG3|CRNN ISPQIQLSGQTEQTQK Y  
Q9UBG3|CRNN AHQTGETVTGSGTQTQAGATQTVEQDSSHQTGR Y 
 
Q6UWP8|SBSN ALDGINSGITHAGR Y  
Q6UWP8|SBSN FGQGVHHGLSEGWK Y  
Q9UBC9|SPRR
3 VPVPGYTK Y 
 
Q9UBC9|SPRR
3 VPEPGC[+57.0]TK Y 
 
 
*Data Searched using NCBI Algorithm PHI-BLAST (Pattern Hit Initiated BLAST), Animalia (taxid: 
33208), Non-redundant UniProt KB/SwissProt sequences database, Molecule Type: Protein 
Update date: 2019/03/26, Number of sequences: 471513. 
NOTES: 
Body fluid identification is confirmed through the mass spectral identification of multiple protein 
markers. Those protein markers, in turn, are confirmed through the detection of multiple tryptic 
peptides per protein. Below is a brief description of the biological function each targeted protein.  
Peripheral Blood is identified through the detection of α-1-antitrypsin, hemopexin, apolipoprotein 
A1, Serotransferrin, and hemoglobin subunit beta. α-1-antitrypsin is a non-specific serine protease 
inhibitor found in human plasma. This protein’s primary role is as an inhibitor of neutrophil elastase 
which protects tissues from proteolytic damage (Kolarich et al.; Parfrey et al.).  Hemopexin is 
produced in the liver and found in plasma. This protein is responsible for trapping free heme in 
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plasma as well as iron recycling in the liver (Ascenzi et al.; Liebert).  Apolipoprotein A1 is a 
component of HDL particles and is involved with the transport of cholesterol from tissues (Breslow 
et al.). Serotransferrin is an iron binding protein responsible for the transport of iron from sites of 
absorption and heme degradation to sites of storage and utilization (Aisen et al.; Yang et 
al.). Hemoglobin subunit beta - The metalloprotein hemoglobin is responsible for oxygen transport 
and is the major protein contained within erythrocytes. Hemoglobin exists as a tetramer containing 
two beta chains and two alpha chains (Berg et al.).  
Vaginal Fluid is identified through the detection of neutrophil gelatinase-associated lipocalin, 
cornulin, ly6/PLAUR domain-containing protein 3, periplakin, involucrin, and suprabasin. Neutrophil 
gelatinase-associated lipocalin belongs to the lipocalin family of transport proteins which have been 
associated with innate immunity though iron sequestration (Goetz et al.). As such, this protein can 
be found in tissues prone to exposure to bacterial and other microorganisms including the 
respiratory tract, salivary glands, uterus, and prostate (Goetz et al.; Cowland and Borregaard). 
Cornulin is also expressed in squamous cells where it plays a role in epithelial cell differentiation. 
It may also play a role in mucosal-epithelial immune response. The protein has been characterized 
in the cervix and in esophageal tissues (Contzler et al.; Arnouk et al.). Ly6/PLAUR domain-
containing protein 3 is involved in the regulation between extracellular structural support scaffolding 
and epithelial cell layers (Smith et al.). Suprabasin is expressed in keratinocytes and plays a role 
in epidermal differentiation. It has been reported to be expressed in the uterus as well as the 
esophagus (Park et al.). Involucrin is a component of cornified cell envelope (CE) of stratified 
squamous epithelia and is involved with membrane protein cross-linking (Djian et al.). Periplakin is 
a component of the cornified envelope of keratinocytes. May link the cornified cell envelope to 
desmosomes and intermediate filaments (Ruhrberg et al.).  
Saliva is confirmed through the detection of statherin, submaxillary gland androgen-regulated 
protein 3B, Cystatin SA, and alpha amylase. Statherin, as well as submaxillary gland androgen-
regulated protein 3B, assist in inhibiting potentially harmful calcium phosphate precipitation in saliva 
(Schlesinger and Hay; Hay et al.). Alpha amylase is the most abundant protein found in saliva 
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where it digests starches into glucose and maltose (Ramasubbu et al.). While highly abundant in 
saliva, this protein can be found in a number of alternate body fluids including vaginal fluid, breast 
milk, fecal matter, urine, blood and semen. Cystatin SA is a cysteine protease inhibitor located in 
the cystatin locus. It is found at high levels in saliva and tears. 
Seminal Fluid identification is based off the detection of Epididymal secretory protein E1, prostatic 
acid phosphatase, semenogelin-I/II, and prostate-specific antigen. Epididymal secretory protein E1 
is involved with intracellular cholesterol transporters. It acts in concert with NPC1 and plays an 
important role in the egress of cholesterol from the lysosomal compartment. Prostatic Acid 
Phosphatase (also known as Seminal Acid Phosphatase or SAP) is a glycoprotein secreted by the 
epithelial cells of the prostate gland. It is capable of hydrolyzing phosphate groups from substrate 
molecules (Yam).  SAP is a seminal fluid protein which has seen utility as a clinical marker for 
prostate cancer (Taira et al.). While largely replaced by PSA/p30 for screening purposes, the 
combination of low expression in non-target tissues and assay detection limits makes this protein 
useful as a potential marker of seminal fluid. Semenogelin-I/II are the most abundant proteins in 
seminal plasma and are responsible for the gel-like matrix of human semen. Both isoforms act as 
substrates for prostate specific antigen (p30), where upon lysis, sperm are able to move freely 
through the seminal matrix (Kise et al.; Malm and Hellman). Prostate-Specific Antigen (also known 
as PSA or p30) is a serine protease produced by epithelial cells located in the prostate (Ward et 
al.). The primary function of prostate-specific antigen is to cleave semenogelin-I/II thus creating a 
soluble, liquid medium, for spermatozoa movement (Ward et al.). Prostate-specific antigen has 
been well studied as an indicator for prostate cancer when serum levels reach approximately 4-10 
ng/mL (Basch et al.).  While this protein is not absolutely seminal fluid-specific, the detection limits 
of most assays make it difficult to detect it in whole blood (Keshishian et al.). As a result, this protein 
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APPENDIX J: GENETIC PROFILES OF CASEWORK SAMPLES 














Sample ID: SA01_02.1 Oral swab with semen from a non-vasectomized donor (sperm fraction) 
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Sample ID: SA02_02.1 Oral swab with semen from a vasectomized donor (sperm fraction) 
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APPENDIX K: PROTEIN IDENTIFICATION OF SEMEN POPULATION SAMPLES 















SEMG2 78.69 301 2.39E+09 1350.90 
KLK3 30.65 8 9.74E+06 296.30 
PPAP 20.98 9 3.45E+07 418.30 
06C7294 




SEMG2 80.58 295 3.24E+09 1404.20 
KLK3 34.87 7 7.17E+06 330.50 
PPAP 16.58 6 1.64E+07 421.50 
06C7352 




SEMG2 75.94 290 2.04E+09 1321.70 
KLK3 40.61 22 1.35E+08 482.70 
PPAP 48.45 64 1.82E+08 698.40 
06C9228 




SEMG2 81.27 322 3.00E+09 1366.40 
KLK3 40.61 19 6.87E+07 542.20 
PPAP 36.27 18 6.41E+07 445.70 
06C9237 




SEMG2 69.42 255 1.57E+09 1301.00 
KLK3 39.08 15 2.12E+07 496.90 
PPAP 28.24 24 2.59E+07 540.00 
07C3133 




SEMG2 74.57 222 2.14E+09 1368.50 
KLK3 40.61 16 2.87E+07 484.00 
PPAP 29.27 17 7.84E+07 496.80 
07C3212 




SEMG2 79.21 304 2.06E+09 1364.20 
KLK3 27.97 6 3.78E+06 445.10 
PPAP 12.18 3 3.21E+06 331.30 
08C3217 




SEMG2 76.46 246 2.12E+09 1373.50 
KLK3 34.87 9 1.44E+07 456.70 
PPAP 32.12 10 1.42E+07 384.00 
09C2531 




SEMG2 71.65 153 1.05E+09 1236.90 
KLK3 19.54 4 2.48E+06 478.80 
PPAP 22.28 8 9.01E+06 412.70 
17_08_505 




SEMG2 72.16 188 6.38E+08 1209.20 
KLK3 21.07 5 2.88E+06 385.80 
PPAP 15.28 5 3.16E+06 305.40 
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SEMG2 65.81 172 5.57E+08 1112.30 
KLK3 40.61 18 4.07E+07 469.80 
PPAP 20.98 16 4.46E+07 412.40 
17_12_513 




SEMG2 79.38 265 2.39E+09 1283.00 
KLK3 30.27 10 1.64E+07 469.00 
PPAP 20.98 9 3.29E+07 418.40 
18_01_691 




SEMG2 77.66 243 2.19E+09 1189.60 
KLK3 40.61 16 4.91E+07 439.40 
PPAP 39.38 24 8.46E+07 522.00 
18_03_543 




SEMG2 74.23 283 2.48E+09 1345.20 
KLK3 30.27 12 1.99E+07 460.20 
PPAP 27.72 26 3.08E+07 573.80 
18_03_579 




SEMG2 78.52 253 2.49E+09 1362.80 
KLK3 40.61 23 1.38E+08 619.50 
PPAP 36.79 28 1.21E+08 533.30 
18_03_579 




SEMG2 77.49 219 2.77E+09 1417.90 
KLK3 14.94 4 5.54E+06 453.50 
PPAP 20.98 7 7.11E+06 409.80 
18_03_615 




SEMG2 83.33 319 3.82E+09 1400.10 
KLK3 31.80 12 2.74E+07 479.60 
PPAP 28.24 17 5.61E+07 440.70 
18_09_594 




SEMG2 80.58 287 3.43E+09 1461.10 
KLK3 40.61 14 3.83E+07 354.10 
PPAP 25.39 14 5.19E+07 450.00 
19_02_507 




SEMG2 82.47 249 2.16E+09 1409.10 
KLK3 37.93 15 8.07E+07 478.90 
PPAP 44.04 20 4.97E+07 441.00 
19_03_518 




SEMG2 77.49 285 2.61E+09 1298.90 
KLK3 40.23 8 1.12E+07 480.00 
PPAP 13.47 4 6.17E+06 396.30 
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SEMG2 74.40 202 2.29E+09 1326.60 
KLK3 33.33 11 4.13E+07 457.90 
PPAP 31.09 25 6.81E+07 466.60 
19_07_577 




SEMG2 76.98 255 2.22E+09 1390.40 
KLK3 31.80 11 2.74E+07 490.40 
PPAP 20.98 11 2.78E+07 411.80 
19_09_609 




SEMG2 79.04 243 3.10E+09 1383.80 
KLK3 40.61 16 5.68E+07 318.90 
PPAP 38.60 20 7.09E+07 441.50 
19_10_584 




SEMG2 74.40 191 1.11E+09 1270.00 
KLK3 21.84 6 3.25E+06 379.90 
PPAP 23.83 13 1.23E+07 334.60 
19_11_614 




SEMG2 73.20 231 2.59E+09 1371.80 
KLK3 23.37 6 8.93E+06 237.90 
PPAP 12.18 4 3.72E+06 382.50 
19_12_573 




SEMG2 80.24 264 2.80E+09 1375.90 
KLK3 31.80 8 1.82E+07 470.60 
PPAP 20.98 7 2.02E+07 405.00 
20_02_628 




SEMG2 75.43 258 2.52E+09 1427.50 
KLK3 39.08 15 4.04E+07 499.10 
PPAP 20.98 7 2.15E+07 400.40 
20_02_628 




SEMG2 75.43 209 1.44E+09 1303.00 
KLK3 38.70 11 1.91E+07 462.70 
PPAP 24.87 14 2.75E+07 402.10 
20_02_694 




SEMG2 78.35 209 2.07E+09 1247.70 
KLK3 11.49 2 2.26E+05 68.80 
PPAP 13.47 4 1.70E+06 245.40 
20_04_559 




SEMG2 79.72 262 3.08E+09 1491.40 
KLK3 33.33 10 2.66E+07 469.40 
PPAP 20.98 8 3.14E+07 472.10 
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SEMG2 80.24 250 2.70E+09 1417.20 
KLK3 41.38 33 2.25E+08 600.60 
PPAP 48.45 54 4.32E+08 669.40 
31978_02 




SEMG2 82.30 295 3.56E+09 1391.60 
KLK3 40.61 21 1.59E+08 503.70 
PPAP 43.78 30 1.84E+08 585.10 
31978_03 




SEMG2 79.72 247 2.67E+09 1360.90 
KLK3 39.08 20 1.32E+08 577.20 
PPAP 48.19 40 1.42E+08 576.20 
31978_04 




SEMG2 82.30 290 2.84E+09 1353.90 
KLK3 37.93 12 1.70E+07 343.50 
PPAP 28.24 12 7.01E+07 536.60 
31978_05 




SEMG2 78.35 301 4.64E+09 1395.00 
KLK3 27.20 8 1.69E+07 478.60 
PPAP 16.58 5 1.93E+07 433.30 
31978-06 




SEMG2 70.6 163 9.09E+08 1359.8 
KLK3 14.2 4 3.77E+06 443.7 
PPAP 4.4 2 1.94E+06 380.4 
31978-07 




SEMG2 76.6 305 1.20E+09 1273.6 
KLK3 0 0 0 0 
PPAP 3.1 2 1.43E+05 206.5 
31978-08 




SEMG2 80.8 272 3.93E+09 1351.5 
KLK3 8.8 2 3.08E+06 286.4 
PPAP 25.6 9 8.28E+06 373.4 
31978-09 




SEMG2 84.4 327 4.36E+09 1315.8 
KLK3 27.2 9 1.94E+07 423.4 
PPAP 25.4 10 2.40E+07 462.3 
31978-10 




SEMG2 74.1 289 1.97E+09 1350.6 
KLK3 31.8 10 1.25E+07 432.5 
PPAP 21 8 1.11E+07 439 
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SEMG2 80.1 272 2.66E+09 1349.2 
KLK3 31.8 9 1.38E+07 297.3 
PPAP 21 8 1.47E+07 386.7 
31978-12 




SEMG2 78.2 310 2.42E+09 1265.8 
KLK3 33.3 14 2.30E+07 493.8 
PPAP 16.6 7 9.46E+06 405.3 
31978-13 




SEMG2 82.1 282 4.61E+09 1332.5 
KLK3 36 9 1.02E+07 409.4 
PPAP 21 6 1.27E+07 438.8 
31978-14 




SEMG2 79.2 323 4.93E+09 1342.4 
KLK3 33.3 16 7.47E+07 542.6 
PPAP 25.4 11 8.03E+07 461.9 
31978-15 




SEMG2 80.2 258 3.38E+09 1354.2 
KLK3 40.2 12 2.47E+07 406.3 
PPAP 25.4 10 5.91E+07 465.2 
31978-16 




SEMG2 77.7 295 2.03E+09 1332.4 
KLK3 37.9 11 1.04E+07 470.1 
PPAP 16.6 5 2.97E+06 378.3 
31978-17 




SEMG2 79.6 266 2.57E+09 1417.2 
KLK3 20.7 6 6.00E+06 309 
PPAP 11.4 2 3.17E+06 313.1 
31978-18 




SEMG2 85.6 331 2.59E+09 1354.2 
KLK3 33.4 30 5.85E+07 605.3 
PPAP 37.2 11 3.61E+07 517.1 
31978_19 




SEMG2 82.13 321 3.37E+09 1443.80 
KLK3 40.61 23 1.42E+08 564.90 
PPAP 53.63 61 2.28E+08 687.20 
31978_20 




SEMG2 83.16 260 3.08E+09 1359.00 
KLK3 39.46 21 8.12E+07 543.60 
PPAP 45.08 31 1.49E+08 574.00 
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SEMG2 79.38 322 2.14E+09 1381.20 
KLK3 40.23 13 5.41E+07 470.60 
PPAP 46.63 29 6.43E+07 567.00 
20_05_510 




SEMG2 76.80 225 2.26E+09 1300.60 
KLK3 40.23 17 6.67E+07 502.90 
PPAP 40.41 27 1.03E+08 593.70 
20_05_515 




SEMG2 69.76 166 9.70E+08 1370.80 
KLK3 9.96 5 3.50E+06 434.40 
PPAP 3.63 1 7.58E+05 231.90 
20_05_522 




SEMG2 79.38 246 2.60E+09 1396.60 
KLK3 41.76 24 1.57E+08 584.10 
PPAP 39.12 27 1.09E+08 546.10 
20_05_523 




SEMG2 76.12 271 4.42E+09 1424.40 
KLK3 44.83 27 1.61E+08 705.00 




















SEMG2 74.57 227 1.78E+09 1360.80 
KLK3 14.18 5 3.64E+06 460.40 
PPAP 3.63 1 3.76E+05 240.70 
19_09_537 
(Vasectomized) 




SEMG2 79.38 299 2.72E+09 1391.20 
KLK3 18.39 7 1.07E+07 443.00 
PPAP 16.58 6 7.01E+06 307.60 
19_10_565 
(Vasectomized) 




SEMG2 76.46 210 1.63E+09 1383.20 
KLK3 23.75 8 1.27E+07 483.60 
PPAP 20.98 9 1.08E+07 428.90 
17_04_533 
(Vasectomized) 




SEMG2 76.29 308 2.65E+09 1375.90 
KLK3 16.86 5 5.24E+06 479.30 
PPAP 11.66 3 3.17E+06 358.10 
17_02_589 
(Vasectomized) 




SEMG2 82.65 302 2.71E+09 1350.80 
KLK3 12.26 2 7.74E+05 137.50 




APPENDIX L: PROTEIN IDENTIFICATION OF SALIVA POPULATION SAMPLES 
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Basic Salivary 2 45.43 31 1.05E+08 757.10 
Basic Salivary 3 64.10 78 3.61E+08 976.40 
Basic Salivary 4 45.16 42 7.03E+07 616.60 
Salivary Acidic 1/2 90.36 156 7.62E+08 928.70 
Statherin 54.84 145 2.09E+08 557.80 
Submaxillary Gland 72.15 76 1.43E+08 496.10 
Histatin 1 66.67 71 6.83E+07 482.60 
Histatin 3 62.74 15 1.66E+07 578.90 
Cystatin-SN 30.50 13 1.26E+07 424.60 
Alpha-Amylase 1 9.59 6 1.86E+06 502.40 
1995 




Basic Salivary 2 85.10 97 2.21E+08 735.90 
Basic Salivary 3 81.55 96 4.82E+08 824.20 
Basic Salivary 4 64.52 61 2.32E+08 595.30 
Salivary Acidic 1/2 90.36 126 7.98E+08 798.10 
Statherin 45.16 53 4.42E+07 397.60 
Submaxillary Gland 72.15 80 1.84E+08 500.00 
Histatin 1 43.86 45 3.62E+07 564.90 
Histatin 3 31.37 4 1.76E+06 319.50 
Cystatin-SN 11.35 6 2.74E+06 382.30 
Alpha-Amylase 1 5.28 4 6.03E+05 234.00 
2407 




Basic Salivary 2 45.91 19 4.88E+07 536.50 
Basic Salivary 3 73.79 76 5.14E+08 927.20 
Basic Salivary 4 26.45 12 1.63E+07 560.60 
Salivary Acidic 1/2 90.36 146 1.36E+09 809.90 
Statherin 54.84 119 2.81E+08 544.90 
Submaxillary Gland 72.15 98 4.70E+08 609.00 
Histatin 1 47.37 104 1.87E+08 567.70 
Histatin 3 60.78 7 4.63E+06 384.00 
Cystatin-SN 19.86 4 9.64E+05 424.70 
Alpha-Amylase 1 4.89 3 7.63E+05 376.60 
3955 




Basic Salivary 2 45.43 26 1.23E+08 674.50 
Basic Salivary 3 70.87 61 3.03E+08 872.50 
Basic Salivary 4 51.29 51 2.15E+08 1024.80 
Salivary Acidic 1/2 90.36 149 1.33E+09 923.30 
Statherin 66.13 96 2.07E+08 482.40 
Submaxillary Gland 72.15 107 7.15E+08 587.70 
Histatin 1 45.61 90 1.58E+08 555.00 
Histatin 3 21.57 3 1.06E+06 338.50 
Cystatin-SN 10.64 4 1.60E+06 408.90 





















Basic Salivary 2 38.70 14 4.16E+07 631.70 
Basic Salivary 3 76.70 79 6.55E+08 1008.40 
Basic Salivary 4 34.52 22 8.05E+07 658.80 
Salivary Acidic 1/2 90.36 131 1.50E+09 961.50 
Statherin 54.84 109 3.37E+08 623.00 
Submaxillary Gland 72.15 80 5.42E+08 617.30 
Histatin 1 66.67 105 2.51E+08 602.10 
Histatin 3 62.74 14 1.58E+07 405.20 
Cystatin-SN 5.67 1 2.18E+05 307.50 
Alpha-Amylase 1 2.15 1 8.82E+05 371.40 
4970 




Basic Salivary 2 93.03 140 5.78E+08 1068.00 
Basic Salivary 3 6.84 1 2.79E+05 125.50 
Basic Salivary 4 63.23 65 1.49E+08 674.50 
Salivary Acidic 1/2 81.32 91 3.01E+08 823.90 
Statherin 54.84 62 7.11E+07 395.70 
Submaxillary Gland 72.15 91 2.47E+08 504.00 
Histatin 1 64.91 89 1.09E+08 502.80 
Histatin 3 62.74 17 1.65E+07 559.10 
Cystatin-SN 13.48 3 7.40E+05 365.20 
Alpha-Amylase 1 0.00 0 0.00E+00 0.00 
5711 




Basic Salivary 2 42.31 20 5.01E+07 685.00 
Basic Salivary 3 71.20 77 4.72E+08 927.00 
Basic Salivary 4 41.61 17 6.32E+07 513.40 
Salivary Acidic 1/2 90.36 161 1.65E+09 881.30 
Statherin 54.84 118 4.10E+08 537.60 
Submaxillary Gland 72.15 100 8.47E+08 633.40 
Histatin 1 47.37 107 2.05E+08 582.40 
Histatin 3 41.18 5 1.88E+06 377.30 
Cystatin-SN 13.48 3 2.25E+06 440.40 
Alpha-Amylase 1 2.15 1 6.11E+05 450.50 
6003 




Basic Salivary 2 90.14 103 3.56E+08 786.40 
Basic Salivary 3 73.79 54 1.98E+08 783.50 
Basic Salivary 4 53.87 58 1.25E+08 635.20 
Salivary Acidic 1/2 90.36 122 8.03E+08 701.00 
Statherin 54.84 114 1.94E+08 506.30 
Submaxillary Gland 72.15 94 5.19E+08 543.90 
Histatin 1 47.37 91 1.36E+08 568.60 
Histatin 3 60.78 13 9.74E+06 470.30 
Cystatin-SN 30.50 13 8.03E+06 482.50 





















Basic Salivary 2 44.71 22 1.23E+08 597.30 
Basic Salivary 3 58.90 62 4.93E+08 1051.10 
Basic Salivary 4 74.84 89 8.56E+08 1027.20 
Salivary Acidic 1/2 90.36 142 9.72E+08 744.30 
Statherin 66.13 106 2.63E+08 527.70 
Submaxillary Gland 67.09 107 5.36E+08 537.30 
Histatin 1 45.61 69 1.31E+08 532.40 
Histatin 3 21.57 4 2.12E+06 299.50 
Cystatin-SN 13.48 9 1.22E+07 520.10 
Alpha-Amylase 1 4.50 2 8.99E+05 499.30 
6066 




Basic Salivary 2 43.75 21 1.11E+08 592.30 
Basic Salivary 3 19.94 4 6.27E+06 425.80 
Basic Salivary 4 67.10 80 3.95E+08 839.80 
Salivary Acidic 1/2 18.07 5 1.53E+07 529.50 
Statherin 66.13 102 2.70E+08 535.70 
Submaxillary Gland 72.15 113 7.10E+08 546.50 
Histatin 1 54.39 117 3.03E+08 550.70 
Histatin 3 60.78 12 7.08E+06 353.10 
Cystatin-SN 10.64 4 1.64E+06 395.90 
Alpha-Amylase 1 2.15 1 7.39E+05 485.40 
6163 




Basic Salivary 2 54.09 51 3.09E+08 867.80 
Basic Salivary 3 46.72 34 1.70E+08 806.90 
Basic Salivary 4 58.39 54 2.72E+08 714.50 
Salivary Acidic 1/2 90.36 83 6.72E+08 735.90 
Statherin 53.22 56 8.83E+07 493.10 
Submaxillary Gland 72.15 94 2.88E+08 635.20 
Histatin 1 66.67 96 1.47E+08 550.80 
Histatin 3 60.78 9 1.88E+07 554.70 
Cystatin-SN 11.35 2 8.45E+05 395.40 
Alpha-Amylase 1 2.15 1 4.00E+05 302.30 
6166 




Basic Salivary 2 50.96 34 1.02E+08 651.30 
Basic Salivary 3 73.79 67 3.06E+08 788.40 
Basic Salivary 4 37.74 36 9.86E+07 584.90 
Salivary Acidic 1/2 90.36 118 6.54E+08 744.70 
Statherin 54.84 100 1.30E+08 545.90 
Submaxillary Gland 72.15 93 3.12E+08 521.60 
Histatin 1 45.61 68 1.07E+08 509.30 
Histatin 3 58.82 6 1.98E+06 450.60 
Cystatin-SN 18.44 7 1.32E+06 328.90 
Alpha-Amylase 1 4.89 2 1.03E+06 454.10 
398 












Basic Salivary 2 83.41 127 5.17E+08 867.20 
Basic Salivary 3 54.42 20 9.01E+07 767.90 
Basic Salivary 4 77.10 94 6.91E+08 895.80 
Salivary Acidic 1/2 90.36 91 4.43E+08 685.20 
Statherin 50.00 76 1.90E+08 510.60 
Submaxillary Gland 72.15 78 4.53E+08 546.00 
Histatin 1 45.61 49 7.33E+07 480.40 
Histatin 3 0.00 0.00 0.00E+00 0.00 
Cystatin-SN 0.00 0.00 0.00E+00 0.00 
Alpha-Amylase 1 4.89 2 6.38E+05 385.60 
6238 




Basic Salivary 2 44.23 18 9.76E+07 699.00 
Basic Salivary 3 73.46 65 5.06E+08 823.90 
Basic Salivary 4 57.10 61 3.59E+08 1068.20 
Salivary Acidic 1/2 18.07 5 9.13E+06 558.50 
Statherin 54.84 87 2.49E+08 528.30 
Submaxillary Gland 72.15 87 7.00E+08 578.80 
Histatin 1 47.37 82 1.34E+08 565.90 
Histatin 3 0 0 0.00E+00 0 
Cystatin-SN 18.44 3 1.44E+06 411.30 
Alpha-Amylase 1 4.89 2 7.70E+05 419.30 
6239 




Basic Salivary 2 2.40 1 5.99E+06 443.70 
Basic Salivary 3 62.39 39 1.48E+08 765.50 
Basic Salivary 4 55.47 36 1.00E+08 525.50 
Salivary Acidic 1/2 81.93 99 5.29E+08 662.80 
Statherin 61.29 70 7.26E+07 425.70 
Submaxillary Gland 67.09 56 4.63E+08 500.00 
Histatin 1 50.88 24 1.55E+07 418.90 
Histatin 3 0 0 0.00E+00 0 
Cystatin-SN 24.11 6 1.49E+06 403.30 
Alpha-Amylase 1 2.74 2 6.76E+05 370.30 
6260 




Basic Salivary 2 88.46 77 1.57E+08 715.20 
Basic Salivary 3 70.87 67 2.43E+08 841.50 
Basic Salivary 4 49.03 42 6.76E+07 628.90 
Salivary Acidic 1/2 21.08 7 5.33E+06 283.40 
Statherin 69.35 127 2.86E+08 491.00 
Submaxillary Gland 72.15 106 4.79E+08 583.40 
Histatin 1 47.37 96 1.10E+08 550.70 
Histatin 3 60.78 9 1.03E+07 473.80 
Cystatin-SN 12.06 2 2.75E+06 443.30 
Alpha-Amylase 1 2.15 1 4.18E+05 381.40 
399 
Sample 

















Basic Salivary 2 18.75 10 4.00E+06 299.10 
Basic Salivary 3 68.95 49 3.36E+08 752.90 
Basic Salivary 4 30.00 21 2.39E+07 438.60 
Salivary Acidic 1/2 87.35 94 5.36E+08 707.80 
Statherin 43.55 55 7.17E+07 460.50 
Submaxillary Gland 67.09 79 7.37E+08 500.40 
Histatin 1 42.10 29 2.89E+07 441.10 
Histatin 3 0 0 0.00E+00 0 
Cystatin-SN 0 0 0.00E+00 0 
Alpha-Amylase 1 2.74 2 9.66E+05 356.80 
6343 




Basic Salivary 2 59.62 47 1.77E+08 921.80 
Basic Salivary 3 55.66 38 2.03E+08 792.00 
Basic Salivary 4 63.55 48 2.70E+08 961.20 
Salivary Acidic 1/2 90.36 94 9.83E+08 1105.80 
Statherin 67.74 101 1.52E+08 527.40 
Submaxillary Gland 72.15 93 4.47E+08 559.50 
Histatin 1 66.67 99 2.87E+08 569.90 
Histatin 3 60.78 15 7.26E+07 670.20 
Cystatin-SN 18.44 6 3.09E+06 466.10 
Alpha-Amylase 1 7.04 3 1.18E+06 497.70 
6462 




Basic Salivary 2 25.48 10 2.19E+07 449.20 
Basic Salivary 3 67.96 70 7.75E+08 924.40 
Basic Salivary 4 53.87 45 3.74E+08 867.70 
Salivary Acidic 1/2 90.36 120 1.42E+09 734.20 
Statherin 51.61 75 1.28E+08 502.10 
Submaxillary Gland 72.15 92 4.31E+08 600.30 
Histatin 1 66.67 80 1.08E+08 535.10 
Histatin 3 58.82 7 2.46E+06 446.70 
Cystatin-SN 0.00 0.00 0.00E+00 0 
Alpha-Amylase 1 4.31 2 1.14E+06 501.80 
6472 




Basic Salivary 2 51.44 34 3.71E+07 583.20 
Basic Salivary 3 60.52 47 1.86E+08 741.00 
Basic Salivary 4 38.71 34 8.53E+07 546.50 
Salivary Acidic 1/2 86.75 147 6.83E+08 836.70 
Statherin 50.00 114 2.56E+08 565.20 
Submaxillary Gland 67.09 95 2.45E+08 494.80 
Histatin 1 42.10 16 2.98E+07 421.10 
Histatin 3 0 0 0.00E+00 0 
Cystatin-SN 30.50 9 4.05E+06 309.40 





















Basic Salivary 2 21.63 11 1.98E+07 471.90 
Basic Salivary 3 69.58 54 2.91E+08 768.30 
Basic Salivary 4 65.16 57 1.62E+08 598.30 
Salivary Acidic 1/2 21.08 12 7.36E+07 623.40 
Statherin 66.13 105 2.53E+08 523.70 
Submaxillary Gland 67.09 134 1.08E+09 540.80 
Histatin 1 50.88 50 7.65E+07 557.30 
Histatin 3 0 0 0.00E+00 0 
Cystatin-SN 15.60 5 6.60E+06 518.30 
Alpha-Amylase 1 2.15 1 3.51E+05 278.30 
6510 




Basic Salivary 2 47.84 30 4.51E+07 624.60 
Basic Salivary 3 67.64 36 8.87E+07 760.50 
Basic Salivary 4 47.74 21 3.13E+07 472.80 
Salivary Acidic 1/2 90.36 85 4.21E+08 903.00 
Statherin 58.06 100 1.81E+08 412.90 
Submaxillary Gland 72.15 88 3.36E+08 542.50 
Histatin 1 43.86 23 9.27E+07 605.20 
Histatin 3 31.37 3 1.19E+06 394.50 
Cystatin-SN 24.82 5 2.52E+06 414.30 
Alpha-Amylase 1 2.15 1 3.44E+05 309.80 
6554 




Basic Salivary 2 51.20 22 5.44E+07 589.70 
Basic Salivary 3 73.14 68 3.75E+08 859.20 
Basic Salivary 4 46.45 39 1.47E+08 708.10 
Salivary Acidic 1/2 90.36 117 1.04E+09 966.20 
Statherin 69.35 120 1.76E+08 447.40 
Submaxillary Gland 72.15 89 6.97E+08 557.90 
Histatin 1 45.61 100 1.77E+08 515.70 
Histatin 3 58.82 12 6.98E+06 588.50 
Cystatin-SN 13.48 3 9.48E+05 393.90 
Alpha-Amylase 1 2.15 1 4.57E+05 375.50 
6557 




Basic Salivary 2 71.39 41 3.16E+07 506.10 
Basic Salivary 3 73.79 73 4.35E+08 787.40 
Basic Salivary 4 41.61 29 8.25E+07 516.30 
Salivary Acidic 1/2 90.36 154 1.06E+09 801.10 
Statherin 54.84 115 2.36E+08 529.10 
Submaxillary Gland 72.15 108 6.68E+08 523.40 
Histatin 1 66.67 92 1.47E+08 505.30 
Histatin 3 45.10 3 5.44E+05 276.70 
Cystatin-SN 0.00 0.00 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 9.23E+05 478.00 
SA_01 




Basic Salivary 2 50.48 29 5.34E+07 651.60 
Basic Salivary 3 75.73 41 1.25E+08 776.10 
Basic Salivary 4 51.94 26 7.05E+07 521.30 
Salivary Acidic 1/2 82.53 80 4.50E+08 964.30 
Statherin 66.13 102 1.47E+08 477.40 
Submaxillary Gland 72.15 63 2.45E+08 507.50 
Histatin 1 64.91 62 1.14E+08 527.70 
Histatin 3 62.74 31 1.30E+08 683.30 
Cystatin-SN 13.48 5 1.93E+06 331.50 



















Basic Salivary 2 7.21 2 1.19E+06 132.00 
Basic Salivary 3 27.07 13 3.16E+07 555.00 
Basic Salivary 4 0.00 0 0.00E+00 0.00 
Salivary Acidic 1/2 62.65 29 1.62E+08 646.60 
Statherin 53.22 51 6.16E+07 542.10 
Submaxillary Gland 72.15 53 9.14E+07 493.70 
Histatin 1 63.16 13 5.14E+06 277.60 
Histatin 3 62.74 17 4.17E+07 597.90 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 2.51E+05 250.40 
IR2 




Basic Salivary 2 55.29 26 9.50E+07 791.20 
Basic Salivary 3 70.55 51 3.01E+08 959.80 
Basic Salivary 4 51.61 38 7.10E+07 597.80 
Salivary Acidic 1/2 90.36 100 8.33E+08 999.10 
Statherin 67.74 176 5.48E+08 535.50 
Submaxillary Gland 72.15 116 9.29E+08 580.00 
Histatin 1 63.16 31 4.62E+07 529.20 
Histatin 3 0.00 0 0.00E+00 0.0 
Cystatin-SN 12.06 3 1.25E+06 441.60 
Alpha-Amylase 1 0.00 0 0.00E+00 0.0 
IR3 




Basic Salivary 2 6.01 3 2.97E+06 445.70 
Basic Salivary 3 75.40 52 1.67E+08 815.50 
Basic Salivary 4 11.29 3 1.06E+06 239.30 
Salivary Acidic 1/2 90.36 95 6.05E+08 743.80 
Statherin 69.35 93 1.07E+08 424.70 
Submaxillary Gland 72.15 75 5.31E+08 496.40 
Histatin 1 45.61 40 2.62E+07 468.40 
Histatin 3 54.90 3 5.81E+05 374.70 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 4.53E+05 351.90 
IR4 




Basic Salivary 2 57.93 24 2.28E+07 463.30 
Basic Salivary 3 66.67 39 8.67E+07 563.10 
Basic Salivary 4 50.00 21 1.69E+07 547.90 
Salivary Acidic 1/2 90.36 74 3.77E+08 737.00 
Statherin 69.35 94 7.75E+07 370.20 
Submaxillary Gland 72.15 78 3.82E+08 545.80 
Histatin 1 64.91 40 3.93E+07 492.70 
Histatin 3 60.78 9 8.94E+06 520.60 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 1.65E+05 216.80 
402 
 















Basic Salivary 2 51.68 29 2.81E+07 485.20 
Basic Salivary 3 68.95 31 7.42E+07 768.30 
Basic Salivary 4 38.39 18 1.75E+07 419.00 
Salivary Acidic 1/2 8.43 4 2.02E+07 274.80 
Statherin 66.13 55 2.54E+07 412.60 
Submaxillary Gland 72.15 54 1.31E+08 543.50 
Histatin 1 33.33 5 1.10E+06 291.30 
Histatin 3 17.65 1 6.24E+04 82.80 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 0.00 0 0.00E+00 0.00 
IR6 




Basic Salivary 2 47.84 18 4.32E+07 430.50 
Basic Salivary 3 55.66 34 2.97E+08 815.40 
Basic Salivary 4 85.42 77 6.00E+08 888.90 
Salivary Acidic 1/2 89.76 108 6.06E+08 692.30 
Statherin 62.90 85 1.34E+08 536.30 
Submaxillary Gland 69.62 130 1.11E+09 620.20 
Histatin 1 24.56 7 1.10E+07 422.80 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 0.00 0 0.00E+00 0.00 
IR7 




Basic Salivary 2 46.15 24 3.50E+07 727.40 
Basic Salivary 3 44.44 27 1.04E+08 834.50 
Basic Salivary 4 29.68 14 3.14E+07 549.10 
Salivary Acidic 1/2 90.36 91 4.58E+08 802.30 
Statherin 61.29 139 3.17E+08 545.00 
Submaxillary Gland 72.15 79 3.39E+08 517.90 
Histatin 1 66.67 53 7.43E+07 535.40 
Histatin 3 62.74 8 1.63E+07 568.00 
Cystatin-SN 5.67 2 1.61E+06 414.50 
Alpha-Amylase 1 2.15 1 2.02E+05 290.30 
IR8 




Basic Salivary 2 0 0 0.00E+00 0 
Basic Salivary 3 41.60 22 4.68E+07 815.90 
Basic Salivary 4 25.81 10 8.11E+06 529.40 
Salivary Acidic 1/2 90.36 78 4.75E+08 904.30 
Statherin 58.06 96 1.58E+08 480.80 
Submaxillary Gland 72.15 65 2.26E+08 568.40 
Histatin 1 63.16 29 2.26E+07 453.10 
Histatin 3 62.74 15 3.45E+07 567.20 
Cystatin-SN 5.67 2 9.82E+05 337.20 




















Basic Salivary 2 0 0 0.00E+00 0 
Basic Salivary 3 40.74 15 2.33E+07 576.80 
Basic Salivary 4 12.90 3 1.05E+06 145.00 
Salivary Acidic 1/2 90.36 76 2.53E+08 679.30 
Statherin 58.06 55 1.77E+07 309.70 
Submaxillary Gland 72.15 49 1.54E+08 539.50 
Histatin 1 66.67 16 3.89E+06 395.10 
Histatin 3 49.02 5 3.21E+06 496.50 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 2.38E+05 307.50 
IR10 




Basic Salivary 2 30.05 19 2.59E+07 458.80 
Basic Salivary 3 54.99 32 7.78E+07 549.40 
Basic Salivary 4 41.70 27 5.73E+07 436.40 
Salivary Acidic 1/2 83.73 127 5.30E+08 720.90 
Statherin 61.29 65 4.53E+07 418.30 
Submaxillary Gland 72.15 140 1.18E+09 581.10 
Histatin 1 36.84 10 7.23E+06 415.00 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 29.79 8 1.33E+06 286.30 
Alpha-Amylase 1 3.13 2 1.95E+06 555.00 
IR11 




Basic Salivary 2 78.37 33 5.22E+07 695.40 
Basic Salivary 3 21.37 14 8.63E+06 839.40 
Basic Salivary 4 0.00 0 0.00E+00 0.00 
Salivary Acidic 1/2 69.28 34 7.56E+07 665.90 
Statherin 67.74 58 6.92E+07 439.50 
Submaxillary Gland 72.15 29 2.08E+07 429.80 
Histatin 1 61.40 19 7.75E+06 443.40 
Histatin 3 62.74 17 1.67E+07 626.70 
Cystatin-SN 5.67 1 7.77E+04 222.80 
Alpha-Amylase 1 2.15 1 1.74E+05 138.20 
IR12 




Basic Salivary 2 87.98 49 3.90E+07 572.70 
Basic Salivary 3 66.95 45 1.43E+08 738.70 
Basic Salivary 4 43.87 26 1.90E+07 425.90 
Salivary Acidic 1/2 90.36 87 4.24E+08 712.80 
Statherin 69.35 158 3.37E+08 480.40 
Submaxillary Gland 72.15 79 3.10E+08 570.80 
Histatin 1 61.40 56 3.63E+07 439.90 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 5.67 1 1.71E+05 333.20 



















Basic Salivary 2 54.81 19 2.48E+07 460.70 
Basic Salivary 3 74.76 44 1.45E+08 806.70 
Basic Salivary 4 51.94 22 7.46E+07 573.40 
Salivary Acidic 1/2 83.13 70 1.91E+08 713.50 
Statherin 51.61 52 3.40E+07 401.40 
Submaxillary Gland 65.82 59 1.09E+08 501.20 
Histatin 1 35.09 10 4.54E+06 414.90 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 2.37E+05 270.60 
IR14 




Basic Salivary 2 2.40 1 2.70E+05 283.40 
Basic Salivary 3 57.60 24 4.88E+07 533.80 
Basic Salivary 4 18.71 8 7.22E+06 328.70 
Salivary Acidic 1/2 83.73 139 6.06E+08 737.40 
Statherin 64.52 80 7.60E+07 384.40 
Submaxillary Gland 72.15 103 9.82E+08 499.30 
Histatin 1 43.86 10 7.60E+06 439.10 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 24.82 6 1.41E+06 232.80 
Alpha-Amylase 1 21.33 16 3.64E+06 368.80 
IR15 




Basic Salivary 2 64.90 28 6.04E+07 575.60 
Basic Salivary 3 72.49 56 2.44E+08 794.00 
Basic Salivary 4 59.68 52 1.58E+08 989.60 
Salivary Acidic 1/2 89.76 78 5.84E+08 709.70 
Statherin 66.13 104 2.07E+08 507.60 
Submaxillary Gland 72.15 58 2.98E+08 527.40 
Histatin 1 45.61 46 6.41E+07 477.20 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 13.48 4 2.94E+06 439.50 
Alpha-Amylase 1 2.15 1 7.86E+05 478.60 
IR16 




Basic Salivary 2 47.84 23 4.31E+07 602.90 
Basic Salivary 3 77.67 48 1.61E+08 810.60 
Basic Salivary 4 54.52 38 9.46E+07 741.30 
Salivary Acidic 1/2 90.36 77 6.44E+08 882.50 
Statherin 54.84 78 9.33E+07 459.10 
Submaxillary Gland 72.15 64 3.70E+08 555.00 
Histatin 1 45.61 58 9.51E+07 596.20 
Histatin 3 45.10 8 2.77E+07 655.90 
Cystatin-SN 13.48 2 4.79E+05 367.00 
Alpha-Amylase 1 2.15 1 3.36E+05 378.60 
405 















Basic Salivary 2 11.06 4 4.15E+06 416.30 
Basic Salivary 3 60.68 33 1.08E+08 552.60 
Basic Salivary 4 45.48 25 4.13E+07 521.10 
Salivary Acidic 1/2 87.35 66 4.96E+08 734.50 
Statherin 58.06 158 1.58E+08 393.60 
Submaxillary Gland 72.15 78 4.43E+08 532.00 
Histatin 1 63.16 13 5.77E+06 497.50 
Histatin 3 39.21 3 1.68E+06 429.20 
Cystatin-SN 12.06 3 1.09E+06 201.10 
Alpha-Amylase 1 2.15 1 3.17E+05 328.30 
IR18 




Basic Salivary 2 10.82 6 1.43E+07 449.10 
Basic Salivary 3 69.26 39 2.12E+08 564.70 
Basic Salivary 4 44.84 23 2.80E+07 432.20 
Salivary Acidic 1/2 90.36 74 5.57E+08 719.70 
Statherin 59.68 105 9.68E+07 461.70 
Submaxillary Gland 72.15 69 6.42E+08 543.20 
Histatin 1 63.16 29 2.84E+07 505.60 
Histatin 3 47.06 4 3.48E+06 527.00 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 2.21E+05 269.00 
IR19 




Basic Salivary 2 95.43 98 5.78E+08 1014.00 
Basic Salivary 3 56.13 32 7.63E+07 772.90 
Basic Salivary 4 39.03 20 4.06E+07 575.30 
Salivary Acidic 1/2 90.36 66 2.76E+08 684.30 
Statherin 67.74 130 1.17E+08 372.40 
Submaxillary Gland 72.15 49 9.52E+07 525.80 
Histatin 1 36.84 20 5.87E+06 404.60 
Histatin 3 62.74 9 6.87E+06 525.10 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 5.28 2 2.15E+05 212.00 
IR20 




Basic Salivary 2 11.78 8 2.76E+07 468.90 
Basic Salivary 3 65.24 43 1.73E+08 574.50 
Basic Salivary 4 56.45 38 1.03E+08 550.40 
Salivary Acidic 1/2 86.75 105 5.53E+08 664.90 
Statherin 61.29 92 8.76E+07 394.10 
Submaxillary Gland 69.62 64 2.71E+08 494.40 
Histatin 1 31.58 4 9.17E+05 273.20 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 19.15 3 4.64E+05 254.90 
Alpha-Amylase 1 2.15 1 3.09E+05 351.40 
406 
 















Basic Salivary 2 95.67 95 4.95E+08 1022.60 
Basic Salivary 3 38.46 29 1.02E+08 524.20 
Basic Salivary 4 37.42 25 4.89E+07 575.70 
Salivary Acidic 1/2 74.10 27 7.83E+07 609.40 
Statherin 67.74 27 1.44E+07 246.80 
Submaxillary Gland 72.15 37 1.19E+08 491.10 
Histatin 1 64.91 44 1.81E+07 347.40 
Histatin 3 62.74 4 4.17E+06 516.50 
Cystatin-SN 0.00 0 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 1.93E+05 271.00 
IR22 




Basic Salivary 2 12.74 7 1.04E+07 493.90 
Basic Salivary 3 75.73 46 2.38E+08 632.80 
Basic Salivary 4 38.39 20 1.36E+08 508.10 
Salivary Acidic 1/2 89.76 140 9.88E+08 717.10 
Statherin 51.61 90 1.62E+08 470.80 
Submaxillary Gland 72.15 89 1.07E+09 507.00 
Histatin 1 31.58 13 7.40E+06 423.50 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 16.31 7 3.74E+06 507.40 
Alpha-Amylase 1 2.15 1 4.40E+05 360.20 
IR23 




Basic Salivary 2 52.16 36 8.21E+07 859.80 
Basic Salivary 3 64.10 42 1.68E+08 783.10 
Basic Salivary 4 7.10 2 1.69E+07 559.20 
Salivary Acidic 1/2 83.73 73 4.67E+08 740.00 
Statherin 69.35 111 1.41E+08 447.00 
Submaxillary Gland 72.15 70 1.96E+08 537.00 
Histatin 1 56.14 31 2.67E+07 474.50 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 10.64 1 3.35E+05 295.10 
Alpha-Amylase 1 2.15 1 6.03E+05 471.20 
IR24 




Basic Salivary 2 85.34 60 1.59E+08 700.50 
Basic Salivary 3 70.87 49 3.16E+08 653.80 
Basic Salivary 4 53.55 42 1.63E+08 579.00 
Salivary Acidic 1/2 89.76 73 3.57E+08 717.00 
Statherin 54.84 83 6.36E+07 424.10 
Submaxillary Gland 72.15 51 1.45E+08 503.70 
Histatin 1 45.61 10 2.47E+06 339.00 
Histatin 3 0.00 0.00 0.00E+00 0.00 
Cystatin-SN 0.00 0.00 0.00E+00 0.00 
Alpha-Amylase 1 2.15 1 2.71E+05 277.40 
IR25 




Basic Salivary 2 22.84 10 1.11E+07 438.00 
Basic Salivary 3 73.79 47 3.06E+08 778.50 
Basic Salivary 4 42.58 32 1.40E+08 566.30 
Salivary Acidic 1/2 86.75 82 4.72E+08 714.80 
Statherin 61.29 63 5.06E+07 426.50 
Submaxillary Gland 67.09 56 2.64E+08 496.20 
Histatin 1 45.61 23 1.21E+07 431.40 
Histatin 3 0.00 0 0.00E+00 0.00 
Cystatin-SN 0.00 0 0.00E+00 0.00 




APPENDIX M: PROTEIN IDENTIFICATION OF VAGINAL FLUID POPULATION SAMPLES 











CRNN 75.2 90 3.85E+08 
1.02E+08 
1099.50 
605.93 SBSN 32.5 17 1.52E+07 647.60 IVL 23.1 8 8.24E+06 476.70 
PPL 0.9 1 2.42E+05 199.90 
4669 
CRNN 29.1 17 3.04E+06 
1.01E+06 
201.40 
121.10 SBSN 2.7 2 1.89E+05 67.30 IVL 1.9 2 8.06E+05 215.70 
PPL 0.0 0 0.00E+00 0.00 
5488 
CRNN 67.5 93 1.91E+08 
5.01E+07 
1105.70 
434.68 SBSN 25.8 14 8.49E+06 345.80 IVL 2.4 1 7.58E+05 287.20 
PPL 0.0 0 0.00E+00 0.00 
5560 
CRNN 40.0 28 9.83E+06 
2.56E+06 
629.50 
189.83 SBSN 0.0 0 0.00E+00 0.00 IVL 1.9 2 4.26E+05 129.80 
PPL 0.0 0 0.00E+00 0.00 
5701 
CRNN 69.1 68 8.39E+07 
2.11E+07 
1007.20 
313.00 SBSN 9.8 3 5.23E+05 244.80 IVL 0.0 0 0.00E+00 0.00 
PPL 0.0 0 0.00E+00 0.00 
5854 
CRNN 54.3 49 9.91E+07 
2.80E+07 
956.00 
444.35 SBSN 12.5 5 2.91E+06 146.50 IVL 22.4 7 9.34E+06 516.80 
PPL 0.9 1 5.62E+05 158.10 
6239 
CRNN 62.0 69 9.54E+07 
2.83E+07 
952.80 
424.98 SBSN 15.4 7 4.17E+06 178.60 IVL 45.5 33 1.38E+07 568.50 
PPL 0.0 0 0.00E+00 0.00 
6241 
CRNN 63.2 68 1.01E+08 
2.65E+07 
1022.00 
407.98 SBSN 5.4 3 9.27E+05 75.40 IVL 20.7 8 3.34E+06 260.60 
PPL 0.9 1 5.36E+05 273.90 
6260 
CRNN 62.6 42 2.22E+07 
5.86E+06 
557.30 
171.03 SBSN 15.4 5 1.26E+06 126.80 IVL 0.0 0 0.00E+00 0.00 
PPL 0.0 0 0.00E+00 0.00 
6291 
CRNN 51.5 39 4.49E+07 
1.29E+07 
652.10 
284.73 SBSN 11.7 5 1.72E+06 177.70 IVL 6.7 5 5.11E+06 309.10 
PPL 0.0 0 0.00E+00 0.00 
408 
 











CRNN 45.1 46 5.61E+07 
1.51E+07 
751.50 
382.08 SBSN 10.5 5 4.13E+06 666.10 IVL 0.0 0 0.00E+00 0.00 
PPL 1.1 1 3.04E+05 110.70 
6310 
CRNN 45.3 62 1.33E+08 
3.50E+07 
971.80 
438.08 SBSN 14.1 8 3.01E+06 298.20 IVL 10.1 5 3.29E+06 354.80 
PPL 0.9 1 6.69E+05 127.50 
6311 
CRNN 66.3 85 1.11E+08 
3.18E+07 
766.70 
463.78 SBSN 31.2 16 1.03E+07 415.00 IVL 13.9 6 3.33E+06 305.10 
PPL 2.5 2 2.63E+06 368.30 
6320 
CRNN 75.8 94 2.87E+08 
8.75E+07 
1054.30 
596.90 SBSN 57.3 35 3.85E+07 678.10 IVL 24.1 11 1.79E+07 356.10 
PPL 5.0 6 6.38E+06 299.10 
6343 
CRNN 3.2 1 8.44E+04 
2.11E+04 
36.60 
9.15 SBSN 0.0 0 0.00E+00 0.00 IVL 0.0 0 0.00E+00 0.00 
PPL 0.0 0 0.00E+00 0.00 
6460 
CRNN 42.8 41 8.54E+07 
2.22E+07 
1033.80 
307.95 SBSN 0.0 0 0.00E+00 0.00 IVL 10.6 2 3.01E+06 160.00 
PPL 2.1 2 2.40E+05 38.00 
6551 
CRNN 43.6 38 5.54E+07 
1.40E+07 
936.90 
286.93 SBSN 0.0 0 0.00E+00 0.00 IVL 7.4 2 7.40E+05 210.80 
PPL 0.0 0 0.00E+00 0.00 
6557 
CRNN 57.6 59 1.62E+08 
5.02E+07 
1044.20 
514.98 SBSN 32.7 27 3.73E+07 683.60 IVL 2.1 2 6.67E+05 271.80 
PPL 1.6 2 9.20E+05 60.30 
6587 
CRNN 59.6 70 1.53E+08 
4.69E+07 
690.20 
441.00 SBSN 35.1 26 3.28E+07 604.90 IVL 13.9 4 1.60E+06 277.40 
PPL 0.9 1 4.26E+05 191.50 
6635 
CRNN 40.6 38 1.60E+07 
9.41E+06 
424.40 
288.25 SBSN 15.6 12 3.03E+06 279.60 IVL 39.7 42 1.86E+07 449.00 
PPL 0.0 0 0.00E+00 0.00 
6636 
CRNN 52.7 48 3.13E+07 
1.23E+07 
465.50 
226.10 SBSN 3.4 2 2.47E+05 106.10 IVL 44.8 45 1.79E+07 332.80 















CRNN 56.6 53 1.95E+08 
5.11E+07 
1023.70 
401.23 SBSN 12.0 7 3.29E+06 215.90 IVL 18.0 5 6.05E+06 365.30 
PPL 0.0 0 0.00E+00 0.00 
6661 
CRNN 68.7 95 2.69E+08 
7.34E+07 
1059.10 
566.78 SBSN 22.7 12 9.44E+06 382.70 IVL 19.5 11 1.49E+07 508.60 
PPL 1.0 1 6.64E+05 316.70 
6674 
CRNN 67.1 84 1.02E+08 
2.61E+07 
976.80 
367.68 SBSN 13.1 5 1.64E+06 223.80 IVL 4.4 2 2.42E+05 270.10 
PPL 0.0 0 0.00E+00 0.00 
6681 
CRNN 58.6 87 1.71E+08 
4.48E+07 
753.70 
382.98 SBSN 12.0 5 2.05E+06 225.90 IVL 13.9 8 5.03E+06 272.50 
PPL 1.7 2 1.35E+06 279.80 
A1 
CRNN 69.9 79 2.44E+08 
7.99E+07 
990.50 
664.75 SBSN 11.2 7 7.76E+06 519.80 IVL 41.2 28 6.61E+07 675.40 
PPL 2.1 2 1.16E+06 473.30 
B1 
CRNN 49.1 32 4.85E+07 
1.29E+07 
883.30 
289.08 SBSN 21.2 5 3.14E+06 271.90 IVL 3.1 1 1.22E+05 1.10 
PPL 0.0 0 0.00E+00 0.00 
C1 
CRNN 0.0 0 0.00E+00 
0.00E+00 
0.00 
0.00 SBSN 0.0 0 0.00E+00 0.00 IVL 0.0 0 0.00E+00 0.00 
PPL 0.0 0 0.00E+00 0.00 
D1 
CRNN 39.4 48 4.34E+07 
1.10E+07 
760.80 
232.90 SBSN 0.0 0 0.00E+00 0.00 IVL 4.6 2 5.87E+05 170.80 
PPL 0.0 0 0.00E+00 0.00 
E1 
CRNN 72.1 79 3.14E+08 
8.62E+07 
1104.70 
646.35 SBSN 13.9 9 8.66E+06 621.60 IVL 23.3 11 2.11E+07 376.90 
PPL 1.1 1 7.97E+05 482.20 
F1 
CRNN 14.6 7 1.33E+06 
3.33E+05 
357.90 
89.48 SBSN 0.0 0 0.00E+00 0.00 IVL 0.0 0 0.00E+00 0.00 
PPL 0.0 0 0.00E+00 0.00 
G1 
CRNN 62.4 62 1.19E+08 
3.13E+07 
1081.40 
529.28 SBSN 10.2 3 3.57E+06 349.50 IVL 6.5 3 2.10E+06 421.10 
PPL 2.0 2 7.29E+05 265.10 
410 
 
APPENDIX N: PEPTIDE IDENTIFICATION OF PERFORMANCE ASSESSMENT SAMPLES 
 
TABLE LEGEND:  
Green Box = Positive target peptide identification 
Grey Box = Negative target peptide identification, positive protein identification 
Red Box = Negative protein identification 
NT = Not Tested 
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